
<html lang="en"     class="pb-page"  data-request-id="58719ef3-beee-4e42-8c52-2300fbefd13b"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2017.60.issue-12;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.7b00475;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases" /></meta><meta name="dc.Creator" content="Anne-Sophie  Cornec" /></meta><meta name="dc.Creator" content="Ludovica  Monti" /></meta><meta name="dc.Creator" content="Jane  Kovalevich" /></meta><meta name="dc.Creator" content="Vishruti  Makani" /></meta><meta name="dc.Creator" content="Michael J.  James" /></meta><meta name="dc.Creator" content="Krishna G.  Vijayendran" /></meta><meta name="dc.Creator" content="Killian  Oukoloff" /></meta><meta name="dc.Creator" content="Yuemang  Yao" /></meta><meta name="dc.Creator" content="Virginia M.-Y.  Lee" /></meta><meta name="dc.Creator" content="John Q.  Trojanowski" /></meta><meta name="dc.Creator" content="Amos B.  Smith, III" /></meta><meta name="dc.Creator" content="Kurt R.  Brunden" /></meta><meta name="dc.Creator" content="Carlo  Ballatore" /></meta><meta name="dc.Description" content="Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved, including those associated with pathological tau and Aβ species as..." /></meta><meta name="Description" content="Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved, including those associated with pathological tau and Aβ species as..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 8, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00475" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00475" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00475" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00475" /></link>
        
    
    

<title>Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00475" /></meta><meta property="og:title" content="Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0015.jpeg" /></meta><meta property="og:description" content="Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved, including those associated with pathological tau and Aβ species as well as neuroinflammation. In this context, the development of single multitargeted therapeutics directed against two or more disease mechanisms could be advantageous. Starting from a series of 1,5-diarylimidazoles with microtubule (MT)-stabilizing activity and structural similarities with known NSAIDs, we conducted structure–activity relationship studies that led to the identification of multitargeted prototypes with activities as MT-stabilizing agents and/or inhibitors of the cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways. Several examples are brain-penetrant and exhibit balanced multitargeted in vitro activity in the low μM range. As brain-penetrant MT-stabilizing agents have proven effective against tau-mediated neurodegeneration in animal models, and because COX- and 5-LOX-derived eicosanoids are thought to contribute to Aβ plaque deposition, these 1,5-diarylimidazoles provide tools to explore novel multitargeted strategies for AD and other neurodegenerative diseases." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00475"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00475">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00475&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00475&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00475&amp;href=/doi/10.1021/acs.jmedchem.7b00475" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 5120-5145</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00468" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00449" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anne-Sophie++Cornec">Anne-Sophie Cornec</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ludovica++Monti">Ludovica Monti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jane++Kovalevich">Jane Kovalevich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Vishruti++Makani">Vishruti Makani</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++James">Michael J. James</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Krishna+G.++Vijayendran">Krishna G. Vijayendran</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Killian++Oukoloff">Killian Oukoloff</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuemang++Yao">Yuemang Yao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Virginia+M.-Y.++Lee">Virginia M.-Y. Lee</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+Q.++Trojanowski">John Q. Trojanowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amos+B.++Smith%2C++III">Amos B. Smith, III</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1712-8567" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kurt+R.++Brunden">Kurt R. Brunden</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carlo++Ballatore">Carlo Ballatore</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-2718-3850" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Center for Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div><div class="corresp-info"><strong>*</strong>For C.B.: phone, 858-822-3663; E-mail, <a href="/cdn-cgi/l/email-protection#ee8d8c8f82828f9a819c8bae9b8d9d8ac08b8a9b"><span class="__cf_email__" data-cfemail="9bf8f9faf7f7faeff4e9fedbeef8e8ffb5feffee">[email protected]</span></a></div><div class="corresp-info"><strong>*</strong>For K.B.: phone, 215-615-5262; E-mail, <a href="/cdn-cgi/l/email-protection#fd969f8f8893999893bd888d989393d3989988"><span class="__cf_email__" data-cfemail="b3d8d1c1c6ddd7d6ddf3c6c3d6dddd9dd6d7c6">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00475&amp;href=/doi/10.1021%2Facs.jmedchem.7b00475" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 5120–5145</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 22, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 March 2017</li><li><span class="item_label"><b>Published</b> online</span>8 June 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 22 June 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00475" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00475</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00475"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">20145</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">24</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00475" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Multitargeted Imidazoles: Potential Therapeutic Leads for Alzheimer’s and Other Neurodegenerative Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Anne-Sophie&quot;,&quot;last_name&quot;:&quot;Cornec&quot;},{&quot;first_name&quot;:&quot;Ludovica&quot;,&quot;last_name&quot;:&quot;Monti&quot;},{&quot;first_name&quot;:&quot;Jane&quot;,&quot;last_name&quot;:&quot;Kovalevich&quot;},{&quot;first_name&quot;:&quot;Vishruti&quot;,&quot;last_name&quot;:&quot;Makani&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. James&quot;},{&quot;first_name&quot;:&quot;Krishna&quot;,&quot;last_name&quot;:&quot;G. Vijayendran&quot;},{&quot;first_name&quot;:&quot;Killian&quot;,&quot;last_name&quot;:&quot;Oukoloff&quot;},{&quot;first_name&quot;:&quot;Yuemang&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Virginia&quot;,&quot;last_name&quot;:&quot;M.-Y. Lee&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;Q. Trojanowski&quot;},{&quot;first_name&quot;:&quot;Amos&quot;,&quot;last_name&quot;:&quot;B. Smith&quot;},{&quot;first_name&quot;:&quot;Kurt&quot;,&quot;last_name&quot;:&quot;R. Brunden&quot;},{&quot;first_name&quot;:&quot;Carlo&quot;,&quot;last_name&quot;:&quot;Ballatore&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;08&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;5120-5145&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00475&quot;},&quot;abstract&quot;:&quot;Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved, including those associated with pathological tau and Aβ species as well as neuroinflammation. In this context, the development of single multitargeted therapeutics directed against two or more disease mechanisms could be advantageous. Starting from a series of 1,5-diarylimidazoles with microtubule (MT)-stabilizing activity and structural similarities with known NSAIDs, we conducted structure–activity relationship studies that led to the identification of multitargeted prototypes with activities as MT-stabilizing agents and/or inhibitors of the cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways. Several examples are brain-penetrant and exhibit balanced multitargeted in vitro activity in the low μM range. As brain-penetrant MT-stabilizing agents have proven effective against tau-mediated neurodegeneration in animal models, and because COX- and 5-LOX-derived eicosanoids are tho&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00475&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00475" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00475&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00475" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00475&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00475" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00475&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00475&amp;href=/doi/10.1021/acs.jmedchem.7b00475" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00475" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00475" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00475%26sid%3Dliteratum%253Aachs%26pmid%3D28530811%26genre%3Darticle%26aulast%3DCornec%26date%3D2017%26atitle%3DMultitargeted%2BImidazoles%253A%2BPotential%2BTherapeutic%2BLeads%2Bfor%2BAlzheimer%25E2%2580%2599s%2Band%2BOther%2BNeurodegenerative%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D12%26spage%3D5120%26epage%3D5145%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290729" title="Nervous system diseases">Nervous system diseases</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292253" title="Imidazoles">Imidazoles</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/jmcmar.2017.60.issue-12/20170622/jmcmar.2017.60.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0015.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Alzheimer’s disease (AD) is a complex, multifactorial disease in which different neuropathological mechanisms are likely involved, including those associated with pathological tau and Aβ species as well as neuroinflammation. In this context, the development of single multitargeted therapeutics directed against two or more disease mechanisms could be advantageous. Starting from a series of 1,5-diarylimidazoles with microtubule (MT)-stabilizing activity and structural similarities with known NSAIDs, we conducted structure–activity relationship studies that led to the identification of multitargeted prototypes with activities as MT-stabilizing agents and/or inhibitors of the cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways. Several examples are brain-penetrant and exhibit balanced multitargeted in vitro activity in the low μM range. As brain-penetrant MT-stabilizing agents have proven effective against tau-mediated neurodegeneration in animal models, and because COX- and 5-LOX-derived eicosanoids are thought to contribute to Aβ plaque deposition, these 1,5-diarylimidazoles provide tools to explore novel multitargeted strategies for AD and other neurodegenerative diseases.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11827" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11827" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In Alzheimer’s disease (AD), aggregated tau proteins and Aβ peptides are thought to participate in disease onset and progression. Moreover, other factors such as neuroinflammation and oxidative stress are also believed to be intimately associated with the neurodegenerative process. Although the precise relationship(s) linking these different neuropathological mechanisms remain the focus of active research, it is clear that AD is a complex and multifactorial disease. Thus far, Aβ amyloidosis has been the target of choice in AD drug discovery, as most drug candidates have been designed to modulate Aβ homeostasis. However, in spite of generally strong preclinical data with such therapeutic candidates, the outcomes of late-stage AD clinical trials have thus far failed to demonstrate clinical efficacy. These disappointing results raise the possibility that AD treatments may have to interfere concurrently with more than one neuropathological mechanism to exert disease modifying benefits. In this context, a single multitargeted drug may have distinctive advantages in terms of efficacy and safety over drug combination therapies.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As such, an increasing number of therapeutic strategies that are based on polypharmacology have been proposed for AD.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2, 3)</a></div><div class="NLM_p">Over the past several years, our laboratories and others have demonstrated that brain-penetrant MT-stabilizing agents have profoundly beneficial effects in animal models of tau pathology due to the ability of these compounds to normalize hyperdynamic axonal MTs, restore axonal transport, reduce the burden of tau pathology, and prevent cognitive impairments and neuron loss associated with tau pathology.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a> Furthermore, our recent work<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> indicates that the binding of cyclooxygenase (COX)- and 5-lipoxygenase (5-LOX)-derived eicosanoids to their cognate receptors in neurons results in increased production of amyloid precursor protein (APP) and Aβ peptides, adding to a body of literature<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20 ref21 ref22 ref23">(9-23)</a> implicating inflammatory eicosanoids as key contributing factors to Aβ plaque deposition in AD. Thus, a stabilization of axonal MTs, combined with a concurrent suppression of eicosanoid production, may be considered as a multitargeted therapeutic strategy that could attenuate both tau- and Aβ-mediated neurodegeneration, as well as MT deficiencies<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and/or neuroinflammation,<a onclick="showRef(event, 'ref25 ref26 ref27 ref28 ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27 ref28 ref29 ref30 ref31">(25-31)</a> in AD. Moreover, this approach may also provide benefit in other neurodegenerative tauopathies.</div><div class="NLM_p">The rational design of multitargeted compounds is challenging, especially when attempting to merge multiple molecular frameworks and the corresponding underlying pharmacophores in a single small molecule.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> However, a series of fungicidal diaryl-pyrazoles (e.g., <b>1</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) and -imidazoles (e.g., <b>2</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) with known MT-stabilizing activity exhibit tricyclic structures similar to those found in known nonsteroidal anti-inflammatory drugs (NSAIDs) such as the potent COX-1 inhibitor<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> SC560 (<b>3</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) and, to a lesser extent, the dual COX/5-LOX inhibitor<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> licofelone (<b>4</b>, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Furthermore, molecular docking studies indicated that selected representative examples of these MT-stabilizing imidazoles could fit within the arachidonic acid binding site of COX-1 with a predicted binding energy that is comparable (i.e., within 2 kcal/mol) to that of <b>3</b> (see <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a> and <a href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf" class="ext-link">Supporting Information</a>). Thus, although MT-stabilizing agents and NSAIDs are different classes of biologically active compounds that interact with unrelated targets, the observed structural commonalities between these compounds suggest that there may be significant degree of crosstalk between the different pharmacophores that could be exploited to identify multitargeted ligands. Toward this end, the synthesis and subsequent evaluation of several closely related 1,5-diarylimidazole congeners led to the identification of specific substitution patterns that are required to achieve different activity profiles in vitro. In particular, in addition to identifying compounds that act selectively as MT-stabilizers and others that are selective inhibitors of the COX- and/or 5-LOX pathways with no effect on MTs, these studies led to the identification of a series of multitargeted molecules that at low μM concentration can concurrently stabilize MTs and inhibit both COX- and 5-LOX derived eicosanoids in cell-based assays. Furthermore, several of these compounds were also confirmed to be brain-penetrant, indicating that molecules of this type may be considered as potential multitargeted prototype structures for AD and related tauopathies.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0001.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Comparison of representative examples of fungicidal diaryl-pyrazoles (<b>1</b>) and -imidazoles (<b>2</b>) with reported MT-stabilizing activity, with known COX- (<b>3</b>) and dual COX/5-LOX (<b>4</b>) inhibitors; molecular docking of <b>2</b> (B) and <b>3</b> (C) within the arachidonic acid binding site of COX-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63883" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63883" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">As part of these studies, a library comprising 81 imidazoles has been synthesized, including 36 known compounds (i.e., <b>2</b>, <b>25</b>, <b>29</b>–<b>31</b>, <b>35</b>, <b>36</b>, <b>38</b>, <b>43</b>–<b>46</b>, <b>51</b>, <b>54</b>, <b>55</b>, <b>57</b>, <b>58</b>, <b>61</b>, <b>62</b>, <b>64</b>, <b>65</b>, <b>67</b>, <b>68</b>, <b>70</b>, <b>71</b>, <b>73</b>, <b>74</b>, <b>83</b>–<b>86</b>, <b>88</b>, <b>92</b>, <b>94</b>, <b>95</b>, and <b>97</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), most with reported antifungal<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> or antimicrobial activity, as well as 45 new structures (i.e., <b>26</b>–<b>28</b>, <b>32</b>–<b>34</b>, <b>37</b>, <b>39</b>–<b>42</b>, <b>47</b>–<b>50</b>, <b>52</b>, <b>53</b>, <b>56</b>, <b>59</b>, <b>60</b>, <b>63</b>, <b>66</b>, <b>69</b>, <b>72</b>, <b>75</b>–<b>82</b>, <b>87</b>, <b>89</b>–<b>91</b>, <b>93</b>, <b>96</b>, <b>98</b>–<b>104</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In general, the synthesis of the 1,5-diarylimidazoles was conducted following the Van Leusen imidazole synthesis.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Thus, after condensation of the appropriate aryl-amine and benzaldehyde, the resulting Schiff base (<b>5</b>–<b>24</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) was cyclized in the presence of toluenesulfonylmethyl isocyanide (TosMIC) to form the 1,5-diarylimidazole (<b>25</b>–<b>28</b>, <b>32</b>, <b>33</b>, <b>37</b>–<b>43</b>, <b>47</b>–<b>53</b>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). Further derivatizations of the imidazole ring included the introduction of small alkyl groups and/or halogens in position 2 and/or 4 (<b>29</b>–<b>31</b>, <b>34</b>–<b>36</b>, and <b>44</b>–<b>46</b> in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> and <b>54</b>–<b>104</b> in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Imidazole derivatives bearing a methyl substituent at C4 were accessed by employing the appropriately C-substituted TosMIC reagent during the cyclization step (<b>29</b>, <b>35</b>, <b>44</b>), while alkylated derivatives at C2 (e.g., <b>34</b>, <b>86</b>) were obtained by treating the appropriate 1,5-diarylimidazole with LDA followed by addition of the desired alkyl iodide. Finally, halogenation of the imidazole ring was accomplished upon treatment with <i>N</i>-chlorosuccinimide. When the halogenation was carried out on imidazoles that were not substituted at C2 and C4, the reaction typically proceeded with the generation of separable mixtures of mono- and dichlorinated imidazoles.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0004.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (a) Dean–Stark apparatus, toluene, 110 °C, 4 days, 99%; (b) 4 Å molecular sieves, Et<sub>2</sub>O, 30 °C, 48 h, 99%; (c) appropriate TosMIC reagent, K<sub>2</sub>CO<sub>3</sub>, DMF/1,2-dimethoxyethane, 100 °C, 16 h, 7–90%; (d) <i>N</i>-chlorosuccinimide, CHCl<sub>3</sub>, 60 °C, 16 h, 43–71%; (e) LDA, methyliodide, THF, −20 °C to rt, 1.5 h, 29–56%.</p></p></figure><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0005.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (a) <i>N</i>-chlorosuccinimide, CHCl<sub>3</sub>, 60 °C, 16 h, 9–77% for monohalogenation at C4, 3–18% for monohalogenation at C2, and 2–20% for dihalogenation at C2/C4; (b) LDA, methyliodide, THF, −20 °C to rt, 1.5 h, 2–48%; (c) NaOMe, MeOH, THF, rt, 19 h, 33–97%; (d) LDA, ethyliodide, THF, −20 °C to rt, 1.5 h, 35%.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Structure–Activity Relationships</h3><div class="NLM_p">The MT-stabilizing activity of test compounds was determined in QBI-293 cells by monitoring compound-induced elevation in acetylated α-tubulin (AcTub),<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> which is a known marker of stable MTs.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Furthermore, as the MT-stabilizing imidazoles are believed to act on MTs in a manner similar to that described for the triazolopyrimidines,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and considering that certain triazolopyrimidines have been found to induce a proteasome-dependent degradation of α-tubulin,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> the effect of compound treatment on total α-tubulin was also monitored. Evaluation of compound inhibition of the biosynthesis of COX- and 5-LOX-derived eicosanoids was conducted in a modified rat basophilic leukemia (RBL-1) cell assay that has previously been described<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> for the evaluation of 5-LOX and which we found can be used to assess both COX-derived prostaglandins (PGs) and 5-LOX-derived leukotrienes (LTs) formed in the presence or absence of test compounds.</div><div class="NLM_p last">All compounds were initially screened at 1 and 10 μM concentration in the QBI cell MT assay and at 10 μM in the RBL-1 cell assay (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). In this initial RBL-1 cell analysis, 5-LOX-derived LTB<sub>4</sub> and COX-derived PGD<sub>2</sub> and PGE<sub>2</sub>, which coeluted during LC/MS/MS, were quantified. Selected compounds (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) exhibiting evidence of multitargeted activity underwent further confirmatory studies in the RBL-1 cell assay, which included concentration–response testing, and further LC/MS/MS analyses using a refined protocol to individually detect and quantitate PGD<sub>2</sub> and PGE<sub>2</sub>, as well as both LTB<sub>4</sub> and LTC<sub>4</sub>. As the formation of each of these eicosanoids depends on separate enzymatic steps in the COX or 5-LOX pathways,<a onclick="showRef(event, 'ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref41 ref42">(41)</a> concurrent analysis of all four of these eicosanoids provides a convenient and reliable method to evaluate the overall effect of test compounds on COX and 5-LOX pathways in a cellular milieu. Finally, several compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were also assessed for their relative brain-to-plasma exposure levels after administration to mice.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> MT-Stabilizing Activity</h3><div class="NLM_p">Evaluation of compounds in the QBI-293 cell MT assay revealed that out of 71 tested compounds, 48 examples exhibited activity on MTs as revealed by statistically significant changes in AcTub levels. Among MT-active compounds, seven examples (i.e., <b>2</b>, <b>58</b>, <b>65</b>, <b>71</b>, <b>85</b>, <b>86</b>, and <b>97</b>) were found to be active at 1 μM compound concentration, whereas the remaining 41 compounds were active only at 10 μM. Consistent with the notion that the MT-stabilizing 1,5-diarylimidazoles may be acting on MTs in a similar manner as the triazolopyrimidines,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> the data presented in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> reveal that like the latter molecules, these imidazoles can be broadly divided into two subsets: one group of 15 entries, which cause a significant reduction in total α-tubulin levels at doses typically required to induce an elevation in AcTub (i.e., <b>2</b>, <b>30</b>, <b>34</b>, <b>58</b>, <b>62</b>, <b>63</b>, <b>65</b>, <b>66</b>, <b>71</b>, <b>73</b>, <b>85</b>, <b>94</b>–<b>97</b>) and a second group of 33 compounds that produce an elevation in AcTub at 1 or 10 μM without decreasing α-tubulin level (<b>29</b>, <b>31</b>, <b>35</b>, <b>36</b>, <b>44</b>–<b>46</b>, <b>54</b>, <b>55</b>–<b>57</b>, <b>59</b>, <b>60</b>, <b>64</b>, <b>67</b>–<b>70</b>, <b>72</b>, <b>74</b>, <b>78</b>, <b>82</b>–<b>84</b>, <b>86</b>–<b>88</b>, <b>90</b>–<b>93</b>, <b>102</b>, <b>104</b>). Also of interest, a comparison of the activities of compounds in the AcTub assay at 1 and 10 μM suggest that selected entries, such as compounds <b>2</b>, <b>58</b>, and <b>71</b>, may exhibit a bell-shaped concentration–response relationship, and it is possible that additional examples would show a similar concentration–response if tested at higher concentrations. This phenomenon was observed in the case of the triazolopyrimidines that reduce α-tubulin level, such as <b>108</b>.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Irrespective of whether or not test compounds cause a reduction in total α-tubulin, the AcTub SAR emerging from the data shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> appear to be in general agreement with SAR from prior studies in which MT-stabilizing 1,5-diarylimidazoles were evaluated for antifungal activity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Thus, our results indicate that ring A is preferably a 4-chloro-phenyl, although examples bearing other substituents in the <i>para</i>-position, such as a trifluoromethoxy (<b>83</b>), are also active. Additional substitutions in the A ring, as in compound <b>77</b> and <b>78</b> in which a fluorine is present in the <i>ortho</i>-position, appear to impact negatively MT interactions of the compound (cf. <b>77</b> with <b>87</b> and <b>78</b> with <b>84</b>). With respect to the B ring, the degree and pattern of fluorination appear to be generally important factors that determine the ability of these imidazoles to produce a significant elevation in the marker of stable MTs in QBI-293 cells. Whereas derivatives with either one or no fluorination in the B ring (i.e., <b>50</b>, <b>51</b>, <b>75</b>, <b>76</b>, <b>98</b>–<b>101</b>) were found to be essentially devoid of MT activity in our assay conditions, other di- and trisubstituted congeners (e.g., <b>54</b>, <b>68</b>, <b>84</b>) produced a significant increase in AcTub. Furthermore, a comparison between the inactive difluorinated derivative <b>80</b> and the active di- and trifluorinated compounds (i.e., <b>54</b>, <b>68</b>, and <b>84</b>) suggests that the presence of two fluorine atoms in the <i>ortho</i>-positions of ring B is required for MT activity. Finally, with respect to the imidazole ring (ring C), our results indicate that 1,5-diarylimidazoles that are not substituted in positions 2 and 4 (e.g., <b>25</b>, <b>26</b>, <b>42</b>, <b>43</b>, <b>48</b>, <b>49</b>, <b>52</b>, and <b>53</b>) do not cause a detectable increase in AcTub, whereas tetrasubstituted imidazoles, including C2/C4 dihalogenated (e.g., <b>88</b>) and dimethylated (e.g., <b>46</b>) derivatives, as well as analogues bearing both a small alkyl- and a chloro-substituent in either C2 or C4 positions (e.g., <b>85</b> and <b>45</b>), are generally more active than corresponding derivatives bearing a single substitution in either position 2 or 4 (cf. <b>87</b>, <b>88</b>, and <b>44</b>, <b>46</b>). These results also suggest that MT activity does not strictly require a halogen in position 4 of the imidazole ring, as was required for optimal antifungal activity,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> because congeners halogenated at C2 appear to retain comparable MT activity (cf. <b>54</b>, <b>56</b> and <b>84</b>, <b>87</b>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Evaluation of Test Compounds as MT-Stabilizing Agents and Inhibitors of COX- and 5-LOX Pathways</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0006.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0007.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0008.gif" alt="" id="GRAPHIC-d7e1144-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0009.gif" alt="" id="GRAPHIC-d7e1145-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0010.gif" alt="" id="GRAPHIC-d7e1146-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0011.gif" alt="" id="GRAPHIC-d7e1147-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0012.gif" alt="" id="GRAPHIC-d7e1148-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Inhibition of COX pathway was determined by monitoring via LC/MS/MS analyses the combined production of COX-derived PGD<sub>2</sub> and PGE<sub>2</sub> in RBL-1 cells upon stimulation with arachidonic acid in the presence or absence of test compounds, with all samples run in at least triplicate.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Inhibition of 5-LOX pathway was determined by monitoring via LC/MS/MS analyses the production of 5-LOX-derived LTB<sub>4</sub> in RBL-1 cells upon stimulation with arachidonic acid in the presence or absence of test compounds, with all samples run in at least triplicate.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">MT-stabilizing activity in QBI-293 cells was determined by monitoring via ELISA the changes in acetylated α-tubulin levels relative to vehicle treatment in response to 4 h treatment with 1 and 10 μM test compounds, with all samples run in at least triplicate. The compound concentrations causing a significant change in AcTub are listed, along with the fold-change in AcTub.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Relative changes in total α-tubulin, as determined by tubulin ELISA, in response to 1 and 10 μM compound treatment, with all samples run in at least triplicate. The compound concentrations causing a significant change in a-Tub are listed, along with the fold-change in a-Tub.</p></div><div class="footnote" id="t1fn6"><sup>Table §</sup><p class="last">, Compound tested at 10 nM.<sup>∧</sup>, Previously published data.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> *, <i>P</i> < 0.05. **, <i>P</i> < 0.01 compared with vehicle (DMSO)-treated controls as determined using an two-tailed unpaired <i>t</i> test. NS, not significant. ND, not determined.</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Inhibition of Prostaglandin Biosynthetic Pathway</h3><div class="NLM_p last">Evaluation of test compounds as potential inhibitors of COX-dependent formation of PGD<sub>2</sub>/PGE<sub>2</sub> in RBL-1 cells revealed that optimal inhibition of PG synthesis is typically achieved when ring A is substituted in the <i>para</i>-position with either a chloride (e.g., <b>54</b>) or methoxy group (e.g., <b>59</b>). With respect to ring B, comparison of <b>54</b>, <b>68</b>, <b>76</b>, <b>79</b>, <b>84</b>, and <b>98</b> clearly suggests that the presence of fluorine substituents is not detrimental, or necessary, for inhibition of PG production. Evaluation of the effect of different substitutions in the imidazole ring reveals that, with the possible exception of compound <b>104</b>, which shows a >50% inhibition in the PGD<sub>2</sub>/PGE<sub>2</sub> assay, tetrasubstituted compounds (e.g., <b>45</b>, <b>46</b>, <b>85</b>, <b>88</b>) are generally devoid of inhibitory activity against PG synthesis. Conversely, 1,5-diarylimidazole congeners with one substitution at either C2 or C4 are generally active, with the presence of a substituent at C4 being possibly preferred over the C2 position (cf. <b>62</b> with <b>63</b>, <b>64</b> with <b>66</b>, <b>84</b> with <b>87</b>, and <b>92</b> with <b>93</b>). Among 1,5-diarylimidazoles that are not substituted at C2 and C4, although these compounds appear to be generally less active than the corresponding compounds bearing a substituent at C2 or C4, selected examples, such as <b>51</b>, have been identified that produce a near complete inhibition of the combined PGD<sub>2</sub>/PGE<sub>2</sub> synthesis in the RBL-1 cell assay when tested at 10 μM.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Inhibition of Leukotriene Biosynthetic Pathway</h3><div class="NLM_p">Finally, evaluation of compound inhibitory activity in the LTB<sub>4</sub> assay revealed that whereas a number of substitutions in the <i>para</i>-position of ring A appeared to be well tolerated, the presence of a 2-chloro-pyridine (see <b>73</b> and <b>74</b>) prevented inhibition of LTB<sub>4</sub> synthesis. In addition, similarly to what was observed for the SAR of PGD<sub>2</sub>/PGE<sub>2</sub> synthesis inhibition, the fluorination of the B ring did not impact activity, as both fluorinated (e.g., <b>59</b>, <b>80</b> and <b>84</b>) and nonfluorinated (e.g., <b>98</b>) congeners exhibit comparable inhibitory activity in the LTB<sub>4</sub> assay. However, in contrast to what was observed for inhibitory activity against PG synthesis, the choice of substituents at C2 and/or C4 of the imidazole ring did not play a critical role as examples of di- (e.g., <b>47</b>), tri- (e.g., <b>89</b> and <b>90</b>) and tetra-substituted (e.g., <b>91</b>) imidazoles were found to exhibit comparable suppression of LTB<sub>4</sub> synthesis in RBL-1 cells at 10 μM.</div><div class="NLM_p">Thus, in light of the observed elements of SAR for the three biological targets, the particular substitution pattern decorating the 1,5-diarylimidazole scaffold can result in compounds with different activity profiles, including multitargeted activity on MTs and/or eicosanoid biosynthesis (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Selected representative examples of multitargeted compounds were evaluated further to determine the IC<sub>50</sub> values in the RBL-1 cell assays and brain penetration (see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a> and <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Moreover, the compounds in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> were also examined with improved LC/MS/MS methodologies for their ability to inhibit the individual COX-derived products PGE<sub>2</sub> and PGD<sub>2</sub> as well as a second 5-LOX-derived product, LTC<sub>4</sub> (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf" class="ext-link">Figure S1</a>). Finally, two example compounds underwent full concentration–response analyses in the AcTub assay (see Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf" class="ext-link">Figure S2</a>). Collectively, these studies confirmed that all <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> compounds effectively inhibited both COX and 5-LOX biosynthetic pathways with multiple compounds exhibiting balanced multitargeted activity in the low μM range. Finally, consistent with the relatively small size of these molecules, these compounds appeared to be generally brain-penetrant.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0002.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Summary of SARs (top) and representative structures exemplifying the different activity profiles exhibited by the 1,5-diarylimidazoles (bottom).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Further Evaluation of Test Compounds with Multitargeted Activity as MT-Stabilizing Agents and/or Inhibitors of COX and 5-LOX Pathways</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0013.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">All concentration–response analyses were conducted at multiple concentrations with triplicate samples per concentration.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">The change in AcTub was assessed as described in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. <sup>#</sup>, Study conducted after a 5 mg/kg i.p. injection of test compound. <sup>∧</sup>, Study conducted after a 2 mg/kg i.p. injection of test compound with drug concentrations adjusted proportionally upward to allow comparison to 5 mg/kg doses. ND, not determined. NS, not significant. ± errors represent standard deviations. All analyses were conducted with groups of three mice.</p></div></div><div></div></div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0003.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative dose–response curves in the RBL-1 cell assays. Samples were run in triplicate at each concentration, with the error bars representing standard error of the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65303" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65303" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Although selected cholinesterase inhibitors and a single NMDA receptor antagonist are approved for the treatment of AD, these provide only a modest and temporary symptomatic improvement in AD patients and thus far there have been no examples of disease-modifying drug candidates for AD with demonstrated efficacy in phase III clinical trials.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> This situation may be due, at least in part, to the fact that several neuropathological mechanisms are likely to provide potentially alternative or redundant pathways to drive/sustain the neurodegenerative process in AD. NSAIDs, for example, once attracted considerable attention as potential candidates for AD treatment due to promising results in a series of preclinical studies in animal models with Aβ plaque pathology,<a onclick="showRef(event, 'ref44 ref45 ref46 ref47 ref48'); return false;" href="javascript:void(0);" class="ref ref44 ref45 ref46 ref47 ref48">(-44-48)</a> coupled with compelling retrospective epidemiological data indicating that individuals who were on sustained regimens of COX-inhibiting NSAIDs had reduced AD risk.<a onclick="showRef(event, 'ref45 ref49'); return false;" href="javascript:void(0);" class="ref ref45 ref49">(45, 49)</a> A series of clinical trials with different COX inhibitors, however, yielded mostly disappointing results.<a onclick="showRef(event, 'ref45 ref50 ref51 ref52'); return false;" href="javascript:void(0);" class="ref ref45 ref50 ref51 ref52">(45, 50-52)</a> Although there may be multiple reasons for the lack of efficacy in these clinical trials, including issues with the particular candidate compounds used in the studies and/or trials that were conducted in patient populations with disease that was too advanced to respond to this therapeutic approach, or who had dementia that was not due to underlying AD pathology, another possible mechanistic explanation may be that even if substantial COX inhibition is achieved within the AD brain, this may not prevent the detrimental effects of inflammatory LTs. Indeed, different studies have now shown that these 5-LOX products are likely to contribute to Aβ plaque pathology,<a onclick="showRef(event, 'ref8 ref18 ref20 ref21 ref23'); return false;" href="javascript:void(0);" class="ref ref8 ref18 ref20 ref21 ref23">(8, 18, 20, 21, 23)</a> and there is evidence that blocking COX metabolism can lead to shunting of arachidonic acid to the 5-LOX pathway.<a onclick="showRef(event, 'ref53 ref54 ref55'); return false;" href="javascript:void(0);" class="ref ref53 ref54 ref55">(53-55)</a> Furthermore, it may be also argued that any potential benefit of lowering Aβ production and plaque pathology alone may be limited if tau pathology persists. Indeed, a recent retrospective analysis of several late-stage AD clinical trials, including the NSAIDs studies, concluded that candidate therapeutics affecting one target alone may not be likely to impact significantly disease progression,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> suggesting that the evaluation and development of multitargeted approaches for AD would be desirable.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> However, although different examples of multitargeted constructs have been proposed as experimental AD treatments, there have been only a few reports<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> of molecules that exhibit polypharmacology against targets that are likely involved in tau and Aβ neuropathology.</div><div class="NLM_p">Prior studies suggested that axonal transport deficits associated with a loss of MTs and/or altered MT dynamics in the axon of neurons comprise a key neuropathological step of tauopathies and possibly other neurodegenerative diseases.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> As part of our ongoing efforts to develop brain-penetrant MT-stabilizing agents as potential treatments for these diseases, we identified selected heterocyclic compounds that are not derived from natural products, as exemplified here by triazolopyrimidine <b>107</b><a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), which exhibit a promising combination of MT-stabilizing activity and brain penetration.<a onclick="showRef(event, 'ref37 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref39">(37, 39)</a> Among compound classes that are structurally and functionally related to the triazolopyrimidines are a series of 1,5-diarylimidazoles.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Like the triazolopyrimidines, these imidazoles are found to promote MT polymerization in cell-free assays and exhibit relatively potent and broad-spectrum fungicidal activity.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Furthermore, considering that these tricyclic compounds exhibit structural similarities with known NSAIDs, they may be considered as possible starting points in the development of small molecules that could concurrently stabilize MTs and lower eicosanoid production. Given that MT dynamics are believed to be affected in AD and other neurodegenerative disorders,<a onclick="showRef(event, 'ref24 ref59'); return false;" href="javascript:void(0);" class="ref ref24 ref59">(24, 59)</a> and considering the involvement of both COX- and 5-LOX derived eicosanoids in AD and likely other neurodegenerative diseases, a normalization of axonal MT dynamics, combined with a suppression of eicosanoid production, may provide a potential multitargeted strategy to mitigate concurrent disease mechanisms in AD and other neurodegenerative conditions.</div><div class="NLM_p">Our multitargeted structure–activity relationship (SAR) studies began with the observation that selected examples from the previously reported fungicidal imidazoles,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> such as <b>2</b>, exhibit evidence of activity both as MT-stabilizing agents and inhibitors of eicosanoid biosynthesis in vitro, suggesting a potentially significant overlap between the pharmacophore of these MT-stabilizing imidazoles and that of NSAIDs such as <b>3</b> (COX-1 inhibitor<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a>). On the basis of these initial findings, and taking into consideration prior SAR studies<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> that defined a set of preferred substitutions on the imidazole ring that are generally important for fungicidal activity, and thus presumably for MT-stabilizing activity, we focused on evaluating whether changes in the substitution patterns of 1,5-diarylimidazoles may result in compounds with improved and balanced multitargeted activities. In particular, given that optimal broad-spectrum fungicidal activity is typically achieved with tetrasubstituted imidazoles (e.g., <b>2</b>) and other related congeners that comprise a 4-chlorophenyl group at N1, a chlorine atom in position 4, and a di- or trifluorinated phenyl group in position 5, we focused primarily on evaluating (a) mono- and disubstitutions in the A ring, (b) chloro- and/or alkyl-substitutions in positions 2 and/or 4 of the imidazole ring, and (c) the effect of varying the degree and pattern of fluorination in the B ring. As shown in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>, these studies demonstrated that relatively small changes in the substitution pattern of 1,5-diarylimidazoles can have profound effect in the activity profile of these molecules and ultimately led to the identification of several compounds with MT-stabilizing activity and inhibitory activity against the COX and/or 5-LOX pathways (see <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). Furthermore, with respect to the MT-stabilizing activity, our studies suggest that like the triazolopyrimidines, MT-stabilizing 1,5-diarylimidazoles are likely to affect MT structures in different ways depending on the particular substitution pattern. In the case of triazolopyrimidines, it was suggested that congeners bearing an alkoxy side chain in the fluorinated phenyl ring (e.g., <b>108</b>) typically produce an unusual cellular phenotype that is characterized by a bell-shaped concentration–response relationship in the AcTub assay and proteasome-dependent degradation of α- and β-tubulin.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Interestingly, a similar type of observation is seen with the 1,5-diarylimidazoles, as all MT-active compounds bearing an alkoxy substituent in ring B (i.e., <b>2</b>, <b>58</b>, <b>95</b>–<b>97</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) produce a loss in α-tubulin at compound concentrations that are required to observe an increase in AcTub. However, our results with the 1,5-diarylimidazoles clearly suggest that the substitution pattern of ring B may not be the only determining factor in whether α-tubulin is affected, as other substitutions in the A and C ring appear to play a role (e.g., compare <b>29</b> with <b>30</b>, and <b>54</b> with <b>73</b>, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). As was noted for the triazolopyrimidines,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> compounds found to cause a reduction in total tubulin may not be desirable for neurodegenerative diseases as this effect would be expected to ultimately compromise rather than restore axonal MT function. Conversely, certain multitargeted congeners, including examples listed in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> that do not appear to reduce total α-tubulin levels at concentrations that increase AcTub, may be more promising candidates for tauopathy treatment. Further studies, however, will be necessary to confirm that these compounds can produce beneficial effects in an animal model of tau pathology, as observed previously with MT-stabilizing natural products like paclitaxel,<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> epothilone D, and dictyostatin.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a></div><div class="NLM_p last">With respect to the ability of these compounds to act as inhibitors of the COX and/or 5-LOX pathways, although the IC<sub>50</sub> values in the COX biosynthetic pathway assay are much higher than the IC<sub>50</sub> of COX inhibitor <b>3</b> (i.e., ∼1 nM), the activity level displayed by these molecules is closely comparable to that of the over-the-counter drug, ibuprofen (<b>105</b>; <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Unlike <b>105</b> or <b>3</b>, however, these multitargeted 1,5-diarylimidazoles (e.g., <b>79</b>, see <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> and <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>) exhibit inhibition activity against the leukotriene biosynthetic pathway, while other derivatives (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) are also capable of affecting MT stability in vitro, with several examples (e.g., <b>68</b>, <b>70</b>, <b>87</b>) exhibiting relatively balanced multitargeted activity. Moreover, an evaluation of the brain penetration of these molecules revealed that these multitargeted prototypes are generally capable of reaching significant brain concentrations after peripheral administration, suggesting that compounds of this type may be appropriate for further evaluation in the context of CNS diseases. Taken together, these results indicate that these 1,5-diarylimidazoles comprise a promising scaffold for the evaluation of CNS-directed multitargeted strategies that either focus on a concurrent inhibition of COX and 5-LOX biosynthetic pathways or on a combined stabilization of MTs and inhibition of eicosanoid production.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i12">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63160" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63160" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from a series of 1,5-diarylimidazoles with reported MT-stabilizing activity and structural similarities with known NSAIDs, the SAR studies reported here led to the identification of a series of congeners that exhibit balanced low μM in vitro activity as MT-stabilizing agents and/or inhibitors of the COX and 5-LOX pathways. Given that prior preclinical studies demonstrated that MT stabilization in neurons is a promising therapeutic strategy to treat tau-mediated neurodegeneration, combined with the considerable body of evidence implicating eicosanoids in Aβ plaque pathology, the balanced polypharmacology and brain penetration displayed by these compounds suggest that they are promising research tools as well as possible lead structures to investigate multitargeted therapeutic approaches for AD.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Materials and Methods</h3><div class="NLM_p">All solvents were reagent grade. All reagents were purchased from Aldrich or Acros and used as received. Thin layer chromatography (TLC) was performed with 0.25 mm E. Merck precoated silica gel plates. Silica gel column chromatography was performed with silica gel 60 (particle size 0.040–0.062 mm) supplied by Silicycle and Sorbent Technologies. TLC spots were detected by viewing under a UV light. Melting points (mp) were acquired on a Thomas–Hoover apparatus and are uncorrected. Infrared (IR) spectra were recorded on a Jasco model FT/IR-480 Plus spectrometer. Proton (<sup>1</sup>H) and carbon (<sup>13</sup>C) NMR spectra were recorded on a Bruker AMX-500 spectrometer. Chemical shifts were reported relative to solvents. High-resolution mass spectra were measured at the University of Pennsylvania Mass Spectrometry Center on either a VG Micromass 70/70H or VG ZAB-E spectrometer. Single-crystal X-ray structure determinations were performed at the University of Pennsylvania with an Enraf Nonius CAD-4 diffractometer. Analytical reverse-phase (Sunfire C18; 4.6 mm × 50 mm, 5 mL) high-performance liquid chromatography (HPLC) was performed with a Waters binary gradient module 2525 equipped with Waters 2996 PDA and Waters micromass ZQ. All samples were analyzed employing a linear gradient from 10% to 90% of CH<sub>3</sub>CN in water over 8 min and flow rate of 1 mL/min, and unless otherwise stated, the purity level was >95%. Preparative reverse-phase HPLC purifications were performed on a Gilson instrument (i.e., Gilson 333 pumps, a 215 liquid handler, 845Z injection module, and PDA detector) employing Waters SunFire preparative C<sub>18</sub> OBD columns (5 μm 19 mm × 50 mm or 19 mm × 100 mm). Purifications were carried out employing a linear gradient from 10% to 90% of CH<sub>3</sub>CN in water for 15 min with a flow rate of 20 mL/min. Unless otherwise stated, all final compounds were found to be >95% pure as determined by HPLC/MS and NMR.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i15" class="anchor-spacer"></div><h4 class="article-section__title" id="_i15"> General Procedure A for the Synthesis of Imines</h4><div class="NLM_p last">A solution of aniline (1 equiv) and benzaldehyde (1 equiv) in toluene (0.2 M) was heated at 110 °C in a Dean–Stark apparatus for 4 days. The reaction mixture was then cooled and evaporated in vacuo to obtain the title compound, which was used in the next step without further purification.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16"> General Procedure B for the Synthesis of Imines</h4><div class="NLM_p last">To a solution of a primary amine (1 equiv) in anhydrous Et<sub>2</sub>O (0.3 M) in the presence of molecular sieves (4 Å, 1.6 mm pellets, 7 g/mmol) was added an aldehyde (1 equiv) according to the Taguchi’s method. The mixture was heated and stirred at 30 °C for 48 h. Molecular sieves were then removed by filtration, and the solvent was evaporated in vacuo to afford the desired imine in quantitative yields.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17"> General Procedure C for the Synthesis of Imidazoles</h4><div class="NLM_p last">To a solution of imine (1 equiv) in a mixture of DMF (0.26 M) and 1,2-dimethoxyethane (0.32 M) were added toluenesulfonylmethyl isocyanide (1.5 equiv) and anhydrous K<sub>2</sub>CO<sub>3</sub> (2.08 equiv). The reaction mixture was heated for 16 h at 100 °C, then cooled to rt, filtered, and evaporated in vacuo. The resulting material was adsorbed on Celite 545 AW and purified by silica gel column chromatography to obtain the desired compound.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> General Procedure D for the Synthesis of 4-Alkylated Imidazoles</h4><div class="NLM_p last">To a solution of imine (1 equiv) in a mixture of DMF (0.14 M) and 1,2-dimethoxyethane (0.17 M) were added 1-((1-isocyanoethyl)sulfonyl)-4-methylbenzene (1.5 equiv) and anhydrous K<sub>2</sub>CO<sub>3</sub> (2.08 equiv). The reaction mixture was heated for 16 h at 100 °C, then cooled to rt, filtered through a pad of Celite 545 AW, and evaporated in vacuo. The resulting material was purified by silica gel column chromatography to obtain the desired compound.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> General Procedure E for the Mono- and Dichlorination of 1,5-Diarylimidazoles</h4><div class="NLM_p last">To a solution of imidazole (1 equiv) in CHCl<sub>3</sub> (0.16 M) was added <i>N</i>-chlorosuccinimide (1.06 equiv). The reaction mixture was heated at 60 °C for 16 h, then cooled to rt and diluted with EtOAc. The organic layer was washed with brine (×3), dried over MgSO<sub>4</sub>, filtered, and evaporated in vacuo. Purification via silica gel column chromatography furnished the mono- and dichlorinated imidazoles.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> General Procedure F for Alkylation of 1,5-Diarylimidazoles</h4><div class="NLM_p last">To a solution of diisopropylamine (1.5 equiv) in THF (0.3 M) at −20 °C was added <i>n</i>-BuLi (2.5 M in hexanes, 1.5 equiv), and the mixture was stirred for 10 min. A solution of imidazole (1 equiv) in THF (0.15 M) was added, and after stirring for 30 min, methyl iodide or ethyl iodide (3 equiv) was added. The mixture was stirred for 30 min at −20 °C and for 30 min at rt. H<sub>2</sub>O was then added to the reaction mixture. The aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine (×3), dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Purification via silica gel column chromatography furnished the desired alkylated imidazoles.</div></div><div id="sec5_1_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> 4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methoxyphenyl)-2-methyl-1<i>H</i>-imidazole (<b>2</b>)</h4><div class="NLM_p last">To a solution of 4-chloro-1-(4-chlorophenyl)-2-methyl-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.004 g, 0.011 mmol) in THF (0.011 mL) at 0 °C was added a 30% sodium methoxide solution in MeOH (0.007 mL). The reaction mixture was stirred for 19 h at rt, then quenched with an aqueous ammonium chloride solution and extracted with EtOAc (3×). The combined organic layers were dried (MgSO<sub>4</sub>), filtered, and concentrated in vacuo. The crude products were purified by preparative reverse-phase HPLC to obtain the title compound as a white solid (0.004 g, 0.011 mmol, 97% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.40 (d, <i>J</i> = 8.5 Hz, 2H), 7.11 (d, <i>J</i> = 8.5 Hz, 2H), 6.41 (d, <i>J</i> = 9.1 Hz, 2H), 3.78 (s, 3H), 2.41 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.04 (t, <i>J</i> = 14.0 Hz), 161.61 (dd, <i>J</i> = 249.5, 8.9 Hz), 145.57, 136.11, 133.46, 130.11, 129.90, 128.65, 128.38, 127.63, 117.32, 98.38 (d, <i>J</i> = 28.0 Hz), 96.57 (t, <i>J</i> = 20.8 Hz), 56.09, 13.37 ppm. IR (KBr) ν 2962, 2928, 2852, 1646, 1575, 1494, 1448, 1152 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>17</sub>H<sub>13</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 369.0373, found 369.0374.</div></div><div id="sec5_1_6_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(2,4,6-trifluorophenyl)methanimine (<b>5</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloroaniline (0.829 g, 6.50 mmol) and 2,4,6-trifluorobenzaldehyde (1.04 g, 6.50 mmol), the title compound was obtained as a brown solid (1.75 g, 6.49 mmol, 99% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.51 (s, 1H), 7.32 (app d, <i>J</i> = 6.7 Hz, 2H), 7.12 (app d, <i>J</i> = 6.8 Hz, 2H), 6.73 (m, 2H) ppm.</div></div><div id="sec5_1_6_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> (<i>E</i>)-<i>N</i>-(4-Methoxyphenyl)-1-(2,4,6-trifluorophenyl)methanimine (<b>6</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-methoxyaniline (0.370 g, 3.00 mmol) and 2,4,6-trifluorobenzaldehyde (0.480 g, 3.00 mmol), the title compound was obtained as a brown solid (0.814 g, 3.07 mmol, 99% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 7.25–7.22 (m, 2H), 6.97–6.90 (m, 2H), 6.81–6.72 (m, 2H), 3.84 (s, 3H) ppm.</div></div><div id="sec5_1_6_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(2,6-difluoro-3-methylphenyl)methanimine (<b>7</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-aniline (0.383 g, 3 mmol) and 2,6-difluoro-3-methylbenzaldehyde (0.377 mL, 3 mmol), the title compound was obtained as a brown solid (0.781 g, 2.94 mmol, 98% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.63 (s, 1H), 7.36 (app d, <i>J</i> = 8.2 Hz, 2H), 7.25 (app q, <i>J</i> = 7.6 Hz, 1H), 7.17 (app d, <i>J</i> = 8.0 Hz, 2H), 6.89 (app t, <i>J</i> = 9.2 Hz, 1H), 2.28 (s, 3H) ppm.</div></div><div id="sec5_1_6_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (<i>E</i>)-1-(3-Chloro-2,6-difluorophenyl)-<i>N</i>-(4-chlorophenyl)methanimine (<b>8</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-aniline (0.383 g, 3 mmol) and 3-chloro-2,6-difluorobenzaldehyde (0.530 g, 3 mmol), the title compound was obtained as a brown solid (0.850 g, 2.97 mmol, 99% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.60 (s, 1H), 7.47 (td, <i>J</i> = 8.4, 5.5 Hz, 1H), 7.37 (app d, <i>J</i> = 8.5 Hz, 2H), 7.17 (app d, <i>J</i> = 8.5 Hz, 2H), 7.00–6.96 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 159.87 (dd, <i>J</i> = 390.8, 5.6 Hz), 157.80 (dd, <i>J</i> = 393.2, 5.6 Hz), 150.87, 150.42, 132.72 (d, <i>J</i> = 10.3 Hz), 132.65, 129.47, 122.29, 117.77 (dd, <i>J</i> = 18.0, 3.9 Hz), 115.03 (t, <i>J</i> = 12.9 Hz), 112.80 (dd, <i>J</i> = 23.0, 4.4 Hz) ppm.</div></div><div id="sec5_1_6_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>E</i>)-1-(3-Bromo-2,6-difluorophenyl)-<i>N</i>-(4-chlorophenyl)methanimine (<b>9</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-aniline (0.383 g, 3 mmol) and 3-bromo-2,6-difluorobenzaldehyde (0.663 g, 3 mmol), the title compound was obtained as a brown solid (0.971 g, 2.94 mmol, 98% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 7.61 (dd, <i>J</i> = 14.2, 7.6 Hz, 1H), 7.36 (app d, <i>J</i> = 8.5 Hz, 2H), 7.17 (app d, <i>J</i> = 8.4 Hz, 2H), 6.93 (t, <i>J</i> = 9.2 Hz, 1H) ppm.</div></div><div id="sec5_1_6_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (<b>10</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-aniline (0.383 g, 3 mmol) and 2,3,6-trifluorobenzaldehyde (0.337 mL, 3 mmol), the title compound was obtained as a brown solid (0.778 g, 2.88 mmol, 96% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.58 (s, 1H), 7.34 (app d, <i>J</i> = 8.3 Hz, 2H), 7.26–7.20 (m, 1H), 7.16 (app d, <i>J</i> = 8.2 Hz, 2H), 6.92 (app t, <i>J</i> = 9.0 Hz, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.28, 156.26, 150.76, 150.19, 148.36–148.23 (m), 146.34 (dd, <i>J</i> = 12.5, 3.6 Hz), 132.51, 129.30, 122.18, 119.33 (dd, <i>J</i> = 19.4, 10.4 Hz), 115.07 (dd, <i>J</i> = 14.2, 9.0 Hz), 111.42 (dt, <i>J</i> = 24.4, 5.3 Hz) ppm.</div></div><div id="sec5_1_6_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (<i>E</i>)-<i>N</i>-(4-Chloro-3-fluorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (<b>11</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-3-fluoroaniline (0.437 g, 3 mmol) and 2,3,6-trifluorobenzaldehyde (0.337 mL, 3 mmol), the title compound was obtained as a brown solid (0.846 g, 2.94 mmol, 98% yield).</div></div><div id="sec5_1_6_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> (<i>E</i>)-<i>N</i>-(6-Chloropyridin-3-yl)-1-(2,4,6-trifluorophenyl)methanimine (<b>12</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 6-chloropyridin-3-amine (0.385 g, 3 mmol) and 2,4,6-trifluorobenzaldehyde (0.480 g, 3 mmol), the title compound was obtained as a brown solid (0.786 g, 2.90 mmol, 97% yield).</div></div><div id="sec5_1_6_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(4-fluorophenyl)methanimine (<b>13</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-aniline (0.383 g, 3 mmol) and 4-fluorobenzaldehyde (0.322 mL, 3 mmol), the title compound was obtained as a brown solid (0.687 g, 2.94 mmol, 98% yield).</div></div><div id="sec5_1_6_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> (<i>E</i>)-<i>N</i>-(4-Chloro-2-fluorophenyl)-1-(2,6-difluorophenyl)methanimine (<b>14</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-2-fluoroaniline (0.437 g, 3 mmol) and 2,6-difluorobenzaldehyde (0.426 g, 3 mmol), the title compound was obtained as a brown solid (0.768 g, 2.85 mmol, 95% yield).</div></div><div id="sec5_1_6_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(2,5-difluorophenyl)methanimine (<b>15</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloro-aniline (0.383 g, 3 mmol) and 2,5-difluorobenzaldehyde (0.326 mL, 3 mmol), the title compound was obtained as a brown solid (0.698 g, 2.77 mmol, 93% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 1H), 7.84 (dt, <i>J</i> = 7.6, 4.2 Hz, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 7.17 (d, <i>J</i> = 8.4 Hz, 2H), 7.14–7.06 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 159.88, 157.92 (dd, <i>J</i> = 7.7, 1.9 Hz), 152.39 (d, <i>J</i> = 1.2 Hz), 149.67, 132.37, 131.65 (d, <i>J</i> = 16.8 Hz), 129.36, 129.11 (dd, <i>J</i> = 51.2, 13.4 Hz), 125.04 (dd, <i>J</i> = 11.3, 7.8 Hz), 122.40 (d, <i>J</i> = 19.7 Hz), 119.85 (dd, <i>J</i> = 24.9, 9.0 Hz), 117.27 (dd, <i>J</i> = 24.0, 8.3 Hz), 113.64 (dd, <i>J</i> = 25.1, 2.9 Hz) ppm.</div></div><div id="sec5_1_6_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (<i>E</i>)-1-(2,6-Difluorophenyl)-<i>N</i>-(4-(trifluoromethoxy)phenyl)methanimine (<b>16</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-(trifluoromethoxy)aniline (0.531 g, 3.00 mmol) and 2,6-difluorobenzaldehyde (0.426 g, 3.00 mmol), the title compound was obtained as a brown liquid (1.034 g, 3.43 mmol, 99% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.65 (s, 1H), 7.46–7.39 (m, 1H), 7.26–7.22 (m, 4H), 7.01 (t, <i>J</i> = 8.6 Hz, 2H) ppm.</div></div><div id="sec5_1_6_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(2,6-difluorophenyl)methanimine (<b>17</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloroaniline (0.829 g, 6.50 mmol) and 2,6-difluorobenzaldehyde (0.924 g, 6.50 mmol), the title compound was obtained as a brown liquid (1.62 g, 6.45 mmol, 99% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.64 (s, 1H), 7.46–7.40 (m, 1H), 7.40–7.34 (m, 2H), 7.20–7.14 (m, 2H), 7.04–6.96 (m, 2H) ppm.</div></div><div id="sec5_1_6_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> (<i>E</i>)-<i>N</i>-(4-(Trifluoromethoxy)phenyl)-1-(2,3,6-trifluorophenyl)methanimine (<b>18</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-(trifluoromethoxy)aniline (0.531 g, 3.00 mmol) and 2,3,6-trifluorobenzaldehyde (0.480 g, 3.00 mmol), the title compound was obtained as a brown solid (1.08 g, 3.47 mmol, 99% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.45–7.25 (m, 2H), 7.27–7.22 (m, 2H), 7.20–7.11 (m, 1H), 7.02–6.93 (m, 1H) ppm.</div></div><div id="sec5_1_6_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(2,6-difluoro-4-methylphenyl)methanimine (<b>19</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloroaniline (0.157 g, 1.23 mmol) and 2,6-difluoro-4-methylbenzaldehyde (0.192 g, 3 mmol), the title compound was obtained as a brown solid (0.183 g, 0.69 mmol, 56% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.59 (s, 1H), 7.36 (d, <i>J</i> = 8.2 Hz, 2H), 7.15 (d, <i>J</i> = 8.2 Hz, 2H), 6.82 (d, <i>J</i> = 10.1 Hz, 2H), 2.40 (s, 3H) ppm.</div></div><div id="sec5_1_6_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(2,6-difluoro-3-methoxyphenyl)methanimine (<b>20</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloroaniline (0.383 g, 3.00 mmol) and 2,6-difluoro-3-methoxybenzaldehyde (0.468 g, 3.00 mmol), the title compound was obtained as a brown solid (0.745 g, 2.64 mmol, 88% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.63 (s, 1H), 7.39–7.32 (m, 2H), 7.20–7.11 (m, 2H), 7.07–6.98 (m, 1H), 6.96–6.87 (m, 1H), 3.90 (s, 3H) ppm.</div></div><div id="sec5_1_6_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-phenylmethanimine (<b>21</b>)</h4><div class="NLM_p last">Following synthetic procedure A using 4-chloroaniline (0.383 g, 3.00 mmol) and benzaldehyde (0.318 g, 3.00 mmol), the title compound was obtained as a brown solid (0.702 g, 3.25 mmol, 99% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.44 (s, 1H), 7.96–7.87 (m, 2H), 7.57–7.45 (m, 3H), 7.36 (d, <i>J</i> = 8.3 Hz, 2H), 7.16 (d, <i>J</i> = 8.3 Hz, 2H) ppm.</div></div><div id="sec5_1_6_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (<i>E</i>)-<i>N</i>-(4-Chlorophenyl)-1-(4-methoxyphenyl)methanimine (<b>22</b>)</h4><div class="NLM_p last">Following synthetic procedure B using 4-chloroaniline (0.765 g, 6.00 mmol) and 4-methoxybenzaldehyde (0.817 g, 6.00 mmol), the title compound was obtained as a yellow solid (1.370 g, 5.58 mmol, 93% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.35 (s, 1H), 7.84 (d, <i>J</i> = 8.4 Hz, 2H), 7.37–7.31 (m, 2H), 7.13 (d, <i>J</i> = 8.5 Hz, 2H), 6.98 (d, <i>J</i> = 8.4 Hz, 2H), 3.87 (s, 3H) ppm.</div></div><div id="sec5_1_6_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (<i>E</i>)-1-(2,6-Difluorophenyl)-<i>N</i>-phenylmethanimine (<b>23</b>)</h4><div class="NLM_p last">Following synthetic procedure B using aniline (0.559 g, 6.00 mmol) and 2,6-difluorobenzaldehyde (0.853 g, 6.00 mmol), the title compound was obtained as a yellow liquid (0.637 g, 2.93 mmol, 49% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.65 (s, 1H), 7.44–7.34 (m, 3H), 7.26–7.19 (m, 3H), 7.02–6.95 (m, 2H) ppm.</div></div><div id="sec5_1_6_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (<i>E</i>)-<i>N</i>-(2-Chlorophenyl)-1-(2,6-difluorophenyl)methanimine (<b>24</b>)</h4><div class="NLM_p last">Following synthetic procedure B using 2-chloroaniline (0.765 g, 6.00 mmol) and 2,6-difluorobenzaldehyde (0.853 g, 6.00 mmol), the title compound was obtained as a yellow liquid (1.41 g, 5.58 mmol, 93% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.62 (s, 1H), 7.49–7.39 (m, 2H), 7.32–7.27 (m, 1H), 7.20–7.14 (m, 1H), 7.06–6.98 (m, 3H) ppm.</div></div><div id="sec5_1_6_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 1-(4-Chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>25</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,4,6-trifluorophenyl)methanimine (0.865 g, 3.21 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a white powder (0.429 g, 1.39 mmol, 43% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.39–7.36 (m, 2H), 7.35 (s, 1H), 7.13–7.10 (m, 2H), 6.71–6.65 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.14 (dt, <i>J</i> = 252.4, 15.3 Hz), 160.75 (ddd, <i>J</i> = 251.5, 14.9, 8.7 Hz), 138.95, 134.96, 134.41, 132.41, 129.76, 125.94, 119.16, 103.78 (td, <i>J</i> = 20.0, 4.6 Hz), 100.97–100.52 (m) ppm. IR (KBr) ν 3114, 3095, 3043, 2922, 1692, 1644, 1600, 1562, 1466, 1438, 1322, 1130 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>ClF<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 309.0401, found 309.0339.</div></div><div id="sec5_1_6_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 1-(4-Methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>26</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-methoxyphenyl)-1-(2,4,6-trifluorophenyl)methanimine (0.814 g, 3.07 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as an orange solid (0.065 g, 0.214 mmol, 7% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.76 (s, 1H), 7.25 (s, 1H), 7.09–7.04 (m, 2H), 6.88–6.83 (m, 2H), 6.66–6.59 (m, 2H), 3.79 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.05 (dt, <i>J</i> = 251.4, 15.1 Hz), 160.93 (ddd, <i>J</i> = 251.1, 14.8, 8.6 Hz), 159.50, 139.30, 131.76, 129.27, 126.21, 119.50, 114.58, 104.15 (td, <i>J</i> = 20.4, 4.9 Hz), 101.30–99.76 (m), 55.61 ppm. IR (KBr) ν 3102, 3008, 2935, 2840, 1689, 1644, 1599, 1564, 1515, 1489, 1465, 1439, 1301, 1250, 1172, 1123, 1033 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>12</sub>F<sub>3</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 309.0902, found 309.0908.</div></div><div id="sec5_1_6_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-(4-Chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1<i>H</i>-imidazole (<b>27</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,6-difluoro-3-methylphenyl)methanimine (0.399 g, 1.5 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20 to 20:80) afforded the title compound as a yellow solid (0.327 g, 1.07 mmol, 72% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.81 (s, 1H), 7.31 (t, <i>J</i> = 7.6 Hz, 3H), 7.15–7.08 (m, <i>J</i> = 15.1, 7.5 Hz, 3H), 6.75 (t, <i>J</i> = 8.6 Hz, 1H), 2.18 (s, 3H) ppm. MS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>ClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 305.07, found 305.03.</div></div><div id="sec5_1_6_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (<b>28</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-1-(3-chloro-2,6-difluorophenyl)-<i>N</i>-(4-chlorophenyl)methanimine (0.429 g, 1.5 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a white solid (0.298 g, 0.916 mmol, 61% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.77 (d, <i>J</i> = 0.5 Hz, 1H), 7.32–7.27 (m, 4H), 7.06–7.04 (m, 2H), 6.78 (td, <i>J</i> = 8.7, 1.4 Hz, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.27 (dd, <i>J</i> = 251.2, 4.4 Hz), 155.38 (dd, <i>J</i> = 252.0, 6.3 Hz), 138.97, 134.65, 134.11, 132.45, 130.90, 130.83, 129.57, 125.53, 119.00, 116.96 (dd, <i>J</i> = 18.6, 4.2 Hz), 112.05 (dd, <i>J</i> = 23.5, 4.1 Hz), 108.51 (t, <i>J</i> = 20.1 Hz) ppm. MS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 325.01, found 324.93.</div></div><div id="sec5_1_6_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> 5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1<i>H</i>-imidazole (<b>29</b>)</h4><div class="NLM_p last">Following synthetic procedure D using (<i>E</i>)-1-(3-chloro-2,6-difluorophenyl)-<i>N</i>-(4-chlorophenyl)methanimine (0.800 g, 2.80 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as an orange solid (0.433 g, 1.28 mmol, 46% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.37 (ddd, <i>J</i> = 9.0, 8.0, 5.6 Hz, 1H), 7.34–7.27 (m, 2H), 7.08–7.01 (m, 2H), 6.84 (ddd, <i>J</i> = 9.0, 8.2, 1.8 Hz, 1H), 2.20 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.82 (dd, <i>J</i> = 250.6, 4.6 Hz), 155.87 (dd, <i>J</i> = 251.8, 6.6 Hz), 140.71, 138.02, 135.11, 134.20, 131.25 (d, <i>J</i> = 9.6 Hz), 129.79, 125.77, 117.22 (dd, <i>J</i> = 18.7, 4.2 Hz), 115.41, 112.29 (dd, <i>J</i> = 23.6, 4.3 Hz), 109.12 (t, <i>J</i> = 20.3 Hz), 13.48 ppm. IR (KBr) ν 3077, 3036, 2960, 2925, 1625, 1568, 1498, 1477, 1453, 1352, 1282, 1269, 1218, 1091, 1003 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 339.0267, found 339.0273.</div></div><div id="sec5_1_6_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 2-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1<i>H</i>-imidazole (<b>30</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1<i>H</i>-imidazole (0.150 g, 0.442 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a white solid (0.071 g, 0.190 mmol, 43% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.39–7.31 (m, 3H), 7.14–7.06 (m, 2H), 6.86–6.75 (m, 1H), 2.17 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.94 (dd, <i>J</i> = 250.9, 4.3 Hz), 156.02 (dd, <i>J</i> = 252.1, 6.2 Hz), 139.23, 135.37, 133.53 (d, <i>J</i> = 11.2 Hz), 131.74 (d, <i>J</i> = 9.8 Hz), 129.85, 129.61, 128.57, 117.71, 117.16 (dd, <i>J</i> = 18.3, 3.5 Hz), 112.23 (dd, <i>J</i> = 23.6, 4.3 Hz), 108.57 (t, <i>J</i> = 20.1 Hz), 13.43 ppm. IR (KBr) ν 3074, 2924, 2848, 1627, 1572, 1494, 1474, 1455, 1388, 1283, 1218, 1092, 1007 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 372.9878, found 372.9874.</div></div><div id="sec5_1_6_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> 5-(3-Chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-2,4-dimethyl-1<i>H</i>-imidazole (<b>31</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-4-methyl-1<i>H</i>-imidazole (0.050 g, 0.147 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as a orange solid (0.029 g, 0.082 mmol, 56% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.34–7.29 (m, 2H), 7.31–7.26 (m, 1H), 7.03 (d, <i>J</i> = 8.4 Hz, 2H), 6.82–6.74 (m, 1H), 2.29 (s, 3H), 2.14 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.99 (dd, <i>J</i> = 249.9, 4.9 Hz), 156.01 (dd, <i>J</i> = 251.2, 6.6 Hz), 146.28, 138.04, 135.07, 134.66, 130.99 (d, <i>J</i> = 9.7 Hz), 129.62, 128.34, 116.96 (dd, <i>J</i> = 19.0, 3.9 Hz), 115.69, 112.05 (dd, <i>J</i> = 23.9, 4.3 Hz), 109.60 (t, <i>J</i> = 20.7 Hz), 14.04, 13.13 ppm. IR (KBr) ν 3052, 2962, 2922, 2849, 1693, 1629, 1593, 1571, 1495, 1474, 1402, 1266, 1218, 1092, 1004 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>17</sub>H<sub>13</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 353.0424, found 353.0413.</div></div><div id="sec5_1_6_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> 5-(3-Bromo-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (<b>32</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-1-(3-bromo-2,6-difluorophenyl)-<i>N</i>-(4-chlorophenyl)methanimine (0.495 g, 1.5 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a yellow solid (0.450 g, 1.22 mmol, 82% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.83 (s, 1H), 7.53 (ddd, <i>J</i> = 8.8, 7.7, 5.8 Hz, 1H), 7.37–7.34 (m, 3H), 7.12–7.11 (m, 2H), 6.82 (td, <i>J</i> = 8.7, 1.4 Hz, 1H) ppm. MS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>BrClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 368.96, found 368.98.</div></div><div id="sec5_1_6_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> 1-(4-Chlorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>33</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (0.405 g, 1.5 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a brown solid (0.350 g, 1.13 mmol, 76% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.80 (s, 1H), 7.34–7.31 (m, 3H), 7.15–7.11 (m, <i>J</i> = 9.0, 5.0 Hz, 1H), 7.09 (d, <i>J</i> = 8.6 Hz, 2H), 6.82–6.78 (m, 1H) ppm. MS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>ClF<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 309.04, found 309.18.</div></div><div id="sec5_1_6_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> 1-(4-Chlorophenyl)-2-methyl-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>34</b>)</h4><div class="NLM_p last">To a solution of diisopropylamine (0.02 mL, 0.146 mmol, 1.5 equiv) in THF (0.3 M) at −20 °C was added <i>n</i>-BuLi (2.5 M in hexanes, 0.06 mL, 0.146 mmol, 1.5 equiv), and the mixture was stirred for 10 min. A solution of 1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.030 g, 0.097 mmol, 1 equiv) in THF (1 mL) was added, and after stirring for 30 min, methyl iodide (0.009 mL, 0.146 mmol, 1.5 equiv) was added. The mixture was stirred for 30 min at −20 °C and for 30 min at rt. H<sub>2</sub>O was added to the reaction mixture, the aqueous phase was extracted with EtOAc, and the combined organic layers were washed with brine (×3), dried over MgSO<sub>4</sub>, filtered, and concentrated. The mixture was purified by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as a yellow solid (0.009 g, 0.028 mmol, 29% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.38–7.33 (m, 2H), 7.19 (s, 1H), 7.11–7.04 (m, 3H), 6.78–6.73 (m, 1H), 2.34 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.73 (dt, <i>J</i> = 246.7, 3.2 Hz), 148.24 (ddd, <i>J</i> = 251.2, 14.2, 6.5 Hz), 147.45, 147.13 (ddd, <i>J</i> = 245.9, 13.2, 3.6 Hz), 134.95, 134.80, 130.14, 129.73, 128.32, 125.88, 119.63, 117.77–117.37 (m), 110.88 (ddd, <i>J</i> = 24.7, 6.9, 4.3 Hz), 109.67 (dd, <i>J</i> = 21.8, 16.1 Hz), 14.24 ppm. IR (KBr) ν 3098, 3061, 2961, 2924, 2850, 1641, 1494, 1402, 1237, 1093 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>F<sub>3</sub>N<sub>2</sub>Cl [M + H]<sup>+</sup> 323.0563, found 323.0568.</div></div><div id="sec5_1_6_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> 1-(4-Chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>35</b>)</h4><div class="NLM_p last">Following synthetic procedure D using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (0.500 g, 1.85 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as an orange solid (0.190 g, 0.589 mmol, 32% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.33–7.29 (m, 2H), 7.15 (qd, <i>J</i> = 9.1, 5.0 Hz, 1H), 7.07–7.02 (m, 2H), 6.85–6.79 (m, 1H), 2.22 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.69 (dt, <i>J</i> = 247.2, 3.4 Hz), 148.15 (ddd, <i>J</i> = 252.2, 14.3, 6.4 Hz), 147.28 (ddd, <i>J</i> = 246.6, 12.8, 4.1 Hz), 140.74, 138.07, 135.11, 134.20, 129.79, 125.77, 117.83 (dd, <i>J</i> = 19.4, 9.7 Hz), 115.33 (d, <i>J</i> = 2.3 Hz), 111.14 (ddd, <i>J</i> = 24.4, 6.9, 4.2 Hz), 109.45 (dd, <i>J</i> = 22.0, 16.2 Hz), 13.48 ppm. IR (KBr) ν 3094, 2925, 1642, 1595, 1500, 1472, 1353, 1269, 1250, 1231, 1092, 1002, 973 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>ClF<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 323.0563, found 323.0557.</div></div><div id="sec5_1_6_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> 2-Chloro-1-(4-chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>36</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-4-methyl-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.100 g, 0.310 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a white solid (0.079 g, 0.221 mmol, 71% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.36–7.31 (m, 2H), 7.17–7.07 (m, 3H), 6.82–6.76 (m, 1H), 2.17 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.82 (dt, <i>J</i> = 247.3, 2.9 Hz), 148.29 (ddd, <i>J</i> = 251.9, 14.1, 7.0 Hz), 147.12 (ddd, <i>J</i> = 246.7, 13.0, 3.9 Hz), 139.27, 135.37, 133.55 (d, <i>J</i> = 5.2 Hz), 129.85, 129.60, 128.57, 118.34 (dd, <i>J</i> = 19.3, 9.9 Hz), 117.60 (d, <i>J</i> = 2.3 Hz), 111.11 (ddd, <i>J</i> = 24.7, 6.9, 4.4 Hz), 108.90 (dd, <i>J</i> = 22.0, 16.2 Hz), 13.44 ppm. IR (KBr) ν 3052, 2983, 2918, 2849, 1494, 1448, 1265, 1236, 1092, 1001 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 357.0173, found 357.0170.</div></div><div id="sec5_1_6_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 1-(4-Chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>37</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chloro-3-fluorophenyl)-1-(2,3,6-trifluorophenyl)methanimine (0.431 g, 1.5 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 50:50) afforded the title compound as an orange solid (0.385 g, 1.18 mmol, 79% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.77 (s, 1H), 7.34 (t, <i>J</i> = 8.2 Hz, 1H), 7.27 (s, 1H), 7.09 (qd, <i>J</i> = 9.1, 5.0 Hz, 1H), 6.95 (dd, <i>J</i> = 9.1, 2.4 Hz, 1H), 6.87 (dd, <i>J</i> = 8.5, 1.0 Hz, 1H), 6.80–6.75 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.92, 156.92, 155.23 (dt, <i>J</i> = 247.6, 2.8 Hz), 147.79 (ddd, <i>J</i> = 252.4, 14.5, 6.4 Hz), 147.14 (ddd, <i>J</i> = 246.3, 13.0, 3.6 Hz), 139.06, 135.89 (d, <i>J</i> = 8.8 Hz), 132.81, 131.35, 121.36, 121.22, 120.81 (d, <i>J</i> = 3.8 Hz), 119.00 (d, <i>J</i> = 1.6 Hz), 117.76 (dd, <i>J</i> = 19.6, 9.6 Hz), 113.15, 112.96, 111.14 (dt, <i>J</i> = 24.5, 5.4 Hz), 108.61 (dd, <i>J</i> = 21.6, 15.7 Hz) ppm. MS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>ClF<sub>4</sub>N<sub>2</sub> [M + H]<sup>+</sup> 327.03, found 327.14.</div></div><div id="sec5_1_6_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 2-Chloro-5-(5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazol-1-yl)pyridine (<b>38</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(6-chloropyridin-3-yl)-1-(2,4,6-trifluorophenyl)methanimine (0.593 g, 2.2 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as an orange solid (0.304 g, 0.982 mmol, 45% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.21 (s, 1H), 7.78 (s, 1H), 7.45 (ddd, <i>J</i> = 8.4, 2.5, 1.2 Hz, 1H), 7.35–7.33 (m, 1H), 7.28 (s, 1H), 6.66–6.63 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.30 (dt, <i>J</i> = 253.2, 15.2 Hz), 160.50 (ddd, <i>J</i> = 251.6, 14.8, 8.5 Hz), 151.19, 145.34, 138.80, 134.72, 132.82, 132.10, 124.96, 119.28, 102.94 (td, <i>J</i> = 19.9, 4.7 Hz), 101.23–100.79 (m) ppm. MS (ES<sup>+</sup>) calculated for C<sub>14</sub>H<sub>8</sub>ClF<sub>3</sub>N<sub>3</sub> [M + H]<sup>+</sup> 310.04, found 310.13.</div></div><div id="sec5_1_6_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> 1-(4-Chlorophenyl)-5-(4-fluorophenyl)-1<i>H</i>-imidazole (<b>39</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(4-fluorophenyl)methanimine (0.350 g, 1.5 mmol), purification by silica gel column chromatography (hexanes/EtOAc 90:10 to 60:40) afforded the title compound as a brown solid (0.260 g, 0.953 mmol, 64% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.39–7.36 (m, 2H), 7.22 (s, 1H), 7.12–7.08 (m, 4H), 7.00–6.96 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 162.48 (d, <i>J</i> = 248.1 Hz), 138.79, 135.13, 134.36, 132.22, 130.18 (d, <i>J</i> = 8.2 Hz), 129.92, 129.20, 126.92, 125.39 (d, <i>J</i> = 3.2 Hz), 115.85 (d, <i>J</i> = 21.8 Hz) ppm. MS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>11</sub>ClFN<sub>2</sub> [M + H]<sup>+</sup> 273.06, found 273.25.</div></div><div id="sec5_1_6_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> 1-(4-Chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>40</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chloro-2-fluorophenyl)-1-(2,6-difluorophenyl)methanimine (0.539 g, 2 mmol), purification by silica gel column chromatography (hexanes/EtOAc 90:10 to 60:40) afforded the title compound as a yellow solid (0.351 g, 1.14 mmol, 57% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.77 (s, 1H), 7.35 (s, 1H), 7.31–7.27 (m, 1H), 7.21–7.19 (m, 1H), 7.15–7.10 (m, <i>J</i> = 6.6 Hz, 2H), 6.88 (quintet, <i>J</i> = 6.8 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.46 (dd, <i>J</i> = 250.9, 5.9 Hz), 156.39 (d, <i>J</i> = 256.0 Hz), 139.44 (d, <i>J</i> = 1.1 Hz), 135.42 (d, <i>J</i> = 9.2 Hz), 131.92, 130.94 (t, <i>J</i> = 10.3 Hz), 128.57, 125.17, 125.14, 123.30 (d, <i>J</i> = 12.7 Hz), 120.88, 117.86, 117.67, 111.71 (dd, <i>J</i> = 20.5, 5.2 Hz), 106.96 (t, <i>J</i> = 19.5 Hz) ppm. MS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>ClF<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 309.04, found 309.12.</div></div><div id="sec5_1_6_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> 1-(4-Chlorophenyl)-5-(2,5-difluorophenyl)-1<i>H</i>-imidazole (<b>41</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,5-difluorophenyl)methanimine (0.378 g, 1.5 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a yellow solid (0.392 g, 1.35 mmol, 90% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.29 (s, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.07 (m, 2H), 6.86–6.83 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.35 (dd, <i>J</i> = 248.6, 7.2 Hz), 155.45 (d, <i>J</i> = 244.1 Hz), 139.09, 135.05, 134.29, 131.29, 129.80, 126.02, 118.66 (dd, <i>J</i> = 17.7, 8.8 Hz), 117.30 (dd, <i>J</i> = 24.8, 3.1 Hz), 117.18 (dd, <i>J</i> = 24.8, 8.9 Hz), 116.56 (dd, <i>J</i> = 23.8, 8.3 Hz) ppm. MS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>10</sub>ClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 291.05, found 291.04.</div></div><div id="sec5_1_6_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> 5-(2,6-Difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-imidazole (<b>42</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-1-(2,6-difluorophenyl)-<i>N</i>-(4-(trifluoromethoxy)phenyl)methanimine (1.03 g, 3.43 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as a white solid (0.644 g, 1.89 mmol, 55% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.20 (s, 1H), 7.54–7.47 (m, 1H), 7.45 (d, <i>J</i> = 8.5 Hz, 2H), 7.35 (d, <i>J</i> = 8.5 Hz, 2H), 7.32 (s, 1H), 7.15 (t, <i>J</i> = 8.2 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 159.54 (dd, <i>J</i> = 248.4, 6.0 Hz), 147.54–147.48 (m), 139.64, 135.08, 131.88, 131.76 (t, <i>J</i> = 5.2 Hz), 126.09, 122.12, 119.91 (q, <i>J</i> = 256.9 Hz), 118.93, 111.98 (dd, <i>J</i> = 20.4, 5.1 Hz), 106.56 (t, <i>J</i> = 19.7 Hz) ppm. IR (KBr) ν 3059, 2917, 2849, 1632, 1580, 1562, 1514, 1472, 1448, 1262, 1212, 1169 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>F<sub>5</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 341.0713, found 341.0714.</div></div><div id="sec5_1_6_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>43</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,6-difluorophenyl)methanimine (1.62 g, 6.45 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as a yellow solid (1.18 g, 4.04 mmol, 63% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.86 (s, 1H), 7.60 (s, 1H), 7.49–7.44 (m, 1H), 7.44–7.40 (m, 2H), 7.21–7.17 (m, 2H), 6.99–6.93 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.46 (dd, <i>J</i> = 253.1, 5.2 Hz), 136.99, 136.90, 133.44 (t, <i>J</i> = 10.2 Hz), 132.54, 130.41, 126.30, 123.71, 122.62, 112.21 (dd, <i>J</i> = 20.4, 4.2 Hz), 103.71 (t, <i>J</i> = 19.4 Hz) ppm. IR (KBr) ν 3104, 2919, 2851, 2612, 1987, 1680, 1590, 1536, 1491, 1469, 1414, 1348, 1148 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>10</sub>ClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 291.0501, found 291.0503.</div></div><div id="sec5_1_6_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1<i>H</i>-imidazole (<b>44</b>)</h4><div class="NLM_p last">Following synthetic procedure D using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,6-difluorophenyl)methanimine (0.618 g, 2.46 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as an orange solid (0.292 g, 0.958 mmol, 39% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.36–7.28 (m, 1H), 7.32–7.25 (m, 2H), 7.08–7.01 (m, 2H), 6.93–6.83 (m, 2H), 2.21 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.61 (dd, <i>J</i> = 250.3, 6.3 Hz), 140.19, 137.61, 135.40, 133.91, 131.00 (t, <i>J</i> = 10.2 Hz), 129.63, 125.7, 116.13, 111.74 (dd, <i>J</i> = 20.1, 5.3 Hz), 107.53 (t, <i>J</i> = 20.0 Hz), 13.44 ppm. IR (KBr) ν 3105, 2921, 2851, 1692, 1630, 1590, 1569, 1498, 1479, 1461, 1274, 1235, 1091, 997 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>12</sub>ClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 305.0657, found 305.0661.</div></div><div id="sec5_1_6_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1<i>H</i>-imidazole (<b>45</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1<i>H</i>-imidazole (0.150 g, 0.492 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow oil (0.079 g, 0.232 mmol, 47% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.31 (d, <i>J</i> = 8.6 Hz, 2H), 7.30–7.26 (m, 1H), 7.12–7.07 (m, 2H), 6.88–6.81 (m, 2H), 2.16 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.70 (dd, <i>J</i> = 250.6, 6.0 Hz), 138.71, 135.08, 133.82, 132.88, 131.46 (t, <i>J</i> = 10.2 Hz), 129.41, 128.60, 118.49, 111.65 (dd, <i>J</i> = 20.6, 5.1 Hz), 107.02 (t, <i>J</i> = 19.8 Hz), 13.37 ppm. IR (KBr) ν 3056, 2959, 2923, 2850, 1633, 1590, 1571, 1495, 1467, 1448, 1387, 1280, 1236, 1092, 998 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 339.0267, found 339.0277.</div></div><div id="sec5_1_6_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> 1-(4-Chlorophenyl)-5-(2,6-difluorophenyl)-2,4-dimethyl-1<i>H</i>-imidazole (<b>46</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-4-methyl-1<i>H</i>-imidazole (0.050 g, 0.164 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as a colorless liquid (0.025 g, 0.078 mmol, 48% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.31–7.27 (m, 2H), 7.25–7.18 (m, 1H), 7.06–7.01 (m, 2H), 6.81 (t, <i>J</i> = 7.6 Hz, 2H), 2.29 (s, 3H), 2.14 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.79 (dd, <i>J</i> = 249.7, 6.3 Hz), 145.79, 137.59, 135.43, 134.38, 130.69 (t, <i>J</i> = 10.2 Hz), 129.44, 128.40, 116.41, 111.49 (dd, <i>J</i> = 20.3, 5.3 Hz), 108.12 (t, <i>J</i> = 20.1 Hz), 14.09, 13.12 ppm. IR (KBr) ν 2958, 2923, 2851, 1633, 1594, 1572, 1495, 1464, 1403, 1274, 1235, 1092 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>17</sub>H<sub>14</sub>ClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 319.0814, found 319.0807.</div></div><div id="sec5_1_6_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> 1-(4-(Trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>47</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-(trifluoromethoxy)phenyl)-1-(2,3,6-trifluorophenyl)methanimine (1.08 g, 3.37 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as a brown solid (0.587 g, 1.64 mmol, 49% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.83 (s, 1H), 7.36 (s, 1H), 7.26–7.17 (m, 4H), 7.14 (qd, <i>J</i> = 9.1, 4.9 Hz, 1H), 6.86–6.77 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.51 (dt, <i>J</i> = 247.8, 3.2 Hz), 149.06–148.90 (m), 148.12 (ddd, <i>J</i> = 261.9, 15.9, 9.2 Hz), 147.33 (ddd, <i>J</i> = 246.6, 12.7, 4.1 Hz), 139.36, 134.80, 132.76, 126.15, 122.02, 120.40 (q, <i>J</i> = 258.6 Hz), 119.39, 117.84 (dd, <i>J</i> = 19.1, 9.6 Hz), 111.17 (ddd, <i>J</i> = 24.6, 6.7, 4.2 Hz), 109.03 (dd, <i>J</i> = 21.9, 15.9 Hz) ppm. IR (KBr) ν 3097, 2917, 2850, 1734, 1642, 1599, 1563, 1514, 1494, 1448, 1383, 1260, 1211, 1167, 1103, 1027, 1016, 994 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>9</sub>F<sub>6</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 359.0619, found 359.0621.</div></div><div id="sec5_1_6_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> 1-(4-Chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1<i>H</i>-imidazole (<b>48</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,6-difluoro-4-methylphenyl)methanimine (0.183 g, 0.689 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as a yellow solid (0.127 g, 0.417 mmol, 61% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.76 (s, 1H), 7.31 (d, <i>J</i> = 8.2 Hz, 2H), 7.26 (s, 1H), 7.08 (d, <i>J</i> = 8.3 Hz, 2H), 6.67 (d, <i>J</i> = 8.2 Hz, 2H), 2.32 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.10 (dd, <i>J</i> = 249.8, 7.0 Hz), 142.34 (t, <i>J</i> = 9.8 Hz), 138.65, 135.27, 134.11, 132.11, 129.68, 125.88, 120.32, 112.32 (dd, <i>J</i> = 19.8, 5.3 Hz), 104.03 (t, <i>J</i> = 19.8 Hz), 21.58 ppm. IR (KBr) ν 3113, 3073, 3037, 2923, 2854, 1642, 1572, 1499, 1464, 1323, 1277, 1249, 1215, 1205, 1091 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>12</sub>ClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 305.0657, found 305.0658.</div></div><div id="sec5_1_6_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> 1-(4-Chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1<i>H</i>-imidazole (<b>49</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(2,6-difluoro-3-methoxyphenyl)methanimine (0.745 g, 2.64 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as a yellow solid (0.278 g, 0.867 mmol, 33% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.79 (s, 1H), 7.35–7.29 (m, 3H), 7.10 (d, <i>J</i> = 8.1 Hz, 2H), 6.94–6.85 (m, 1H), 6.79 (t, <i>J</i> = 8.8 Hz, 1H), 3.83 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 153.72 (dd, <i>J</i> = 243.6, 4.1 Hz), 149.74 (dd, <i>J</i> = 250.3, 5.9 Hz), 144.52 (dd, <i>J</i> = 11.1, 3.0 Hz), 138.92, 135.18, 134.20, 132.42, 129.73, 125.86, 120.12, 113.94 (dd, <i>J</i> = 9.4, 2.9 Hz), 110.40 (dd, <i>J</i> = 23.1, 4.3 Hz), 108.08 (dd, <i>J</i> = 21.4, 16.8 Hz), 56.86 ppm. IR (KBr) ν 3098, 2941, 2842, 1592, 1500, 1441, 1318, 1281, 1247, 1172, 1110, 1049 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>12</sub>ClF<sub>2</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 321.0606, found 321.0606.</div></div><div id="sec5_1_6_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> 1-(4-Chlorophenyl)-5-phenyl-1<i>H</i>-imidazole (<b>50</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-phenylmethanimine (0.702 g, 3.25 mmol), purification by silica gel column chromatography (hexanes/EtOAc 60:40) afforded the title compound as a orange solid (0.088 g, 0.345 mmol, 11% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.36 (d, <i>J</i> = 8.0 Hz, 2H), 7.30–7.26 (m, 4H), 7.16–7.09 (m, 4H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 138.80, 135.25, 134.08, 133.08, 129.77, 129.19, 129.15, 128.66, 128.28, 127.80, 126.84 ppm. IR (KBr) ν 3115, 3062, 2957, 2921, 2851, 1604, 1495, 1468, 1269, 1117, 1093 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>12</sub>ClN<sub>2</sub> [M + H]<sup>+</sup> 255.0689, found 255.0690.</div></div><div id="sec5_1_6_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> 1-(4-Chlorophenyl)-5-(4-methoxyphenyl)-1<i>H</i>-imidazole (<b>51</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(4-chlorophenyl)-1-(4-methoxyphenyl)methanimine (0.100 g, 0.407 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as a orange solid (0.065 g, 0.228 mmol, 56% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 7.38–7.30 (m, 2H), 7.18 (s, 1H), 7.14–7.07 (m, 2H), 7.08–6.99 (m, 2H), 6.85–6.75 (m, 2H), 3.78 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 159.35, 138.30, 135.38, 134.01, 132.95, 129.74, 128.50, 126.88, 121.62, 114.17, 55.35 ppm. IR (KBr) ν 3118, 3046, 2960, 2916, 2836, 1614, 1557, 1497, 1466, 1297, 1271, 1250, 1178, 1113, 1093, 1063, 1030 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>14</sub>ClN<sub>2</sub>O [M + H]<sup>+</sup> 285.0795, found 285.0798.</div></div><div id="sec5_1_6_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> 5-(2,6-Difluorophenyl)-1-phenyl-1<i>H</i>-imidazole (<b>52</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-1-(2,6-difluorophenyl)-<i>N</i>-phenylmethanimine (0.600 g, 2.76 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as an orange solid (0.193 g, 0.753 mmol, 27% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.84 (s, 1H), 7.41–7.34 (m, 3H), 7.34 (s, 1H), 7.34–7.25 (m, 1H), 7.21–7.15 (m, 2H), 6.91–6.83 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.55 (dd, <i>J</i> = 250.5, 6.2 Hz), 138.99, 136.71, 132.15, 130.67 (t, <i>J</i> = 10.2 Hz), 129.46, 128.25, 124.59, 120.06, 111.61 (dd, <i>J</i> = 20.4, 5.0 Hz), 107.65 (t, <i>J</i> = 19.7 Hz) ppm. IR (KBr) ν 3103, 3070, 3045, 2916, 2848, 1631, 1597, 1563, 1498, 1470, 1447, 1278, 1255, 1236, 1216, 1116, 1077, 998 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>11</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 257.0890, found 257.0881.</div></div><div id="sec5_1_6_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> 1-(2-Chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>53</b>)</h4><div class="NLM_p last">Following synthetic procedure C using (<i>E</i>)-<i>N</i>-(2-chlorophenyl)-1-(2,6-difluorophenyl)methanimine (0.600 g, 2.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 65:35) afforded the title compound as a yellow solid (0.478 g, 1.64 mmol, 69% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.41–7.37 (m, 1H), 7.32–7.24 (m, 2H), 7.25–7.14 (m, 3H), 6.82–6.74 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.49 (dd, <i>J</i> = 250.9, 6.1 Hz), 139.5, 134.11, 131.55, 131.53, 130.68 (t, <i>J</i> = 10.2 Hz), 130.54, 130.13, 129.00, 127.44, 121.01, 111.52 (dd, <i>J</i> = 20.3, 5.0 Hz), 107.32 (t, <i>J</i> = 19.4 Hz) ppm. IR (KBr) ν 3104, 3062, 1632, 1587, 1566, 1491, 1467, 1444, 1275, 1235, 1213, 1110, 1089, 1045, 999 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>10</sub>ClF<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 291.0501, found 291.0494.</div></div><div id="sec5_1_6_51" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> 4-Chloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>54</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.400 g, 1.3 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 70:30) afforded the title compound as a white solid (0.305 g, 0.889 mmol, 69% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.68 (s, 1H), 7.36–7.33 (m, 2H), 7.09–7.07 (m, 2H), 6.71–6.65 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.93 (dt, <i>J</i> = 253.4, 15.3 Hz), 161.04 (ddd, <i>J</i> = 253.0, 15.1, 8.4 Hz), 136.90, 135.09, 134.44, 132.62, 129.98, 126.00, 115.23, 101.87 (td, <i>J</i> = 20.3, 4.8 Hz), 101.21–100.77 (m) ppm. IR (KBr) ν 3050, 2987, 2919, 2848, 1646, 1595, 1498, 1444, 1265, 1125, 1037, 908, 735 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 343.0017, found 343.0008.</div></div><div id="sec5_1_6_52" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> 4-Chloro-1-(4-chlorophenyl)-2-methyl-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>55</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 4-chloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.100 g, 0.290 mmol), purification by silica gel column chromatography (hexanes/EtOAc 90:10 to 70:30) afforded the title compound as a white solid (9 mg, 9% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.81 (s, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (d, <i>J</i> = 8.4 Hz, 2H), 6.66 (t, <i>J</i> = 9.0 Hz, 1H), 2.12 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.87 (dt, <i>J</i> = 253.2, 15.3 Hz, 1C), 161.27 (ddd, <i>J</i> = 252.3, 15.1, 8.5 Hz), 145.85, 135.65, 134.21, 130.25, 129.96, 128.37, 115.30, 102.36 (td, <i>J</i> = 20.6, 4.2 Hz), 101.05–100.60 (m), 14.02 ppm. IR (KBr) ν 2962, 2927, 2852, 1644, 1585, 1495, 1442, 1400, 1122, 1038, 999 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 357.0173, found 357.0171.</div></div><div id="sec5_1_6_53" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> 2-Chloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>56</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.400 g, 1.3 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 70:30) afforded the title compound as a white solid (0.058 g, 0.169 mmol, 13% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.37–7.34 (m, 2H), 7.16 (s, 1H), 7.11 (d, <i>J</i> = 8.6 Hz, 2H), 6.64–6.58 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.54 (dt, <i>J</i> = 253.0, 15.2 Hz), 161.05 (ddd, <i>J</i> = 251.8, 15.1, 8.4 Hz), 135.66, 134.53, 133.38, 130.58, 129.69, 128.62, 121.59, 103.44 (td, <i>J</i> = 20.1, 4.6 Hz), 100.99–100.54 (m) ppm. IR (KBr) ν 3459, 1645, 1599, 1568, 1495, 1447, 1124, 1034 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 343.0017, found 343.0022.</div></div><div id="sec5_1_6_54" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> 2,4-Dichloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>57</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.400 g, 1.3 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 70:30) afforded the title compound as a white solid (0.016 g, 0.042 mmol, 3% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.39–7.36 (m, 2H), 7.12 (d, <i>J</i> = 8.6 Hz, 2H), 6.69–6.63 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.23 (dt, <i>J</i> = 254.2, 15.3 Hz), 161.26 (ddd, <i>J</i> = 253.1, 15.1, 8.3 Hz), 136.22, 132.94, 132.88, 130.83, 129.91, 128.57, 117.68, 101.61 (td, <i>J</i> = 20.2, 4.9 Hz), 101.23–100.78 (m) ppm. IR (KBr) ν 3100, 3067, 2962, 2928, 2857, 1645, 1599, 1495, 1446, 1121, 1038, 998 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>7</sub>Cl<sub>3</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 376.9627, found 376.9627.</div></div><div id="sec5_1_6_55" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> 2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methoxyphenyl)-1<i>H</i>-imidazole (<b>58</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloro-1-(4-chlorophenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.032 g, 0.085 mmol) in THF (0.53 mL) at 0 °C was added a 30% sodium methoxide solution in MeOH (0.031 mL). The reaction mixture was stirred for 16 h at rt, then quenched with an aqueous ammonium chloride solution and extracted with EtOAc (3×). The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude products were purified by preparative reverse-phase HPLC to obtain the title compound as a white solid (0.011 g, 0.028 mmol, 33% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.38–7.35 (m, 2H), 7.12 (d, <i>J</i> = 8.6 Hz, 2H), 6.41 (q, <i>J</i> = 7.3 Hz, 2H), 3.78 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 162.97 (t, <i>J</i> = 14.0 Hz), 161.59 (dd, <i>J</i> = 249.7, 9.1 Hz), 135.90, 133.24, 132.20, 130.42, 129.75, 118.83, 101.00 (td, <i>J</i> = 26.4, 3.1 Hz), 98.46–98.24 (m), 97.03 (t, <i>J</i> = 20.6 Hz), 56.07 ppm. IR (KBr) ν 3390, 2965, 2924, 2848, 1644, 1574, 1495, 1445, 1384, 1352, 1150 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 388.9827, found 388.9830.</div></div><div id="sec5_1_6_56" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> 4-Chloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>59</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.086 g, 0.283 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.043 g, 0.127 mmol, 45% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 77.64 (s, 1H), 7.06 (d, <i>J</i> = 8.6 Hz, 2H), 6.88–6.82 (m, 2H), 6.71–6.61 (m, 2H), 3.79 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.80 (dt, <i>J</i> = 252.7, 15.1 Hz), 161.21 (ddd, <i>J</i> = 252.7, 15.3, 8.6 Hz), 159.90, 137.20, 131.91, 128.82, 126.27, 115.50, 114.71, 102.27 (td, <i>J</i> = 20.4, 4.7 Hz), 101.15–100.40 (m), 55.62 ppm. IR (KBr) ν 3149, 3047, 2983, 2941, 2916, 2838, 1644, 1595, 1564, 1517, 1468, 1439, 1249, 1179, 1128, 1028 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>ClF<sub>3</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 339.0512, found 339.0481.</div></div><div id="sec5_1_6_57" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> 2-Chloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>60</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.086 g, 0.283 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.015 g, 0.044 mmol, 16% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.14 (s, 1H), 7.11–7.06 (m, 2H), 6.89–6.84 (m, 2H), 6.64–6.56 (m, 2H), 3.81 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 163.34 (dt, <i>J</i> = 252.7, 15.4 Hz), 161.13 (ddd, <i>J</i> = 251.5, 15.0, 8.5 Hz), 160.07, 134.94, 130.16, 128.51, 127.52, 121.78, 114.42, 103.86 (td, <i>J</i> = 20.3, 4.7 Hz), 101.08–100.00 (m), 55.59 ppm. IR (KBr) ν 3053, 2962, 2917, 2847, 1645, 1596, 1570, 1514, 1485, 1448, 1253, 1171, 1124, 1035 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>ClF<sub>3</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 339.0512, found 339.0499.</div></div><div id="sec5_1_6_58" class="NLM_sec NLM_sec_level_3"><div id="ac_i78" class="anchor-spacer"></div><h4 class="article-section__title" id="_i78"> 2,4-Dichloro-1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>61</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-methoxyphenyl)-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazole (0.086 g, 0.283 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.010 g, 0.027 mmol, 9% yield). <sup>1</sup>H NMR (500 MHz; CDCl<sub>3</sub>) δ 7.11–7.06 (m, 2H), 6.89–6.84 (m, 2H), 6.67–6.60 (m, 2H), 3.81 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.01 (dt, <i>J</i> = 253.2, 15.2 Hz), 161.30 (ddd, <i>J</i> = 252.8, 14.8, 8.5 Hz), 160.40, 133.20, 131.10, 130.15, 128.99, 128.46, 127.07, 117.87, 114.60, 101.95 (td, <i>J</i> = 20.2, 4.6 Hz), 101.36–100.34 (m), 55.63 ppm. IR (KBr) ν 2960, 2918, 2849, 1643, 1513, 1445, 1255, 1121, 1036 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 373.0122, found 373.0112.</div></div><div id="sec5_1_6_59" class="NLM_sec NLM_sec_level_3"><div id="ac_i79" class="anchor-spacer"></div><h4 class="article-section__title" id="_i79"> 4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1<i>H</i>-imidazole (<b>62</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1<i>H</i>-imidazole (0.326 g, 1.07 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a beige solid (0.187 g, 0.551 mmol, 52% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.73 (s, 1H), 7.36–7.33 (m, 2H), 7.22 (q, <i>J</i> = 7.5 Hz, 1H), 7.14–7.11 (m, 2H), 6.81 (td, <i>J</i> = 8.5, 0.9 Hz, 1H), 2.22 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.49 (ddd, <i>J</i> = 249.9, 12.8, 5.7 Hz), 136.49, 134.57, 134.56, 133.20 (dd, <i>J</i> = 9.5, 7.1 Hz), 131.96, 129.69, 125.74, 121.03 (dd, <i>J</i> = 17.6, 3.8 Hz), 116.38, 110.95 (dd, <i>J</i> = 21.2, 3.9 Hz), 104.53 (t, <i>J</i> = 20.1 Hz), 14.10 (d, <i>J</i> = 3.2 Hz) ppm. IR (KBr) ν 3121, 3096, 2924, 2852, 1497, 1482, 1265, 1093, 958 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 339.0267, found 339.0269.</div></div><div id="sec5_1_6_60" class="NLM_sec NLM_sec_level_3"><div id="ac_i80" class="anchor-spacer"></div><h4 class="article-section__title" id="_i80"> 2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1<i>H</i>-imidazole (<b>63</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methylphenyl)-1<i>H</i>-imidazole (0.326 g, 1.07 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a brown solid (0.030 g, 0.088 mmol, 8% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.35–7.32 (m, 2H), 7.16 (s, 1H), 7.14–7.08 (m, 3H), 6.71 (td, <i>J</i> = 8.5, 1.1 Hz, 1H), 2.15 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.66 (ddd, <i>J</i> = 248.9, 13.9, 5.4 Hz), 135.30, 134.12, 133.71, 132.66 (t, <i>J</i> = 8.2 Hz), 130.33, 129.48, 128.68, 123.01, 120.95 (dd, <i>J</i> = 18.0, 4.0 Hz), 110.88 (dd, <i>J</i> = 21.7, 3.8 Hz), 106.33 (t, <i>J</i> = 20.1 Hz), 14.27 (d, <i>J</i> = 3.1 Hz) ppm. IR (KBr) ν 3445, 2919, 2848, 1496, 1478, 1443, 1093, 1042 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 339.0267, found 339.0257.</div></div><div id="sec5_1_6_61" class="NLM_sec NLM_sec_level_3"><div id="ac_i81" class="anchor-spacer"></div><h4 class="article-section__title" id="_i81"> 4-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (<b>64</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (0.280 g, 0.434 mmol, 0.861 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a yellow solid (0.156 g, 0.434 mmol, 50% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 7.41 (td, <i>J</i> = 8.6, 5.6 Hz, 1H), 7.34–7.31 (m, 2H), 7.09 7.06 (m, 2H), 6.88–6.84 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.79 (dd, <i>J</i> = 252.6, 4.4 Hz), 155.89 (dd, <i>J</i> = 253.6, 6.2 Hz), 137.09, 135.05, 134.27, 132.65, 132.28 (d, <i>J</i> = 9.6 Hz), 129.97, 125.85, 117.26 (dd, <i>J</i> = 18.4, 4.1 Hz), 115.25, 112.37 (dd, <i>J</i> = 23.3, 4.2 Hz), 106.79 (t, <i>J</i> = 20.1 Hz) ppm. IR (KBr) ν 3121, 3104, 3075, 2932, 2848, 1558, 1497, 1472, 1453, 1267, 1092 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 358.9721, found 358.9724.</div></div><div id="sec5_1_6_62" class="NLM_sec NLM_sec_level_3"><div id="ac_i82" class="anchor-spacer"></div><h4 class="article-section__title" id="_i82"> 4-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-2-methyl-1<i>H</i>-imidazole (<b>65</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 4-chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (0.078 g, 0.216 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a brown solid (0.039 g, 0.104 mmol, 48% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.38–7.33 (m, 3H), 7.07 (d, <i>J</i> = 8.6 Hz, 2H), 6.83–6.79 (m, 1H), 2.30 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 159.02 (dd, <i>J</i> = 251.5, 4.4 Hz), 156.10 (dd, <i>J</i> = 252.9, 6.3 Hz), 146.08, 135.50, 134.14, 132.05 (d, <i>J</i> = 9.6 Hz), 130.54, 129.91, 128.29, 117.08 (dd, <i>J</i> = 18.5, 4.1 Hz), 115.24, 112.19 (dd, <i>J</i> = 23.5, 4.4 Hz), 107.42 (t, <i>J</i> = 20.5 Hz), 14.06 ppm. IR (KBr) ν 3100, 3071, 2928, 2848, 1558, 1495, 1465, 1399, 1495, 1465, 1399, 1338, 1287, 1242, 1219, 1092, 1011, 997 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>C<sub>l3</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 372.9878, found 372.9864.</div></div><div id="sec5_1_6_63" class="NLM_sec NLM_sec_level_3"><div id="ac_i83" class="anchor-spacer"></div><h4 class="article-section__title" id="_i83"> 2-Chloro-5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (<b>66</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 5-(3-chloro-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (0.280 g, 0.861 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a yellow solid (0.050 g, 0.139 mmol, 16% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.37–7.32 (m, 3H), 7.20 (s, 1H), 7.14–7.11 (m, 2H), 6.80 (td, <i>J</i> = 8.6, 1.4 Hz, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.83 (dd, <i>J</i> = 251.3, 4.1 Hz), 155.97 (dd, <i>J</i> = 252.5, 6.2 Hz), 135.64, 134.85, 133.35, 131.78, 131.70, 130.88, 129.69, 128.57, 121.65, 117.22 (dd, <i>J</i> = 18.6, 4.1 Hz), 112.19 (dd, <i>J</i> = 23.6, 4.3 Hz), 108.44 (t, <i>J</i> = 20.3 Hz) ppm. IR (KBr) ν 3100, 3071, 2928, 2857, 1683, 1652, 1635, 1558, 1538, 1495 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 358.9721, found 358.9717.</div></div><div id="sec5_1_6_64" class="NLM_sec NLM_sec_level_3"><div id="ac_i84" class="anchor-spacer"></div><h4 class="article-section__title" id="_i84"> 5-(3-Bromo-2,6-difluorophenyl)-4-chloro-1-(4-chlorophenyl)-1<i>H</i>-imidazole (<b>67</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 5-(3-bromo-2,6-difluorophenyl)-1-(4-chlorophenyl)-1<i>H</i>-imidazole (0.452 g, 1.223 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a brown solid (0.224 g, 0.554 mmol, 45% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.68 (s, 1H), 7.55 (ddd, <i>J</i> = 8.9, 7.7, 5.8 Hz, 1H), 7.33–7.31 (m, 2H), 7.08–7.06 (m, 2H), 6.83–6.79 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 159.51 (dd, <i>J</i> = 252.8, 4.5 Hz), 156.83 (dd, <i>J</i> = 252.0, 6.2 Hz), 137.04, 135.14, 135.07, 135.06 (d, <i>J</i> = 1.3 Hz), 135.06, 135.00, 134.23, 132.59, 129.93, 125.81, 115.25, 112.89 (dd, <i>J</i> = 22.8, 4.2 Hz, 1C), 106.70 (t, <i>J</i> = 20.7 Hz), 104.44 (dd, <i>J</i> = 21.8, 4.3 Hz) ppm. IR (KBr) ν 3092, 2915, 2848, 1558, 1497, 1471, 1327, 1267, 1216, 1090, 1015, 999, 959 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>BrCl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 402.9216, found 402.9217.</div></div><div id="sec5_1_6_65" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> 4-Chloro-1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>68</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.406 g, 1.316 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a beige solid (0.244 g, 0.711 mmol, 55% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 7.33–7.31 (m, 2H), 7.18 (qd, <i>J</i> = 9.1, 5.0 Hz, 1H), 7.09–7.07 (m, 2H), 6.85–6.80 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.66 (dt, <i>J</i> = 248.9, 2.9 Hz), 148.20 (ddd, <i>J</i> = 253.9, 14.4, 6.4 Hz), 147.08 (ddd, <i>J</i> = 246.5, 12.7, 3.7 Hz), 137.12, 135.02, 134.27, 132.63, 129.92, 125.83, 118.88 (dd, <i>J</i> = 19.6, 9.5 Hz), 115.11 (d, <i>J</i> = 1.9 Hz), 111.25 (ddd, <i>J</i> = 24.1, 6.5, 4.4 Hz), 107.09 (dd, <i>J</i> = 21.5, 15.8 Hz) ppm. IR (KBr) ν 3054, 2987, 2924, 2852, 1499, 1265, 739, 704 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 343.0017, found 343.0005.</div></div><div id="sec5_1_6_66" class="NLM_sec NLM_sec_level_3"><div id="ac_i86" class="anchor-spacer"></div><h4 class="article-section__title" id="_i86"> 2-Chloro-1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>69</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.406 g, 1.316 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a brown solid (0.220 g, 0.641 mmol, 5% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.36 (d, <i>J</i> = 8.6 Hz, 2H), 7.22 (s, 1H), 7.16–7.08 (m, 3H), 6.81–6.76 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.76 (dt, <i>J</i> = 247.8, 3.0 Hz), 148.33 (ddd, <i>J</i> = 252.7, 14.5, 6.2 Hz), 147.14 (ddd, <i>J</i> = 246.7, 13.0, 3.7 Hz), 135.73, 134.93, 133.32, 130.74, 130.06, 129.72, 128.59, 121.62, 118.53–118.29 (m), 111.11 (ddd, <i>J</i> = 24.5, 6.5, 4.4 Hz), 108.71 (dd, <i>J</i> = 21.7, 15.9 Hz) ppm. IR (KBr) ν 3092, 3058, 2924, 2857, 1496, 1461, 1433, 1318, 1235, 1094 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 343.0017, found 343.0007.</div></div><div id="sec5_1_6_67" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> 4-Chloro-1-(4-chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>70</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.370 g, 1.13 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a yellow solid (0.126 g, 0.349 mmol, 31% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.40 (t, <i>J</i> = 8.1 Hz, 1H), 7.22 (qd, <i>J</i> = 9.1, 5.0 Hz, 1H), 6.99 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 6.91 (dd, <i>J</i> = 8.5, 1.0 Hz, 1H), 6.89–6.84 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.05 (d, <i>J</i> = 252.6 Hz), 155.63 (dt, <i>J</i> = 248.8, 2.8 Hz), 148.20 (ddd, <i>J</i> = 254.0, 14.4, 6.4 Hz), 147.17 (ddd, <i>J</i> = 246.9, 12.7, 3.7 Hz), 137.11, 135.29 (d, <i>J</i> = 8.7 Hz), 133.06, 131.69, 122.28, 122.14, 121.01 (d, <i>J</i> = 3.8 Hz), 119.14 (dd, <i>J</i> = 19.9, 9.7 Hz), 115.09 (d, <i>J</i> = 1.5 Hz), 113.32 (d, <i>J</i> = 24.0 Hz), 111.42 (ddd, <i>J</i> = 24.1, 6.6, 4.3 Hz), 106.82 (dd, <i>J</i> = 21.5, 15.9 Hz) ppm. IR (KBr) ν 3126, 3096, 3058, 2915, 2848, 1497, 1266, 1225, 1197, 1004, 888, 863, 814, 738 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>7</sub>Cl<sub>2</sub>F<sub>4</sub>N<sub>2</sub> [M + H]<sup>+</sup> 360.9922, found 360.9917.</div></div><div id="sec5_1_6_68" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> 4-Chloro-1-(4-chloro-3-fluorophenyl)-2-methyl-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>71</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 4-chloro-1-(4-chloro-3-fluorophenyl)-5-(2,3,6- trifluorophenyl)-1<i>H</i>-imidazole (0.100 g, 0.277 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 90:10) afforded the title compound as a white solid (0.014 g, 0.037 mmol, 13% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.43 (t, <i>J</i> = 8.1 Hz, 1H), 7.17 (qd, <i>J</i> = 9.1, 5.0 Hz, 1H), 6.99 (dd, <i>J</i> = 8.8, 2.2 Hz, 1H), 6.91 (d, <i>J</i> = 8.5 Hz, 1H), 6.84–6.80 (m, 1H), 2.33 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.00 (d, <i>J</i> = 253.0 Hz), 155.94 (dt, <i>J</i> = 248.2, 3.0 Hz), 148.48 (ddd, <i>J</i> = 253.4, 14.4, 6.3 Hz), 147.17 (ddd, <i>J</i> = 244.4, 12.9, 3.8 Hz), 146.11, 135.15 (d, <i>J</i> = 8.6 Hz), 131.59, 130.83, 123.69 (d, <i>J</i> = 3.8 Hz), 122.96 (d, <i>J</i> = 17.4 Hz), 118.97 (dd, <i>J</i> = 19.6, 9.8 Hz), 115.86 (d, <i>J</i> = 23.1 Hz), 115.23 (d, <i>J</i> = 2.1 Hz), 111.22 (ddd, <i>J</i> = 24.3, 6.7, 4.3 Hz), 107.44 (dd, <i>J</i> = 21.9, 16.1 Hz), 14.05 ppm. IR (KBr) ν 1493, 1435, 1394, 1249, 1234, 1222, 1077, 1058, 997 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>4</sub>N<sub>2</sub> [M + H]<sup>+</sup> 375.0079, found 375.0070.</div></div><div id="sec5_1_6_69" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> 2-Chloro-1-(4-chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>72</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chloro-3-fluorophenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.370 g, 1.13 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 60:40) afforded the title compound as a yellow solid (0.074 g, 0.205 mmol, 18% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.42 (t, <i>J</i> = 8.1 Hz, 1H), 7.21 (s, 1H), 7.14 (qd, <i>J</i> = 9.0, 5.0 Hz, 1H), 7.05 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 6.94 (d, <i>J</i> = 8.3 Hz, 1H), 6.81 (tdd, <i>J</i> = 8.7, 3.3, 1.9 Hz, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 157.84 (d, <i>J</i> = 252.4 Hz), 155.60 (dt, <i>J</i> = 248.0, 2.9 Hz), 148.19 (ddd, <i>J</i> = 253.1, 14.6, 6.0 Hz), 147.11 (ddd, <i>J</i> = 247.0, 12.8, 3.6 Hz), 134.77, 134.25 (d, <i>J</i> = 8.6 Hz), 131.23, 131.08, 123.87 (d, <i>J</i> = 3.8 Hz), 122.93, 122.79, 121.47 (d, <i>J</i> = 1.3 Hz), 118.53 (dd, <i>J</i> = 19.2, 9.9 Hz), 116.11 (d, <i>J</i> = 23.5 Hz), 111.23 (ddd, <i>J</i> = 24.4, 6.5, 4.4 Hz), 108.37 (dd, <i>J</i> = 21.6, 15.9 Hz) ppm. IR (KBr) ν 3094, 3058, 2932, 2860, 1587, 1494, 1459, 1426, 1313, 1238, 1074, 1009 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>7</sub>Cl<sub>2</sub>F<sub>4</sub>N<sub>2</sub> [M + H]<sup>+</sup> 360.9922, found 360.9917.</div></div><div id="sec5_1_6_70" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> 2-Chloro-5-(4-chloro-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazol-1-yl)pyridine (<b>73</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 2-chloro-5-(5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazol-1-yl)pyridine (0.304 g, 0.98 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 70:30) afforded the title compound as a brown solid (0.172 g, 0.500 mmol, 51% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.24 (d, <i>J</i> = 2.7 Hz, 1H), 7.71 (s, 1H), 7.47 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 1H), 6.71 (t, <i>J</i> = 8.0 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.22 (dt, <i>J</i> = 254.5, 15.2 Hz), 160.97 (ddd, <i>J</i> = 253.1, 15.1, 8.4 Hz), 151.97, 145.53, 136.91, 134.87, 133.36, 131.72, 125.18, 115.41, 101.48–101.04 (m) ppm. IR (KBr) ν 3100, 3058, 1646, 1599, 1575, 1558 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>14</sub>H<sub>7</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub> [M + H]<sup>+</sup> 343.9969, found 343.9976.</div></div><div id="sec5_1_6_71" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> 2-Chloro-5-(4-chloro-2-methyl-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazol-1-yl)pyridine (<b>74</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 2-chloro-5-(4-chloro-5-(2,4,6-trifluorophenyl)-1<i>H</i>-imidazol-1-yl)pyridine (0.120 g, 0.349 mmol), purification by reverse-phase HPLC afforded the title compound as a white solid (0.003 g, 0.008 mmol, 2% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.24 (d, <i>J</i> = 2.6 Hz, 1H), 7.48 (dd, <i>J</i> = 8.4, 2.6 Hz, 1H), 7.42 (d, <i>J</i> = 8.3 Hz, 1H), 6.68 (t, <i>J</i> = 8.0 Hz, 2H), 2.38 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 164.28 (dt, <i>J</i> = 254.7, 15.4 Hz), 161.13 (ddd, <i>J</i> = 252.8, 15.0, 8.4 Hz), 152.78, 152.31, 147.82, 146.34, 145.63, 137.11, 134.97, 131.20, 130.32, 125.31, 115.88, 101.21 (td, <i>J</i> = 26.1, 3.8 Hz), 13.68 ppm. IR (KBr) ν 3067, 2962, 2924, 1733, 1683, 1646, 1558, 1539, 1506 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>3</sub> [M + H]<sup>+</sup> 358.0126, found 358.0123.</div></div><div id="sec5_1_6_72" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> 2-Chloro-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1<i>H</i>-imidazole (<b>75</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(4-fluorophenyl)-1<i>H</i>-imidazole (0.124 g, 0.455 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a yellow solid (0.009 g, 0.029 mmol, 7% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 7.37–7.31 (m, 4H), 7.20–7.19 (m, 2H), 7.06 (d, <i>J</i> = 8.0 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 162.62 (d, <i>J</i> = 249.6 Hz), 135.75, 135.01, 134.79, 134.58, 131.70 (d, <i>J</i> = 8.3 Hz), 130.05, 129.94, 129.81, 128.65, 128.49, 127.38, 126.69, 126.66, 116.02, 115.84 ppm. IR (KBr) ν 3067, 2924, 2852, 1562, 1496 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>10</sub>Cl<sub>2</sub>FN<sub>2</sub> [M + H]<sup>+</sup> 307.0205, found 307.0210.</div></div><div id="sec5_1_6_73" class="NLM_sec NLM_sec_level_3"><div id="ac_i93" class="anchor-spacer"></div><h4 class="article-section__title" id="_i93"> 4-Chloro-1-(4-chlorophenyl)-5-(4-fluorophenyl)-1<i>H</i>-imidazole (<b>76</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(4-fluorophenyl)-1<i>H</i>-imidazole (0.124 g, 0.455 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a white solid (0.060 g, 0.195 mmol, 43% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.57 (s, 1H), 7.36–7.33 (m, 2H), 7.18–7.15 (m, 2H), 7.06–6.99 (m, 4H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 162.58 (d, <i>J</i> = 249.6 Hz), 135.74, 134.73 (d, <i>J</i> = 3.7 Hz), 131.66 (d, <i>J</i> = 8.2 Hz), 129.99, 129.33, 126.66, 126.23, 123.39 (d, <i>J</i> = 3.4 Hz), 115.96, 115.78 ppm. IR (KBr) ν 3117, 3062, 2962, 2916, 2848, 1683, 1652, 1599, 1575, 1558, 1497 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>10</sub>Cl<sub>2</sub>FN<sub>2</sub> [M + H]<sup>+</sup> 307.0205, found 307.0206.</div></div><div id="sec5_1_6_74" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> 2-Chloro-1-(4-chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>77</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.351 g, 1.14 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a yellow solid (0.025 g, 0.073 mmol, 6% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.31–7.26 (m, 1H), 7.22 (s, 1H), 7.19 (d, <i>J</i> = 9.3 Hz, 1H), 7.15 (d, <i>J</i> = 3.1 Hz, 2H), 6.85 (t, <i>J</i> = 7.6 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.60 (dd, <i>J</i> = 251.4, 5.9 Hz), 157.37 (d, <i>J</i> = 257.9 Hz), 136.78 (d, <i>J</i> = 9.2 Hz), 134.86, 131.52 (t, <i>J</i> = 10.3 Hz), 130.78, 130.32, 125.13, 125.10, 122.95, 121.74 (d, <i>J</i> = 13.0 Hz), 117.73 (d, <i>J</i> = 23.1 Hz), 111.69 (dd, <i>J</i> = 20.5, 5.0 Hz), 106.50 (t, <i>J</i> = 19.5 Hz) ppm. IR (KBr) ν 3104, 3071, 2936, 2860, 1683, 1652, 1634, 1587, 1558, 1538, 1505 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 343.0017, found 343.0013.</div></div><div id="sec5_1_6_75" class="NLM_sec NLM_sec_level_3"><div id="ac_i95" class="anchor-spacer"></div><h4 class="article-section__title" id="_i95"> 4-Chloro-1-(4-chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>78</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chloro-2-fluorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.351 g, 1.14 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 80:20) afforded the title compound as a yellow solid (0.126 g, 0.367 mmol, 32% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.65 (s, 1H), 7.38–7.33 (m, 1H), 7.19–7.17 (m, 1H), 7.13 (q, <i>J</i> = 6.4 Hz, 2H), 6.90 (t, <i>J</i> = 7.8 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.74 (dd, <i>J</i> = 252.5, 5.9 Hz), 156.36 (d, <i>J</i> = 256.9 Hz), 137.49, 136.16 (d, <i>J</i> = 9.2 Hz), 132.18, 132.13 (t, <i>J</i> = 10.1 Hz), 128.61, 125.34 (d, <i>J</i> = 3.7 Hz), 122.69 (d, <i>J</i> = 12.6 Hz), 117.87 (d, <i>J</i> = 22.8 Hz), 116.88, 111.80 (dd, <i>J</i> = 20.6, 4.5 Hz), 105.04 (t, <i>J</i> = 19.6 Hz) ppm. IR (KBr) ν 3105, 2932, 1683, 1652, 1634, 1590, 1568, 1506 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 343.0017, found 343.0018.</div></div><div id="sec5_1_6_76" class="NLM_sec NLM_sec_level_3"><div id="ac_i96" class="anchor-spacer"></div><h4 class="article-section__title" id="_i96"> 2-Chloro-1-(4-chlorophenyl)-5-(2,5-difluorophenyl)-1<i>H</i>-imidazole (<b>79</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,5-difluorophenyl)-1<i>H</i>-imidazole (0.300 g, 1.03 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 50:50) afforded the title compound as a yellow solid (0.010 g, 0.031 mmol, 3% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.41–7.38 (m, 2H), 7.22 (s, 1H), 7.15–7.12 (m, 2H), 6.98–6.94 (m, 2H), 6.81–6.77 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.39 (dd, <i>J</i> = 245.6, 4.0 Hz), 155.71 (dd, <i>J</i> = 247.1, 3.7 Hz), 135.57, 134.62, 133.73, 129.79, 129.68 (d, <i>J</i> = 2.8 Hz), 128.87, 128.49, 118.43 (dd, <i>J</i> = 16.0, 10.3 Hz), 117.45–116.90 (m) ppm. IR (KBr) ν 3071, 2932, 2857, 1495 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 325.0111, found 325.0110.</div></div><div id="sec5_1_6_77" class="NLM_sec NLM_sec_level_3"><div id="ac_i97" class="anchor-spacer"></div><h4 class="article-section__title" id="_i97"> 4-Chloro-1-(4-chlorophenyl)-5-(2,5-difluorophenyl)-1<i>H</i>-imidazole (<b>80</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,5-difluorophenyl)-1<i>H</i>-imidazole (0.300 g, 1.03 mmol), purification by silica gel column chromatography (hexanes/EtOAc 100:0 to 50:50) afforded the title compound as a yellow solid (0.030 g, 0.092 mmol, 9% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.64 (s, 1H), 7.35–7.33 (m, 2H), 7.10–7.03 (m, 4H), 6.96 (td, <i>J</i> = 8.8, 4.5 Hz, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 158.48 (dd, <i>J</i> = 244.1, 2.0 Hz), 155.77 (dd, <i>J</i> = 246.1, 1.7 Hz), 144.02, 136.41, 134.84, 134.79, 131.12, 129.97, 129.80, 129.45, 127.34, 125.83, 123.07, 121.05, 118.61 (dd, <i>J</i> = 24.9, 2.7 Hz), 117.94 (dd, <i>J</i> = 24.0, 8.5 Hz), 117.36 (dd, <i>J</i> = 24.5, 8.9 Hz), 116.91 (dd, <i>J</i> = 18.1, 9.0 Hz) ppm. IR (KBr) ν 3126, 3100, 3067, 2924, 2857, 1733, 1683, 1652, 1558, 1539, 1497 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 325.0111, found 325.0095.</div></div><div id="sec5_1_6_78" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> 4-Chloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-imidazole (<b>81</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-imidazole (0.400 g, 1.17 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.192 g, 0.512 mmol, 44% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.70 (s, 1H), 7.43–7.33 (m, 1H), 7.24–7.16 (m, 4H), 6.91 (t, <i>J</i> = 7.8 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.71 (dd, <i>J</i> = 252.1, 6.0 Hz), 149.23–149.16 (m), 136.84, 134.52, 132.53, 132.20 (t, <i>J</i> = 10.2 Hz), 126.25, 122.01, 120.39 (q, <i>J</i> = 238.7 Hz), 116.18, 111.88 (dd, <i>J</i> = 20.5, 5.1 Hz), 105.32 (t, <i>J</i> = 19.7 Hz) ppm. IR (KBr) ν 3121, 3088, 1632, 1588, 1565, 1513, 1473, 1330, 1259, 1212, 1169, 1099 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>9</sub>ClF<sub>5</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 375.0324, found 375.0334.</div></div><div id="sec5_1_6_79" class="NLM_sec NLM_sec_level_3"><div id="ac_i99" class="anchor-spacer"></div><h4 class="article-section__title" id="_i99"> 2-Chloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-imidazole (<b>82</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-imidazole (0.400 g, 1.17 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.033 g, 0.088 mmol, 8% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.34–7.25 (m, 1H), 7.27–7.20 (m, 4H), 7.20 (s, 1H), 6.88–6.82 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.59 (dd, <i>J</i> = 251.3, 5.8 Hz), 149.51–149.44 (m), 134.36, 133.35, 131.57 (t, <i>J</i> = 10.2 Hz), 130.53, 128.96, 122.52, 121.41, 120.39 (q, <i>J</i> = 259.6 Hz), 111.67 (dd, <i>J</i> = 21.2, 4.6 Hz), 106.84 (t, <i>J</i> = 19.5 Hz) ppm. IR (KBr) ν 3077, 2920, 2852, 1632, 1586, 1511, 1469, 1436, 1388, 1261, 1211, 1172, 1001 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>8</sub>ClF<sub>5</sub>N<sub>2</sub>NaO [M + Na]<sup>+</sup> 397.0143, found 397.0149.</div></div><div id="sec5_1_6_80" class="NLM_sec NLM_sec_level_3"><div id="ac_i100" class="anchor-spacer"></div><h4 class="article-section__title" id="_i100"> 2,4-Dichloro-5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-imidazole (<b>83</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 5-(2,6-difluorophenyl)-1-(4-(trifluoromethoxy)phenyl)-1<i>H</i>-imidazole (0.400 g, 1.17 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.028 g, 0.068 mmol, 6% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.40–7.30 (m, 1H), 7.27–7.19 (m, 4H), 6.91–6.84 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.74 (dd, <i>J</i> = 252.3, 5.6 Hz), 149.85–149.77 (m), 132.76, 132.65, 132.61 (t, <i>J</i> = 10.3 Hz), 130.50, 128.96, 121.54, 120.34 (q, <i>J</i> = 258.7 Hz), 118.60, 111.81 (dd, <i>J</i> = 21.0, 4.3 Hz), 104.93 (t, <i>J</i> = 19.4 Hz) ppm. IR (KBr) ν 3079, 2921, 2851, 1633, 1590, 1570, 1511, 1468, 1439, 1388, 1263, 1213, 1174 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>5</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 408.9934, found 408.9940.</div></div><div id="sec5_1_6_81" class="NLM_sec NLM_sec_level_3"><div id="ac_i101" class="anchor-spacer"></div><h4 class="article-section__title" id="_i101"> 4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>84</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.400 g, 1.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.265 g, 0.815 mmol, 59% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.69 (s, 1H), 7.41–7.35 (m, 1H), 7.33 (d, <i>J</i> = 8.0 Hz, 2H), 7.12–7.05 (m, 2H), 6.91 (t, <i>J</i> = 7.9 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.67 (dd, <i>J</i> = 252.0, 5.9 Hz), 136.75, 134.89, 134.65, 132.40, 132.12 (t, <i>J</i> = 10.1 Hz), 129.91, 125.93, 116.10, 111.88 (dd, <i>J</i> = 21.1, 4.3 Hz), 105.36 (t, <i>J</i> = 19.5 Hz) ppm. IR (KBr) ν 3128, 2917, 2849, 1631, 1587, 1564, 1497, 1470, 1453, 1383, 1265, 1236, 1091, 998 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 325.0111, found 325.0122.</div></div><div id="sec5_1_6_82" class="NLM_sec NLM_sec_level_3"><div id="ac_i102" class="anchor-spacer"></div><h4 class="article-section__title" id="_i102"> 4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-2-methyl-1<i>H</i>-imidazole (<b>85</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 4-chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.050 g, 0.154 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a white solid (0.020 g, 0.059 mmol, 38% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.37–7.31 (m, 2H), 7.31–7.27 (m, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 2H), 6.89–6.82 (m, 2H), 2.31 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.83 (dd, <i>J</i> = 250.5, 6.9 Hz), 145.60, 135.23, 134.48, 131.79 (t, <i>J</i> = 10.1 Hz), 130.20, 129.75, 128.37, 116.02, 111.63 (dd, <i>J</i> = 20.4, 4.8 Hz), 105.96 (t, <i>J</i> = 17.7 Hz), 14.13 ppm. IR (KBr) ν 3064, 2960, 2921, 2850, 1634, 1576, 1494, 1467, 1402, 1278, 1238, 1093, 999 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 339.0267, found 339.0265.</div></div><div id="sec5_1_6_83" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> 4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-2-ethyl-1<i>H</i>-imidazole (<b>86</b>)</h4><div class="NLM_p last">Following synthetic procedure F using 4-chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.040 g, 0.123 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.015 g, 0.042 mmol, 35% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.36–7.30 (m, 2H), 7.30–7.27 (m, 1H), 7.09 (d, <i>J</i> = 8.5 Hz, 2H), 6.87–6.81 (m, 2H), 2.58 (q, <i>J</i> = 7.5 Hz, 2H), 1.26 (t, <i>J</i> = 7.4 Hz, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.87 (dd, <i>J</i> = 251.5, 5.8 Hz), 150.43, 135.27, 134.34, 131.77 (t, <i>J</i> = 10.3 Hz), 130.33, 129.71, 128.59, 115.90, 111.61 (dd, <i>J</i> = 20.7, 5.4 Hz), 105.96 (t, <i>J</i> = 20.3 Hz), 21.16, 12.21 ppm. IR (KBr) ν 3070, 2973, 2923, 2852, 1633, 1586, 1494, 1468, 1411, 1276, 1238, 1092, 1001 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>17</sub>H<sub>13</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 353.0424, found 353.0429.</div></div><div id="sec5_1_6_84" class="NLM_sec NLM_sec_level_3"><div id="ac_i104" class="anchor-spacer"></div><h4 class="article-section__title" id="_i104"> 2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>87</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.400 g, 1.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.056 g, 0.172 mmol, 12% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.36–7.31 (m, 2H), 7.31–7.23 (m, 1H), 7.18 (s, 1H), 7.12 (d, <i>J</i> = 8.2 Hz, 2H), 6.84 (t, <i>J</i> = 7.9 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.33 (dd, <i>J</i> = 251.1, 5.8 Hz), 135.10, 134.03, 133.32, 131.24 (t, <i>J</i> = 10.3 Hz), 130.21, 129.27, 128.36, 122.21, 111.39 (dd, <i>J</i> = 20.4, 4.8 Hz), 106.64 (t, <i>J</i> = 19.5 Hz) ppm. IR (KBr) ν 3098, 3063, 2919, 2847, 1632, 1585, 1564, 1495, 1468, 1434, 1384, 1315, 1276, 1235, 1092, 1001 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub>Na [M + Na]<sup>+</sup> 346.9930, found 346.9933.</div></div><div id="sec5_1_6_85" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> 2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>88</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.400 g, 1.38 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a white solid (0.026 g, 0.072 mmol, 5% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.39–7.30 (m, 3H), 7.13 (d, <i>J</i> = 8.1 Hz, 2H), 6.88 (t, <i>J</i> = 8.0 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.75 (dd, <i>J</i> = 252.3, 5.6 Hz), 135.94, 133.03, 132.59, 132.54 (t, <i>J</i> = 10.2 Hz), 130.43, 129.75, 128.57, 118.55, 111.81 (dd, <i>J</i> = 21.2, 4.2 Hz), 105.00 (t, <i>J</i> = 19.7 Hz) ppm. IR (KBr) ν 2961, 2918, 2850, 1632, 1589, 1568, 1495, 1468, 1434, 1384, 1262, 1236, 1092, 1003 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 358.9721, found 358.9725.</div></div><div id="sec5_1_6_86" class="NLM_sec NLM_sec_level_3"><div id="ac_i106" class="anchor-spacer"></div><h4 class="article-section__title" id="_i106"> 4-Chloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>89</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.500 g, 1.40 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow oil (0.198 g, 0.504 mmol, 36% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.72 (s, 1H), 7.25–7.17 (m, 5H), 6.88–6.82 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.78 (dt, <i>J</i> = 248.9, 3.1 Hz), 149.38–149.32 (m), 148.35 (ddd, <i>J</i> = 253.2, 14.1, 6.8 Hz), 147.23 (ddd, <i>J</i> = 247.2, 12.8, 3.7 Hz), 137.27, 134.21, 132.94, 126.29, 122.13, 120.36 (q, <i>J</i> = 258.7 Hz), 119.05 (dd, <i>J</i> = 19.2, 9.6 Hz), 115.30, 111.35 (ddd, <i>J</i> = 24.2, 6.8, 4.2 Hz), 107.15 (dd, <i>J</i> = 21.7, 15.8 Hz) ppm. IR (KBr) ν 3095, 2918, 2850, 1568, 1513, 1493, 1467, 1383, 1162, 1110, 999 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>7</sub>ClF<sub>6</sub>N<sub>2</sub>NaO [M + Na]<sup>+</sup> 415.0049, found 415.0059.</div></div><div id="sec5_1_6_87" class="NLM_sec NLM_sec_level_3"><div id="ac_i107" class="anchor-spacer"></div><h4 class="article-section__title" id="_i107"> 2-Chloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>90</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.500 g, 1.40 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.047 g, 0.120 mmol, 9% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.29–7.24 (m, 5H), 7.16 (qd, <i>J</i> = 9.1, 5.0 Hz, 1H), 6.86–6.78 (m, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 155.69 (dt, <i>J</i> = 248.0, 3.1 Hz), 149.67–149.59 (m), 148.28 (ddd, <i>J</i> = 252.4, 14.7, 5.9 Hz), 147.13 (ddd, <i>J</i> = 246.5, 12.4, 3.6 Hz), 134.96, 133.11, 130.95, 128.93, 121.59, 121.52, 120.37 (q, <i>J</i> = 258.7 Hz), 118.40 (dd, <i>J</i> = 19.2, 9.7 Hz), 111.10 (ddd, <i>J</i> = 24.3, 6.7, 4.1 Hz), 108.67 (dd, <i>J</i> = 21.8, 15.9 Hz) ppm. IR (KBr) ν 3081, 2920, 1511, 1493, 1460, 1433, 1387, 1260, 1211, 1172, 1113, 1018, 998 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>8</sub>ClF<sub>6</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 393.0229, found 393.0232.</div></div><div id="sec5_1_6_88" class="NLM_sec NLM_sec_level_3"><div id="ac_i108" class="anchor-spacer"></div><h4 class="article-section__title" id="_i108"> 2,4-Dichloro-1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (<b>91</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-(trifluoromethoxy)phenyl)-5-(2,3,6-trifluorophenyl)-1<i>H</i>-imidazole (0.500 g, 1.40 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.010 g, 0.023 mmol, 2% yield). <sup>1</sup>H NMR (600 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.72–7.63 (m, 1H), 7.57 (d, <i>J</i> = 8.8 Hz, 2H), 7.53–7.48 (m, 2H), 7.27–7.21 (m, 1H) ppm. <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.16 (dt, <i>J</i> = 248.0, 3.1 Hz), 148.96 (q, <i>J</i> = 2.0 Hz), 147.29 (ddd, <i>J</i> = 252.1, 14.5, 6.2 Hz), 146.31 (ddd, <i>J</i> = 244.4, 12.4, 4.1 Hz), 133.01, 132.51, 129.62, 129.15, 122.11, 120.66 (dd, <i>J</i> = 19.3, 9.7 Hz), 119.87 (q, <i>J</i> = 258.7 Hz), 119.55, 112.27 (ddd, <i>J</i> = 24.2, 7.6, 4.4 Hz), 105.61 (dd, <i>J</i> = 22.5, 16.2 Hz) ppm. IR (KBr) ν 2919, 2850, 1642, 1383, 1247, 1179 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>7</sub>Cl<sub>2</sub>F<sub>6</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 426.9840, found 426.9850.</div></div><div id="sec5_1_6_89" class="NLM_sec NLM_sec_level_3"><div id="ac_i109" class="anchor-spacer"></div><h4 class="article-section__title" id="_i109"> 4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1<i>H</i>-imidazole (<b>92</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1<i>H</i>-imidazole (0.100 g, 0.328 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.070 g, 0.206 mmol, 63% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.35–7.29 (m, 2H), 7.11–7.05 (m, 2H), 6.71 (d, <i>J</i> = 8.4 Hz, 2H), 2.35 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.37 (dd, <i>J</i> = 251.2, 6.9 Hz), 143.68 (t, <i>J</i> = 9.9 Hz), 136.56, 134.77, 134.75, 132.25, 129.86, 125.96, 116.31, 112.46 (dd, <i>J</i> = 20.3, 4.9 Hz), 102.16 (t, <i>J</i> = 19.8 Hz), 21.74 ppm. IR (KBr) ν 3064, 2922, 1644, 1568, 1496, 1412, 1321, 1265, 1205, 1086, 1037 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 339.0267, found 339.0259.</div></div><div id="sec5_1_6_90" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> 2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1<i>H</i>-imidazole (<b>93</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1<i>H</i>-imidazole (0.100 g, 0.328 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.009 g, 0.026 mmol, 8% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.38–7.31 (m, 2H), 7.18–7.10 (m, 3H), 6.65 (d, <i>J</i> = 8.5 Hz, 2H), 2.31 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.30 (dd, <i>J</i> = 250.0, 6.7 Hz), 143.00 (t, <i>J</i> = 9.9 Hz), 135.27, 134.04, 133.66, 130.31, 129.52, 128.68, 122.73, 112.24 (dd, <i>J</i> = 21.0, 4.4 Hz), 103.73 (t, <i>J</i> = 19.4 Hz), 21.68 ppm. IR (KBr) ν 2918, 2850, 1644, 1494, 1440, 1383, 1315, 1205, 1094, 1039 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 339.0267, found 339.0263.</div></div><div id="sec5_1_6_91" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> 2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1<i>H</i>-imidazole (<b>94</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-4-methylphenyl)-1<i>H</i>-imidazole (0.100 g, 0.328 mmol), purification by silica gel column chromatography (hexanes/EtOAc 85:15) afforded the title compound as a yellow solid (0.024 g, 0.064 mmol, 20% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.35 (d, <i>J</i> = 8.3 Hz, 2H), 7.12 (d, <i>J</i> = 8.3 Hz, 2H), 6.68 (d, <i>J</i> = 8.5 Hz, 2H), 2.33 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.45 (dd, <i>J</i> = 251.3, 6.7 Hz), 144.17 (t, <i>J</i> = 9.9 Hz), 135.85, 133.15, 132.32, 130.31, 129.72, 128.61, 118.80, 112.40 (dd, <i>J</i> = 20.2, 4.1 Hz), 101.84 (t, <i>J</i> = 20.0 Hz), 21.79 ppm. IR (KBr) ν 3065, 2924, 2853, 1645, 1573, 1493, 1436, 1385, 1324, 1263, 1237, 1206, 1093, 1040 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 372.9878, found 372.9869.</div></div><div id="sec5_1_6_92" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> 4-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1<i>H</i>-imidazole (<b>95</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1<i>H</i>-imidazole (0.132 g, 0.412 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as white foam (0.065 g, 0.183 mmol, 45% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.67 (s, 1H), 7.32 (d, <i>J</i> = 8.7 Hz, 2H), 7.09 (d, <i>J</i> = 8.3 Hz, 2H), 6.96 (td, <i>J</i> = 9.2, 5.0 Hz, 1H), 6.85–6.77 (m, 1H), 3.83 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 153.82 (dd, <i>J</i> = 244.9, 3.7 Hz), 149.93 (dd, <i>J</i> = 251.9, 5.9 Hz), 144.49 (dd, <i>J</i> = 10.6, 2.7 Hz), 136.77, 134.84, 134.59, 132.37, 129.88, 125.92, 116.10, 114.96 (dd, <i>J</i> = 9.5, 2.1 Hz), 110.52 (dd, <i>J</i> = 22.6, 4.3 Hz), 106.13 (dd, <i>J</i> = 21.1, 16.7 Hz), 56.81 ppm. IR (KBr) ν 3097, 2925, 2843, 1591, 1563, 1495, 1463, 1440, 1328, 1257, 1203, 1094, 1070 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 355.0217, found 355.0203.</div></div><div id="sec5_1_6_93" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> 2-Chloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1<i>H</i>-imidazole (<b>96</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1<i>H</i>-imidazole (0.132 g, 0.412 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.015 g, 0.042 mmol, 10% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.38–7.31 (m, 2H), 7.18 (s, 1H), 7.16–7.11 (m, 2H), 6.88 (td, <i>J</i> = 9.1, 5.0 Hz, 1H), 6.80–6.72 (m, 1H), 3.82 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 153.85 (dd, <i>J</i> = 243.6, 4.2 Hz), 149.92 (dd, <i>J</i> = 250.9, 5.9 Hz), 144.38 (dd, <i>J</i> = 11.0, 3.4 Hz), 135.36, 134.38, 133.55, 130.48, 129.57, 128.66, 122.51, 114.40 (dd, <i>J</i> = 9.5, 3.2 Hz), 110.34 (dd, <i>J</i> = 23.3, 4.4 Hz), 107.70 (dd, <i>J</i> = 21.2, 16.9 Hz), 56.84 ppm. IR (KBr) ν 3096, 2923, 2849, 1590, 1493, 1459, 1438, 1383, 1318, 1244, 1175, 1123, 1093, 1058 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 355.0217, found 355.0219.</div></div><div id="sec5_1_6_94" class="NLM_sec NLM_sec_level_3"><div id="ac_i114" class="anchor-spacer"></div><h4 class="article-section__title" id="_i114"> 2,4-Dichloro-1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1<i>H</i>-imidazole (<b>97</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(2,6-difluoro-3-methoxyphenyl)-1<i>H</i>-imidazole (0.132 g, 0.412 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.009 g, 0.023 mmol, 6% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.37–7.34 (m, 2H), 7.15–7.12 (m, 2H), 6.94 (td, <i>J</i> = 9.2, 5.0 Hz, 1H), 6.81–6.77 (m, 1H), 3.83 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 153.94 (dd, <i>J</i> = 244.9, 4.0 Hz), 150.12 (dd, <i>J</i> = 252.5, 5.6 Hz), 144.45 (dd, <i>J</i> = 10.6, 3.4 Hz), 135.95, 133.06, 132.65, 130.49, 129.78, 128.61, 118.59, 115.43 (dd, <i>J</i> = 9.8, 3.0 Hz), 110.51 (dd, <i>J</i> = 22.8, 4.3 Hz), 105.84 (dd, <i>J</i> = 21.4, 16.8 Hz), 56.88 ppm. IR (KBr) ν 2921, 2850, 1639, 1494, 1440, 1384, 1331, 1251, 1090 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>10</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub>O [M + H]<sup>+</sup> 388.9827, found 388.9832.</div></div><div id="sec5_1_6_95" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> 4-Chloro-1-(4-chlorophenyl)-5-phenyl-1<i>H</i>-imidazole (<b>98</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-phenyl-1<i>H</i>-imidazole (0.070 g, 0.275 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.061 g, 0.211 mmol, 77% yield). X-ray quality crystals were obtained by slow evaporation from a CH<sub>2</sub>Cl<sub>2</sub>/hexanes solution (see <a href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf" class="ext-link">Supporting Information</a>): mp (CH<sub>2</sub>Cl<sub>2</sub>/hexanes) 126–128 °C. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.58 (s, 1H), 7.36–7.29 (m, 5H), 7.22–7.16 (m, 2H), 7.09–7.02 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 135.72, 134.91, 134.49, 129.89, 129.75, 129.24, 128.62, 128.44, 127.28, 127.09, 126.61 ppm. IR (KBr) ν 3121, 3096, 3034, 2917, 2849, 1607, 1558, 1497, 1483, 1467, 1413, 1329, 1259, 1199, 1090 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>11</sub>Cl<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 289.0299, found 289.0300.</div></div><div id="sec5_1_6_96" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> 2-Chloro-1-(4-chlorophenyl)-5-phenyl-1<i>H</i>-imidazole (<b>99</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-phenyl-1<i>H</i>-imidazole (0.070 g, 0.275 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.007 g, 0.025 mmol, 9% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.45–7.38 (m, 2H), 7.27–7.22 (m, 3H), 7.20–7.12 (m, 3H), 7.10–7.03 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 135.32, 134.09, 133.77, 129.85, 129.37, 128.95, 128.76, 128.12, 127.94, 127.21, 125.13 ppm. IR (KBr) ν 2956, 2918, 2850, 1487, 1457, 1432, 1383, 1307, 1256, 1146, 1146, 1093 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>11</sub>Cl<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 289.0299, found 289.0324.</div></div><div id="sec5_1_6_97" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> 2,4-Dichloro-1-(4-chlorophenyl)-5-phenyl-1<i>H</i>-imidazole (<b>100</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-phenyl-1<i>H</i>-imidazole (0.070 g, 0.275 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.008 g, 0.024 mmol, 9% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.40–7.36 (m, 2H), 7.30–7.27 (m, 3H), 7.16–7.12 (m, 2H), 7.12–7.08 (m, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 135.64, 133.57, 131.34, 129.89, 129.59, 129.21, 128.71, 128.65, 127.20, 127.05 ppm. IR (KBr) ν 2956, 2917, 2849, 1493, 1452, 1381, 1230, 1091 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>10</sub>Cl<sub>3</sub>N<sub>2</sub> [M + H]<sup>+</sup> 322.9910, found 322.9906.</div></div><div id="sec5_1_6_98" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> 4-Chloro-1-(4-chlorophenyl)-5-(4-methoxyphenyl)-1<i>H</i>-imidazole (<b>101</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(4-chlorophenyl)-5-(4-methoxyphenyl)-1<i>H</i>-imidazole (0.220 g, 0.773 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a yellow solid (0.159 g, 0.498 mmol, 65% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.55 (s, 1H), 7.36–7.31 (m, 2H), 7.11 (d, <i>J</i> = 8.1 Hz, 2H), 7.06 (d, <i>J</i> = 7.9 Hz, 2H), 6.84 (d, <i>J</i> = 8.3 Hz, 2H), 3.79 (s, 3H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 159.66, 135.29, 135.02, 134.43, 131.15, 129.87, 128.71, 127.05, 126.64, 119.49, 114.17, 55.36 ppm. IR (KBr) ν 3116, 3004, 2960, 2836, 1713, 1614, 1556, 1497, 1467, 1290, 1253, 1179, 1087 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>16</sub>H<sub>12</sub>Cl<sub>2</sub>N<sub>2</sub>NaO [M + Na]<sup>+</sup> 341.0224, found 341.0229.</div></div><div id="sec5_1_6_99" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> 4-Chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>102</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.260 g, 0.894 mmol), purification by silica gel column chromatography (hexanes/EtOAc 75:25) afforded the title compound as a white solid (0.187 g, 0.575 mmol, 64% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.63 (s, 1H), 7.42 (d, <i>J</i> = 7.9 Hz, 1H), 7.36–7.29 (m, 2H), 7.29–7.26 (m, 2H), 6.85 (t, <i>J</i> = 8.6 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.77 (dd, <i>J</i> = 252.5, 5.9 Hz), 137.58, 133.55, 131.88 (t, <i>J</i> = 10.2 Hz), 131.70, 131.67, 130.73, 130.61, 129.10, 127.60, 117.02, 111.64 (dd, <i>J</i> = 21.8, 3.6 Hz), 105.35 (t, <i>J</i> = 19.5 Hz) ppm. IR (KBr) ν 3129, 3052, 2988, 2922, 2846, 1633, 1589, 1568, 1492, 1471, 1455, 1266, 1238, 1003 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 325.0111, found 325.0111.</div></div><div id="sec5_1_6_100" class="NLM_sec NLM_sec_level_3"><div id="ac_i120" class="anchor-spacer"></div><h4 class="article-section__title" id="_i120"> 2-Chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>103</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.260 g, 0.894 mmol), purification by silica gel column chromatography (hexanes/EtOAc 75:25) afforded the title compound as a white solid (0.026 g, 0.080 mmol, 9% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 7.36–7.27 (m, 3H), 7.25–7.16 (m, 2H), 6.79 (t, <i>J</i> = 7.7 Hz, 2H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 160.72 (dd, <i>J</i> = 251.5, 5.8 Hz), 134.75, 133.21, 132.81, 131.34 (t, <i>J</i> = 10.2 Hz), 131.06, 130.51, 130.44, 130.32, 127.44, 122.84, 111.53 (dd, <i>J</i> = 20.6, 5.1 Hz), 106.87 (t, <i>J</i> = 19.5 Hz) ppm. IR (KBr) ν 2916, 2852, 1633, 1587, 1487, 1468, 1435, 1383, 1313, 1277, 1235, 1000 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>9</sub>Cl<sub>2</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 325.0111, found 325.0119.</div></div><div id="sec5_1_6_101" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> 2,4-Dichloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (<b>104</b>)</h4><div class="NLM_p last">Following synthetic procedure E using 4-chloro-1-(2-chlorophenyl)-5-(2,6-difluorophenyl)-1<i>H</i>-imidazole (0.060 g, 0.184 mmol), purification by silica gel column chromatography (hexanes/EtOAc 80:20) afforded the title compound as a white solid (0.047 g, 0.131 mmol, 71% yield). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 7.44 (d, <i>J</i> = 7.9 Hz, 1H), 7.40–7.27 (m, 4H), 6.88 (t, <i>J</i> = 8.5 Hz, 1H), 6.82 (t, <i>J</i> = 8.6 Hz, 1H) ppm. <sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>) δ 161.07 (dd, <i>J</i> = 254.4, 5.9 Hz), 133.11, 133.08, 132.37 (t, <i>J</i> = 11.2 Hz), 131.53, 130.56, 130.39, 130.24, 130.22, 127.62, 118.89, 111.95 (dd, <i>J</i> = 21.7, 3.5 Hz), 111.41 (dd, <i>J</i> = 21.8, 3.7 Hz), 104.92 (t, <i>J</i> = 19.8 Hz) ppm. IR (KBr) ν 3073, 2918, 2853, 1633, 1588, 1487, 1466, 1439, 1384, 1278, 1237, 1002 cm<sup>–1</sup>. HRMS (ES<sup>+</sup>) calculated for C<sub>15</sub>H<sub>8</sub>Cl<sub>3</sub>F<sub>2</sub>N<sub>2</sub> [M + H]<sup>+</sup> 358.9721, found 358.9717.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> Acetyl-Tubulin Assay</h3><div class="NLM_p last">QBI-293 cells (ATCC, Manassas, VA, USA) were maintained in Dulbecco’s Modified Eagle’s Medium (Mediatech Inc., Manassas, VA, USA) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, USA), 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine (Mediatech), 50 units/mL penicillin, and 50 μg/mL streptomycin (1% penicillin/streptomycin; Thermo Fisher Scientific, Waltham, MA, USA). Cells were maintained at 37 °C in a humidified atmosphere (5% CO<sub>2</sub>) for all experiments. For compound testing, cells were dissociated with trypsin/EDTA (Thermo Fisher Scientific) and plated at 6 × 10<sup>5</sup> cells/well in 6-well plates. The medium was aspirated after overnight incubation and fresh medium containing vehicle or test compound was added. After incubating for 4 h, cells were washed once with 1× phosphate-buffered saline (PBS), pH 7.4 and then lysed in 200 μL RIPA buffer containing protease inhibitor cocktail, 1 mM PMSF, and 1 μM TSA. Lysed cells were scraped into 1.5 mL Beckman ultracentrifuge tubes (Beckman, Brea, CA, USA) and centrifuged at 100000<i>g</i> for 30 min at 4 °C. Following centrifugation, the supernatant from each sample was collected and analyzed for protein content by BCA assay. The samples subsequently underwent analysis for acetyl-tubulin and α-tubulin levels by ELISA, as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> RBL-1 Cell PG and LT Assay</h3><div class="NLM_p last">Inhibition of PG and LT synthesis by test compounds was determined through the utilization of an established RBL-1 cell assay.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Briefly, RBL-1 cells (ATCC) were maintained in RPMI 1640 medium (Mediatech Inc., Manassas, VA) containing 10% fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA), 1 mM <span class="smallcaps smallerCapital">l</span>-glutamine (Mediatech), 50 U/mL penicillin, and 0.05 mg/mL streptomycin (Thermo Fisher Scientific). For analysis of PG and LT production, RBL-1 cells were plated at a density of 9 × 10<sup>5</sup> cells/well in 24-well plates. After 2 h incubation at 37 °C, cells were added with indicated concentrations of test compounds. Following 2 h incubation with test compounds, cells were incubated with 12 μM calcium ionophore, A23187, for 15 min to induce arachidonic acid production. Cell culture supernatants (200 μL/well) were then collected and treated with 600 μL of MeOH containing 0.01% BHT (butylated hydroxytoluene) to extract eicosanoids. After centrifugation, the supernatant was dried with a vacuum centrifugation and redissolved in 200 μL of 50% acetonitrile. Enzyme products were quantified with an Acquity UPLC-TQ MS system (Waters Corporation, Milford, MA). Injections (10 μL) were separated on an Acquity BEH C18, 1.7 μm, 2.1 mm × 50 mm column at 37 °C using a gradient from 5 to 95% acetonitrile with 10 mM ammonium formate over 2 min at 0.6 mL/min. Combined PGD<sub>2</sub>+PGE<sub>2</sub>, as well as LTB<sub>4</sub>, were detected in negative ion mode using compound specific collision induced mass transitions (PGD<sub>2</sub> and PGE<sub>2</sub>, 351 > 315; LTB<sub>4</sub>, 335 > 195). To separate the isomeric prostaglandins PGD<sub>2</sub> and PGE<sub>2</sub>, a higher resolution gradient from 5 to 60% acetonitrile over 3 min at 0.6 mL/min was used. The cysteinyl leukotriene LTC<sub>4</sub> was separated using a gradient from 5 to 95% acetonitrile with 0.1% formic acid over 2 min at 0.6 mL/min. LTC<sub>4</sub> was detected using electrospray ionization in positive mode while monitoring for a compound specific mass transition (626 > 189). Chromatograms are integrated and peak areas used to quantitate unknowns against a curve of standards (Cayman Chemical, Ann Arbor, MI) from 1 to 50 ng/mL in 50% acetonitrile.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> Brain and Plasma Compound Determinations</h3><div class="NLM_p last">All animal protocols were approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC). Test compounds were administered to groups of three 2–5 month old CD-1 or B6SJL mice, with both female and male mice used but not mixed within experimental groups. For standard single time-point brain and plasma determinations, mice were injected i.p. with a single dose of 5 mg/kg compound dissolved in DMSO, or a dose of 2 mg/kg if two or three compounds were dosed concurrently (cassette dosing). Compounds were quantified in plasma and brain homogenates as previously described.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i125"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00475">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00475" class="ext-link">10.1021/acs.jmedchem.7b00475</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">NMR spectra of test compounds; X-ray crystal structures of compound <b>98</b> (CCDC 1529316); details for the docking studies; analysis of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> compounds for their ability to reduce multiple COX and 5-LOX products (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES string structures along the full data set in tabular form (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf">jm7b00475_si_001.pdf (3.12 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_002.csv">jm7b00475_si_002.csv (5.92 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00475" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41877" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41877" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kurt R. Brunden</span> - <span class="hlFld-Affiliation affiliation">Center for
Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a9c2cbdbdcc7cdccc7e9dcd9ccc7c787cccddc"><span class="__cf_email__" data-cfemail="02696070776c66676c427772676c6c2c676677">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carlo Ballatore</span> - <span class="hlFld-Affiliation affiliation">Skaggs School of Pharmacy and Pharmaceutical
Sciences, University of California, San
Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-2718-3850" title="Orcid link">http://orcid.org/0000-0002-2718-3850</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#492a2b282525283d263b2c093c2a3a2d672c2d3c"><span class="__cf_email__" data-cfemail="7f1c1d1e13131e0b100d1a3f0a1c0c1b511a1b0a">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anne-Sophie Cornec</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry,
School of Arts and Sciences, University
of Pennsylvania, 231
South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ludovica Monti</span> - <span class="hlFld-Affiliation affiliation">Skaggs School of Pharmacy and Pharmaceutical
Sciences, University of California, San
Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jane Kovalevich</span> - <span class="hlFld-Affiliation affiliation">Center for
Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vishruti Makani</span> - <span class="hlFld-Affiliation affiliation">Center for
Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. James</span> - <span class="hlFld-Affiliation affiliation">Center for
Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Krishna G. Vijayendran</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry,
School of Arts and Sciences, University
of Pennsylvania, 231
South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Killian Oukoloff</span> - <span class="hlFld-Affiliation affiliation">Skaggs School of Pharmacy and Pharmaceutical
Sciences, University of California, San
Diego, 9500 Gilman Drive, La Jolla, California 92093, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuemang Yao</span> - <span class="hlFld-Affiliation affiliation">Center for
Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Virginia M.-Y. Lee</span> - <span class="hlFld-Affiliation affiliation">Center for
Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John Q. Trojanowski</span> - <span class="hlFld-Affiliation affiliation">Center for
Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, Pennsylvania 19104-6323, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amos B. Smith</span> - <span class="hlFld-Affiliation affiliation">Department of Chemistry,
School of Arts and Sciences, University
of Pennsylvania, 231
South 34th Street, Philadelphia, Pennsylvania 19104-6323, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1712-8567" title="Orcid link">http://orcid.org/0000-0002-1712-8567</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e8068-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i127">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53831" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53831" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Financial support for this work has been provided in part by NIH/NIA (grant AG044332-01), the Woods Charitable Foundation, and the Cenci Bolognetti Foundation (LM).</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i128" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i128"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i129" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i129"> Abbreviations Used</h2><tr><td class="NLM_term">TosMIC</td><td class="NLM_def"><p class="first last">toluenesulfonylmethyl isocyanide</p></td></tr><tr><td class="NLM_term">LDA</td><td class="NLM_def"><p class="first last">lithium diisopropylamide</p></td></tr><tr><td class="NLM_term">AcTub</td><td class="NLM_def"><p class="first last">acetylated α-tubulin</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i130">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30457" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30457" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 60 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0lhAXvO6osb-dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Geldenhuys, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span> </span><span class="NLM_article-title">Rationally designed multi-targeted agents against neurodegenerative diseases</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1662</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.2174/09298673113209990112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.2174%2F09298673113209990112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23410161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1662-1672&author=W.+J.+Geldenhuysauthor=C.+J.+Van+der+Schyf&title=Rationally+designed+multi-targeted+agents+against+neurodegenerative+diseases&doi=10.2174%2F09298673113209990112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed multi-targeted agents against neurodegenerative diseases</span></div><div class="casAuthors">Geldenhuys, W. J.; Van der Schyf, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1662-1672</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases are complex disorders with several pathoetiol. pathways leading to cell death.  Rationally designed multi-targeted agents, or "multi-targeted designed drugs" (MTDD) show significant promise in preclin. studies as neuroprotective and disease-modifying agents.  In this review, we highlight the use of chem. scaffolds that lend themselves exquisitely to the development of MTDDs in neurodegeneration.  Notably, synthetic polycyclic cage compds. have served as scaffolds for novel voltage-gated calcium channel blockers, NMDA receptor antagonists, and sigma-receptor ligands - attractive targets in neurodegeneration.  In an entirely different approach, compds. contg. the thiazolidinedione moiety (referred to as glitazones) alter mitochondrial function through the mitochondrial protein mitoNEET, an attractive new drug target for the treatment of neurodegenerative diseases.  The design strategy for yet another agent, ladostigil, employed the amalgamation of active chem. moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compd. that targets both enzymes simultaneously.  Natural products have also served as design templates for several MTDD design studies.  In particular, the stilbene scaffold has become popular in particular due to the neuroprotective effects of the non-flavonoid natural product resveratrol.  Recently, stilbene scaffold-based compds. were developed to reduce - through chelation with metal ions that interact with beta-amyloid - both metal-induced beta-amyloid protein aggregation, and ROS generated from this aggregate.  Other subtle modifications of the stilbene motif led to the creation of reversible, non-competitive MAO inhibitors.  Finally, compds. derived from the xanthine scaffold afford neuroprotection in Parkinson's disease through mechanisms that include dual adenosine A2A receptor antagonism and MAO-B inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZJN4lAGwOrVg90H21EOLACvtfcHk0lhAXvO6osb-dQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D&md5=626f69acb3b3ff995e31b042e48dfba3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F09298673113209990112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113209990112%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DRationally%2520designed%2520multi-targeted%2520agents%2520against%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1662%26epage%3D1672%26doi%3D10.2174%2F09298673113209990112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumiatti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0liHF1j1-pcqrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Makani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassalas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy</span> <span class="citation_source-journal">Acta Neuropathol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="refDoi"> DOI: 10.1186/s40478-016-0378-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1186%2Fs40478-016-0378-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=27687527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVahs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=106&author=V.+Makaniauthor=B.+Zhangauthor=H.+Hanauthor=Y.+Yaoauthor=P.+Lassalasauthor=K.+Louauthor=I.+Patersonauthor=V.+M.+Y.+Leeauthor=J.+Q.+Trojanowskiauthor=C.+Ballatoreauthor=A.+B.+Smithauthor=K.+R.+Brunden&title=Evaluation+of+the+brain-penetrant+microtubule-stabilizing+agent%2C+dictyostatin%2C+in+the+PS19+tau+transgenic+mouse+model+of+tauopathy&doi=10.1186%2Fs40478-016-0378-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy</span></div><div class="casAuthors">Makani, Vishruti; Zhang, Bin; Han, Heeoon; Yao, Yuemang; Lassalas, Pierrik; Lou, Kevin; Paterson, Ian; Lee, Virginia M. Y.; Trojanowski, John Q.; Ballatore, Carlo; Smith, Amos B., III; Brunden, Kurt R.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106/1-106/12</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Neurodegenerative disorders referred to as tauopathies, which includes Alzheimer's disease (AD), are characterized by insol. deposits of the tau protein within neuron cell bodies and dendritic processes in the brain.  Tau is normally assocd. with microtubules (MTs) in axons, where it provides MT stabilization and may modulate axonal transport.  However, tau becomes hyperphosphorylated and dissocs. from MTs in tauopathies, with evidence of reduced MT stability and defective axonal transport.  This has led to the hypothesis that MT-stabilizing drugs may have potential for the treatment of tauopathies.  Prior studies demonstrated that the brain-penetrant MT-stabilizing drug, epothilone D, had salutary effects in transgenic (Tg) mouse models of tauopathy, improving MT d. and axonal transport, while reducing axonal dystrophy.  Moreover, epothilone D enhanced cognitive performance and decreased hippocampal neuron loss, with evidence of reduced tau pathol.  To date, epothilone D has been the only non-peptide small mol. MT-stabilizing agent to be evaluated in Tg tau mice.  Herein, we demonstrate the efficacy of another small mol. brain-penetrant MT-stabilizing agent, dictyostatin, in the PS19 tau Tg mouse model.  Although dictyostatin was poorly tolerated at once-weekly doses of 1 mg/kg or 0.3 mg/kg, likely due to gastrointestinal (GI) complications, a dictyostatin dose of 0.1 mg/kg was better tolerated, such that the majority of 6-mo old PS19 mice, which harbor a moderate level of brain tau pathol., completed a 3-mo dosing study without evidence of significant body wt. loss.  Importantly, as previously obsd. with epothilone D, the dictyostatin-treated PS19 mice displayed improved MT d. and reduced axonal dystrophy, with a redn. of tau pathol. and a trend toward increased hippocampal neuron survival relative to vehicle-treated PS19 mice.  Thus, despite evidence of dose-limiting peripheral side effects, the obsd. pos. brain outcomes in dictyostatin-treated aged PS19 mice reinforces the concept that MT-stabilizing compds. have significant potential for the treatment of tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAlkQNMCw8grVg90H21EOLACvtfcHk0liHF1j1-pcqrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVahs7zN&md5=d0ee514e0ec3870dc1c7deb31ee290d2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2Fs40478-016-0378-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-016-0378-4%26sid%3Dliteratum%253Aachs%26aulast%3DMakani%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLassalas%26aufirst%3DP.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DPaterson%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DV.%2BM.%2BY.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DEvaluation%2520of%2520the%2520brain-penetrant%2520microtubule-stabilizing%2520agent%252C%2520dictyostatin%252C%2520in%2520the%2520PS19%2520tau%2520transgenic%2520mouse%2520model%2520of%2520tauopathy%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2016%26volume%3D4%26spage%3D106%26doi%3D10.1186%2Fs40478-016-0378-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potuzak, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3601</span><span class="NLM_x">–</span> <span class="NLM_lpage">3611</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.4922-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.4922-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22423084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlOlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=3601-3611&author=B.+Zhangauthor=J.+Carrollauthor=J.+Q.+Trojanowskiauthor=Y.+Yaoauthor=M.+Ibaauthor=J.+S.+Potuzakauthor=A.+M.+Hoganauthor=S.+X.+Xieauthor=C.+Ballatoreauthor=A.+B.+Smithauthor=V.+M.+Leeauthor=K.+R.+Brunden&title=The+microtubule-stabilizing+agent%2C+epothilone+D%2C+reduces+axonal+dysfunction%2C+neurotoxicity%2C+cognitive+deficits%2C+and+Alzheimer-like+pathology+in+an+interventional+study+with+aged+tau+transgenic+mice&doi=10.1523%2FJNEUROSCI.4922-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice</span></div><div class="casAuthors">Zhang, Bin; Carroll, Jenna; Trojanowski, John Q.; Yao, Yuemang; Iba, Michiyo; Potuzak, Justin S.; Hogan, Anne-Marie L.; Xie, Sharon X.; Ballatore, Carlo; Smith, Amos B., III; Lee, Virginia M.-Y.; Brunden, Kurt R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3601-3611</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neurodegenerative tauopathies, such as Alzheimer's disease (AD), are characterized by insol. deposits of hyperphosphorylated tau protein within brain neurons.  Increased phosphorylation and decreased soly. has been proposed to diminish normal tau stabilization of microtubules (MTs), thereby leading to neuronal dysfunction.  Earlier studies have provided evidence that small mol. MT-stabilizing drugs that are used in the treatment of cancer may have utility in the treatment of tauopathies.  However, it has not been established whether treatment with a small mol. MT-stabilizing compd. will provide benefit in a transgenic model with preexisting tau pathol., as would be seen in human patients with clin. symptoms.  Accordingly, we describe here an interventional study of the brain-penetrant MT-stabilizing agent, epothilone D (EpoD), in aged PS19 mice with existing tau pathol. and related behavioral deficits.  EpoD treatment reduced axonal dystrophy and increased axonal MT d. in the aged PS19 mice, which led to improved fast axonal transport and cognitive performance.  Moreover, the EpoD-treated PS19 mice had less forebrain tau pathol. and increased hippocampal neuronal integrity, with no dose-limiting side effects.  These data reveal that brain-penetrant MT-stabilizing drugs hold promise for the treatment of AD and related tauopathies, and that EpoD could be a candidate for clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHk7y2bIOfKbVg90H21EOLACvtfcHk0liHF1j1-pcqrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlOlsbg%253D&md5=9ef57c897e3ff5c8c1930599607e5270</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4922-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4922-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCarroll%26aufirst%3DJ.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DIba%26aufirst%3DM.%26aulast%3DPotuzak%26aufirst%3DJ.%2BS.%26aulast%3DHogan%26aufirst%3DA.%2BM.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DThe%2520microtubule-stabilizing%2520agent%252C%2520epothilone%2520D%252C%2520reduces%2520axonal%2520dysfunction%252C%2520neurotoxicity%252C%2520cognitive%2520deficits%252C%2520and%2520Alzheimer-like%2520pathology%2520in%2520an%2520interventional%2520study%2520with%2520aged%2520tau%2520transgenic%2520mice%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26spage%3D3601%26epage%3D3611%26doi%3D10.1523%2FJNEUROSCI.4922-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potuzak, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span> </span><span class="NLM_article-title">Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">13861</span><span class="NLM_x">–</span> <span class="NLM_lpage">13866</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.3059-10.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.3059-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=20943926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlegsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=13861-13866&author=K.+R.+Brundenauthor=B.+Zhangauthor=J.+Carrollauthor=Y.+Yaoauthor=J.+S.+Potuzakauthor=A.+M.+Hoganauthor=M.+Ibaauthor=M.+J.+Jamesauthor=S.+X.+Xieauthor=C.+Ballatoreauthor=A.+B.+Smithauthor=V.+M.+Leeauthor=J.+Q.+Trojanowski&title=Epothilone+D+improves+microtubule+density%2C+axonal+integrity%2C+and+cognition+in+a+transgenic+mouse+model+of+tauopathy&doi=10.1523%2FJNEUROSCI.3059-10.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy</span></div><div class="casAuthors">Brunden, Kurt R.; Zhang, Bin; Carroll, Jenna; Yao, Yuemang; Potuzak, Justin S.; Hogan, Anne-Marie L.; Iba, Michiyo; James, Michael J.; Xie, Sharon X.; Ballatore, Carlo; Smith, Amos B., III; Lee, Virginia M.-Y.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">13861-13866</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neurons in the brains of those with Alzheimer's disease (AD) and many frontotemporal dementias (FTDs) contain neurofibrillary tangles comprised of hyperphosphorylated tau protein.  Tau normally stabilizes microtubules (MTs), and tau misfolding could lead to a loss of this function with consequent MT destabilization and neuronal dysfunction.  Accordingly, a possible therapeutic strategy for AD and related "tauopathies" is treatment with a MT-stabilizing anti-cancer drug such as paclitaxel.  However, paclitaxel and related taxanes have poor blood-brain barrier permeability and thus are unsuitable for diseases of the brain.  We demonstrate here that the MT-stabilizing agent, epothilone D (EpoD), is brain-penetrant and we subsequently evaluated whether EpoD can compensate for tau loss-of-function in PS19 tau transgenic mice that develop forebrain tau inclusions, axonal degeneration and MT deficits.  Treatment of 3-mo-old male PS19 mice with low doses of EpoD once weekly for a 3 mo period significantly improved CNS MT d. and axonal integrity without inducing notable side-effects.  Moreover, EpoD treatment reduced cognitive deficits that were obsd. in the PS19 mice.  These results suggest that certain brain-penetrant MT-stabilizing agents might provide a viable therapeutic strategy for the treatment of AD and FTDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1RAI4CQiMZLVg90H21EOLACvtfcHk0liLaeuOkqRW8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlegsLbP&md5=5a53dea5ef5dac0d48b476d9c12623ce</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3059-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3059-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCarroll%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DPotuzak%26aufirst%3DJ.%2BS.%26aulast%3DHogan%26aufirst%3DA.%2BM.%26aulast%3DIba%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DM.%2BJ.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DEpothilone%2520D%2520improves%2520microtubule%2520density%252C%2520axonal%2520integrity%252C%2520and%2520cognition%2520in%2520a%2520transgenic%2520mouse%2520model%2520of%2520tauopathy%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D13861%26epage%3D13866%26doi%3D10.1523%2FJNEUROSCI.3059-10.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Barten, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andorfer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoque, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, P. Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadelina, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCarr, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fessler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protassio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riff, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankaranarayanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meredith, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albright, C. F.</span><span> </span><span class="NLM_article-title">Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">7137</span><span class="NLM_x">–</span> <span class="NLM_lpage">7145</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.0188-12.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.0188-12.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22623658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFKksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=7137-7145&author=D.+M.+Bartenauthor=P.+Fanaraauthor=C.+Andorferauthor=N.+Hoqueauthor=P.+Y.+A.+Wongauthor=K.+H.+Hustedauthor=G.+W.+Cadelinaauthor=L.+B.+DeCarrauthor=L.+Yangauthor=L.+Liuauthor=C.+Fesslerauthor=J.+Protassioauthor=T.+Riffauthor=H.+Turnerauthor=C.+G.+Janusauthor=S.+Sankaranarayananauthor=C.+Polsonauthor=J.+E.+Meredithauthor=G.+Grayauthor=A.+Hannaauthor=R.+E.+Olsonauthor=S.+H.+Kimauthor=G.+D.+Viteauthor=F.+Y.+Leeauthor=C.+F.+Albright&title=Hyperdynamic+microtubules%2C+cognitive+deficits%2C+and+pathology+are+improved+in+tau+transgenic+mice+with+low+doses+of+the+microtubule-stabilizing+agent+BMS-241027&doi=10.1523%2FJNEUROSCI.0188-12.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027</span></div><div class="casAuthors">Barten, Donna M.; Fanara, Patrizia; Andorfer, Cathy; Hoque, Nina; Wong, P. Y. Anne; Husted, Kristofor H.; Cadelina, Gregory W.; DeCarr, Lynn B.; Yang, Ling; Liu, Victoria; Fessler, Chancy; Protassio, Joan; Riff, Timothy; Turner, Holly; Janus, Christopher G.; Sankaranarayanan, Sethu; Polson, Craig; Meredith, Jere E.; Gray, Gemma; Hanna, Amanda; Olson, Richard E.; Kim, Soong-Hoon; Vite, Gregory D.; Lee, Francis Y.; Albright, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7137-7145</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tau is a microtubule (MT)-stabilizing protein that is altered in Alzheimer's disease (AD) and other tauopathies.  It is hypothesized that the hyperphosphorylated, conformationally altered, and multimeric forms of tau lead to a disruption of MT stability; however, direct evidence is lacking in vivo.  In this study, an in vivo stable isotope-mass spectrometric technique was used to measure the turnover, or dynamicity, of MTs in brains of living animals.  We demonstrated an age-dependent increase in MT dynamics in two different tau transgenic mouse models, 3xTg and rTg4510.  MT hyperdynamicity was dependent on tau expression, since a redn. of transgene expression with doxycycline reversed the MT changes.  Treatment of rTg4510 mice with the epothilone, BMS-241027, also restored MT dynamics to baseline levels.  In addn., MT stabilization with BMS-241027 had beneficial effects on Morris water maze deficits, tau pathol., and neurodegeneration.  Interestingly, pathol. and functional benefits of BMS-241027 were obsd. at doses that only partially reversed MT hyperdynamicity.  Together, these data suggest that tau-mediated loss of MT stability may contribute to disease progression and that very low doses of BMS-241027 may be useful in the treatment of AD and other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTUE0FB4RfBrVg90H21EOLACvtfcHk0liLaeuOkqRW8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFKksb8%253D&md5=e7dfb8668c6b69dd3dc55ff290e6e7fa</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0188-12.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0188-12.2012%26sid%3Dliteratum%253Aachs%26aulast%3DBarten%26aufirst%3DD.%2BM.%26aulast%3DFanara%26aufirst%3DP.%26aulast%3DAndorfer%26aufirst%3DC.%26aulast%3DHoque%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DP.%2BY.%2BA.%26aulast%3DHusted%26aufirst%3DK.%2BH.%26aulast%3DCadelina%26aufirst%3DG.%2BW.%26aulast%3DDeCarr%26aufirst%3DL.%2BB.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFessler%26aufirst%3DC.%26aulast%3DProtassio%26aufirst%3DJ.%26aulast%3DRiff%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DH.%26aulast%3DJanus%26aufirst%3DC.%2BG.%26aulast%3DSankaranarayanan%26aufirst%3DS.%26aulast%3DPolson%26aufirst%3DC.%26aulast%3DMeredith%26aufirst%3DJ.%2BE.%26aulast%3DGray%26aufirst%3DG.%26aulast%3DHanna%26aufirst%3DA.%26aulast%3DOlson%26aufirst%3DR.%2BE.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26atitle%3DHyperdynamic%2520microtubules%252C%2520cognitive%2520deficits%252C%2520and%2520pathology%2520are%2520improved%2520in%2520tau%2520transgenic%2520mice%2520with%2520low%2520doses%2520of%2520the%2520microtubule-stabilizing%2520agent%2520BMS-241027%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26spage%3D7137%26epage%3D7145%26doi%3D10.1523%2FJNEUROSCI.0188-12.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Herbst-Robinson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">18286</span><span class="refDoi"> DOI: 10.1038/srep18286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1038%2Fsrep18286" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=18286&author=K.+J.+Herbst-Robinsonauthor=L.+Liuauthor=M.+Jamesauthor=Y.+Yaoauthor=S.+X.+Xieauthor=K.+R.+Brunden&title=Inflammatory+eicosanoids+increase+amyloid+precursor+protein+expression+via+activation+of+multiple+neuronal+receptors&doi=10.1038%2Fsrep18286"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsrep18286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18286%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst-Robinson%26aufirst%3DK.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DInflammatory%2520eicosanoids%2520increase%2520amyloid%2520precursor%2520protein%2520expression%2520via%2520activation%2520of%2520multiple%2520neuronal%2520receptors%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D5%26spage%3D18286%26doi%3D10.1038%2Fsrep18286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidell, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markesbery, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. J.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span> </span><span class="NLM_article-title">Elevated CSF prostaglandin E2 levels in patients with probable AD</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">1498</span><span class="refDoi"> DOI: 10.1212/WNL.53.7.1495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1212%2FWNL.53.7.1495" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1999&pages=1495-1498&author=T.+J.+Montineauthor=K.+R.+Sidellauthor=B.+C.+Crewsauthor=W.+R.+Markesberyauthor=L.+J.+Marnettauthor=L.+J.+Robertsauthor=J.+D.+Morrow&title=Elevated+CSF+prostaglandin+E2+levels+in+patients+with+probable+AD&doi=10.1212%2FWNL.53.7.1495"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1212%2FWNL.53.7.1495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.53.7.1495%26sid%3Dliteratum%253Aachs%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DSidell%26aufirst%3DK.%2BR.%26aulast%3DCrews%26aufirst%3DB.%2BC.%26aulast%3DMarkesbery%26aufirst%3DW.%2BR.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DRoberts%26aufirst%3DL.%2BJ.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26atitle%3DElevated%2520CSF%2520prostaglandin%2520E2%2520levels%2520in%2520patients%2520with%2520probable%2520AD%26jtitle%3DNeurology%26date%3D1999%26volume%3D53%26spage%3D1495%26epage%3D1498%26doi%3D10.1212%2FWNL.53.7.1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Manev, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzitoyeva, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manev, R.</span><span> </span><span class="NLM_article-title">Cyclooxygenases and 5-lipoxygenase in Alzheimer’s disease</span> <span class="citation_source-journal">Prog. Neuro-Psychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span><span class="refDoi"> DOI: 10.1016/j.pnpbp.2010.07.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.pnpbp.2010.07.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=20691748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVaqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=315-319&author=H.+Manevauthor=H.+Chenauthor=S.+Dzitoyevaauthor=R.+Manev&title=Cyclooxygenases+and+5-lipoxygenase+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.pnpbp.2010.07.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease</span></div><div class="casAuthors">Manev, Hari; Chen, Hu; Dzitoyeva, Svetlana; Manev, Radmila</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-319</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Typically, cyclooxygenases (COXs) and 5-lipoxygenase (5-LOX), enzymes that generate biol. active lipid mols. termed eicosanoids, are considered inflammatory.  Hence, their putative role in Alzheimer's disease (AD) has been explored in the framework of possible inflammatory mechanisms of AD pathobiol.  More recent data indicate that these enzymes and the biol. active lipid mols. they generate could influence the functioning of the central nervous system and the pathobiol. of neurodegenerative disorders such as AD via mechanisms different from classical inflammation.  These mechanisms include the cell-specific localization of COXs and 5-LOX in the brain, the type of lipid mols. generated by the activity of these enzymes, the type and the localization of receptors selective for a type of lipid mol., and the putative interactions of the COXs and 5-LOX pathways with intracellular components relevant for AD such as the gamma-secretase complex.  Considering the importance of these multiple and not necessarily inflammatory mechanisms may help us delineate the exact nature of the involvement of the brain COXs and 5-LOX in AD and would reinvigorate the search for novel targets for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowCfvWyONgErVg90H21EOLACvtfcHk0lh0gDPUv7ue7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVaqsro%253D&md5=31ec759a2b6b927d789d44bb4dd9ae93</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2010.07.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2010.07.032%26sid%3Dliteratum%253Aachs%26aulast%3DManev%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDzitoyeva%26aufirst%3DS.%26aulast%3DManev%26aufirst%3DR.%26atitle%3DCyclooxygenases%2520and%25205-lipoxygenase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2011%26volume%3D35%26spage%3D315%26epage%3D319%26doi%3D10.1016%2Fj.pnpbp.2010.07.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimohama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakimura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebicke-Haerter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span> </span><span class="NLM_article-title">Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x">, </span> <span class="NLM_fpage">582</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1006/bbrc.1998.9981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1006%2Fbbrc.1998.9981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1999&pages=582-586&author=Y.+Kitamuraauthor=S.+Shimohamaauthor=H.+Koikeauthor=J.+Kakimuraauthor=Y.+Matsuokaauthor=Y.+Nomuraauthor=P.+J.+Gebicke-Haerterauthor=T.+Taniguchi&title=Increased+expression+of+cyclooxygenases+and+peroxisome+proliferator-activated+receptor-gamma+in+Alzheimer%E2%80%99s+disease+brains&doi=10.1006%2Fbbrc.1998.9981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1998.9981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1998.9981%26sid%3Dliteratum%253Aachs%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DShimohama%26aufirst%3DS.%26aulast%3DKoike%26aufirst%3DH.%26aulast%3DKakimura%26aufirst%3DJ.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DNomura%26aufirst%3DY.%26aulast%3DGebicke-Haerter%26aufirst%3DP.%2BJ.%26aulast%3DTaniguchi%26aufirst%3DT.%26atitle%3DIncreased%2520expression%2520of%2520cyclooxygenases%2520and%2520peroxisome%2520proliferator-activated%2520receptor-gamma%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1999%26volume%3D254%26spage%3D582%26epage%3D586%26doi%3D10.1006%2Fbbrc.1998.9981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Fujimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakisaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwaki, T.</span><span> </span><span class="NLM_article-title">Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer’s disease: the Hisayama Study</span> <span class="citation_source-journal">Dementia Geriatr. Cognit. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1159/000101957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1159%2F000101957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=17457030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Sqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2007&pages=423-431&author=K.+Fujimiauthor=K.+Nodaauthor=K.+Sasakiauthor=Y.+Wakisakaauthor=Y.+Tanizakiauthor=M.+Iidaauthor=Y.+Kiyoharaauthor=S.+Kanbaauthor=T.+Iwaki&title=Altered+expression+of+COX-2+in+subdivisions+of+the+hippocampus+during+aging+and+in+Alzheimer%E2%80%99s+disease%3A+the+Hisayama+Study&doi=10.1159%2F000101957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: the hisayama study</span></div><div class="casAuthors">Fujimi, Kouhei; Noda, Kazuhito; Sasaki, Kensuke; Wakisaka, Yoshinobu; Tanizaki, Yumihiro; Iida, Mitsuo; Kiyohara, Yutaka; Kanba, Shigenobu; Iwaki, Toru</div><div class="citationInfo"><span class="NLM_cas:title">Dementia and Geriatric Cognitive Disorders</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">DGCDFX</span>;
        ISSN:<span class="NLM_cas:issn">1420-8008</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">It has been reported that nonsteroidal anti-inflammatory drugs may delay the onset of Alzheimer's disease (AD).  Since nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase (COX), COX-2, an inducible form of COX, may be involved in the pathol. of AD in assocn. with the arachidonic acid cascade.  In addn., it has been suggested that alterations in the balance of polyunsatd. fatty acids are assocd. with brain dysfunctions such as neurodegenerative pathologies of the aging brain.  To explore COX-2 expression in the hippocampus, we analyzed 45 consecutive autopsy subjects without dementia and 25 AD patients derived from the town of Hisayama, Japan.  The neuronal expression of COX-2 in the CA3 subdivision of the hippocampus, subiculum, entorhinal cortex and transentorhinal cortex were consistently obsd. in both nondemented and AD brains, and COX-2 immunoreactivity correlated with age in nondemented brains.  In AD patients, neurons of CA1 exhibited increased COX-2 immunoreactivity which correlated with the severity of AD pathol.  This correlation was not apparent in nondemented subjects.  These results suggest that COX-2 expression may be differentially regulated among subdivisions of the hippocampus and that elevated COX-2 expression in the CA1 of AD brains may be assocd. with AD pathol. and thus cognitive dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfc15HXFpqybVg90H21EOLACvtfcHk0lhkGznlMJ0dZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Sqsbg%253D&md5=991777f555947382c082f5cd225d021d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1159%2F000101957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000101957%26sid%3Dliteratum%253Aachs%26aulast%3DFujimi%26aufirst%3DK.%26aulast%3DNoda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DWakisaka%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DKiyohara%26aufirst%3DY.%26aulast%3DKanba%26aufirst%3DS.%26aulast%3DIwaki%26aufirst%3DT.%26atitle%3DAltered%2520expression%2520of%2520COX-2%2520in%2520subdivisions%2520of%2520the%2520hippocampus%2520during%2520aging%2520and%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520the%2520Hisayama%2520Study%26jtitle%3DDementia%2520Geriatr.%2520Cognit.%2520Disord.%26date%3D2007%26volume%3D23%26spage%3D423%26epage%3D431%26doi%3D10.1159%2F000101957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Zhen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yocum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrowolski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narumiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, S.</span><span> </span><span class="NLM_article-title">PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer’s disease</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2215</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2011.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neurobiolaging.2011.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22015313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSgt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=2215-2219&author=G.+Zhenauthor=Y.+T.+Kimauthor=R.+C.+Liauthor=J.+Yocumauthor=N.+Kapoorauthor=J.+Langerauthor=P.+Dobrowolskiauthor=T.+Maruyamaauthor=S.+Narumiyaauthor=S.+Dore&title=PGE2+EP1+receptor+exacerbated+neurotoxicity+in+a+mouse+model+of+cerebral+ischemia+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neurobiolaging.2011.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease</span></div><div class="casAuthors">Zhen, Gehua; Kim, Yun Tai; Li, Rung-chi; Yocum, Jennifer; Kapoor, Nidhi; Langer, John; Dobrowolski, Peter; Maruyama, Takayuki; Narumiya, Shuh; Dore, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2215-2219</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Stroke and Alzheimer's disease (AD) are major age-related neurodegenerative diseases that may worsen the prognosis of each other.  Our study was designed to delineate the prostaglandin E2 EP1 receptor role in AD and in the setting of cerebral ischemia.  Genetic deletion of the prostaglandin EP1 receptor significantly attenuated the more severe neuronal damage (38.5 ± 10.6%) and memory loss induced by ischemic insult obsd. in AD transgenic mice (percentage of viable hippocampal CA1 neurons: 11.2 ± 2.9%) when compared with wild type mice (45.1 ± 9.1%).  In addn., we found that the amyloid plaques were reduced in EP1 deleted AD mice. β-amyloid-induced toxicity (18.0 ± 7.1%) and Ca2+ response (91.8 ± 12.9%) were also reduced in EP1-/- neurons compared with control neurons in in vitro.  Hence, EP1 might mediate most of the toxicity assocd. with cyclooxygenase-2 and contribute substantially to the cell death pathways in AD and stroke.  Exploring potential therapeutic agent targeting EP1 receptor could potentially benefit treatments for stroke and AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQHW6rIXIcUrVg90H21EOLACvtfcHk0lhkGznlMJ0dZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSgt7zF&md5=9fd9a156469fd8fdea9f043e0526eb81</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2011.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2011.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DY.%2BT.%26aulast%3DLi%26aufirst%3DR.%2BC.%26aulast%3DYocum%26aufirst%3DJ.%26aulast%3DKapoor%26aufirst%3DN.%26aulast%3DLanger%26aufirst%3DJ.%26aulast%3DDobrowolski%26aufirst%3DP.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DNarumiya%26aufirst%3DS.%26aulast%3DDore%26aufirst%3DS.%26atitle%3DPGE2%2520EP1%2520receptor%2520exacerbated%2520neurotoxicity%2520in%2520a%2520mouse%2520model%2520of%2520cerebral%2520ischemia%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2012%26volume%3D33%26spage%3D2215%26epage%3D2219%26doi%3D10.1016%2Fj.neurobiolaging.2011.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hand, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasson, K.</span><span> </span><span class="NLM_article-title">Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">10180</span><span class="NLM_x">–</span> <span class="NLM_lpage">10187</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.3591-05.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.3591-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=16267225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wqt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=10180-10187&author=X.+Liangauthor=Q.+Wangauthor=T.+Handauthor=L.+Wuauthor=R.+M.+Breyerauthor=T.+J.+Montineauthor=K.+Andreasson&title=Deletion+of+the+prostaglandin+E2+EP2+receptor+reduces+oxidative+damage+and+amyloid+burden+in+a+model+of+Alzheimer%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.3591-05.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease</span></div><div class="casAuthors">Liang, Xibin; Wang, Qian; Hand, Tracey; Wu, Liejun; Breyer, Richard M.; Montine, Thomas J.; Andreasson, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">10180-10187</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Epidemiol. studies demonstrate that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) in normal aging populations reduces the risk of developing Alzheimer's disease (AD).  NSAIDs inhibit the enzymic activity of cyclooxygenase-1 (COX-1) and inducible COX-2, which catalyze the first committed step in the synthesis of prostaglandins.  These studies implicate COX-mediated inflammation as an early and potentially reversible preclin. event; however, the mechanism by which COX activity promotes development of AD has not been detd.  Recent studies implicate the prostaglandin E2 (PGE2) E prostanoid subtype 2 (EP2) receptor in the development of the innate immune response in brain.  Here, we report that deletion of the PGE2 EP2 receptor in the APPSwe-PS1ΔE9 model of familial AD results in marked redns. in lipid peroxidn. in aging mice.  This redn. in oxidative stress is assocd. with significant decreases in levels of amyloid-β (Aβ) 40 and 42 peptides and amyloid deposition.  Aged APPSwe-PS1ΔE9 mice lacking the EP2 receptor harbor lower levels of β C-terminal fragments, the product of β-site APP cleaving enzyme (BACE1) processing of amyloid precursor protein.  Increases in BACE1 processing have been demonstrated in models of aging and AD and after oxidative stress.  Our results indicate that PGE2 signaling via the EP2 receptor promotes age-dependent oxidative damage and increased Aβ peptide burden in this model of AD, possibly via effects on BACE1 activity.  Our findings identify EP2 receptor signaling as a novel proinflammatory and proamyloidogenic pathway in this model of AD, and suggest a rationale for development of therapeutics targeting the EP2 receptor in neuroinflammatory diseases such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvQcRSqBUHdrVg90H21EOLACvtfcHk0lhkGznlMJ0dZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wqt77I&md5=fadd58f101e78d983b0be1832c5bbb10</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3591-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3591-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHand%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBreyer%26aufirst%3DR.%2BM.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DAndreasson%26aufirst%3DK.%26atitle%3DDeletion%2520of%2520the%2520prostaglandin%2520E2%2520EP2%2520receptor%2520reduces%2520oxidative%2520damage%2520and%2520amyloid%2520burden%2520in%2520a%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D10180%26epage%3D10187%26doi%3D10.1523%2FJNEUROSCI.3591-05.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodling, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priyam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loui, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasson, K.</span><span> </span><span class="NLM_article-title">Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1002/ana.23677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fana.23677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22915243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1Sr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=788-798&author=J.+Shiauthor=Q.+Wangauthor=J.+U.+Johanssonauthor=X.+Liangauthor=N.+S.+Woodlingauthor=P.+Priyamauthor=T.+M.+Louiauthor=M.+Merchantauthor=R.+M.+Breyerauthor=T.+J.+Montineauthor=K.+Andreasson&title=Inflammatory+prostaglandin+E2+signaling+in+a+mouse+model+of+Alzheimer+disease&doi=10.1002%2Fana.23677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease</span></div><div class="casAuthors">Shi, Ju; Wang, Qian; Johansson, Jenny U.; Liang, Xibin; Woodling, Nathaniel S.; Priyam, Prachi; Loui, Taylor M.; Merchant, Milton; Breyer, Richard M.; Montine, Thomas J.; Andreasson, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-798</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: : There is significant evidence for a central role of inflammation in the development of Alzheimer disease (AD).  Epidemiol. studies indicate that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD in healthy aging populations.  As NSAIDs inhibit the enzymic activity of the inflammatory cyclooxygenases COX-1 and COX-2, these findings suggest that downstream prostaglandin signaling pathways function in the preclin. development of AD.  Here, we investigate the function of prostaglandin E2 (PGE2) signaling through its EP3 receptor in the neuroinflammatory response to Aβ peptide.  Methods: : The function of PGE2 signaling through its EP3 receptor was examd. in vivo in a model of subacute neuroinflammation induced by administration of Aβ42 peptides.  Our findings were then confirmed in young adult APPSwe-PS1ΔE9 transgenic mice.  Results: : Deletion of the PGE2 EP3 receptor in a model of Aβ42 peptide-induced neuroinflammation reduced proinflammatory gene expression, cytokine prodn., and oxidative stress.  In the APPSwe-PS1ΔE9 model of familial AD, deletion of the EP3 receptor blocked induction of proinflammatory gene and protein expression and lipid peroxidn.  In addn., levels of Aβ peptides were significantly decreased, as were β-secretase and β C-terminal fragment levels, suggesting that generation of Aβ peptides may be increased as a result of proinflammatory EP3 signaling.  Finally, deletion of EP3 receptor significantly reversed the decline in presynaptic proteins seen in APPSwe-PS1ΔE9 mice.  Interpretation: : Our findings identify the PGE2 EP3 receptor as a novel proinflammatory, proamyloidogenic, and synaptotoxic signaling pathway, and suggest a role for COX-PGE2-EP3 signaling in the development of AD.  ANN NEUROL 2012;72:788-798.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRmaJmkoToq7Vg90H21EOLACvtfcHk0ljQgszTiX-gGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1Sr&md5=a414b92089014b683619767d49a57831</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fana.23677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.23677%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DJohansson%26aufirst%3DJ.%2BU.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWoodling%26aufirst%3DN.%2BS.%26aulast%3DPriyam%26aufirst%3DP.%26aulast%3DLoui%26aufirst%3DT.%2BM.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DBreyer%26aufirst%3DR.%2BM.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DAndreasson%26aufirst%3DK.%26atitle%3DInflammatory%2520prostaglandin%2520E2%2520signaling%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2012%26volume%3D72%26spage%3D788%26epage%3D798%26doi%3D10.1002%2Fana.23677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Hoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narumiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizushima, T.</span><span> </span><span class="NLM_article-title">Improvement of cognitive function in Alzheimer’s disease model mice by genetic and pharmacological inhibition of the EP(4) receptor</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2011.07567.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fj.1471-4159.2011.07567.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22044482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XksFCnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=795-805&author=T.+Hoshinoauthor=T.+Nambaauthor=M.+Takeharaauthor=N.+Muraoauthor=T.+Matsushimaauthor=Y.+Sugimotoauthor=S.+Narumiyaauthor=T.+Suzukiauthor=T.+Mizushima&title=Improvement+of+cognitive+function+in+Alzheimer%E2%80%99s+disease+model+mice+by+genetic+and+pharmacological+inhibition+of+the+EP%284%29+receptor&doi=10.1111%2Fj.1471-4159.2011.07567.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP4 receptor</span></div><div class="casAuthors">Hoshino, Tatsuya; Namba, Takushi; Takehara, Masaya; Murao, Naoya; Matsushima, Takahide; Sugimoto, Yukihiko; Narumiya, Shuh; Suzuki, Toshiharu; Mizushima, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">5 & 6</span>),
    <span class="NLM_cas:pages">795-805</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Amyloid-β peptide (Aβ), which is generated by the β- and γ-secretase-mediated proteolysis of β-amyloid precursor protein (APP), plays an important role in the pathogenesis of Alzheimer's disease (AD).  We recently reported that prostaglandin E2 (PGE2) stimulates the prodn. of Aβ through both EP2 and EP4 receptors and that activation of the EP4 receptor stimulates Aβ prodn. through endocytosis and activation of γ-secretase.  We here found that transgenic mice expressing mutant APP (APP23) mice showed a greater or lesser apparent cognitive deficit when they were crossed with mice lacking EP2 or EP4 receptors, resp.  Mice lacking the EP4 receptor also displayed lower levels of Aβ plaque deposition and less neuronal and synaptic loss than control mice.  Oral administration of a specific EP4 receptor antagonist, AE3-208 to APP23 mice, improved their cognitive performance, as well as decreasing brain levels of Aβ and suppressing endocytosis and activation of γ-secretase.  Taken together, these results suggest that inhibition of the EP4 receptor improves the cognitive function of APP23 mice by suppressing Aβ prodn. and reducing neuronal and synaptic loss.  We therefore propose that EP4 receptor antagonists, such as AE3-208, could be therapeutically beneficial for the prevention and treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6B8rTHzbvCLVg90H21EOLACvtfcHk0ljQgszTiX-gGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksFCnt7g%253D&md5=973f037bca8e48ff2a4989f3bb15c543</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07567.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07567.x%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DT.%26aulast%3DNamba%26aufirst%3DT.%26aulast%3DTakehara%26aufirst%3DM.%26aulast%3DMurao%26aufirst%3DN.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DNarumiya%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMizushima%26aufirst%3DT.%26atitle%3DImprovement%2520of%2520cognitive%2520function%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520model%2520mice%2520by%2520genetic%2520and%2520pharmacological%2520inhibition%2520of%2520the%2520EP%25284%2529%2520receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D2012%26volume%3D120%26spage%3D795%26epage%3D805%26doi%3D10.1111%2Fj.1471-4159.2011.07567.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Woodling, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priyam, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagol-Ikapitte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutaud, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasson, K. I.</span><span> </span><span class="NLM_article-title">Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">5882</span><span class="NLM_x">–</span> <span class="NLM_lpage">5894</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.0410-14.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.0410-14.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24760848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OmtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=5882-5894&author=N.+S.+Woodlingauthor=Q.+Wangauthor=P.+G.+Priyamauthor=P.+Larkinauthor=J.+Shiauthor=J.+U.+Johanssonauthor=I.+Zagol-Ikapitteauthor=O.+Boutaudauthor=K.+I.+Andreasson&title=Suppression+of+Alzheimer-associated+inflammation+by+microglial+prostaglandin-E2+EP4+receptor+signaling&doi=10.1523%2FJNEUROSCI.0410-14.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling</span></div><div class="casAuthors">Woodling, Nathaniel S.; Wang, Qian; Priyam, Prachi G.; Larkin, Paul; Shi, Ju; Johansson, Jenny U.; Zagol-Ikapitte, Irene; Boutaud, Olivier; Andreasson, Katrin I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5882-5894, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">A persistent and nonresolving inflammatory response to accumulating Aβ peptide species is a cardinal feature in the development of Alzheimer's disease (AD).  In response to accumulating Aβ peptide species, microglia, the innate immune cells of the brain, generate a toxic inflammatory response that accelerates synaptic and neuronal injury.  Many proinflammatory signaling pathways are linked to progression of neurodegeneration.  However, endogenous anti-inflammatory pathways capable of suppressing Aβ-induced inflammation represent a relatively unexplored area.  Here we report that signaling through the prostaglandin-E2 (PGE2) EP4 receptor potently suppresses microglial inflammatory responses to Aβ42 peptides.  In cultured microglial cells, EP4 stimulation attenuated levels of Aβ42-induced inflammatory factors and potentiated phagocytosis of Aβ42.  Microarray anal. demonstrated that EP4 stimulation broadly opposed Aβ42-driven gene expression changes in microglia, with enrichment for targets of IRF1, IRF7, and NF-κB transcription factors.  In vivo, conditional deletion of microglial EP4 in APPSwe-PS1ΔE9 (APP-PS1) mice conversely increased inflammatory gene expression, oxidative protein modification, and Aβ deposition in brain at early stages of pathol., but not at later stages, suggesting an early anti-inflammatory function of microglial EP4 signaling in the APP-PS1 model.  Finally, EP4 receptor levels decreased significantly in human cortex with progression from normal to AD states, suggesting that early loss of this beneficial signaling system in preclin. AD development may contribute to subsequent progression of pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb5JcrDRCBeLVg90H21EOLACvtfcHk0ljQgszTiX-gGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OmtrrL&md5=e00802138b2f71d01d0422b50beaa290</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0410-14.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0410-14.2014%26sid%3Dliteratum%253Aachs%26aulast%3DWoodling%26aufirst%3DN.%2BS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DPriyam%26aufirst%3DP.%2BG.%26aulast%3DLarkin%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJohansson%26aufirst%3DJ.%2BU.%26aulast%3DZagol-Ikapitte%26aufirst%3DI.%26aulast%3DBoutaud%26aufirst%3DO.%26aulast%3DAndreasson%26aufirst%3DK.%2BI.%26atitle%3DSuppression%2520of%2520Alzheimer-associated%2520inflammation%2520by%2520microglial%2520prostaglandin-E2%2520EP4%2520receptor%2520signaling%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D5882%26epage%3D5894%26doi%3D10.1523%2FJNEUROSCI.0410-14.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Firuzi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnici, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratico, D.</span><span> </span><span class="NLM_article-title">5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer’s disease</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1169</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span><span class="refDoi"> DOI: 10.1096/fj.07-9131.com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1096%2Ffj.07-9131.com" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=1169-1178&author=O.+Firuziauthor=J.+Zhuoauthor=C.+M.+Chinniciauthor=T.+Wisniewskiauthor=D.+Pratico&title=5-Lipoxygenase+gene+disruption+reduces+amyloid-beta+pathology+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1096%2Ffj.07-9131.com"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1096%2Ffj.07-9131.com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.07-9131.com%26sid%3Dliteratum%253Aachs%26aulast%3DFiruzi%26aufirst%3DO.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DChinnici%26aufirst%3DC.%2BM.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DPratico%26aufirst%3DD.%26atitle%3D5-Lipoxygenase%2520gene%2520disruption%2520reduces%2520amyloid-beta%2520pathology%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D22%26spage%3D1169%26epage%3D1178%26doi%3D10.1096%2Ffj.07-9131.com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Ikonomovic, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamson, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manev, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekosky, S. T.</span><span> </span><span class="NLM_article-title">Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer’s disease</span> <span class="citation_source-journal">J. Histochem. Cytochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1369/jhc.2008.951855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1369%2Fjhc.2008.951855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=18678882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVaitbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2008&pages=1065-1073&author=M.+D.+Ikonomovicauthor=E.+E.+Abrahamsonauthor=T.+Uzauthor=H.+Manevauthor=S.+T.+Dekosky&title=Increased+5-lipoxygenase+immunoreactivity+in+the+hippocampus+of+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1369%2Fjhc.2008.951855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease</span></div><div class="casAuthors">Ikonomovic, Milos D.; Abrahamson, Eric E.; Uz, Tolga; Manev, Hari; DeKosky, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">The proinflammatory enzyme 5-lipoxygenase (5-LOX) is upregulated in Alzheimer's disease (AD), but its localization and assocn. with the hallmark lesions of the disease, β-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs), is unknown.  This study examd. the distribution and cellular localization of 5-LOX in the medial temporal lobe from AD and control subjects.  The spatial relationship between 5-LOX immunoreactive structures and AD lesions was also examd.  We report that, in AD subjects, 5-LOX immunoreactivity is elevated relative to controls, and its localization is dependent on the antibody-targeted portion of the 5-LOX amino acid sequence.  Carboxy terminus-directed antibodies detected 5-LOX in glial cells and neurons, but less frequently in neurons with dystrophic (NFT) morphol.  In contrast, immunoreactivity obsd. using 5-LOX amino terminus-directed antibodies was virtually absent in neurons and abundant in NFTs, neuritic plaques, and glia.  Double-labeling studies showed a close assocn. of 5-LOX-immunoreactive processes and glial cells with Aβ immunoreactive plaques and vasculature and also detected 5-LOX in tau immunoreactive and amyloid contg. NFTs.  Different immunolabeling patterns with antibodies against carboxy vs amino terminus of 5-LOX may be caused by post-translational modifications of 5-LOX protein in Aβ plaques and NFTs.  The relationship between elevated intracellular 5-LOX and hallmark AD pathol. lesions provides further evidence that neuroinflammatory pathways contribute to the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp68zh8DbrN97Vg90H21EOLACvtfcHk0lgHFT1Y_CxtFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVaitbzM&md5=0460938d96ba7bbd04ce02955fae4a8f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1369%2Fjhc.2008.951855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252Fjhc.2008.951855%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomovic%26aufirst%3DM.%2BD.%26aulast%3DAbrahamson%26aufirst%3DE.%2BE.%26aulast%3DUz%26aufirst%3DT.%26aulast%3DManev%26aufirst%3DH.%26aulast%3DDekosky%26aufirst%3DS.%2BT.%26atitle%3DIncreased%25205-lipoxygenase%2520immunoreactivity%2520in%2520the%2520hippocampus%2520of%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2008%26volume%3D56%26spage%3D1065%26epage%3D1073%26doi%3D10.1369%2Fjhc.2008.951855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannopoulos, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceballos-Diaz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golde, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratico, D.</span><span> </span><span class="NLM_article-title">5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">442</span><span class="NLM_x">–</span> <span class="NLM_lpage">454</span><span class="refDoi"> DOI: 10.1002/ana.23642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fana.23642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23034916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVentb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=442-454&author=J.+Chuauthor=P.+F.+Giannopoulosauthor=C.+Ceballos-Diazauthor=T.+E.+Goldeauthor=D.+Pratico&title=5-Lipoxygenase+gene+transfer+worsens+memory%2C+amyloid%2C+and+tau+brain+pathologies+in+a+mouse+model+of+Alzheimer+disease&doi=10.1002%2Fana.23642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">5-lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease</span></div><div class="casAuthors">Chu, Jin; Giannopoulos, Phillip F.; Ceballos-Diaz, Carolina; Golde, Todd E.; Pratico, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">442-454</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: : The 5-lipoxygenase (5LO) enzyme is upregulated in Alzheimer disease (AD), and its genetic absence reduces Aβ levels in APP mice.  However, its functional role in modulating tau neuropathol. remains to be elucidated.  Methods: To this end, we generated triple transgenic mice (3xTg-AD) overexpressing neuronal 5LO and investigated their phenotype.  Results: Compared with controls, 3xTg-AD mice overexpressing 5LO manifested an exacerbation of memory deficits, plaques, and tangle pathologies.  The elevation in Aβ was secondary to an upregulation of γ-secretase pathway, whereas tau hyperphosphorylation resulted from an activation of the Cdk5 kinase.  In vitro study confirmed the involvement of this kinase in the 5LO-dependent tau phosphorylation, which was independent of the effect on Aβ.  Interpretation: Our findings highlight the novel functional role that neuronal 5LO plays in exacerbating AD-related tau pathologies.  They provide crit. preclin. evidence to justify testing selective 5LO inhibitors for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd-DgJyv0S3rVg90H21EOLACvtfcHk0lgHFT1Y_CxtFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVentb7E&md5=fbbacd2edec1dc2811efd16dd78a0236</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fana.23642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.23642%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DGiannopoulos%26aufirst%3DP.%2BF.%26aulast%3DCeballos-Diaz%26aufirst%3DC.%26aulast%3DGolde%26aufirst%3DT.%2BE.%26aulast%3DPratico%26aufirst%3DD.%26atitle%3D5-Lipoxygenase%2520gene%2520transfer%2520worsens%2520memory%252C%2520amyloid%252C%2520and%2520tau%2520brain%2520pathologies%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2012%26volume%3D72%26spage%3D442%26epage%3D454%26doi%3D10.1002%2Fana.23642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratico, D.</span><span> </span><span class="NLM_article-title">Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer’s disease transgenic mouse model involvement of gamma-secretase</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1016/j.ajpath.2010.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.ajpath.2010.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=21435457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2011&pages=1762-1769&author=J.+Chuauthor=D.+Pratico&title=Pharmacologic+blockade+of+5-lipoxygenase+improves+the+amyloidotic+phenotype+of+an+Alzheimer%E2%80%99s+disease+transgenic+mouse+model+involvement+of+gamma-secretase&doi=10.1016%2Fj.ajpath.2010.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model: Involvement of γ-Secretase</span></div><div class="casAuthors">Chu, Jin; Pratico, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1762-1769</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The 5-lipoxygenase (5-LO) enzyme is widely distributed within the central nervous system.  Previous works showed that this protein is up-regulated in Alzheimer's disease (AD) and that its genetic absence results in a redn. of amyloid β (Aβ) levels in Tg2576 mice.  In the present study, we examd. the effect of 5-LO pharmacol. inhibition on the amyloidotic phenotype of these mice.  Aβ deposition in the brains of mice receiving zileuton, a selective and specific 5-LO inhibitor, was significantly reduced when compared with control Tg2576 mice receiving vehicle.  This redn. was assocd. with a similar decrease in brain Aβ peptides levels.  Zileuton treatment did not induce any change in the steady state levels of amyloid-β precursor protein (APP), BACE1 or ADAM10.  By contrast, it resulted in a significant redn. of presenilin 1 (PSEN1, alias PS1), nicastrin (NCSTN), presenilin enhancer 2 homolog (PSNEN, alias, Pen-2), and anterior pharynx defective 1 (APH-1), the four components of the γ-secretase complex-at the protein and message level.  Furthermore, in vitro studies confirmed that zileuton prevents Aβ formation by modulating γ-secretase complex levels without affecting Notch signaling.  These data establish a functional role for 5-LO in the pathogenesis of AD-like amyloidosis, whereby it modulates the γ-secretase pathway.  They suggest that pharmacol. inhibition of 5-LO could provide a novel therapeutic opportunity for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzjUbxjvX30rVg90H21EOLACvtfcHk0lgHFT1Y_CxtFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVKgu78%253D&md5=7c7ac68e942efc88b44c90994e1ee57d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2010.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2010.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DPratico%26aufirst%3DD.%26atitle%3DPharmacologic%2520blockade%2520of%25205-lipoxygenase%2520improves%2520the%2520amyloidotic%2520phenotype%2520of%2520an%2520Alzheimer%25E2%2580%2599s%2520disease%2520transgenic%2520mouse%2520model%2520involvement%2520of%2520gamma-secretase%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2011%26volume%3D178%26spage%3D1762%26epage%3D1769%26doi%3D10.1016%2Fj.ajpath.2010.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Hawkes, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaurin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carare, R. O.</span><span> </span><span class="NLM_article-title">MK886 reduces cerebral amyloid angiopathy severity in TgCRND8 mice</span> <span class="citation_source-journal">Neurodegener. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1159/000351096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1159%2F000351096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24021653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVShsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=17-23&author=C.+A.+Hawkesauthor=J.+E.+Shawauthor=M.+Brownauthor=A.+P.+Sampsonauthor=J.+McLaurinauthor=R.+O.+Carare&title=MK886+reduces+cerebral+amyloid+angiopathy+severity+in+TgCRND8+mice&doi=10.1159%2F000351096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">MK886 Reduces Cerebral Amyloid Angiopathy Severity in TgCRND8 Mice</span></div><div class="casAuthors">Hawkes, Cheryl A.; Shaw, James E.; Brown, Mary; Sampson, Anthony P.; McLaurin, JoAnne; Carare, Roxana O.</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Deposition of amyloid-β (Aβ) in blood vessel walls as cerebral amyloid angiopathy (CAA) is obsd. in the majority of Alzheimer's disease (AD) brains.  Inhibition of the 5-lipoxygenase (5-LOX) pathway has recently been suggested to play a role in reducing parenchymal Aβ deposition.  However, products of the 5-LOX pathway also activate the peroxisome proliferator-activated receptor (PPAR) family, which promotes clearance of Aβ from the brain.  Methods: In the present study, we investigated the effect of MK886, a 5-LOX-activating protein (FLAP) inhibitor and PPARα antagonist, on CAA severity in TgCRND8 mice overexpressing the human Swedish and Indiana amyloid precursor protein mutations.  Results: We found that MK886 significantly reduced brain levels of nicastrin and PPARα, but did not affect levels of β-secretase, apolipoprotein E or low-d. lipoprotein receptor-related protein-1.  CAA severity and parenchymal plaque load was significantly decreased in both the cortex and hippocampus of mice treated with MK886 compared to control mice.  Conclusion: These data suggest that 5-LOX and FLAP inhibitors may be useful in the treatment of CAA and AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRE-PMQ_tPI7Vg90H21EOLACvtfcHk0lh22Ab38TvoSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVShsr3L&md5=9ceac602d6c3e5da3cdbd7ee5ef15b65</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1159%2F000351096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000351096%26sid%3Dliteratum%253Aachs%26aulast%3DHawkes%26aufirst%3DC.%2BA.%26aulast%3DShaw%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSampson%26aufirst%3DA.%2BP.%26aulast%3DMcLaurin%26aufirst%3DJ.%26aulast%3DCarare%26aufirst%3DR.%2BO.%26atitle%3DMK886%2520reduces%2520cerebral%2520amyloid%2520angiopathy%2520severity%2520in%2520TgCRND8%2520mice%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2014%26volume%3D13%26spage%3D17%26epage%3D23%26doi%3D10.1159%2F000351096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Tang, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F. Y.</span><span> </span><span class="NLM_article-title">Leukotriene D4 induces cognitive impairment through enhancement of CysLT(1) R-mediated amyloid-beta generation in mice</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuropharm.2012.08.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=182-192&author=S.+S.+Tangauthor=X.+Y.+Wangauthor=H.+Hongauthor=Y.+Longauthor=Y.+Q.+Liauthor=G.+Q.+Xiangauthor=L.+Y.+Jiangauthor=H.+T.+Zhangauthor=L.+P.+Liuauthor=M.+X.+Miaoauthor=M.+Huauthor=T.+T.+Zhangauthor=W.+Huauthor=H.+Jiauthor=F.+Y.+Ye&title=Leukotriene+D4+induces+cognitive+impairment+through+enhancement+of+CysLT%281%29+R-mediated+amyloid-beta+generation+in+mice&doi=10.1016%2Fj.neuropharm.2012.08.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DXiang%26aufirst%3DG.%2BQ.%26aulast%3DJiang%26aufirst%3DL.%2BY.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DLiu%26aufirst%3DL.%2BP.%26aulast%3DMiao%26aufirst%3DM.%2BX.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DT.%2BT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DF.%2BY.%26atitle%3DLeukotriene%2520D4%2520induces%2520cognitive%2520impairment%2520through%2520enhancement%2520of%2520CysLT%25281%2529%2520R-mediated%2520amyloid-beta%2520generation%2520in%2520mice%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D65%26spage%3D182%26epage%3D192%26doi%3D10.1016%2Fj.neuropharm.2012.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span> </span><span class="NLM_article-title">Altered microtubule dynamics in neurodegenerative disease: therapeutic potential of microtubule-stabilizing drugs</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">2016</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="refDoi"> DOI: 10.1016/j.nbd.2016.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.nbd.2016.12.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2017&pages=21&author=K.+R.+Brundenauthor=V.+M.+Leeauthor=A.+B.+Smithauthor=J.+Q.+Trojanowskiauthor=C.+Ballatore&title=Altered+microtubule+dynamics+in+neurodegenerative+disease%3A+therapeutic+potential+of+microtubule-stabilizing+drugs&doi=10.1016%2Fj.nbd.2016.12.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DAltered%2520microtubule%2520dynamics%2520in%2520neurodegenerative%2520disease%253A%2520therapeutic%2520potential%2520of%2520microtubule-stabilizing%2520drugs%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2017%26volume%3D2016%26spage%3D21%26doi%3D10.1016%2Fj.nbd.2016.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Phillis, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horrocks, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farooqui, A. A.</span><span> </span><span class="NLM_article-title">Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/j.brainresrev.2006.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.brainresrev.2006.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=16647138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFCit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2006&pages=201-243&author=J.+W.+Phillisauthor=L.+A.+Horrocksauthor=A.+A.+Farooqui&title=Cyclooxygenases%2C+lipoxygenases%2C+and+epoxygenases+in+CNS%3A+their+role+and+involvement+in+neurological+disorders&doi=10.1016%2Fj.brainresrev.2006.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders</span></div><div class="casAuthors">Phillis, John W.; Horrocks, Lloyd A.; Farooqui, Akhlaq A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-243</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Three enzyme systems, i.e., cyclooxygenases that generate prostaglandins, lipoxygenases that form hydroxy derivs. and leukotrienes, and epoxygenases that give rise to epoxyeicosatrienoic products, metabolize arachidonic acid after its release from neural membrane phospholipids by the action of phospholipase A2.  Lysophospholipids, the other products of phospholipase A2 reactions, are either reacylated or metabolized to platelet-activating factor.  Under normal conditions, these metabolites play important roles in synaptic function, cerebral blood flow regulation, apoptosis, angiogenesis, and gene expression.  Increased activities of cyclooxygenases, lipoxygenases, and epoxygenases under pathol. situations such as ischemia, epilepsy, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease produce neuroinflammation involving vasodilation and vasoconstriction, platelet aggregation, leukocyte chemotaxis and release of cytokines, and oxidative stress.  These are closely assocd. with the neural cell injury which occurs in these neurol. conditions.  The metabolic products of docosahexaenoic acid, through these enzymes, generate a new class of lipid mediators, namely docosatrienes and resolvins.  These metabolites antagonize the effect of metabolites derived from arachidonic acid.  Recent studies provide insight into how these arachidonic acid metabolites interact with each other and other bioactive mediators such as platelet-activating factor, endocannabinoids, and docosatrienes under normal and pathol. conditions.  A review of present knowledge of the functions of cyclooxygenases, lipoxygenases, and epoxygenases in brain and their assocn. with neurodegenerative diseases is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5_dHeDa_ayLVg90H21EOLACvtfcHk0li47hXoFSebYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFCit7k%253D&md5=aeedeb2b8a4e576d770c4a24e350c7cd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2006.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2006.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DPhillis%26aufirst%3DJ.%2BW.%26aulast%3DHorrocks%26aufirst%3DL.%2BA.%26aulast%3DFarooqui%26aufirst%3DA.%2BA.%26atitle%3DCyclooxygenases%252C%2520lipoxygenases%252C%2520and%2520epoxygenases%2520in%2520CNS%253A%2520their%2520role%2520and%2520involvement%2520in%2520neurological%2520disorders%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2006%26volume%3D52%26spage%3D201%26epage%3D243%26doi%3D10.1016%2Fj.brainresrev.2006.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Kang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hour, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, W. M.</span><span> </span><span class="NLM_article-title">Protection of dopaminergic neurons by 5-lipoxygenase inhibitor</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">–</span> <span class="NLM_lpage">387</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuropharm.2013.06.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=380-387&author=K.+H.+Kangauthor=H.+H.+Liouauthor=M.+J.+Hourauthor=H.+C.+Liouauthor=W.+M.+Fu&title=Protection+of+dopaminergic+neurons+by+5-lipoxygenase+inhibitor&doi=10.1016%2Fj.neuropharm.2013.06.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DK.%2BH.%26aulast%3DLiou%26aufirst%3DH.%2BH.%26aulast%3DHour%26aufirst%3DM.%2BJ.%26aulast%3DLiou%26aufirst%3DH.%2BC.%26aulast%3DFu%26aufirst%3DW.%2BM.%26atitle%3DProtection%2520of%2520dopaminergic%2520neurons%2520by%25205-lipoxygenase%2520inhibitor%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D73%26spage%3D380%26epage%3D387%26doi%3D10.1016%2Fj.neuropharm.2013.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Chou, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holman, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning-Bog, A. B.</span><span> </span><span class="NLM_article-title">Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2012.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuroscience.2012.10.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2013&pages=73-82&author=V.+P.+Chouauthor=T.+R.+Holmanauthor=A.+B.+Manning-Bog&title=Differential+contribution+of+lipoxygenase+isozymes+to+nigrostriatal+vulnerability&doi=10.1016%2Fj.neuroscience.2012.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2012.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2012.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DV.%2BP.%26aulast%3DHolman%26aufirst%3DT.%2BR.%26aulast%3DManning-Bog%26aufirst%3DA.%2BB.%26atitle%3DDifferential%2520contribution%2520of%2520lipoxygenase%2520isozymes%2520to%2520nigrostriatal%2520vulnerability%26jtitle%3DNeuroscience%26date%3D2013%26volume%3D228%26spage%3D73%26epage%3D82%26doi%3D10.1016%2Fj.neuroscience.2012.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Thakur, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehru, B.</span><span> </span><span class="NLM_article-title">Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson’s disease</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2012.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuroscience.2012.11.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2013&pages=420-431&author=P.+Thakurauthor=B.+Nehru&title=Anti-inflammatory+properties+rather+than+anti-oxidant+capability+is+the+major+mechanism+of+neuroprotection+by+sodium+salicylate+in+a+chronic+rotenone+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neuroscience.2012.11.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2012.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2012.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DP.%26aulast%3DNehru%26aufirst%3DB.%26atitle%3DAnti-inflammatory%2520properties%2520rather%2520than%2520anti-oxidant%2520capability%2520is%2520the%2520major%2520mechanism%2520of%2520neuroprotection%2520by%2520sodium%2520salicylate%2520in%2520a%2520chronic%2520rotenone%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuroscience%26date%3D2013%26volume%3D231%26spage%3D420%26epage%3D431%26doi%3D10.1016%2Fj.neuroscience.2012.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Teismann, P.</span><span> </span><span class="NLM_article-title">COX-2 in the neurodegenerative process of Parkinson’s disease</span> <span class="citation_source-journal">Biofactors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span><span class="refDoi"> DOI: 10.1002/biof.1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fbiof.1035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=395-397&author=P.+Teismann&title=COX-2+in+the+neurodegenerative+process+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fbiof.1035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fbiof.1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiof.1035%26sid%3Dliteratum%253Aachs%26aulast%3DTeismann%26aufirst%3DP.%26atitle%3DCOX-2%2520in%2520the%2520neurodegenerative%2520process%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBiofactors%26date%3D2012%26volume%3D38%26spage%3D395%26epage%3D397%26doi%3D10.1002%2Fbiof.1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Yokota, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishizu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayabara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Checler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span> </span><span class="NLM_article-title">Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia</span> <span class="citation_source-journal">Acta Neuropathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span><span class="refDoi"> DOI: 10.1007/s00401-004-0826-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1007%2Fs00401-004-0826-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=14991384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2004&pages=399-405&author=O.+Yokotaauthor=S.+Teradaauthor=H.+Ishizuauthor=T.+Ishiharaauthor=H.+Nakashimaauthor=A.+Kugoauthor=K.+Tsuchiyaauthor=K.+Ikedaauthor=T.+Hayabaraauthor=Y.+Saitoauthor=S.+Murayamaauthor=K.+Uedaauthor=F.+Checlerauthor=S.+Kuroda&title=Increased+expression+of+neuronal+cyclooxygenase-2+in+the+hippocampus+in+amyotrophic+lateral+sclerosis+both+with+and+without+dementia&doi=10.1007%2Fs00401-004-0826-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia</span></div><div class="casAuthors">Yokota, Osamu; Terada, Seishi; Ishizu, Hideki; Ishihara, Takeshi; Nakashima, Hanae; Kugo, Aki; Tsuchiya, Kuniaki; Ikeda, Kenji; Hayabara, Toshiyuki; Saito, Yuko; Murayama, Shigeo; Ueda, Kenji; Checler, Frederic; Kuroda, Shigetoshi</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">399-405</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The pathophysiol. basis of cognitive dysfunction, including frontotemporal dementia (FTD), in patients with amyotrophic lateral sclerosis (ALS) and ALS with dementia (ALSD) remains unclear.  On the other hand, increased expression of cyclooxygenase-2 (COX-2) in the spinal cord is thought to play a pivotal role in motor neuron degeneration in ALS.  In this study, to assess the relationship between the neuronal COX-2 expression in the cerebrum, the formation of tau- and α-synuclein-neg. but ubiquitin-pos. neuronal inclusions (UPIs), and dementia in motor neuron disease (MND), we examd. neuronal COX-2 immunoreactivity in the frontal cortex and hippocampus of patients with non-demented ALS without UPIs (n=11), ALSD with UPIs (n=6), and normal controls (n=24) using a quant. immunohistochem. technique.  Neuronal COX-2 expression in all CA1-4 in the hippocampus was significantly up-regulated in the ALSD group, and, to lesser degree but significantly, in the ALS group.  Neuronal COX-2 expression in the frontal cortex was also significantly up-regulated in the ALSD group but not in the ALS group.  These findings suggest that (1) the frontal cortex and hippocampus of MND are involved in the same pathogenic process assocd. with COX-2 induction that has been obsd. in spinal anterior horn cells, (2) COX-2 induction in the cerebrum is a pathogenic process that can occur even in the absence of UPI formation in MND, and (3) COX-2 expression in the cerebrum may be assocd. with cognitive dysfunction in MND.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDF9FZbt1OtbVg90H21EOLACvtfcHk0liBpGspiN8dEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVWltL8%253D&md5=c2e9aad997b91f538151ec2e3238a3b7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs00401-004-0826-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-004-0826-2%26sid%3Dliteratum%253Aachs%26aulast%3DYokota%26aufirst%3DO.%26aulast%3DTerada%26aufirst%3DS.%26aulast%3DIshizu%26aufirst%3DH.%26aulast%3DIshihara%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DKugo%26aufirst%3DA.%26aulast%3DTsuchiya%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DHayabara%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DMurayama%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DChecler%26aufirst%3DF.%26aulast%3DKuroda%26aufirst%3DS.%26atitle%3DIncreased%2520expression%2520of%2520neuronal%2520cyclooxygenase-2%2520in%2520the%2520hippocampus%2520in%2520amyotrophic%2520lateral%2520sclerosis%2520both%2520with%2520and%2520without%2520dementia%26jtitle%3DActa%2520Neuropathol.%26date%3D2004%26volume%3D107%26spage%3D399%26epage%3D405%26doi%3D10.1007%2Fs00401-004-0826-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Kong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganea, D.</span><span> </span><span class="NLM_article-title">The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation</span> <span class="citation_source-journal">Brain, Behav., Immun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1016/j.bbi.2015.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.bbi.2015.11.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2016&pages=59-71&author=W.+Kongauthor=K.+M.+Hooperauthor=D.+Ganea&title=The+natural+dual+cyclooxygenase+and+5-lipoxygenase+inhibitor+flavocoxid+is+protective+in+EAE+through+effects+on+Th1%2FTh17+differentiation+and+macrophage%2Fmicroglia+activation&doi=10.1016%2Fj.bbi.2015.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2015.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2015.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DW.%26aulast%3DHooper%26aufirst%3DK.%2BM.%26aulast%3DGanea%26aufirst%3DD.%26atitle%3DThe%2520natural%2520dual%2520cyclooxygenase%2520and%25205-lipoxygenase%2520inhibitor%2520flavocoxid%2520is%2520protective%2520in%2520EAE%2520through%2520effects%2520on%2520Th1%252FTh17%2520differentiation%2520and%2520macrophage%252Fmicroglia%2520activation%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2016%26volume%3D53%26spage%3D59%26epage%3D71%26doi%3D10.1016%2Fj.bbi.2015.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Morphy, R.; Rankovic, Z.; Abraham, D. J.</span><span> </span><span class="NLM_article-title">Medicinal chemistry approaches for multitarget drugs</span>. In  <span class="citation_source-book">Burger’s Medicinal Chemistry and Drug Discovery</span>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=249-274&author=R.+Morphy&author=Z.+Rankovic&author=D.+J.+Abraham&title=Burger%E2%80%99s+Medicinal+Chemistry+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DMedicinal%2520chemistry%2520approaches%2520for%2520multitarget%2520drugs%26btitle%3DBurger%25E2%2580%2599s%2520Medicinal%2520Chemistry%2520and%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2003%26spage%3D249%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Smith, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboldt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masferrer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakson, P. C.</span><span> </span><span class="NLM_article-title">Pharmacological analysis of cyclooxygenase-1 in inflammation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">13313</span><span class="NLM_x">–</span> <span class="NLM_lpage">13318</span><span class="refDoi"> DOI: 10.1073/pnas.95.22.13313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1073%2Fpnas.95.22.13313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=9789085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADyaK1cXntFWrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=13313-13318&author=C.+J.+Smithauthor=Y.+Zhangauthor=C.+M.+Koboldtauthor=J.+Muhammadauthor=B.+S.+Zweifelauthor=A.+Shafferauthor=J.+J.+Talleyauthor=J.+L.+Masferrerauthor=K.+Seibertauthor=P.+C.+Isakson&title=Pharmacological+analysis+of+cyclooxygenase-1+in+inflammation&doi=10.1073%2Fpnas.95.22.13313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological analysis of cyclooxygenase-1 in inflammation</span></div><div class="casAuthors">Smith, Christopher J.; Zhang, Yan; Koboldt, Carol M.; Muhammad, Jerry; Zweifel, Ben S.; Shaffer, Alex; Talley, John J.; Masferrer, Jaime L.; Seibert, Karen; Isakson, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13313-13318</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The enzymes cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane.  These lipid mediators play important roles in inflammation and pain and in normal physiol. functions.  While there are abundant data indicating that the inducible isoform, COX-2, is important in inflammation and pain, the constitutively expressed isoform, COX-1, has also been suggested to play a role in inflammatory processes.  To address the latter question pharmacol., we used a highly selective COX-1 inhibitor, SC-560 (COX-1 IC50 = 0.009 μM; COX-2 IC50 = 6.3 μM).  SC-560 inhibited COX-1-derived platelet thromboxane B2, gastric PGE2, and dermal PGE2 prodn., indicating that it was orally active, but did not inhibit COX-2-derived PGs in the lipopolysaccharide-induced rat air pouch.  Therapeutic or prophylactic administration of SC-560 in the rat carrageenan footpad model did not affect acute inflammation or hyperalgesia at doses that markedly inhibited in vivo COX-1 activity.  By contrast, celecoxib, a selective COX-2 inhibitor, was anti-inflammatory and analgesic in this model.  Paradoxically, both SC-560 and celecoxib reduced paw PGs to equiv. levels.  Increased levels of PGs were found in the cerebrospinal fluid after carrageenan injection and were markedly reduced by celecoxib, but were not affected by SC-560.  These results suggest that, in addn. to the role of peripherally produced PGs, there is a crit., centrally mediated neurol. component to inflammatory pain that is mediated at least in part by COX-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo05VnKZU2CJrVg90H21EOLACvtfcHk0liC16M6Jbu9Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFWrsLY%253D&md5=5b1af3003f9e099205bccf7e274401d9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.22.13313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.22.13313%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKoboldt%26aufirst%3DC.%2BM.%26aulast%3DMuhammad%26aufirst%3DJ.%26aulast%3DZweifel%26aufirst%3DB.%2BS.%26aulast%3DShaffer%26aufirst%3DA.%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DMasferrer%26aufirst%3DJ.%2BL.%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DIsakson%26aufirst%3DP.%2BC.%26atitle%3DPharmacological%2520analysis%2520of%2520cyclooxygenase-1%2520in%2520inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D13313%26epage%3D13318%26doi%3D10.1073%2Fpnas.95.22.13313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dannhardt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, W.</span><span> </span><span class="NLM_article-title">6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1894</span><span class="NLM_x">–</span> <span class="NLM_lpage">1897</span><span class="refDoi"> DOI: 10.1021/jm00038a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00038a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1894-1897&author=S.+A.+Lauferauthor=J.+Augustinauthor=G.+Dannhardtauthor=W.+Kiefer&title=6%2C7-Diaryldihydropyrrolizin-5-yl%29acetic+acids%2C+a+novel+class+of+potent+dual+inhibitors+of+both+cyclooxygenase+and+5-lipoxygenase&doi=10.1021%2Fjm00038a021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm00038a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00038a021%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DAugustin%26aufirst%3DJ.%26aulast%3DDannhardt%26aufirst%3DG.%26aulast%3DKiefer%26aufirst%3DW.%26atitle%3D6%252C7-Diaryldihydropyrrolizin-5-yl%2529acetic%2520acids%252C%2520a%2520novel%2520class%2520of%2520potent%2520dual%2520inhibitors%2520of%2520both%2520cyclooxygenase%2520and%25205-lipoxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1894%26epage%3D1897%26doi%3D10.1021%2Fjm00038a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Lamberth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumeunier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendeborn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneiter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corran, A.</span><span> </span><span class="NLM_article-title">Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 3: imidazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.bmc.2012.10.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23218777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyntbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=127-134&author=C.+Lamberthauthor=R.+Dumeunierauthor=S.+Trahauthor=S.+Wendebornauthor=J.+Godwinauthor=P.+Schneiterauthor=A.+Corran&title=Synthesis+and+fungicidal+activity+of+tubulin+polymerisation+promoters.+Part+3%3A+imidazoles&doi=10.1016%2Fj.bmc.2012.10.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 3: Imidazoles</span></div><div class="casAuthors">Lamberth, Clemens; Dumeunier, Raphael; Trah, Stephan; Wendeborn, Sebastian; Godwin, Jeremy; Schneiter, Peter; Corran, Andy</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-134</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of exptl. fungicides has been discovered, which consists of special tetrasubstituted imidazoles.  They are highly active against important phytopathogens, such as Botrytis cinerea (gray mold), Uncinula necator (grape powdery mildew), Mycosphaerella graminicola (wheat leaf blotch) and Alternaria solani (potato and tomato early blight).  Their fungicidal efficacy is due to their ability to promote fungal tubulin polymn., which leads to a disruption of microtubule dynamics.  These imidazoles are five-membered ring analogs of similar substituted triazolopyrimidines and pyridazines with the same mode of action.  A concise four-step synthesis route, using Vilsmeier reagent, has been used to prep. them from com. available starting materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojYoEF0X_pGLVg90H21EOLACvtfcHk0liC16M6Jbu9Uw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyntbzK&md5=b945bfaff745f5d5c39187266889e8c8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DLamberth%26aufirst%3DC.%26aulast%3DDumeunier%26aufirst%3DR.%26aulast%3DTrah%26aufirst%3DS.%26aulast%3DWendeborn%26aufirst%3DS.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DSchneiter%26aufirst%3DP.%26aulast%3DCorran%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520fungicidal%2520activity%2520of%2520tubulin%2520polymerisation%2520promoters.%2520Part%25203%253A%2520imidazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D127%26epage%3D134%26doi%3D10.1016%2Fj.bmc.2012.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Van Leusen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildeman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldenziel, O. H.</span><span> </span><span class="NLM_article-title">Chemistry of sulfonylmethyl isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span><span class="refDoi"> DOI: 10.1021/jo00427a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00427a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADyaE2sXhvV2ku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1977&pages=1153-1159&author=A.+M.+Van+Leusenauthor=J.+Wildemanauthor=O.+H.+Oldenziel&title=Chemistry+of+sulfonylmethyl+isocyanides.+12.+Base-induced+cycloaddition+of+sulfonylmethyl+isocyanides+to+carbon%2Cnitrogen+double+bonds.+Synthesis+of+1%2C5-disubstituted+and+1%2C4%2C5-trisubstituted+imidazoles+from+aldimines+and+imidoyl+chlorides&doi=10.1021%2Fjo00427a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry of sulfonylmethyl isocyanides.  12.  Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds.  Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides</span></div><div class="casAuthors">Van Leusen, Albert M.; Wildeman, Jurjen; Oldenziel, Otto H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1153-9</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Base-induced cycloaddn. of tosylmethyl isocyanide (I) to aldimines R1CH:NR2 [R1 = Me, CMe3, CHMe2, C6H4R3-4 (R3 = H, Me, Cl, NO2); R2 = Me, Et, CHMe2, cyclohexyl, C6H4R4-4(R4 = H, Cl, NO2)] in protic medium occurs with concomitant elimination of p-toluenesulfinic acid to give the otherwise more difficultly accessible 1,5-disubstituted imidazoles II.  The influence of R1 and R2 on the formation of II was analyzed qual. α-Tosylbenzyl isocyanide and α-tosylethyl isocyanide, likewise, gave 1,4,5-trisubstituted imidazoles III (R1 = Me, Ph; R2 = Me, CMe3, Ph, C6H4NO2-4; R3 = Me, Ph (5 compds.).  The cycloaddn. of I to imidoyl chlorides was accompanied by loss of HCl, instead of 4-MeC6H4SO3H, and gave 1,4,5-trisubstituted imidazoles III (R1 = Ph, R2 = Ph, cyclohexyl, C6H4NO2-4, R1 = C6H4NO2-4, R2 = Ph, cyclohexyl, R3 = tosyl).  Under aprotic conditions trans-1,5-diaryl-4-tosyl-2-imidazolines IV (R1 = Ph, R2 = C6H4NO2-4, Ph; R1 = C6H4Me-4, R2 = Ph) were isolated and identified as the primary cycloadducts of I and aldimines, leading ultimately to the imidazoles II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO_gFMQFymTLVg90H21EOLACvtfcHk0liB0JsDOu8ojQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvV2ku7s%253D&md5=429e9513419831f7e45baff226acf4ce</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo00427a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00427a012%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLeusen%26aufirst%3DA.%2BM.%26aulast%3DWildeman%26aufirst%3DJ.%26aulast%3DOldenziel%26aufirst%3DO.%2BH.%26atitle%3DChemistry%2520of%2520sulfonylmethyl%2520isocyanides.%252012.%2520Base-induced%2520cycloaddition%2520of%2520sulfonylmethyl%2520isocyanides%2520to%2520carbon%252Cnitrogen%2520double%2520bonds.%2520Synthesis%2520of%25201%252C5-disubstituted%2520and%25201%252C4%252C5-trisubstituted%2520imidazoles%2520from%2520aldimines%2520and%2520imidoyl%2520chlorides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1977%26volume%3D42%26spage%3D1153%26epage%3D1159%26doi%3D10.1021%2Fjo00427a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Lou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoye, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span> </span><span class="NLM_article-title">Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer’s disease and related tauopathies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6116</span><span class="NLM_x">–</span> <span class="NLM_lpage">6127</span><span class="refDoi"> DOI: 10.1021/jm5005623</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005623" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6116-6127&author=K.+Louauthor=Y.+Yaoauthor=A.+T.+Hoyeauthor=M.+J.+Jamesauthor=A.+S.+Cornecauthor=E.+Hydeauthor=B.+Gayauthor=V.+M.+Leeauthor=J.+Q.+Trojanowskiauthor=A.+B.+Smithauthor=K.+R.+Brundenauthor=C.+Ballatore&title=Brain-penetrant%2C+orally+bioavailable+microtubule-stabilizing+small+molecules+are+potential+candidate+therapeutics+for+Alzheimer%E2%80%99s+disease+and+related+tauopathies&doi=10.1021%2Fjm5005623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer's Disease and Related Tauopathies</span></div><div class="casAuthors">Lou, Kevin; Yao, Yuemang; Hoye, Adam T.; James, Michael J.; Cornec, Anne-Sophie; Hyde, Edward; Gay, Bryant; Lee, Virginia M.-Y.; Trojanowski, John Q.; Smith, Amos B., III; Brunden, Kurt R.; Ballatore, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6116-6127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Microtubule (MT) stabilizing drugs hold promise as potential treatments for Alzheimer's disease (AD) and related tauopathies.  However, thus far epothilone D has been the only brain-penetrant MT-stabilizer to be evaluated in tau transgenic mice and in AD patients.  Furthermore, this natural product exhibits potential deficiencies as a drug candidate, including an i.v. route of administration and the inhibition of the P-glycoprotein (Pgp) transporter.  Thus, the identification of alternative CNS-active MT-stabilizing agents that lack these potential limitations is of interest.  Toward this objective, the authors have evaluated representative compds. from known classes of non-naturally occurring MT-stabilizing small mols.  This led to the identification of selected triazolopyrimidines and phenylpyrimidines that are orally bioavailable and brain-penetrant without disruption of Pgp function.  Pharmacodynamic studies confirmed that representative compds. from these series enhance MT-stabilization in the brains of wild-type mice.  Thus, these classes of MT-stabilizers hold promise for the development of orally active, CNS-directed MT-stabilizing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYBaimrh_xYLVg90H21EOLACvtfcHk0lh5udufHVVRDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtrnI&md5=17f0c92ee4515762f3f3b88fb37e38f2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm5005623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005623%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DHoye%26aufirst%3DA.%2BT.%26aulast%3DJames%26aufirst%3DM.%2BJ.%26aulast%3DCornec%26aufirst%3DA.%2BS.%26aulast%3DHyde%26aufirst%3DE.%26aulast%3DGay%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DBrain-penetrant%252C%2520orally%2520bioavailable%2520microtubule-stabilizing%2520small%2520molecules%2520are%2520potential%2520candidate%2520therapeutics%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520tauopathies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6116%26epage%3D6127%26doi%3D10.1021%2Fjm5005623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Fukushima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujiuchi, T.</span><span> </span><span class="NLM_article-title">Post-translational modifications of tubulin in the nervous system</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2009.06013.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fj.1471-4159.2009.06013.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=19250341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=683-693&author=N.+Fukushimaauthor=D.+Furutaauthor=Y.+Hidakaauthor=R.+Moriyamaauthor=T.+Tsujiuchi&title=Post-translational+modifications+of+tubulin+in+the+nervous+system&doi=10.1111%2Fj.1471-4159.2009.06013.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Post-translational modifications of tubulin in the nervous system</span></div><div class="casAuthors">Fukushima, Nobuyuki; Furuta, Daisuke; Hidaka, Yuji; Moriyama, Ryutaro; Tsujiuchi, Toshifumi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683-693</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Many studies have shown that microtubules (MTs) interact with MT-assocd. proteins (MAPs) and motor proteins.  These interactions are essential for the formation and maintenance of the polarized morphol. of neurons and have been proposed to be regulated in part by highly diverse, unusual post-translational modifications (PTMs) of tubulin, including acetylation, tyrosination, detyrosination, Δ2 modification, polyglutamylation, polyglycylation, palmitoylation, and phosphorylation.  However, the precise mechanisms of PTM generation and the properties of modified MTs have been poorly understood until recently.  Recent PTM research has uncovered the enzymes mediating tubulin PTMs and provided new insights into the regulation of MT-based functions.  The identification of tubulin deacetylase and discovery of its specific inhibitors have paved the way to understand the roles of acetylated MTs in kinesin-mediated axonal transport and neurodegenerative diseases such as Huntington's disease.  Studies with tubulin tyrosine ligase (TTL)-null mice have shown that tyrosinated MTs are essential in normal brain development.  The discovery of TTL-like genes encoding polyglutamylase has led to the finding that polyglutamylated MTs which accumulate during brain development are involved in synapse vesicle transport or neurite outgrowth through interactions with motor proteins or MAPs, resp.  Here, the authors review current exciting topics that are expected to advance MT research in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi_rjIFYcHo7Vg90H21EOLACvtfcHk0lh5udufHVVRDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFykt70%253D&md5=4e6bf1ac11e7228edfb585f6ab0c0441</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2009.06013.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2009.06013.x%26sid%3Dliteratum%253Aachs%26aulast%3DFukushima%26aufirst%3DN.%26aulast%3DFuruta%26aufirst%3DD.%26aulast%3DHidaka%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DR.%26aulast%3DTsujiuchi%26aufirst%3DT.%26atitle%3DPost-translational%2520modifications%2520of%2520tubulin%2520in%2520the%2520nervous%2520system%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D109%26spage%3D683%26epage%3D693%26doi%3D10.1111%2Fj.1471-4159.2009.06013.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kovalevich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer’s disease and related tauopathies</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1124/jpet.115.231175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1124%2Fjpet.115.231175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=26980057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2016&pages=432-450&author=J.+Kovalevichauthor=A.+S.+Cornecauthor=Y.+Yaoauthor=M.+Jamesauthor=A.+Croweauthor=V.+M.+Leeauthor=J.+Q.+Trojanowskiauthor=A.+B.+Smithauthor=C.+Ballatoreauthor=K.+R.+Brunden&title=Characterization+of+brain-penetrant+pyrimidine-containing+molecules+with+differential+microtubule-stabilizing+activities+developed+as+potential+therapeutic+agents+for+Alzheimer%E2%80%99s+disease+and+related+tauopathies&doi=10.1124%2Fjpet.115.231175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer's disease and related tauopathies</span></div><div class="casAuthors">Kovalevich, Jane; Cornec, Anne-Sophie; Yao, Yuemang; James, Michael; Crowe, Alexander; Lee, Virginia M.-Y.; Trojanowski, John Q.; Smith, Amos B., III; Ballatore, Carlo; Brunden, Kurt R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">432-450</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The microtubule (MT)-stabilizing protein tau disengages from MTs and forms intracellular inclusions known as neurofibrillary tangles in Alzheimer's disease and related tauopathies.  Reduced tau binding to MTs in tauopathies may contribute to neuronal dysfunction through decreased MT stabilization and disrupted axonal transport.  Thus, the introduction of brain-penetrant MT-stabilizing compds. might normalize MT dynamics and axonal deficits in these disorders.  We previously described a no. of phenylpyrimidines and triazolopyrimidines (TPDs) that induce tubulin post-translational modifications indicative of MT stabilization.  We now further characterize the biol. properties of these small mols., and our results reveal that these compds. can be divided into two general classes based on the cellular response they evoke.  One group composed of the phenylpyrimidines and several TPD examples showed a bell-shaped concn.-response effect on markers of MT stabilization in cellular assays.  Moreover, these compds. induced proteasome-dependent degrdn. of α- and β-tubulin and caused altered MT morphol. in both dividing cells and neuron cultures.  In contrast, a second group comprising a subset of TPD mols. (TPD+) increased markers of stable MTs in a concn.-dependent manner in dividing cells and in neurons without affecting total tubulin levels or disrupting MT architecture.  Moreover, an example TPD+ compd. was shown to increase MTs in a neuron culture model with induced tau hyperphosphorylation and assocd. MT deficits.  Several TPD+ compds. were shown to be both brain penetrant and orally bioavailable, and a TPD+ example increased MT stabilization in the mouse brain, making these compds. potential candidate therapeutics for neurodegenerative tauopathies such as Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCEADXoI6tlbVg90H21EOLACvtfcHk0lhU0bXa3s8Jdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zK&md5=14cc76d21739ed6b63ba6f2754287b51</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.231175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.231175%26sid%3Dliteratum%253Aachs%26aulast%3DKovalevich%26aufirst%3DJ.%26aulast%3DCornec%26aufirst%3DA.%2BS.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DCrowe%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DCharacterization%2520of%2520brain-penetrant%2520pyrimidine-containing%2520molecules%2520with%2520differential%2520microtubule-stabilizing%2520activities%2520developed%2520as%2520potential%2520therapeutic%2520agents%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520tauopathies%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D357%26spage%3D432%26epage%3D450%26doi%3D10.1124%2Fjpet.115.231175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Tries, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neupert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2</span> <span class="citation_source-journal">Inflammation Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1007/PL00000285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1007%2FPL00000285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=12005204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=135-143&author=S.+Triesauthor=W.+Neupertauthor=S.+Laufer&title=The+mechanism+of+action+of+the+new+antiinflammatory+compound+ML3000%3A+inhibition+of+5-LOX+and+COX-1%2F2&doi=10.1007%2FPL00000285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of the new anti-inflammatory compound ML3000: inhibition of 5-LOX and COX-1/2</span></div><div class="casAuthors">Tries, S.; Neupert, W.; Laufer, S.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">This work examd. the effects of ML3000 and other nonsteroidal anti-inflammatory drugs (NSAIDs) (indomethacin, diclofenac) on the synthesis of 5-lipoxygenase (5-LOX) products (LTB4, LTC4) and cyclooxygenase (COX)-1 and -2 products (TXB2, PGE2) in vitro and ex vivo in order to further elucidate the mechanism of action of ML3000.  The effect of ML3000 on the shunt of arachidonic acid to the LOX pathway when COX is blocked was studied in a human whole-blood assay.  ML3000 (0.3, 1, 3, 10, 30 μg/mL) and indomethacin (0.3, 1, 3, 10, 30 μg/mL) concn.-dependently inhibited the synthesis of PGE2 (IC50 = 3.9 and 4.5 μM, resp.).  In contrast to ML3000, indomethacin increased LTC4 by ≤155.5% of control values.  5-LOX inhibition was further tested in a basophilic leukemia cell assay using RBL-1 cells.  ML3000 (1-10 μM) inhibited the synthesis of LTB4 in a concn.-related manner (IC50: 3.6 μM).  In carrageenan- induced rat paw edema, ML3000 and indomethacin completely blocked the formation of PGE2 in the inflamed tissue.  LTB4 prodn. in the inflamed paw was reduced to basal levels by ML3000, whereas LTB4 concns. remained markedly elevated after indomethacin.  5-LOX inhibition in the inflamed rat colon was investigated by measuring LTB4 synthesis.  MK-886 and ML3000 at 10 mg/kg orally reduced LTB4 prodn. as compared to that in controls.  LTB4 levels in the rat stomach were comparable to control values after oral administration of ML3000 (10, 30, 100 mg/kg), whereas oral treatment with indomethacin (0.3, 1, 3 mg/kg) or diclofenac (1, 3 mg/kg) increased LTB4.  These results provide further evidence, that ML3000 inhibits 5-LOX as well as COX-1 and COX-2 in vitro and in animal expts.  The favorable gastrointestinal tolerability of the compd. is believed to be linked to the mechanism of combined 5-LOX and COX-1/2 inhibition by ML3000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2o9PX_wP1LrVg90H21EOLACvtfcHk0lhU0bXa3s8Jdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFGqtLg%253D&md5=a015f1529175b3e3107bee0f103b6913</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2FPL00000285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00000285%26sid%3Dliteratum%253Aachs%26aulast%3DTries%26aufirst%3DS.%26aulast%3DNeupert%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520the%2520new%2520antiinflammatory%2520compound%2520ML3000%253A%2520inhibition%2520of%25205-LOX%2520and%2520COX-1%252F2%26jtitle%3DInflammation%2520Res.%26date%3D2002%26volume%3D51%26spage%3D135%26epage%3D143%26doi%3D10.1007%2FPL00000285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Meirer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhilber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proschak, E.</span><span> </span><span class="NLM_article-title">Inhibitors of the arachidonic acid cascade: interfering with multiple pathways</span> <span class="citation_source-journal">Basic Clin. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1111/bcpt.12134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fbcpt.12134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24015667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=83-91&author=K.+Meirerauthor=D.+Steinhilberauthor=E.+Proschak&title=Inhibitors+of+the+arachidonic+acid+cascade%3A+interfering+with+multiple+pathways&doi=10.1111%2Fbcpt.12134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways</span></div><div class="casAuthors">Meirer, Karin; Steinhilber, Dieter; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Modulators of the arachidonic acid cascade have been in the focus of research for treatments of inflammation and pain for several decades.  Targeting this complex pathway experiences a paradigm change towards the design and development of multi-target inhibitors, exhibiting improved efficacy and less undesired side effects.  This minireview summarizes recent developments in the field of designed multi-target ligands of the arachidonic acid cascade.  In addn. to the well-known dual inhibitors of 5-lipoxygenase and cyclooxygenase-2 such as licofelone, very recent developments are discussed.  Esp., multi-target inhibitors interfering with the cytochrome P 450 pathway via inhibition of sol. epoxide hydrolase seem to offer a novel opportunity for development of novel anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIto5Wb10iLVg90H21EOLACvtfcHk0lhU0bXa3s8Jdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF&md5=1b7c01f7e30d699dc57b25c215e4da9e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12134%26sid%3Dliteratum%253Aachs%26aulast%3DMeirer%26aufirst%3DK.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DInhibitors%2520of%2520the%2520arachidonic%2520acid%2520cascade%253A%2520interfering%2520with%2520multiple%2520pathways%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D83%26epage%3D91%26doi%3D10.1111%2Fbcpt.12134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Gillard, J. W.; Morton, H. E.; Fortin, R.; Guindon, Y.</span><span> </span><span class="NLM_article-title">Preparation and formulation of 3-hetero-substituted-<i>N</i>-benzyl-indoles as inhibitors of leukotriene biosynthesis</span>. EP275667A1,<span class="NLM_x"> </span><span class="NLM_year">1988</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&author=J.+W.+Gillard&author=H.+E.+Morton&author=R.+Fortin&author=Y.+Guindon&title=Preparation+and+formulation+of+3-hetero-substituted-N-benzyl-indoles+as+inhibitors+of+leukotriene+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DJ.%2BW.%26atitle%3DPreparation%2520and%2520formulation%2520of%25203-hetero-substituted-N-benzyl-indoles%2520as%2520inhibitors%2520of%2520leukotriene%2520biosynthesis%26date%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Schneider, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangialasche, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacobini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantua, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mecocci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winblad, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivipelto, M.</span><span> </span><span class="NLM_article-title">Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014</span> <span class="citation_source-journal">J. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span><span class="refDoi"> DOI: 10.1111/joim.12191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fjoim.12191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24605808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BC2crhsFaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2014&pages=251-283&author=L.+S.+Schneiderauthor=F.+Mangialascheauthor=N.+Andreasenauthor=H.+Feldmanauthor=E.+Giacobiniauthor=R.+Jonesauthor=V.+Mantuaauthor=P.+Mecocciauthor=L.+Paniauthor=B.+Winbladauthor=M.+Kivipelto&title=Clinical+trials+and+late-stage+drug+development+for+Alzheimer%E2%80%99s+disease%3A+an+appraisal+from+1984+to+2014&doi=10.1111%2Fjoim.12191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014</span></div><div class="casAuthors">Schneider L S; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of internal medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The modern era of drug development for Alzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer's disease.  Since then, despite the evaluation of numerous potential treatments in clinical trials, only four cholinesterase inhibitors and memantine have shown sufficient safety and efficacy to allow marketing approval at an international level.  Although this is probably because the other drugs tested were ineffective, inadequate clinical development methods have also been blamed for the failures.  Here, we review the development of treatments for Alzheimer's disease during the past 30 years, considering the drugs, potential targets, late-stage clinical trials, development methods, emerging use of biomarkers and evolution of regulatory considerations in order to summarize advances and anticipate future developments.  We have considered late-stage Alzheimer's disease drug development from 1984 to 2013, including individual clinical trials, systematic and qualitative reviews, meta-analyses, methods, commentaries, position papers and guidelines.  We then review the evolution of drugs in late clinical development, methods, biomarkers and regulatory issues.  Although a range of small molecules and biological products against many targets have been investigated in clinical trials, the predominant drug targets have been the cholinergic system and the amyloid cascade.  Trial methods have evolved incrementally: inclusion criteria have largely remained focused on mild-to-moderate Alzheimer's disease criteria, recently extending to early or prodromal Alzheimer disease or 'mild cognitive impairment due to Alzheimer's disease', for drugs considered to be disease modifying.  The duration of trials has remained at 6-12 months for drugs intended to improve symptoms; 18- to 24-month trials have been established for drugs expected to attenuate clinical course.  Cognitive performance, activities of daily living, global change and severity ratings have persisted as the primary clinically relevant outcomes.  Regulatory guidance and oversight have evolved to allow for enrichment of early-stage Alzheimer's disease trial samples using biomarkers and phase-specific outcomes.  In conclusion, validated drug targets for Alzheimer's disease remain to be developed.  Only drugs that affect an aspect of cholinergic function have shown consistent, but modest, clinical effects in late-phase trials.  There is opportunity for substantial improvements in drug discovery and clinical development methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiLqeiU50WDCA3UY9EwTNrfW6udTcc2ea4Ck2IRebL2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crhsFaqug%253D%253D&md5=7e34762560c7cb2ce25084827c348cdc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fjoim.12191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjoim.12191%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DMangialasche%26aufirst%3DF.%26aulast%3DAndreasen%26aufirst%3DN.%26aulast%3DFeldman%26aufirst%3DH.%26aulast%3DGiacobini%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMantua%26aufirst%3DV.%26aulast%3DMecocci%26aufirst%3DP.%26aulast%3DPani%26aufirst%3DL.%26aulast%3DWinblad%26aufirst%3DB.%26aulast%3DKivipelto%26aufirst%3DM.%26atitle%3DClinical%2520trials%2520and%2520late-stage%2520drug%2520development%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520appraisal%2520from%25201984%2520to%25202014%26jtitle%3DJ.%2520Intern.%2520Med.%26date%3D2014%26volume%3D275%26spage%3D251%26epage%3D283%26doi%3D10.1111%2Fjoim.12191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Choi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracciolo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niikura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosetti, F.</span><span> </span><span class="NLM_article-title">Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1111/jnc.12059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fjnc.12059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23083210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslyns7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2013&pages=59-68&author=S.+H.+Choiauthor=S.+Aidauthor=L.+Caraccioloauthor=S.+S.+Minamiauthor=T.+Niikuraauthor=Y.+Matsuokaauthor=R.+S.+Turnerauthor=M.+P.+Mattsonauthor=F.+Bosetti&title=Cyclooxygenase-1+inhibition+reduces+amyloid+pathology+and+improves+memory+deficits+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1111%2Fjnc.12059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Choi, Sang-Ho; Aid, Saba; Caracciolo, Luca; Sakura Minami, S.; Niikura, Takako; Matsuoka, Yasuji; Turner, R. Scott; Mattson, Mark P.; Bosetti, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1&2</span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Several epidemiol. and preclin. studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase (COX), reduce the risk of Alzheimer's disease (AD) and can lower β-amyloid (Aβ) prodn. and inhibit neuroinflammation.  However, follow-up clin. trials, mostly using selective cyclooxygenase (COX)-2 inhibitors, failed to show any beneficial effect in AD patients with mild to severe cognitive deficits.  Recent data indicated that COX-1, classically viewed as the homeostatic isoform, is localized in microglia and is actively involved in brain injury induced by pro-inflammatory stimuli including Aβ, lipopolysaccharide, and interleukins.  We hypothesized that neuroinflammation is crit. for disease progression and selective COX-1 inhibition, rather than COX-2 inhibition, can reduce neuroinflammation and AD pathol.  Here, we show that treatment of 20-mo-old triple transgenic AD (3 × Tg-AD) mice with the COX-1 selective inhibitor SC-560 improved spatial learning and memory, and reduced amyloid deposits and tau hyperphosphorylation.  SC-560 also reduced glial activation and brain expression of inflammatory markers in 3 × Tg-AD mice, and switched the activated microglia phenotype promoting their phagocytic ability.  The present findings are the first to demonstrate that selective COX-1 inhibition reduces neuroinflammation, neuropathol., and improves cognitive function in 3 × Tg-AD mice.  Thus, selective COX-1 inhibition should be further investigated as a potential therapeutic approach for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Fk5r6Fvr8bVg90H21EOLACvtfcHk0ljK1YnF1Ef4KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslyns7fI&md5=9fb95148a77a7b1787f4c56ef92f456f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12059%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DAid%26aufirst%3DS.%26aulast%3DCaracciolo%26aufirst%3DL.%26aulast%3DMinami%26aufirst%3DS.%2BS.%26aulast%3DNiikura%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DTurner%26aufirst%3DR.%2BS.%26aulast%3DMattson%26aufirst%3DM.%2BP.%26aulast%3DBosetti%26aufirst%3DF.%26atitle%3DCyclooxygenase-1%2520inhibition%2520reduces%2520amyloid%2520pathology%2520and%2520improves%2520memory%2520deficits%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2013%26volume%3D124%26spage%3D59%26epage%3D68%26doi%3D10.1111%2Fjnc.12059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">McGeer, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGeer, E. G.</span><span> </span><span class="NLM_article-title">NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2006.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neurobiolaging.2006.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=16697488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislSrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=639-647&author=P.+L.+McGeerauthor=E.+G.+McGeer&title=NSAIDs+and+Alzheimer+disease%3A+epidemiological%2C+animal+model+and+clinical+studies&doi=10.1016%2Fj.neurobiolaging.2006.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies</span></div><div class="casAuthors">McGeer, Patrick L.; McGeer, Edith G.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-647</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This review reports correlations between four independent fields related to inflammation and Alzheimer disease: fundamental pathol., epidemiol., transgenic animal studies and clin. trials.  Activated microglia, along with a spectrum of inflammatory mediators, have been identified in assocn. with the lesions of Alzheimer disease (AD), suggesting that antiinflammatory agents such as NSAIDs should protect against the disease.  In multiple epidemiol. investigations testing this hypothesis, a significant risk redn., or a trend towards such a redn. has been obsd. in long term as opposed to short term users of traditional NSAIDs.  In studies where such NSAIDs have been administered to AD transgenic mice, a dose dependent redn. in pathol. was obsd.  The selective C0X-2 inhibitors were ineffective.  Results of clin. investigations have so far been disappointing but have nevertheless correlated with fundamental pathol. findings and with transgenic mouse results.  Four clin. trials using selective COX-2 inhibitors failed which is in keeping with the animal results and is consistent with pathol. findings demonstrating that COX-1 and not COX-2 is the appropriate target in activated human microglia.  A low dose trial of the traditional NSAID naproxen also failed, but pilot trials using therapeutically established doses of indomethacin and diclofenac/misoprostol showed promise.  Further clin. investigations with relatively high doses of traditional NSAIDs might be warranted, although significant side effects should be anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr5CYtCv9mQ7Vg90H21EOLACvtfcHk0ljK1YnF1Ef4KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislSrt74%253D&md5=b5b3f0052c0a0e8fdf1dea09f2541fa9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2006.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2006.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DMcGeer%26aufirst%3DE.%2BG.%26atitle%3DNSAIDs%2520and%2520Alzheimer%2520disease%253A%2520epidemiological%252C%2520animal%2520model%2520and%2520clinical%2520studies%26jtitle%3DNeurobiol.%2520Aging%26date%3D2007%26volume%3D28%26spage%3D639%26epage%3D647%26doi%3D10.1016%2Fj.neurobiolaging.2006.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Yan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu-Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biere, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Citron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landreth, G.</span><span> </span><span class="NLM_article-title">Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">7504</span><span class="NLM_x">–</span> <span class="NLM_lpage">7509</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=12930788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFaisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=7504-7509&author=Q.+Yanauthor=J.+Zhangauthor=H.+Liuauthor=S.+Babu-Khanauthor=R.+Vassarauthor=A.+L.+Biereauthor=M.+Citronauthor=G.+Landreth&title=Anti-inflammatory+drug+therapy+alters+beta-amyloid+processing+and+deposition+in+an+animal+model+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease</span></div><div class="casAuthors">Yan, Qiao; Zhang, Jianhua; Liu, Hantao; Babu-Khan, Safura; Vassar, Robert; Biere, Anja Leona; Citron, Martin; Landreth, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7504-7509</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain.  Nonsteroidal anti-inflammatory drug (NSAID) treatment reduces AD risk, slows disease progression, and reduces microglial activation; however, the basis of these effects is unknown.  We report that treatment of 11-mo-old Tg2576 mice overexpressing human amyloid precursor protein (APP) with the NSAID ibuprofen for 16 wk resulted in the dramatic and selective redn. of SDS-sol. β-amyloid (Aβ)42, whereas it had smaller effects on SDS-sol. Aβ40 levels.  Ibuprofen treatment resulted in 60% redn. of amyloid plaque load in the cortex of these animals.  In vitro studies using APP-expressing 293 cells showed that ibuprofen directly affected APP processing, specifically reducing the prodn. of Aβ42.  Ibuprofen treatment resulted in a significant redn. in microglial activation in the Tg2576 mice, as measured by CD45 and CD11b expression.  NSAIDs activate the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ); however, a potent agonist of this receptor, pioglitazone, only modestly reduced SDS-sol.  Aβ levels and did not affect amyloid plaque burden or microglia activation, indicating that PPARγ activation is not involved in the Aβ lowering effect of NSAIDs.  These data show that chronic NSAID treatment can reduce brain Aβ levels, amyloid plaque burden, and microglial activation in an animal model of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4w_7ZE_lvKbVg90H21EOLACvtfcHk0ljK1YnF1Ef4KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFaisLg%253D&md5=ae17d7abd50d1fd812e88dd86d62c29b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DBiere%26aufirst%3DA.%2BL.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DLandreth%26aufirst%3DG.%26atitle%3DAnti-inflammatory%2520drug%2520therapy%2520alters%2520beta-amyloid%2520processing%2520and%2520deposition%2520in%2520an%2520animal%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26spage%3D7504%26epage%3D7509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Lim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubeda, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashe, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frautschy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, G. M.</span><span> </span><span class="NLM_article-title">Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5709</span><span class="NLM_x">–</span> <span class="NLM_lpage">5714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10908610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=5709-5714&author=G.+P.+Limauthor=F.+Yangauthor=T.+Chuauthor=P.+Chenauthor=W.+Beechauthor=B.+Teterauthor=T.+Tranauthor=O.+Ubedaauthor=K.+H.+Asheauthor=S.+A.+Frautschyauthor=G.+M.+Cole&title=Ibuprofen+suppresses+plaque+pathology+and+inflammation+in+a+mouse+model+for+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease</span></div><div class="casAuthors">Lim, G. P.; Yang, F.; Chu, T.; Chen, P.; Beech, W.; Teter, B.; Tran, T.; Ubeda, O.; Ashe, K. Hsiao; Frautschy, S. A.; Cole, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5709-5714</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The brain in Alzheimer's disease (AD) shows a chronic inflammatory response characterized by activated glial cells and increased expression of cytokines and complement factors surrounding amyloid deposits.  Several epidemiol. studies have demonstrated a reduced risk for AD in patients using nonsteroidal anti-inflammatory drugs (NSAIDs), prompting further inquiries about how NSAIDs might influence the development of AD pathol. and inflammation in the CNS.  We tested the impact of chronic orally administered ibuprofen, the most commonly used NSAID, in a transgenic model of AD displaying widespread microglial activation, age-related amyloid deposits, and dystrophic neurites.  These mice were created by overexpressing a variant of the amyloid precursor protein found in familial AD.  Transgene-pos. (Tg+) and neg. (Tg-) mice began receiving chow contg. 375 ppm ibuprofen at 10 mo of age, when amyloid plaques first appear, and were fed continuously for 6 mo.  This treatment produced significant redns. in final interleukin-1β and glial fibrillary acidic protein levels, as well as a significant diminution in the ultimate no. and total area of β-amyloid deposits.  Redns. in amyloid deposition were supported by ELISA measurements showing significantly decreased SDS-insol. Aβ.  Ibuprofen also decreased the nos. of ubiquitin-labeled dystrophic neurites and the percentage area per plaque of antiphosphotyrosine-labeled microglia.  Thus, the anti-inflammatory drug ibuprofen, which has been assocd. with reduced AD risk in human epidemiol. studies, can significantly delay some forms of AD pathol., including amyloid deposition, when administered early in the disease course of a transgenic mouse model of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu-NFgSW3HzrVg90H21EOLACvtfcHk0lipbQYFnxoUWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbk%253D&md5=980c52238707aa8fba6cce1c1cdfc399</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DG.%2BP.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBeech%26aufirst%3DW.%26aulast%3DTeter%26aufirst%3DB.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DUbeda%26aufirst%3DO.%26aulast%3DAshe%26aufirst%3DK.%2BH.%26aulast%3DFrautschy%26aufirst%3DS.%2BA.%26aulast%3DCole%26aufirst%3DG.%2BM.%26atitle%3DIbuprofen%2520suppresses%2520plaque%2520pathology%2520and%2520inflammation%2520in%2520a%2520mouse%2520model%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26spage%3D5709%26epage%3D5714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Lim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gahtan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubeda, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overmier, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao-Ashec, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frautschy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, G. M.</span><span> </span><span class="NLM_article-title">Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">991</span><span class="refDoi"> DOI: 10.1016/S0197-4580(01)00299-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2FS0197-4580%2801%2900299-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=11755007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFyksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=983-991&author=G.+P.+Limauthor=F.+Yangauthor=T.+Chuauthor=E.+Gahtanauthor=O.+Ubedaauthor=W.+Beechauthor=J.+B.+Overmierauthor=K.+Hsiao-Ashecauthor=S.+A.+Frautschyauthor=G.+M.+Cole&title=Ibuprofen+effects+on+Alzheimer+pathology+and+open+field+activity+in+APPsw+transgenic+mice&doi=10.1016%2FS0197-4580%2801%2900299-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice</span></div><div class="casAuthors">Lim, G. P.; Yang, F.; Chu, T.; Gahtan, E.; Ubeda, O.; Beech, W.; Overmier, J. B.; Hsiao-Ashec, K.; Frautschy, S. A.; Cole, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">983-991</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">We previously showed the non-steroidal anti-inflammatory drug (NSAID) ibuprofen suppresses inflammation and amyloid in the APPsw (Tg2576) Tg2576 transgenic mouse.  The mechanism for these effects and the impact on behavior are unknown.  We now show ibuprofen's effects were not mediated by alterations in amyloid precursor protein (APP) expression or oxidative damage (carbonyls).  Six months ibuprofen treatment in Tg+ females caused a decrease in open field behavior (p < 0.05), restoring values similar to Tg- mice.  Reduced caspase activation per plaque provided further evidence for a neuroprotective action of ibuprofen.  The impact of a shorter 3 mo duration ibuprofen trial, beginning at a later age (from 14 to 17 mo), was also investigated.  Repeated measures ANOVA of Aβ levels (sol. and insol.) demonstrated a significant ibuprofen treatment effect (p < 0.05).  Post-hoc anal. showed that ibuprofen-dependent redns. of both sol. Aβ and Aβ42 were most marked in entorhinal cortex (p < 0.05).  Although interleukin-1β and insol. Aβ were more effectively reduced with longer treatment, the magnitude of the effect on sol. Aβ was not dependent on treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoApEz_j49VfrVg90H21EOLACvtfcHk0lipbQYFnxoUWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFyksrw%253D&md5=8070317c22b4881300673110619ce5e1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0197-4580%2801%2900299-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-4580%252801%252900299-8%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DG.%2BP.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DGahtan%26aufirst%3DE.%26aulast%3DUbeda%26aufirst%3DO.%26aulast%3DBeech%26aufirst%3DW.%26aulast%3DOvermier%26aufirst%3DJ.%2BB.%26aulast%3DHsiao-Ashec%26aufirst%3DK.%26aulast%3DFrautschy%26aufirst%3DS.%2BA.%26aulast%3DCole%26aufirst%3DG.%2BM.%26atitle%3DIbuprofen%2520effects%2520on%2520Alzheimer%2520pathology%2520and%2520open%2520field%2520activity%2520in%2520APPsw%2520transgenic%2520mice%26jtitle%3DNeurobiol.%2520Aging%26date%3D2001%26volume%3D22%26spage%3D983%26epage%3D991%26doi%3D10.1016%2FS0197-4580%2801%2900299-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Szekely, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorne, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zandi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messias, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, S. N.</span><span> </span><span class="NLM_article-title">Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review</span> <span class="citation_source-journal">Neuroepidemiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1159/000078501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1159%2F000078501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=159-169&author=C.+A.+Szekelyauthor=J.+E.+Thorneauthor=P.+P.+Zandiauthor=M.+Ekauthor=E.+Messiasauthor=J.+C.+Breitnerauthor=S.+N.+Goodman&title=Nonsteroidal+anti-inflammatory+drugs+for+the+prevention+of+Alzheimer%E2%80%99s+disease%3A+a+systematic+review&doi=10.1159%2F000078501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1159%2F000078501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078501%26sid%3Dliteratum%253Aachs%26aulast%3DSzekely%26aufirst%3DC.%2BA.%26aulast%3DThorne%26aufirst%3DJ.%2BE.%26aulast%3DZandi%26aufirst%3DP.%2BP.%26aulast%3DEk%26aufirst%3DM.%26aulast%3DMessias%26aufirst%3DE.%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DGoodman%26aufirst%3DS.%2BN.%26atitle%3DNonsteroidal%2520anti-inflammatory%2520drugs%2520for%2520the%2520prevention%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520systematic%2520review%26jtitle%3DNeuroepidemiology%26date%3D2004%26volume%3D23%26spage%3D159%26epage%3D169%26doi%3D10.1159%2F000078501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Martin, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekely, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piantadosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craft, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullan, M.</span><span> </span><span class="NLM_article-title">Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib</span> <span class="citation_source-journal">Arch. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span><span class="refDoi"> DOI: 10.1001/archneur.2008.65.7.nct70006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1001%2Farchneur.2008.65.7.nct70006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=18474729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BD1cvksFGntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=896-905&author=B.+K.+Martinauthor=C.+Szekelyauthor=J.+Brandtauthor=S.+Piantadosiauthor=J.+C.+Breitnerauthor=S.+Craftauthor=D.+Evansauthor=R.+Greenauthor=M.+Mullan&title=Cognitive+function+over+time+in+the+Alzheimer%E2%80%99s+Disease+Anti-inflammatory+Prevention+Trial+%28ADAPT%29%3A+results+of+a+randomized%2C+controlled+trial+of+naproxen+and+celecoxib&doi=10.1001%2Farchneur.2008.65.7.nct70006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib</span></div><div class="casAuthors">Martin Barbara K; Szekely Christine; Brandt Jason; Piantadosi Steven; Breitner John C S; Craft Suzanne; Evans Denis; Green Robert; Mullan Michael</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">896-905</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs.  OBJECTIVE:  To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults.  DESIGN:  Randomized, double-masked chemoprevention trial.  SETTING:  Six US memory clinics.  PARTICIPANTS:  Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment.  INTERVENTIONS:  Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively.  MAIN OUTCOME MEASURES:  Seven tests of cognitive function and a global summary score measured annually.  RESULTS:  Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]).  Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences.  Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses.  CONCLUSIONS:  Use of naproxen or celecoxib did not improve cognitive function.  There was weak evidence for a detrimental effect of naproxen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5MiMEA4EjlJ0d-O_J5C0AfW6udTcc2eaGw1ZZXypaIrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvksFGntg%253D%253D&md5=b1b9434737024bf183ab43d8a34afb31</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1001%2Farchneur.2008.65.7.nct70006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.2008.65.7.nct70006%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DB.%2BK.%26aulast%3DSzekely%26aufirst%3DC.%26aulast%3DBrandt%26aufirst%3DJ.%26aulast%3DPiantadosi%26aufirst%3DS.%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DCraft%26aufirst%3DS.%26aulast%3DEvans%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DMullan%26aufirst%3DM.%26atitle%3DCognitive%2520function%2520over%2520time%2520in%2520the%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Anti-inflammatory%2520Prevention%2520Trial%2520%2528ADAPT%2529%253A%2520results%2520of%2520a%2520randomized%252C%2520controlled%2520trial%2520of%2520naproxen%2520and%2520celecoxib%26jtitle%3DArch.%2520Neurol.%26date%3D2008%26volume%3D65%26spage%3D896%26epage%3D905%26doi%3D10.1001%2Farchneur.2008.65.7.nct70006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinert, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyketsos, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashe, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craft, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbagh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tariot, P. N.</span><span> </span><span class="NLM_article-title">Extended results of the Alzheimer’s disease anti-inflammatory prevention trial</span> <span class="citation_source-journal">Alzheimer's Dementia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span><span class="refDoi"> DOI: 10.1016/j.jalz.2010.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.jalz.2010.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=21784351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BC3MjgslemtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=402-411&author=J.+C.+Breitnerauthor=L.+D.+Bakerauthor=T.+J.+Montineauthor=C.+L.+Meinertauthor=C.+G.+Lyketsosauthor=K.+H.+Asheauthor=J.+Brandtauthor=S.+Craftauthor=D.+E.+Evansauthor=R.+C.+Greenauthor=M.+S.+Ismailauthor=B.+K.+Martinauthor=M.+J.+Mullanauthor=M.+Sabbaghauthor=P.+N.+Tariot&title=Extended+results+of+the+Alzheimer%E2%80%99s+disease+anti-inflammatory+prevention+trial&doi=10.1016%2Fj.jalz.2010.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Extended results of the Alzheimer's disease anti-inflammatory prevention trial</span></div><div class="casAuthors">Breitner John C; Baker Laura D; Montine Thomas J; Meinert Curtis L; Lyketsos Constantine G; Ashe Karen H; Brandt Jason; Craft Suzanne; Evans Denis E; Green Robert C; Ismail M Saleem; Martin Barbara K; Mullan Michael J; Sabbagh Marwan; Tariot Pierre N</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer's dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD.  The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments were terminated.  During the treatment interval, 32 cases of AD revealed increased rates in both NSAID-assigned groups.  METHODS:  We continued the double-masked ADAPT protocol for 2 additional years to investigate incidence of AD (primary outcome).  We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Aβ(1-42.)  RESULTS:  Including 40 new events observed during follow-up of 2,071 randomized individuals (92% of participants at treatment cessation), there were 72 AD cases.  Overall, NSAID-related harm was no longer evident, but secondary analyses showed that increased risk remained notable in the first 2.5 years of observations, especially in 54 persons enrolled with cognitive impairment--no dementia (CIND).  These same analyses showed later reduction in AD incidence among asymptomatic enrollees who were given naproxen.  CSF biomarker assays suggested that the latter result reflected reduced Alzheimer-type neurodegeneration.  CONCLUSIONS:  These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years.  Thus, treatment effects differ at various stages of disease.  This hypothesis is consistent with data from both trials and epidemiological studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRp1vb8yEF2ZtenUz0lpNqnfW6udTcc2ebj9qmQZg7A_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjgslemtQ%253D%253D&md5=72baff395a1e0c2ead0e181d7d82a0f8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2010.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2010.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DBaker%26aufirst%3DL.%2BD.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DMeinert%26aufirst%3DC.%2BL.%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26aulast%3DAshe%26aufirst%3DK.%2BH.%26aulast%3DBrandt%26aufirst%3DJ.%26aulast%3DCraft%26aufirst%3DS.%26aulast%3DEvans%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DR.%2BC.%26aulast%3DIsmail%26aufirst%3DM.%2BS.%26aulast%3DMartin%26aufirst%3DB.%2BK.%26aulast%3DMullan%26aufirst%3DM.%2BJ.%26aulast%3DSabbagh%26aufirst%3DM.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26atitle%3DExtended%2520results%2520of%2520the%2520Alzheimer%25E2%2580%2599s%2520disease%2520anti-inflammatory%2520prevention%2520trial%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2011%26volume%3D7%26spage%3D402%26epage%3D411%26doi%3D10.1016%2Fj.jalz.2010.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Leoutsakos, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthen, B. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyketsos, C. G.</span><span> </span><span class="NLM_article-title">Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial</span> <span class="citation_source-journal">Int. J. Geriatr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1002/gps.2723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fgps.2723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=21560159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BC38rmsFOiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=364-374&author=J.+M.+Leoutsakosauthor=B.+O.+Muthenauthor=J.+C.+Breitnerauthor=C.+G.+Lyketsos&title=Effects+of+non-steroidal+anti-inflammatory+drug+treatments+on+cognitive+decline+vary+by+phase+of+pre-clinical+Alzheimer+disease%3A+findings+from+the+randomized+controlled+Alzheimer%E2%80%99s+Disease+Anti-inflammatory+Prevention+Trial&doi=10.1002%2Fgps.2723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial</span></div><div class="casAuthors">Leoutsakos Jeannie-Marie S; Muthen Bengt O; Breitner John C S; Lyketsos Constantine G</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">364-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  We examined the effects of non-steroidal anti-inflammatory drugs on cognitive decline as a function of phase of pre-clinical Alzheimer disease.  METHODS:  Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer disease.  We fit growth mixture models of Modified Mini-Mental State (3MS) Examination trajectories with data from 2388 participants in the Alzheimer's Disease Anti-inflammatory Prevention Trial and included class-specific effects of naproxen and celecoxib.  RESULTS:  We identified three classes: "no decline", "slow decline", and "fast decline", and examined the effects of celecoxib and naproxen on linear slope and rate of change by class.  Inclusion of quadratic terms improved fit of the model (-2 log likelihood difference: 369.23; p < 0.001) but resulted in reversal of effects over time.  Over 4 years, participants in the slow-decline class on placebo typically lost 6.6 3MS points, whereas those on naproxen lost 3.1 points (p-value for difference: 0.19).  Participants in the fast-decline class on placebo typically lost 11.2 points, but those on celecoxib first declined and then gained points (p-value for difference from placebo: 0.04), whereas those on naproxen showed a typical decline of 24.9 points (p-value for difference from placebo: <0.0001).  CONCLUSIONS:  Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times.  Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners.  Celecoxib appeared to have similar effects at first but then attenuated change in fast decliners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQnJ0tKP6v-QyMywPm6HgQfW6udTcc2ebj9qmQZg7A_rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rmsFOiuw%253D%253D&md5=ba28ea938db996c5273eb44f64358537</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fgps.2723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.2723%26sid%3Dliteratum%253Aachs%26aulast%3DLeoutsakos%26aufirst%3DJ.%2BM.%26aulast%3DMuthen%26aufirst%3DB.%2BO.%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26atitle%3DEffects%2520of%2520non-steroidal%2520anti-inflammatory%2520drug%2520treatments%2520on%2520cognitive%2520decline%2520vary%2520by%2520phase%2520of%2520pre-clinical%2520Alzheimer%2520disease%253A%2520findings%2520from%2520the%2520randomized%2520controlled%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Anti-inflammatory%2520Prevention%2520Trial%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2012%26volume%3D27%26spage%3D364%26epage%3D374%26doi%3D10.1002%2Fgps.2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Maxis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delalandre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel-Pelletier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duval, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lajeunesse, D.</span><span> </span><span class="NLM_article-title">The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">R181</span><span class="refDoi"> DOI: 10.1186/ar2092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1186%2Far2092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=R181&author=K.+Maxisauthor=A.+Delalandreauthor=J.+Martel-Pelletierauthor=J.+P.+Pelletierauthor=N.+Duvalauthor=D.+Lajeunesse&title=The+shunt+from+the+cyclooxygenase+to+lipoxygenase+pathway+in+human+osteoarthritic+subchondral+osteoblasts+is+linked+with+a+variable+expression+of+the+5-lipoxygenase-activating+protein&doi=10.1186%2Far2092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2Far2092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far2092%26sid%3Dliteratum%253Aachs%26aulast%3DMaxis%26aufirst%3DK.%26aulast%3DDelalandre%26aufirst%3DA.%26aulast%3DMartel-Pelletier%26aufirst%3DJ.%26aulast%3DPelletier%26aufirst%3DJ.%2BP.%26aulast%3DDuval%26aufirst%3DN.%26aulast%3DLajeunesse%26aufirst%3DD.%26atitle%3DThe%2520shunt%2520from%2520the%2520cyclooxygenase%2520to%2520lipoxygenase%2520pathway%2520in%2520human%2520osteoarthritic%2520subchondral%2520osteoblasts%2520is%2520linked%2520with%2520a%2520variable%2520expression%2520of%2520the%25205-lipoxygenase-activating%2520protein%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2006%26volume%3D8%26spage%3DR181%26doi%3D10.1186%2Far2092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Varghese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockey, R. F.</span><span> </span><span class="NLM_article-title">Aspirin-exacerbated asthma</span> <span class="citation_source-journal">Allergy, Asthma, Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1186/1710-1492-4-2-75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1186%2F1710-1492-4-2-75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=20525128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVaisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=75-83&author=M.+Vargheseauthor=R.+F.+Lockey&title=Aspirin-exacerbated+asthma&doi=10.1186%2F1710-1492-4-2-75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Aspirin-exacerbated asthma</span></div><div class="casAuthors">Varghese, Mathew; Lockey, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Allergy, Asthma, and Clinical Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-83</span>CODEN:
                <span class="NLM_cas:coden">AACIB3</span>;
        ISSN:<span class="NLM_cas:issn">1710-1484</span>.
    
            (<span class="NLM_cas:orgname">BC Decker Inc.</span>)
        </div><div class="casAbstract">This review focuses on aspirin-exacerbated asthma (AEA).  The review includes historical perspective of aspirin, prevalence, pathogenesis, clin. features and treatment of AEA.  The pathogenesis of AEA involves the cyclooxygenase and lipooxygenase pathway.  Aspirin affects both of these pathways by inhibiting the enzyme cycooxygenase-1 (COX-1).  Inhibition of COX-1 leads to a decrease in prostaglandin E2 (PGE2).  The decrease in PGE2 results in an increase in cysteinyl leukotrienes by the lipooxygenase pathway involving the enzyme 5-lipooxygenase (5-LO).  Leukotriene C4 (LTC4) synthase is the enzyme responsible for the prodn. of leukotriene C4, the chief cysteinyl leukotriene responsible for AEA.  There have been familial occurrences of AEA.  An allele of the LTC4 synthase gene in AEA is known as allele C.  Allele C has a higher frequency in AEA.  Clin. presentation includes a history of asthma after ingestion of aspirin, nasal congestion, watery rhinorrhea and nasal polyposis.  Treatment includes leukotriene receptor antagonists, leukotriene inhibitors, aspirin desensitization and surgery.  AEA is the most well-defined phenotype of asthma.  Although AEA affects adults and children with physician-diagnosed asthma, in some cases there is no history of asthma and AEA often goes unrecognized and underdiagnosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLd2EYSDJtr7Vg90H21EOLACvtfcHk0lgwpdFwlM5ilA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVaisb8%253D&md5=c0a02be15197a112112b1fd3dfa0e0bc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1710-1492-4-2-75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1710-1492-4-2-75%26sid%3Dliteratum%253Aachs%26aulast%3DVarghese%26aufirst%3DM.%26aulast%3DLockey%26aufirst%3DR.%2BF.%26atitle%3DAspirin-exacerbated%2520asthma%26jtitle%3DAllergy%252C%2520Asthma%252C%2520Clin.%2520Immunol.%26date%3D2008%26volume%3D4%26spage%3D75%26epage%3D83%26doi%3D10.1186%2F1710-1492-4-2-75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Duffield-Lillico, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butala, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subbaramaiah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milne, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dannenberg, A. J.</span><span> </span><span class="NLM_article-title">Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway</span> <span class="citation_source-journal">Cancer Prev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span><span class="refDoi"> DOI: 10.1158/1940-6207.CAPR-09-0005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1158%2F1940-6207.CAPR-09-0005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=19336727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFKgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=322-329&author=A.+J.+Duffield-Lillicoauthor=J.+O.+Boyleauthor=X.+K.+Zhouauthor=A.+Ghoshauthor=G.+S.+Butalaauthor=K.+Subbaramaiahauthor=R.+A.+Newmanauthor=J.+D.+Morrowauthor=G.+L.+Milneauthor=A.+J.+Dannenberg&title=Levels+of+prostaglandin+E+metabolite+and+leukotriene+E%284%29+are+increased+in+the+urine+of+smokers%3A+evidence+that+celecoxib+shunts+arachidonic+acid+into+the+5-lipoxygenase+pathway&doi=10.1158%2F1940-6207.CAPR-09-0005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway</span></div><div class="casAuthors">Duffield-Lillico, Anna J.; Boyle, Jay O.; Zhou, Xi Kathy; Ghosh, Aradhana; Butala, Geera S.; Subbaramaiah, Kotha; Newman, Robert A.; Morrow, Jason D.; Milne, Ginger L.; Dannenberg, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association of Cancer Research</span>)
        </div><div class="casAbstract">Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) play a role in inflammation and carcinogenesis.  Biomarkers that reflect tobacco smoke-induced tissue injury are needed.  In this study, levels of urinary prostaglandin E metabolite (PGE-M) and leukotriene E4 (LTE4), biomarkers of the COX and 5-LO pathways, were compared in never smokers, former smokers, and current smokers.  The effects of celecoxib, a selective COX-2 inhibitor, on levels of PGE-M and LTE4 were detd.  Baseline levels of PGE-M and LTE4 were pos. assocd. with smoking status; levels of PGE-M and LTE4 were higher in current vs. never smokers.  Treatment with 200 mg celecoxib twice daily for 6 ± 1 days led to a redn. in urinary PGE-M levels in all groups but exhibited the greatest effect among subjects with high baseline PGE-M levels.  Thus, high baseline PGE-M levels in smokers reflected increased COX-2 activity.  In individuals with high baseline PGE-M levels, treatment with celecoxib led to a significant increase in levels of urinary LTE4, an effect that was not found in individuals with low baseline PGE-M levels.  In conclusion, increased levels of urinary PGE-M and LTE4 were found in human smokers, a result that may reflect subclin. lung inflammation.  In individuals with high baseline levels of PGE-M (elevated COX-2 activity), celecoxib administration shunted arachidonic acid into the proinflammatory 5-LO pathway.  Because 5-LO activity and LTE4 have been suggested to play a role in cardiovascular disease, these results may help to explain the link between use of COX-2 inhibitors and cardiovascular complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQXJp1FZG--LVg90H21EOLACvtfcHk0lgwpdFwlM5ilA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFKgu74%253D&md5=245a39372c092dba4b0417ed19018105</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-09-0005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-09-0005%26sid%3Dliteratum%253Aachs%26aulast%3DDuffield-Lillico%26aufirst%3DA.%2BJ.%26aulast%3DBoyle%26aufirst%3DJ.%2BO.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DButala%26aufirst%3DG.%2BS.%26aulast%3DSubbaramaiah%26aufirst%3DK.%26aulast%3DNewman%26aufirst%3DR.%2BA.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26aulast%3DMilne%26aufirst%3DG.%2BL.%26aulast%3DDannenberg%26aufirst%3DA.%2BJ.%26atitle%3DLevels%2520of%2520prostaglandin%2520E%2520metabolite%2520and%2520leukotriene%2520E%25284%2529%2520are%2520increased%2520in%2520the%2520urine%2520of%2520smokers%253A%2520evidence%2520that%2520celecoxib%2520shunts%2520arachidonic%2520acid%2520into%2520the%25205-lipoxygenase%2520pathway%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2009%26volume%3D2%26spage%3D322%26epage%3D329%26doi%3D10.1158%2F1940-6207.CAPR-09-0005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Perry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilts, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salloway, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribkoff, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrillo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bens, C.</span><span> </span><span class="NLM_article-title">Building a roadmap for developing combination therapies for Alzheimer’s disease</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1586/14737175.2015.996551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1586%2F14737175.2015.996551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=25708309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1ansrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=327-333&author=D.+Perryauthor=R.+Sperlingauthor=R.+Katzauthor=D.+Berryauthor=D.+Diltsauthor=D.+Hannaauthor=S.+Sallowayauthor=J.+Q.+Trojanowskiauthor=C.+Bountraauthor=M.+Kramsauthor=J.+Luthmanauthor=S.+Potkinauthor=V.+Gribkoffauthor=R.+Templeauthor=Y.+Wangauthor=M.+C.+Carrilloauthor=D.+Stephensonauthor=H.+Snyderauthor=E.+Liuauthor=T.+Wareauthor=J.+McKewauthor=F.+O.+Fieldsauthor=L.+J.+Bainauthor=C.+Bens&title=Building+a+roadmap+for+developing+combination+therapies+for+Alzheimer%E2%80%99s+disease&doi=10.1586%2F14737175.2015.996551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Building a roadmap for developing combination therapies for Alzheimer's disease</span></div><div class="casAuthors">Perry, Daniel; Sperling, Reisa; Katz, Russell; Berry, Donald; Dilts, David; Hanna, Debra; Salloway, Stephen; Trojanowski, John Q.; Bountra, Chas; Krams, Michael; Luthman, Johan; Potkin, Steven; Gribkoff, Val; Temple, Robert; Wang, Yaning; Carrillo, Maria C.; Stephenson, Diane; Snyder, Heather; Liu, Enchi; Ware, Tony; McKew, John; Fields, F. Owen; Bain, Lisa J.; Bens, Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-333</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases.  A growing no. of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease.  A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Crit. Path Institute and the Alzheimer's Assocn. addressed challenges in designing clin. trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqreFl8-aV74LVg90H21EOLACvtfcHk0lgjLgHWzrgTJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1ansrs%253D&md5=7791d6ba7ee40aed546917a4d3e853a1</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.996551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.996551%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DD.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DKatz%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DD.%26aulast%3DDilts%26aufirst%3DD.%26aulast%3DHanna%26aufirst%3DD.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DKrams%26aufirst%3DM.%26aulast%3DLuthman%26aufirst%3DJ.%26aulast%3DPotkin%26aufirst%3DS.%26aulast%3DGribkoff%26aufirst%3DV.%26aulast%3DTemple%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DStephenson%26aufirst%3DD.%26aulast%3DSnyder%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DWare%26aufirst%3DT.%26aulast%3DMcKew%26aufirst%3DJ.%26aulast%3DFields%26aufirst%3DF.%2BO.%26aulast%3DBain%26aufirst%3DL.%2BJ.%26aulast%3DBens%26aufirst%3DC.%26atitle%3DBuilding%2520a%2520roadmap%2520for%2520developing%2520combination%2520therapies%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D327%26epage%3D333%26doi%3D10.1586%2F14737175.2015.996551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Mariano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralinaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer’s disease</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1198</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1021/cn5001815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5001815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1198-202&author=M.+Marianoauthor=C.+Schmittauthor=P.+Miralinaghiauthor=M.+Cattoauthor=R.+W.+Hartmannauthor=A.+Carottiauthor=M.+Engel&title=First+selective+dual+inhibitors+of+tau+phosphorylation+and+Beta-amyloid+aggregation%2C+two+major+pathogenic+mechanisms+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fcn5001815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer's Disease</span></div><div class="casAuthors">Mariano, Marica; Schmitt, Christian; Miralinaghi, Parisa; Catto, Marco; Hartmann, Rolf W.; Carotti, Angelo; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1198-1202</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In Alzheimer's disease (AD), multiple factors account for the accumulation of neurocellular changes, which may begin several years before symptoms appear.  The most important pathogenic brain changes that are contributing to the development of AD are the formation of the cytotoxic β-amyloid aggregates and of the neurofibrillary tangles, which originate from amyloid-β peptides and hyperphosphorylated tau protein, resp.  New therapeutic agents that target both major pathogenic mechanisms may be particularly efficient.  In this study, the authors introduce bis(hydroxyphenyl)-substituted thiophenes I [R1 = 3-Me, 3-MeO, 3-Me-4-MeO, 3-Et-4-MeO; R2 = 3-MeO, 4-MeO, 3-Me-4-MeO, 3-Et-4-MeO] as a novel class of selective, dual inhibitors of the tau kinase Dyrk1A and of the amyloid-β aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgPu3VSQ64rVg90H21EOLACvtfcHk0lgV51lt_rnxRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K&md5=31754e003032609beeb9568418bc30d7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fcn5001815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5001815%26sid%3Dliteratum%253Aachs%26aulast%3DMariano%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DMiralinaghi%26aufirst%3DP.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3DFirst%2520selective%2520dual%2520inhibitors%2520of%2520tau%2520phosphorylation%2520and%2520Beta-amyloid%2520aggregation%252C%2520two%2520major%2520pathogenic%2520mechanisms%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D1198%26epage%3D202%26doi%3D10.1021%2Fcn5001815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afragola, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1021/jm060717i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060717i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtleiu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=319-327&author=N.+Zhangauthor=S.+Ayral-Kaloustianauthor=T.+Nguyenauthor=J.+Afragolaauthor=R.+Hernandezauthor=J.+Lucasauthor=J.+Gibbonsauthor=C.+Beyer&title=Synthesis+and+SAR+of+%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5Dpyrimidines%2C+a+class+of+anticancer+agents+with+a+unique+mechanism+of+tubulin+inhibition&doi=10.1021%2Fjm060717i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of [1,2,4]Triazolo[1,5-a]pyrimidines, a Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition</span></div><div class="casAuthors">Zhang, Nan; Ayral-Kaloustian, Semiramis; Nguyen, Thai; Afragola, Jay; Hernandez, Richard; Lucas, Judy; Gibbons, James; Beyer, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of [1,2,4]triazolo[1,5-a]pyrimidines I [R1 = Cl, Br; R2, R3 = H, Me; R4 = H, F, Me2N(CH2)3S, HO(CH2)4O, Me2N(CH2)3NH, etc.; R5 = H, F, Me2N(CH2)3O; R6 = H, F] was synthesized via arom. nucleophilic substitution reactions using alcs., thiols or amines as nucleophiles, and the structure-activity relationship of the products as anticancer agents was evaluated.  (1S)-2,2,2-Trifluoro-1-methylethylamino group or an achiral 2,2,2-trifluoroethylamino group is required at the 5-position to achieve high potency.  On the Ph ring, both fluoro atoms, at the positions ortho to the triazolopyrimidine core, are needed for optimal activity.  At the position para to the triazolopyrimidine core, on the Ph ring, the best activity is achieved with an oxygen linkage followed by a three-methylene unit, and an alkylamino or a hydroxy group.  The mechanism of action for this series of triazolopyrimidines was shown to be unique in that they promoted tubulin polymn. in vitro, but did not bind competitively with paclitaxel.  Instead, these compds. inhibit the binding of vincas to tubulin.  Selected compds. were studied further, and it was shown that these compds. were able to overcome resistance attributed to several multidrug resistance transporter proteins.  Lead compds. were shown to inhibit tumor growth in several nude mouse xenograft models, with high potency and efficacy, when dosed either orally or i.v.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomL5qunsB_7bVg90H21EOLACvtfcHk0lgV51lt_rnxRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtleiu7fN&md5=769f225dbaa90b634cd86ff5f0c9504d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm060717i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060717i%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DAfragola%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DR.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DBeyer%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dpyrimidines%252C%2520a%2520class%2520of%2520anticancer%2520agents%2520with%2520a%2520unique%2520mechanism%2520of%2520tubulin%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D319%26epage%3D327%26doi%3D10.1021%2Fjm060717i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span> </span><span class="NLM_article-title">Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5040</span><span class="NLM_x">–</span> <span class="NLM_lpage">5049</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.bmc.2013.12.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5040-5049&author=K.+R.+Brundenauthor=J.+Q.+Trojanowskiauthor=A.+B.+Smithauthor=V.+M.+Leeauthor=C.+Ballatore&title=Microtubule-stabilizing+agents+as+potential+therapeutics+for+neurodegenerative+disease&doi=10.1016%2Fj.bmc.2013.12.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DMicrotubule-stabilizing%2520agents%2520as%2520potential%2520therapeutics%2520for%2520neurodegenerative%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5040%26epage%3D5049%26doi%3D10.1016%2Fj.bmc.2013.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shively, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakhani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald-Jones, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toleikis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span> </span><span class="NLM_article-title">Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1073/pnas.0406361102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1073%2Fpnas.0406361102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=15615853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=227-231&author=B.+Zhangauthor=A.+Maitiauthor=S.+Shivelyauthor=F.+Lakhaniauthor=G.+McDonald-Jonesauthor=J.+Bruceauthor=E.+B.+Leeauthor=S.+X.+Xieauthor=S.+Joyceauthor=C.+Liauthor=P.+M.+Toleikisauthor=V.+M.+Y.+Leeauthor=J.+Q.+Trojanowski&title=Microtubule-binding+drugs+offset+tau+sequestration+by+stabilizing+microtubules+and+reversing+fast+axonal+transport+deficits+in+a+tauopathy+model&doi=10.1073%2Fpnas.0406361102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model</span></div><div class="casAuthors">Zhang, Bin; Maiti, Arpita; Shively, Sharon; Lakhani, Fara; McDonald-Jones, Gaye; Bruce, Jennifer; Lee, Edward B.; Xie, Sharon X.; Joyce, Sonali; Li, Chi; Toleikis, Philip M.; Lee, Virginia M.-Y.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">227-231</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We tested the hypothesis that microtubule (MT)-binding drugs could be therapeutically beneficial in tauopathies by functionally substituting for the MT-binding protein tau, which is sequestered into inclusions of human tauopathies and transgenic mouse models thereof.  Transgenic mice were treated for 12 wk with weekly i.p. injections of 10 or 25 mg/m2 paclitaxel (Paxceed).  Both doses restored fast axonal transport in spinal axons, wherein MT nos. and stable (detyrosinated) tubulins were increased, compared with sham treatment, and only Paxceed ameliorated motor impairments in tau transgenic mice.  Thus, MT-stabilizing drugs could have therapeutic potential for treating neurodegenerative tauopathies by offsetting losses of tau function that result from the sequestration of this MT-stabilizing protein into filamentous inclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Xfh_fgcZrLVg90H21EOLACvtfcHk0lgZdRvqA9hJjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlemtA%253D%253D&md5=bf2746acbdcf115ac7fc9042232c9c36</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0406361102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0406361102%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMaiti%26aufirst%3DA.%26aulast%3DShively%26aufirst%3DS.%26aulast%3DLakhani%26aufirst%3DF.%26aulast%3DMcDonald-Jones%26aufirst%3DG.%26aulast%3DBruce%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DJoyce%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DToleikis%26aufirst%3DP.%2BM.%26aulast%3DLee%26aufirst%3DV.%2BM.%2BY.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DMicrotubule-binding%2520drugs%2520offset%2520tau%2520sequestration%2520by%2520stabilizing%2520microtubules%2520and%2520reversing%2520fast%2520axonal%2520transport%2520deficits%2520in%2520a%2520tauopathy%2520model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D227%26epage%3D231%26doi%3D10.1073%2Fpnas.0406361102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 24 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Ludovica Monti, Anne-Sophie Cornec, Killian Oukoloff, Jane Kovalevich, Kristen Prijs, Thibault Alle, Kurt R. Brunden, Amos B. Smith, III, Nelly El-Sakkary, Lawrence J. Liu, Ali Syed, Danielle E. Skinner, Carlo Ballatore, <span class="NLM_string-name hlFld-ContribAuthor">Conor R. Caffrey</span>. </span><span class="cited-content_cbyCitation_article-title">Congeners Derived from Microtubule-Active Phenylpyrimidines Produce a Potent and Long-Lasting Paralysis of Schistosoma mansoni In Vitro. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (5)
                                     , 1089-1103. <a href="https://doi.org/10.1021/acsinfecdis.0c00508" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00508%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DCongeners%252BDerived%252Bfrom%252BMicrotubule-Active%252BPhenylpyrimidines%252BProduce%252Ba%252BPotent%252Band%252BLong-Lasting%252BParalysis%252Bof%252BSchistosoma%252Bmansoni%252BIn%252BVitro%26aulast%3DMonti%26aufirst%3DLudovica%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D15072020%26date%3D31102020%26volume%3D7%26issue%3D5%26spage%3D1089%26epage%3D1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Timofey D. Moseev, Mikhail V. Varaksin, Denis A. Gorlov, Valery N. Charushin, <span class="NLM_string-name hlFld-ContribAuthor">Oleg N. Chupakhin</span>. </span><span class="cited-content_cbyCitation_article-title">Transition-Metal-Free C–H/C–Li Coupling of Nonaromatic 2H-Imidazole 1-Oxides with Pentafluorophenyl Lithium in the Design of Novel Fluorophores with Intramolecular Charge Transfer Effect. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (17)
                                     , 11124-11133. <a href="https://doi.org/10.1021/acs.joc.0c01042" title="DOI URL">https://doi.org/10.1021/acs.joc.0c01042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.0c01042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.0c01042%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DTransition-Metal-Free%252BC%2525E2%252580%252593H%25252FC%2525E2%252580%252593Li%252BCoupling%252Bof%252BNonaromatic%252B2H-Imidazole%252B1-Oxides%252Bwith%252BPentafluorophenyl%252BLithium%252Bin%252Bthe%252BDesign%252Bof%252BNovel%252BFluorophores%252Bwith%252BIntramolecular%252BCharge%252BTransfer%252BEffect%26aulast%3DMoseev%26aufirst%3DTimofey%2BD.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D28042020%26date%3D27072020%26date%3D13072020%26volume%3D85%26issue%3D17%26spage%3D11124%26epage%3D11133" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Annachiara Gandini, Manuela Bartolini, Daniele Tedesco, Loreto Martinez-Gonzalez, Carlos Roca, Nuria E. Campillo, Josefa Zaldivar-Diez, Concepción Perez, Giampaolo Zuccheri, Andrea Miti, Alessandra Feoli, Sabrina Castellano, Sabrina Petralla, Barbara Monti, Martina Rossi, Fabio Moda, Giuseppe Legname, Ana Martinez, <span class="NLM_string-name hlFld-ContribAuthor">Maria Laura Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (17)
                                     , 7640-7656. <a href="https://doi.org/10.1021/acs.jmedchem.8b00610" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00610</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00610%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTau-Centric%252BMultitarget%252BApproach%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%25253A%252BDevelopment%252Bof%252BFirst-in-Class%252BDual%252BGlycogen%252BSynthase%252BKinase%252B3%2525CE%2525B2%252Band%252BTau-Aggregation%252BInhibitors%26aulast%3DGandini%26aufirst%3DAnnachiara%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D17042018%26date%3D24082018%26date%3D04082018%26volume%3D61%26issue%3D17%26spage%3D7640%26epage%3D7656" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Sneha R. Sagar, Devendra Pratap Singh, Nirupa B. Panchal, Rajesh D. Das, Dhaivat H. Pandya, Vasudevan Sudarsanam, Manish Nivsarkar, <span class="NLM_string-name hlFld-ContribAuthor">Kamala K. Vasu</span>. </span><span class="cited-content_cbyCitation_article-title">Thiazolyl-thiadiazines as Beta Site Amyloid Precursor Protein Cleaving Enzyme-1 (BACE-1) Inhibitors and Anti-inflammatory Agents: Multitarget-Directed Ligands for the Efficient Management of Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2018,</strong> <em>9 </em>
                                    (7)
                                     , 1663-1679. <a href="https://doi.org/10.1021/acschemneuro.8b00063" title="DOI URL">https://doi.org/10.1021/acschemneuro.8b00063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.8b00063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.8b00063%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DThiazolyl-thiadiazines%252Bas%252BBeta%252BSite%252BAmyloid%252BPrecursor%252BProtein%252BCleaving%252BEnzyme-1%252B%252528BACE-1%252529%252BInhibitors%252Band%252BAnti-inflammatory%252BAgents%25253A%252BMultitarget-Directed%252BLigands%252Bfor%252Bthe%252BEfficient%252BManagement%252Bof%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DSagar%26aufirst%3DSneha%2BR.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D09022018%26date%3D26042018%26date%3D10052018%26date%3D26042018%26volume%3D9%26issue%3D7%26spage%3D1663%26epage%3D1679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Xiong</span>, <span class="hlFld-ContribAuthor ">Xiao  Wei</span>, <span class="hlFld-ContribAuthor ">Zi-Ming  Liu</span>, and <span class="hlFld-ContribAuthor ">Ming-Wu  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">One-Pot Synthesis of Polysubstituted Imidazoles via Sequential Staudinger/aza-Wittig/Ag(I)-Catalyzed Cyclization/Isomerization. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2017,</strong> <em>82 </em>
                                    (24)
                                     , 13735-13739. <a href="https://doi.org/10.1021/acs.joc.7b02606" title="DOI URL">https://doi.org/10.1021/acs.joc.7b02606</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.7b02606&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.7b02606%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BSynthesis%252Bof%252BPolysubstituted%252BImidazoles%252Bvia%252BSequential%252BStaudinger%25252Faza-Wittig%25252FAg%252528I%252529-Catalyzed%252BCyclization%25252FIsomerization%26aulast%3DXiong%26aufirst%3DJun%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D12102017%26date%3D28112017%26date%3D15122017%26date%3D17112017%26volume%3D82%26issue%3D24%26spage%3D13735%26epage%3D13739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cauê Benito  Scarim</span>, <span class="hlFld-ContribAuthor ">Chung Man  Chin</span>. </span><span class="cited-content_cbyCitation_article-title">The use of heterocyclic-based azo compounds bearing pyrrolidine, imidazole, triazole, and thiazole moieties for the treatment of neglected tropical disease caused by Schistosoma mansoni. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry Reports</span><span> <strong>2021,</strong> <em>1 </em>, 100001. <a href="https://doi.org/10.1016/j.ejmcr.2021.100001" title="DOI URL">https://doi.org/10.1016/j.ejmcr.2021.100001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmcr.2021.100001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmcr.2021.100001%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%2520Reports%26atitle%3DThe%252Buse%252Bof%252Bheterocyclic-based%252Bazo%252Bcompounds%252Bbearing%252Bpyrrolidine%25252C%252Bimidazole%25252C%252Btriazole%25252C%252Band%252Bthiazole%252Bmoieties%252Bfor%252Bthe%252Btreatment%252Bof%252Bneglected%252Btropical%252Bdisease%252Bcaused%252Bby%252BSchistosoma%252Bmansoni%26aulast%3DScarim%26aufirst%3DCau%25C3%25AA%2BBenito%26date%3D2021%26volume%3D1%26spage%3D100001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Timofey D.  Moseev</span>, <span class="hlFld-ContribAuthor ">Mikhail V.  Varaksin</span>, <span class="hlFld-ContribAuthor ">Denis A.  Gorlov</span>, <span class="hlFld-ContribAuthor ">Valery N.  Charushin</span>, <span class="hlFld-ContribAuthor ">Oleg N.  Chupakhin</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the functionalization of polyfluoro(aza)aromatics
              via
              C–C coupling strategies. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2021,</strong> <em>19 </em>
                                    (20)
                                     , 4429-4459. <a href="https://doi.org/10.1039/D1OB00472G" title="DOI URL">https://doi.org/10.1039/D1OB00472G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1OB00472G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1OB00472G%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bfunctionalization%252Bof%252Bpolyfluoro%252528aza%252529aromatics%252Bvia%252BC%2525E2%252580%252593C%252Bcoupling%252Bstrategies%26aulast%3DMoseev%26aufirst%3DTimofey%2BD.%26date%3D2021%26date%3D2021%26volume%3D19%26issue%3D20%26spage%3D4429%26epage%3D4459" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Conor R.  Caffrey</span>, <span class="hlFld-ContribAuthor ">Dietmar  Steverding</span>, <span class="hlFld-ContribAuthor ">Rafaela S.  Ferreira</span>, <span class="hlFld-ContribAuthor ">Renata B.  Oliveira</span>, <span class="hlFld-ContribAuthor ">Anthony J.  O'Donoghue</span>, <span class="hlFld-ContribAuthor ">Ludovica  Monti</span>, <span class="hlFld-ContribAuthor ">Carlo  Ballatore</span>, <span class="hlFld-ContribAuthor ">Kelly A.  Bachovchin</span>, <span class="hlFld-ContribAuthor ">Lori  Ferrins</span>, <span class="hlFld-ContribAuthor ">Michael P.  Pollastri</span>, <span class="hlFld-ContribAuthor ">Kimberley M.  Zorn</span>, <span class="hlFld-ContribAuthor ">Daniel H.  Foil</span>, <span class="hlFld-ContribAuthor ">Alex M.  Clark</span>, <span class="hlFld-ContribAuthor ">Melina  Mottin</span>, <span class="hlFld-ContribAuthor ">Carolina H.  Andrade</span>, <span class="hlFld-ContribAuthor ">Jair L.  Siqueira‐Neto</span>, <span class="hlFld-ContribAuthor ">Sean  Ekins</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery and Development for Kinetoplastid Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 1-79. <a href="https://doi.org/10.1002/0471266949.bmc235.pub2" title="DOI URL">https://doi.org/10.1002/0471266949.bmc235.pub2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/0471266949.bmc235.pub2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F0471266949.bmc235.pub2%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BDiscovery%252Band%252BDevelopment%252Bfor%252BKinetoplastid%252BDiseases%26aulast%3DCaffrey%26aufirst%3DConor%2BR.%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D79%26pub%3DWiley%26atitle%3DBurger%252527s%252BMedicinal%252BChemistry%252Band%252BDrug%252BDiscovery%26aulast%3DAbraham%26aufirst%3DDonald%2BJ.%26date%3D2003%26date%3D2003%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Faranak  Manteghi</span>, <span class="hlFld-ContribAuthor ">Fatemeh  Zakeri</span>, <span class="hlFld-ContribAuthor ">Owen James  Guy</span>, <span class="hlFld-ContribAuthor ">Zari  Tehrani</span>. </span><span class="cited-content_cbyCitation_article-title">MIL-101(Cr), an Efficient Heterogeneous Catalyst for One Pot Synthesis of 2,4,5-tri Substituted Imidazoles under Solvent Free Conditions. </span><span class="cited-content_cbyCitation_journal-name">Nanomaterials</span><span> <strong>2021,</strong> <em>11 </em>
                                    (4)
                                     , 845. <a href="https://doi.org/10.3390/nano11040845" title="DOI URL">https://doi.org/10.3390/nano11040845</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/nano11040845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fnano11040845%26sid%3Dliteratum%253Aachs%26jtitle%3DNanomaterials%26atitle%3DMIL-101%252528Cr%252529%25252C%252Ban%252BEfficient%252BHeterogeneous%252BCatalyst%252Bfor%252BOne%252BPot%252BSynthesis%252Bof%252B2%25252C4%25252C5-tri%252BSubstituted%252BImidazoles%252Bunder%252BSolvent%252BFree%252BConditions%26aulast%3DManteghi%26aufirst%3DFaranak%26date%3D2021%26date%3D2021%26volume%3D11%26issue%3D4%26spage%3D845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Faryal  Chaudhry</span>, <span class="hlFld-ContribAuthor ">Wardah  Shahid</span>, <span class="hlFld-ContribAuthor ">Mariya  al-Rashida</span>, <span class="hlFld-ContribAuthor ">Muhammad  Ashraf</span>, <span class="hlFld-ContribAuthor ">Munawar  Ali Munawar</span>, <span class="hlFld-ContribAuthor ">Misbahul  Ain Khan</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of imidazole-pyrazole conjugates bearing aryl spacer and exploring their enzyme inhibition potentials. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>108 </em>, 104686. <a href="https://doi.org/10.1016/j.bioorg.2021.104686" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104686</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104686&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104686%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DSynthesis%252Bof%252Bimidazole-pyrazole%252Bconjugates%252Bbearing%252Baryl%252Bspacer%252Band%252Bexploring%252Btheir%252Benzyme%252Binhibition%252Bpotentials%26aulast%3DChaudhry%26aufirst%3DFaryal%26date%3D2021%26volume%3D108%26spage%3D104686" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A G  Eliewi</span>, <span class="hlFld-ContribAuthor ">Z S  Al-Garawi</span>, <span class="hlFld-ContribAuthor ">F F  Al-Kazzaz</span>, <span class="hlFld-ContribAuthor ">A J K  Atia</span>. </span><span class="cited-content_cbyCitation_article-title">Multi target-directed imidazole derivatives for neurodegenerative diseases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Physics: Conference Series</span><span> <strong>2021,</strong> <em>1853 </em>
                                    (1)
                                     , 012066. <a href="https://doi.org/10.1088/1742-6596/1853/1/012066" title="DOI URL">https://doi.org/10.1088/1742-6596/1853/1/012066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1088/1742-6596/1853/1/012066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1088%2F1742-6596%2F1853%2F1%2F012066%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Physics%253A%2520Conference%2520Series%26atitle%3DMulti%252Btarget-directed%252Bimidazole%252Bderivatives%252Bfor%252Bneurodegenerative%252Bdiseases%26aulast%3DEliewi%26aufirst%3DA%2BG%26date%3D2021%26volume%3D1853%26issue%3D1%26spage%3D012066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniela  Zampino</span>, <span class="hlFld-ContribAuthor ">Sonia  Pedotti</span>, <span class="hlFld-ContribAuthor ">Martina  Ussia</span>, <span class="hlFld-ContribAuthor ">Sandro  Dattilo</span>, <span class="hlFld-ContribAuthor ">Monique  Mancuso</span>, <span class="hlFld-ContribAuthor ">Renata  Zaccone</span>, <span class="hlFld-ContribAuthor ">Angela  Patti</span>. </span><span class="cited-content_cbyCitation_article-title">Preparation, characterization, and antimicrobial activity of ferrocene‐containing polymeric materials. </span><span class="cited-content_cbyCitation_journal-name">Journal of Applied Polymer Science</span><span> <strong>2021,</strong> <em>138 </em>
                                    (7)
                                     , 49852. <a href="https://doi.org/10.1002/app.49852" title="DOI URL">https://doi.org/10.1002/app.49852</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/app.49852&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fapp.49852%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Applied%2520Polymer%2520Science%26atitle%3DPreparation%25252C%252Bcharacterization%25252C%252Band%252Bantimicrobial%252Bactivity%252Bof%252Bferrocene%2525E2%252580%252590containing%252Bpolymeric%252Bmaterials%26aulast%3DZampino%26aufirst%3DDaniela%26date%3D2021%26date%3D2020%26volume%3D138%26issue%3D7%26spage%3D49852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jih Ru  Hwu</span>, <span class="hlFld-ContribAuthor ">Avijit  Panja</span>, <span class="hlFld-ContribAuthor ">Nitesh K.  Gupta</span>, <span class="hlFld-ContribAuthor ">Yu‐Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Kui‐Thong  Tan</span>, <span class="hlFld-ContribAuthor ">Chun‐Cheng  Lin</span>, <span class="hlFld-ContribAuthor ">Kuo‐Chu  Hwang</span>, <span class="hlFld-ContribAuthor ">Ming‐Hua  Hsu</span>, <span class="hlFld-ContribAuthor ">Wen‐Chieh  Huang</span>, <span class="hlFld-ContribAuthor ">Shwu‐Chen  Tsay</span>. </span><span class="cited-content_cbyCitation_article-title">Domino Processes of Arynes Reacting with Three Classes of Nucleophiles for Organic Syntheses. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>2021 </em>
                                    (4)
                                     , 683-693. <a href="https://doi.org/10.1002/ejoc.202001499" title="DOI URL">https://doi.org/10.1002/ejoc.202001499</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ejoc.202001499&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fejoc.202001499%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDomino%252BProcesses%252Bof%252BArynes%252BReacting%252Bwith%252BThree%252BClasses%252Bof%252BNucleophiles%252Bfor%252BOrganic%252BSyntheses%26aulast%3DHwu%26aufirst%3DJih%2BRu%26date%3D2021%26date%3D2021%26volume%3D2021%26issue%3D4%26spage%3D683%26epage%3D693" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anand Babu  Velappan</span>, <span class="hlFld-ContribAuthor ">Dhrubajyoti  Datta</span>, <span class="hlFld-ContribAuthor ">Rui  Ma</span>, <span class="hlFld-ContribAuthor ">Shiwani  Rana</span>, <span class="hlFld-ContribAuthor ">Kalyan Sundar  Ghosh</span>, <span class="hlFld-ContribAuthor ">Natarajan  Hari</span>, <span class="hlFld-ContribAuthor ">Scott G.  Franzblau</span>, <span class="hlFld-ContribAuthor ">Joy  Debnath</span>. </span><span class="cited-content_cbyCitation_article-title">2-Aryl benzazole derived new class of anti-tubercular compounds: Endowed to eradicate mycobacterium tuberculosis in replicating and non-replicating forms. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>103 </em>, 104170. <a href="https://doi.org/10.1016/j.bioorg.2020.104170" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104170</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104170&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104170%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3D2-Aryl%252Bbenzazole%252Bderived%252Bnew%252Bclass%252Bof%252Banti-tubercular%252Bcompounds%25253A%252BEndowed%252Bto%252Beradicate%252Bmycobacterium%252Btuberculosis%252Bin%252Breplicating%252Band%252Bnon-replicating%252Bforms%26aulast%3DVelappan%26aufirst%3DAnand%2BBabu%26date%3D2020%26volume%3D103%26spage%3D104170" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sahar  Dastmard</span>, <span class="hlFld-ContribAuthor ">Manouchehr  Mamaghani</span>, <span class="hlFld-ContribAuthor ">Mehdi  Rassa</span>. </span><span class="cited-content_cbyCitation_article-title">Ultrasound‐assisted efficient synthesis of polyfunctional 1,2,4‐triazoles as novel antibacterial and antioxidant agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of the Chinese Chemical Society</span><span> <strong>2020,</strong> <em>67 </em>
                                    (8)
                                     , 1437-1445. <a href="https://doi.org/10.1002/jccs.201900430" title="DOI URL">https://doi.org/10.1002/jccs.201900430</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jccs.201900430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjccs.201900430%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520Chinese%2520Chemical%2520Society%26atitle%3DUltrasound%2525E2%252580%252590assisted%252Befficient%252Bsynthesis%252Bof%252Bpolyfunctional%252B1%25252C2%25252C4%2525E2%252580%252590triazoles%252Bas%252Bnovel%252Bantibacterial%252Band%252Bantioxidant%252Bagents%26aulast%3DDastmard%26aufirst%3DSahar%26date%3D2020%26date%3D2020%26volume%3D67%26issue%3D8%26spage%3D1437%26epage%3D1445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fang  Chen</span>, <span class="hlFld-ContribAuthor ">Arijit  Ghosh</span>, <span class="hlFld-ContribAuthor ">Jingran  Lin</span>, <span class="hlFld-ContribAuthor ">Chunteng  Zhang</span>, <span class="hlFld-ContribAuthor ">Yining  Pan</span>, <span class="hlFld-ContribAuthor ">Abhimanyu  Thakur</span>, <span class="hlFld-ContribAuthor ">Kunal  Singh</span>, <span class="hlFld-ContribAuthor ">Hao  Hong</span>, <span class="hlFld-ContribAuthor ">Susu  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential therapeutic targets for Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Brain, Behavior, and Immunity</span><span> <strong>2020,</strong> <em>88 </em>, 844-855. <a href="https://doi.org/10.1016/j.bbi.2020.03.022" title="DOI URL">https://doi.org/10.1016/j.bbi.2020.03.022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbi.2020.03.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbi.2020.03.022%26sid%3Dliteratum%253Aachs%26jtitle%3DBrain%252C%2520Behavior%252C%2520and%2520Immunity%26atitle%3D5-lipoxygenase%252Bpathway%252Band%252Bits%252Bdownstream%252Bcysteinyl%252Bleukotrienes%252Bas%252Bpotential%252Btherapeutic%252Btargets%252Bfor%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DChen%26aufirst%3DFang%26date%3D2020%26volume%3D88%26spage%3D844%26epage%3D855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaohong  Fan</span>, <span class="hlFld-ContribAuthor ">Junfang  Li</span>, <span class="hlFld-ContribAuthor ">Xuemei  Deng</span>, <span class="hlFld-ContribAuthor ">Yingmei  Lu</span>, <span class="hlFld-ContribAuthor ">Yiyue  Feng</span>, <span class="hlFld-ContribAuthor ">Shumeng  Ma</span>, <span class="hlFld-ContribAuthor ">Huaixiu  Wen</span>, <span class="hlFld-ContribAuthor ">Quanyi  Zhao</span>, <span class="hlFld-ContribAuthor ">Wen  Tan</span>, <span class="hlFld-ContribAuthor ">Tao  Shi</span>, <span class="hlFld-ContribAuthor ">Zhen  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and bioactivity study of N-salicyloyl tryptamine derivatives as multifunctional agents for the treatment of neuroinflammation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>193 </em>, 112217. <a href="https://doi.org/10.1016/j.ejmech.2020.112217" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112217</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112217&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112217%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbioactivity%252Bstudy%252Bof%252BN-salicyloyl%252Btryptamine%252Bderivatives%252Bas%252Bmultifunctional%252Bagents%252Bfor%252Bthe%252Btreatment%252Bof%252Bneuroinflammation%26aulast%3DFan%26aufirst%3DXiaohong%26date%3D2020%26volume%3D193%26spage%3D112217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Renzo  Rossi</span>, <span class="hlFld-ContribAuthor ">Maurizio  Ciofalo</span>. </span><span class="cited-content_cbyCitation_article-title">Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Current Organic Chemistry</span><span> <strong>2019,</strong> <em>23 </em>
                                    (19)
                                     , 2016-2101. <a href="https://doi.org/10.2174/1385272823666191014154129" title="DOI URL">https://doi.org/10.2174/1385272823666191014154129</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1385272823666191014154129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1385272823666191014154129%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Organic%2520Chemistry%26atitle%3DCurrent%252BAdvances%252Bin%252Bthe%252BSynthesis%252Band%252BBiological%252BEvaluation%252Bof%252BPharmacologically%252BRelevant%252B1%25252C2%25252C4%25252C5-Tetrasubstituted-1H-Imidazole%252BDerivatives%26aulast%3DRossi%26aufirst%3DRenzo%26date%3D2019%26volume%3D23%26issue%3D19%26spage%3D2016%26epage%3D2101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pengfei  Zhang</span>, <span class="hlFld-ContribAuthor ">Shengtao  Xu</span>, <span class="hlFld-ContribAuthor ">Zheying  Zhu</span>, <span class="hlFld-ContribAuthor ">Jinyi  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Multi-target design strategies for the improved treatment of Alzheimer's disease. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>176 </em>, 228-247. <a href="https://doi.org/10.1016/j.ejmech.2019.05.020" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.05.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.05.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.05.020%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMulti-target%252Bdesign%252Bstrategies%252Bfor%252Bthe%252Bimproved%252Btreatment%252Bof%252BAlzheimer%252527s%252Bdisease%26aulast%3DZhang%26aufirst%3DPengfei%26date%3D2019%26volume%3D176%26spage%3D228%26epage%3D247" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ludovica  Monti</span>, <span class="hlFld-ContribAuthor ">Steven C  Wang</span>, <span class="hlFld-ContribAuthor ">Killian  Oukoloff</span>, <span class="hlFld-ContribAuthor ">Amos B.  Smith</span>, <span class="hlFld-ContribAuthor ">Kurt R.  Brunden</span>, <span class="hlFld-ContribAuthor ">Conor R.  Caffrey</span>, <span class="hlFld-ContribAuthor ">Carlo  Ballatore</span>. </span><span class="cited-content_cbyCitation_article-title">Brain-Penetrant Triazolopyrimidine and Phenylpyrimidine Microtubule Stabilizers as Potential Leads to Treat Human African Trypanosomiasis. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (17)
                                     , 1751-1754. <a href="https://doi.org/10.1002/cmdc.201800404" title="DOI URL">https://doi.org/10.1002/cmdc.201800404</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800404%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DBrain-Penetrant%252BTriazolopyrimidine%252Band%252BPhenylpyrimidine%252BMicrotubule%252BStabilizers%252Bas%252BPotential%252BLeads%252Bto%252BTreat%252BHuman%252BAfrican%252BTrypanosomiasis%26aulast%3DMonti%26aufirst%3DLudovica%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D17%26spage%3D1751%26epage%3D1754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rocío  Lajarín-Cuesta</span>, <span class="hlFld-ContribAuthor ">Raquel L.  Arribas</span>, <span class="hlFld-ContribAuthor ">Carmen  Nanclares</span>, <span class="hlFld-ContribAuthor ">Eva M.  García-Frutos</span>, <span class="hlFld-ContribAuthor ">Luis  Gandía</span>, <span class="hlFld-ContribAuthor ">Cristóbal  de los Ríos</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of multipotent 3-aminomethylindoles and 7-azaindoles with enhanced protein phosphatase 2A-activating profile and neuroprotection. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>157 </em>, 294-309. <a href="https://doi.org/10.1016/j.ejmech.2018.07.030" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.07.030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.07.030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.07.030%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bmultipotent%252B3-aminomethylindoles%252Band%252B7-azaindoles%252Bwith%252Benhanced%252Bprotein%252Bphosphatase%252B2A-activating%252Bprofile%252Band%252Bneuroprotection%26aulast%3DLajar%25C3%25ADn-Cuesta%26aufirst%3DRoc%25C3%25ADo%26date%3D2018%26volume%3D157%26spage%3D294%26epage%3D309" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cindy Juliet Cristancho  Ortiz</span>, <span class="hlFld-ContribAuthor ">Matheus  de Freitas Silva</span>, <span class="hlFld-ContribAuthor ">Vanessa Silva  Gontijo</span>, <span class="hlFld-ContribAuthor ">Flávia Pereira Dias  Viegas</span>, <span class="hlFld-ContribAuthor ">Kris Simone Tranches  Dias</span>, <span class="hlFld-ContribAuthor ">Claudio  Viegas</span>. </span><span class="cited-content_cbyCitation_article-title">Design of Multi-target Directed Ligands as a Modern Approach for the Development of Innovative Drug Candidates for Alzheimer’s Disease. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 255-351. <a href="https://doi.org/10.1007/7653_2018_2" title="DOI URL">https://doi.org/10.1007/7653_2018_2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7653_2018_2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7653_2018_2%26sid%3Dliteratum%253Aachs%26atitle%3DDesign%252Bof%252BMulti-target%252BDirected%252BLigands%252Bas%252Ba%252BModern%252BApproach%252Bfor%252Bthe%252BDevelopment%252Bof%252BInnovative%252BDrug%252BCandidates%252Bfor%252BAlzheimer%2525E2%252580%252599s%252BDisease%26aulast%3DOrtiz%26aufirst%3DCindy%2BJuliet%2BCristancho%26date%3D2018%26date%3D2018%26spage%3D255%26epage%3D351%26pub%3DSpringer%2520New%2520York%26atitle%3DMulti-Target%252BDrug%252BDesign%252BUsing%252BChem-Bioinformatic%252BApproaches%26aulast%3DRoy%26aufirst%3DKunal%26date%3D2019%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chaoyu  Hu</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent development of lipoxygenase inhibitors as anti-inflammatory agents. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 212-225. <a href="https://doi.org/10.1039/C7MD00390K" title="DOI URL">https://doi.org/10.1039/C7MD00390K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00390K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00390K%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DRecent%252Bdevelopment%252Bof%252Blipoxygenase%252Binhibitors%252Bas%252Banti-inflammatory%252Bagents%26aulast%3DHu%26aufirst%3DChaoyu%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D212%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie  Jouanne</span>, <span class="hlFld-ContribAuthor ">Sylvain  Rault</span>, <span class="hlFld-ContribAuthor ">Anne-Sophie  Voisin-Chiret</span>. </span><span class="cited-content_cbyCitation_article-title">Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>139 </em>, 153-167. <a href="https://doi.org/10.1016/j.ejmech.2017.07.070" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.07.070</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.07.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.07.070%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTau%252Bprotein%252Baggregation%252Bin%252BAlzheimer%252527s%252Bdisease%25253A%252BAn%252Battractive%252Btarget%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bnovel%252Btherapeutic%252Bagents%26aulast%3DJouanne%26aufirst%3DMarie%26date%3D2017%26volume%3D139%26spage%3D153%26epage%3D167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0015.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0001.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Comparison of representative examples of fungicidal diaryl-pyrazoles (<b>1</b>) and -imidazoles (<b>2</b>) with reported MT-stabilizing activity, with known COX- (<b>3</b>) and dual COX/5-LOX (<b>4</b>) inhibitors; molecular docking of <b>2</b> (B) and <b>3</b> (C) within the arachidonic acid binding site of COX-1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0004.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (a) Dean–Stark apparatus, toluene, 110 °C, 4 days, 99%; (b) 4 Å molecular sieves, Et<sub>2</sub>O, 30 °C, 48 h, 99%; (c) appropriate TosMIC reagent, K<sub>2</sub>CO<sub>3</sub>, DMF/1,2-dimethoxyethane, 100 °C, 16 h, 7–90%; (d) <i>N</i>-chlorosuccinimide, CHCl<sub>3</sub>, 60 °C, 16 h, 43–71%; (e) LDA, methyliodide, THF, −20 °C to rt, 1.5 h, 29–56%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0005.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (a) <i>N</i>-chlorosuccinimide, CHCl<sub>3</sub>, 60 °C, 16 h, 9–77% for monohalogenation at C4, 3–18% for monohalogenation at C2, and 2–20% for dihalogenation at C2/C4; (b) LDA, methyliodide, THF, −20 °C to rt, 1.5 h, 2–48%; (c) NaOMe, MeOH, THF, rt, 19 h, 33–97%; (d) LDA, ethyliodide, THF, −20 °C to rt, 1.5 h, 35%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0002.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Summary of SARs (top) and representative structures exemplifying the different activity profiles exhibited by the 1,5-diarylimidazoles (bottom).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/medium/jm-2017-00475m_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0003.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Representative dose–response curves in the RBL-1 cell assays. Samples were run in triplicate at each concentration, with the error bars representing standard error of the mean.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-12/acs.jmedchem.7b00475/20170616/images/large/jm-2017-00475m_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00475&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i130">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75618" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75618" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 60 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Anighoro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bajorath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rastelli, G.</span><span> </span><span class="NLM_article-title">Polypharmacology: challenges and opportunities in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7874</span><span class="NLM_x">–</span> <span class="NLM_lpage">7887</span><span class="refDoi"> DOI: 10.1021/jm5006463</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5006463" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7874-7887&author=A.+Anighoroauthor=J.+Bajorathauthor=G.+Rastelli&title=Polypharmacology%3A+challenges+and+opportunities+in+drug+discovery&doi=10.1021%2Fjm5006463"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology: Challenges and Opportunities in Drug Discovery</span></div><div class="casAuthors">Anighoro, Andrew; Bajorath, Jurgen; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">7874-7887</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  At present, the legendary magic bullet, i.e., a drug with high potency and selectivity toward a specific biol. target, shares the spotlight with an emerging and alternative polypharmacol. approach.  Polypharmacol. suggests that more effective drugs can be developed by specifically modulating multiple targets.  It is generally thought that complex diseases such as cancer and central nervous system diseases may require complex therapeutic approaches.  In this respect, a drug that "hits" multiple sensitive nodes belonging to a network of interacting targets offers the potential for higher efficacy and may limit drawbacks generally arising from the use of a single-target drug or a combination of multiple drugs.  In this review, we will compare advantages and disadvantages of multitarget vs. combination therapies, discuss potential drug promiscuity arising from off-target effects, comment on drug repurposing, and introduce approaches to the computational design of multitarget drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFOTyEu80AZrVg90H21EOLACvtfcHk0liSR-FS2kHYkQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVShsL3I&md5=5ab36c961a84462d90bc25130d90a281</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1021%2Fjm5006463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5006463%26sid%3Dliteratum%253Aachs%26aulast%3DAnighoro%26aufirst%3DA.%26aulast%3DBajorath%26aufirst%3DJ.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DPolypharmacology%253A%2520challenges%2520and%2520opportunities%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7874%26epage%3D7887%26doi%3D10.1021%2Fjm5006463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Geldenhuys, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van der Schyf, C. J.</span><span> </span><span class="NLM_article-title">Rationally designed multi-targeted agents against neurodegenerative diseases</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1662</span><span class="NLM_x">–</span> <span class="NLM_lpage">1672</span><span class="refDoi"> DOI: 10.2174/09298673113209990112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.2174%2F09298673113209990112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23410161" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=1662-1672&author=W.+J.+Geldenhuysauthor=C.+J.+Van+der+Schyf&title=Rationally+designed+multi-targeted+agents+against+neurodegenerative+diseases&doi=10.2174%2F09298673113209990112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Rationally designed multi-targeted agents against neurodegenerative diseases</span></div><div class="casAuthors">Geldenhuys, W. J.; Van der Schyf, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1662-1672</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative diseases are complex disorders with several pathoetiol. pathways leading to cell death.  Rationally designed multi-targeted agents, or "multi-targeted designed drugs" (MTDD) show significant promise in preclin. studies as neuroprotective and disease-modifying agents.  In this review, we highlight the use of chem. scaffolds that lend themselves exquisitely to the development of MTDDs in neurodegeneration.  Notably, synthetic polycyclic cage compds. have served as scaffolds for novel voltage-gated calcium channel blockers, NMDA receptor antagonists, and sigma-receptor ligands - attractive targets in neurodegeneration.  In an entirely different approach, compds. contg. the thiazolidinedione moiety (referred to as glitazones) alter mitochondrial function through the mitochondrial protein mitoNEET, an attractive new drug target for the treatment of neurodegenerative diseases.  The design strategy for yet another agent, ladostigil, employed the amalgamation of active chem. moieties of the AChE inhibitor rivastigmine, and the monoamine oxidase-B (MAO-B) inhibitor rasagiline, leading to a single compd. that targets both enzymes simultaneously.  Natural products have also served as design templates for several MTDD design studies.  In particular, the stilbene scaffold has become popular in particular due to the neuroprotective effects of the non-flavonoid natural product resveratrol.  Recently, stilbene scaffold-based compds. were developed to reduce - through chelation with metal ions that interact with beta-amyloid - both metal-induced beta-amyloid protein aggregation, and ROS generated from this aggregate.  Other subtle modifications of the stilbene motif led to the creation of reversible, non-competitive MAO inhibitors.  Finally, compds. derived from the xanthine scaffold afford neuroprotection in Parkinson's disease through mechanisms that include dual adenosine A2A receptor antagonism and MAO-B inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqZJN4lAGwOrVg90H21EOLACvtfcHk0lify4zkT3G6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotl2jtbw%253D&md5=626f69acb3b3ff995e31b042e48dfba3</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.2174%2F09298673113209990112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F09298673113209990112%26sid%3Dliteratum%253Aachs%26aulast%3DGeldenhuys%26aufirst%3DW.%2BJ.%26aulast%3DVan%2Bder%2BSchyf%26aufirst%3DC.%2BJ.%26atitle%3DRationally%2520designed%2520multi-targeted%2520agents%2520against%2520neurodegenerative%2520diseases%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2013%26volume%3D20%26spage%3D1662%26epage%3D1672%26doi%3D10.2174%2F09298673113209990112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Cavalli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolognesi, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minarini, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumiatti, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Recanatini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Melchiorre, C.</span><span> </span><span class="NLM_article-title">Multi-target-directed ligands to combat neurodegenerative diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">347</span><span class="NLM_x">–</span> <span class="NLM_lpage">372</span><span class="refDoi"> DOI: 10.1021/jm7009364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm7009364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=347-372&author=A.+Cavalliauthor=M.+L.+Bolognesiauthor=A.+Minariniauthor=M.+Rosiniauthor=V.+Tumiattiauthor=M.+Recanatiniauthor=C.+Melchiorre&title=Multi-target-directed+ligands+to+combat+neurodegenerative+diseases&doi=10.1021%2Fjm7009364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Multi-target-Directed Ligands to Combat Neurodegenerative Diseases</span></div><div class="casAuthors">Cavalli, Andrea; Bolognesi, Maria Laura; Minarini, Anna; Rosini, Michela; Tumiatti, Vincenzo; Recanatini, Maurizio; Melchiorre, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">347-372</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The authors review the investigations reported in the past decade that illustrate the ability of medicinal chemists to design multi-target-directed ligands (MTDLs) to confront neurodegenerative diseases.  The authors briefly illustrate the multifactorial nature of these diseases before discussing the possible development of MTDLs in light of the known mol. bases of the main neurodegenerative pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYY0I0UHEir7Vg90H21EOLACvtfcHk0lify4zkT3G6kg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsl2qsbk%253D&md5=c682235151489316d043cf97f78e56f3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1021%2Fjm7009364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm7009364%26sid%3Dliteratum%253Aachs%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRecanatini%26aufirst%3DM.%26aulast%3DMelchiorre%26aufirst%3DC.%26atitle%3DMulti-target-directed%2520ligands%2520to%2520combat%2520neurodegenerative%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D347%26epage%3D372%26doi%3D10.1021%2Fjm7009364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Makani, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassalas, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy</span> <span class="citation_source-journal">Acta Neuropathol. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">106</span><span class="refDoi"> DOI: 10.1186/s40478-016-0378-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1186%2Fs40478-016-0378-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=27687527" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVahs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&pages=106&author=V.+Makaniauthor=B.+Zhangauthor=H.+Hanauthor=Y.+Yaoauthor=P.+Lassalasauthor=K.+Louauthor=I.+Patersonauthor=V.+M.+Y.+Leeauthor=J.+Q.+Trojanowskiauthor=C.+Ballatoreauthor=A.+B.+Smithauthor=K.+R.+Brunden&title=Evaluation+of+the+brain-penetrant+microtubule-stabilizing+agent%2C+dictyostatin%2C+in+the+PS19+tau+transgenic+mouse+model+of+tauopathy&doi=10.1186%2Fs40478-016-0378-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the brain-penetrant microtubule-stabilizing agent, dictyostatin, in the PS19 tau transgenic mouse model of tauopathy</span></div><div class="casAuthors">Makani, Vishruti; Zhang, Bin; Han, Heeoon; Yao, Yuemang; Lassalas, Pierrik; Lou, Kevin; Paterson, Ian; Lee, Virginia M. Y.; Trojanowski, John Q.; Ballatore, Carlo; Smith, Amos B., III; Brunden, Kurt R.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">106/1-106/12</span>CODEN:
                <span class="NLM_cas:coden">ANCCC9</span>;
        ISSN:<span class="NLM_cas:issn">2051-5960</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Neurodegenerative disorders referred to as tauopathies, which includes Alzheimer's disease (AD), are characterized by insol. deposits of the tau protein within neuron cell bodies and dendritic processes in the brain.  Tau is normally assocd. with microtubules (MTs) in axons, where it provides MT stabilization and may modulate axonal transport.  However, tau becomes hyperphosphorylated and dissocs. from MTs in tauopathies, with evidence of reduced MT stability and defective axonal transport.  This has led to the hypothesis that MT-stabilizing drugs may have potential for the treatment of tauopathies.  Prior studies demonstrated that the brain-penetrant MT-stabilizing drug, epothilone D, had salutary effects in transgenic (Tg) mouse models of tauopathy, improving MT d. and axonal transport, while reducing axonal dystrophy.  Moreover, epothilone D enhanced cognitive performance and decreased hippocampal neuron loss, with evidence of reduced tau pathol.  To date, epothilone D has been the only non-peptide small mol. MT-stabilizing agent to be evaluated in Tg tau mice.  Herein, we demonstrate the efficacy of another small mol. brain-penetrant MT-stabilizing agent, dictyostatin, in the PS19 tau Tg mouse model.  Although dictyostatin was poorly tolerated at once-weekly doses of 1 mg/kg or 0.3 mg/kg, likely due to gastrointestinal (GI) complications, a dictyostatin dose of 0.1 mg/kg was better tolerated, such that the majority of 6-mo old PS19 mice, which harbor a moderate level of brain tau pathol., completed a 3-mo dosing study without evidence of significant body wt. loss.  Importantly, as previously obsd. with epothilone D, the dictyostatin-treated PS19 mice displayed improved MT d. and reduced axonal dystrophy, with a redn. of tau pathol. and a trend toward increased hippocampal neuron survival relative to vehicle-treated PS19 mice.  Thus, despite evidence of dose-limiting peripheral side effects, the obsd. pos. brain outcomes in dictyostatin-treated aged PS19 mice reinforces the concept that MT-stabilizing compds. have significant potential for the treatment of tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAlkQNMCw8grVg90H21EOLACvtfcHk0lixtccXkHa42A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVahs7zN&md5=d0ee514e0ec3870dc1c7deb31ee290d2</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1186%2Fs40478-016-0378-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs40478-016-0378-4%26sid%3Dliteratum%253Aachs%26aulast%3DMakani%26aufirst%3DV.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DHan%26aufirst%3DH.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DLassalas%26aufirst%3DP.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DPaterson%26aufirst%3DI.%26aulast%3DLee%26aufirst%3DV.%2BM.%2BY.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DEvaluation%2520of%2520the%2520brain-penetrant%2520microtubule-stabilizing%2520agent%252C%2520dictyostatin%252C%2520in%2520the%2520PS19%2520tau%2520transgenic%2520mouse%2520model%2520of%2520tauopathy%26jtitle%3DActa%2520Neuropathol.%2520Commun.%26date%3D2016%26volume%3D4%26spage%3D106%26doi%3D10.1186%2Fs40478-016-0378-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potuzak, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">3601</span><span class="NLM_x">–</span> <span class="NLM_lpage">3611</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.4922-11.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.4922-11.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22423084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlOlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=3601-3611&author=B.+Zhangauthor=J.+Carrollauthor=J.+Q.+Trojanowskiauthor=Y.+Yaoauthor=M.+Ibaauthor=J.+S.+Potuzakauthor=A.+M.+Hoganauthor=S.+X.+Xieauthor=C.+Ballatoreauthor=A.+B.+Smithauthor=V.+M.+Leeauthor=K.+R.+Brunden&title=The+microtubule-stabilizing+agent%2C+epothilone+D%2C+reduces+axonal+dysfunction%2C+neurotoxicity%2C+cognitive+deficits%2C+and+Alzheimer-like+pathology+in+an+interventional+study+with+aged+tau+transgenic+mice&doi=10.1523%2FJNEUROSCI.4922-11.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice</span></div><div class="casAuthors">Zhang, Bin; Carroll, Jenna; Trojanowski, John Q.; Yao, Yuemang; Iba, Michiyo; Potuzak, Justin S.; Hogan, Anne-Marie L.; Xie, Sharon X.; Ballatore, Carlo; Smith, Amos B., III; Lee, Virginia M.-Y.; Brunden, Kurt R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3601-3611</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neurodegenerative tauopathies, such as Alzheimer's disease (AD), are characterized by insol. deposits of hyperphosphorylated tau protein within brain neurons.  Increased phosphorylation and decreased soly. has been proposed to diminish normal tau stabilization of microtubules (MTs), thereby leading to neuronal dysfunction.  Earlier studies have provided evidence that small mol. MT-stabilizing drugs that are used in the treatment of cancer may have utility in the treatment of tauopathies.  However, it has not been established whether treatment with a small mol. MT-stabilizing compd. will provide benefit in a transgenic model with preexisting tau pathol., as would be seen in human patients with clin. symptoms.  Accordingly, we describe here an interventional study of the brain-penetrant MT-stabilizing agent, epothilone D (EpoD), in aged PS19 mice with existing tau pathol. and related behavioral deficits.  EpoD treatment reduced axonal dystrophy and increased axonal MT d. in the aged PS19 mice, which led to improved fast axonal transport and cognitive performance.  Moreover, the EpoD-treated PS19 mice had less forebrain tau pathol. and increased hippocampal neuronal integrity, with no dose-limiting side effects.  These data reveal that brain-penetrant MT-stabilizing drugs hold promise for the treatment of AD and related tauopathies, and that EpoD could be a candidate for clin. testing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHk7y2bIOfKbVg90H21EOLACvtfcHk0lixtccXkHa42A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlOlsbg%253D&md5=9ef57c897e3ff5c8c1930599607e5270</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.4922-11.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.4922-11.2012%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCarroll%26aufirst%3DJ.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DIba%26aufirst%3DM.%26aulast%3DPotuzak%26aufirst%3DJ.%2BS.%26aulast%3DHogan%26aufirst%3DA.%2BM.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DThe%2520microtubule-stabilizing%2520agent%252C%2520epothilone%2520D%252C%2520reduces%2520axonal%2520dysfunction%252C%2520neurotoxicity%252C%2520cognitive%2520deficits%252C%2520and%2520Alzheimer-like%2520pathology%2520in%2520an%2520interventional%2520study%2520with%2520aged%2520tau%2520transgenic%2520mice%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26spage%3D3601%26epage%3D3611%26doi%3D10.1523%2FJNEUROSCI.4922-11.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potuzak, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogan, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iba, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span> </span><span class="NLM_article-title">Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">13861</span><span class="NLM_x">–</span> <span class="NLM_lpage">13866</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.3059-10.2010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.3059-10.2010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=20943926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlegsLbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2010&pages=13861-13866&author=K.+R.+Brundenauthor=B.+Zhangauthor=J.+Carrollauthor=Y.+Yaoauthor=J.+S.+Potuzakauthor=A.+M.+Hoganauthor=M.+Ibaauthor=M.+J.+Jamesauthor=S.+X.+Xieauthor=C.+Ballatoreauthor=A.+B.+Smithauthor=V.+M.+Leeauthor=J.+Q.+Trojanowski&title=Epothilone+D+improves+microtubule+density%2C+axonal+integrity%2C+and+cognition+in+a+transgenic+mouse+model+of+tauopathy&doi=10.1523%2FJNEUROSCI.3059-10.2010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy</span></div><div class="casAuthors">Brunden, Kurt R.; Zhang, Bin; Carroll, Jenna; Yao, Yuemang; Potuzak, Justin S.; Hogan, Anne-Marie L.; Iba, Michiyo; James, Michael J.; Xie, Sharon X.; Ballatore, Carlo; Smith, Amos B., III; Lee, Virginia M.-Y.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">13861-13866</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Neurons in the brains of those with Alzheimer's disease (AD) and many frontotemporal dementias (FTDs) contain neurofibrillary tangles comprised of hyperphosphorylated tau protein.  Tau normally stabilizes microtubules (MTs), and tau misfolding could lead to a loss of this function with consequent MT destabilization and neuronal dysfunction.  Accordingly, a possible therapeutic strategy for AD and related "tauopathies" is treatment with a MT-stabilizing anti-cancer drug such as paclitaxel.  However, paclitaxel and related taxanes have poor blood-brain barrier permeability and thus are unsuitable for diseases of the brain.  We demonstrate here that the MT-stabilizing agent, epothilone D (EpoD), is brain-penetrant and we subsequently evaluated whether EpoD can compensate for tau loss-of-function in PS19 tau transgenic mice that develop forebrain tau inclusions, axonal degeneration and MT deficits.  Treatment of 3-mo-old male PS19 mice with low doses of EpoD once weekly for a 3 mo period significantly improved CNS MT d. and axonal integrity without inducing notable side-effects.  Moreover, EpoD treatment reduced cognitive deficits that were obsd. in the PS19 mice.  These results suggest that certain brain-penetrant MT-stabilizing agents might provide a viable therapeutic strategy for the treatment of AD and FTDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1RAI4CQiMZLVg90H21EOLACvtfcHk0lhzSblH6Lctvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlegsLbP&md5=5a53dea5ef5dac0d48b476d9c12623ce</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3059-10.2010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3059-10.2010%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DCarroll%26aufirst%3DJ.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DPotuzak%26aufirst%3DJ.%2BS.%26aulast%3DHogan%26aufirst%3DA.%2BM.%26aulast%3DIba%26aufirst%3DM.%26aulast%3DJames%26aufirst%3DM.%2BJ.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DEpothilone%2520D%2520improves%2520microtubule%2520density%252C%2520axonal%2520integrity%252C%2520and%2520cognition%2520in%2520a%2520transgenic%2520mouse%2520model%2520of%2520tauopathy%26jtitle%3DJ.%2520Neurosci.%26date%3D2010%26volume%3D30%26spage%3D13861%26epage%3D13866%26doi%3D10.1523%2FJNEUROSCI.3059-10.2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Barten, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fanara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andorfer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoque, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, P. Y. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadelina, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeCarr, L. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fessler, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protassio, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riff, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janus, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sankaranarayanan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meredith, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vite, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, F. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albright, C. F.</span><span> </span><span class="NLM_article-title">Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">7137</span><span class="NLM_x">–</span> <span class="NLM_lpage">7145</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.0188-12.2012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.0188-12.2012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22623658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvFKksb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=7137-7145&author=D.+M.+Bartenauthor=P.+Fanaraauthor=C.+Andorferauthor=N.+Hoqueauthor=P.+Y.+A.+Wongauthor=K.+H.+Hustedauthor=G.+W.+Cadelinaauthor=L.+B.+DeCarrauthor=L.+Yangauthor=L.+Liuauthor=C.+Fesslerauthor=J.+Protassioauthor=T.+Riffauthor=H.+Turnerauthor=C.+G.+Janusauthor=S.+Sankaranarayananauthor=C.+Polsonauthor=J.+E.+Meredithauthor=G.+Grayauthor=A.+Hannaauthor=R.+E.+Olsonauthor=S.+H.+Kimauthor=G.+D.+Viteauthor=F.+Y.+Leeauthor=C.+F.+Albright&title=Hyperdynamic+microtubules%2C+cognitive+deficits%2C+and+pathology+are+improved+in+tau+transgenic+mice+with+low+doses+of+the+microtubule-stabilizing+agent+BMS-241027&doi=10.1523%2FJNEUROSCI.0188-12.2012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027</span></div><div class="casAuthors">Barten, Donna M.; Fanara, Patrizia; Andorfer, Cathy; Hoque, Nina; Wong, P. Y. Anne; Husted, Kristofor H.; Cadelina, Gregory W.; DeCarr, Lynn B.; Yang, Ling; Liu, Victoria; Fessler, Chancy; Protassio, Joan; Riff, Timothy; Turner, Holly; Janus, Christopher G.; Sankaranarayanan, Sethu; Polson, Craig; Meredith, Jere E.; Gray, Gemma; Hanna, Amanda; Olson, Richard E.; Kim, Soong-Hoon; Vite, Gregory D.; Lee, Francis Y.; Albright, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7137-7145</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tau is a microtubule (MT)-stabilizing protein that is altered in Alzheimer's disease (AD) and other tauopathies.  It is hypothesized that the hyperphosphorylated, conformationally altered, and multimeric forms of tau lead to a disruption of MT stability; however, direct evidence is lacking in vivo.  In this study, an in vivo stable isotope-mass spectrometric technique was used to measure the turnover, or dynamicity, of MTs in brains of living animals.  We demonstrated an age-dependent increase in MT dynamics in two different tau transgenic mouse models, 3xTg and rTg4510.  MT hyperdynamicity was dependent on tau expression, since a redn. of transgene expression with doxycycline reversed the MT changes.  Treatment of rTg4510 mice with the epothilone, BMS-241027, also restored MT dynamics to baseline levels.  In addn., MT stabilization with BMS-241027 had beneficial effects on Morris water maze deficits, tau pathol., and neurodegeneration.  Interestingly, pathol. and functional benefits of BMS-241027 were obsd. at doses that only partially reversed MT hyperdynamicity.  Together, these data suggest that tau-mediated loss of MT stability may contribute to disease progression and that very low doses of BMS-241027 may be useful in the treatment of AD and other tauopathies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTUE0FB4RfBrVg90H21EOLACvtfcHk0lhzSblH6Lctvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvFKksb8%253D&md5=e7dfb8668c6b69dd3dc55ff290e6e7fa</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0188-12.2012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0188-12.2012%26sid%3Dliteratum%253Aachs%26aulast%3DBarten%26aufirst%3DD.%2BM.%26aulast%3DFanara%26aufirst%3DP.%26aulast%3DAndorfer%26aufirst%3DC.%26aulast%3DHoque%26aufirst%3DN.%26aulast%3DWong%26aufirst%3DP.%2BY.%2BA.%26aulast%3DHusted%26aufirst%3DK.%2BH.%26aulast%3DCadelina%26aufirst%3DG.%2BW.%26aulast%3DDeCarr%26aufirst%3DL.%2BB.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DFessler%26aufirst%3DC.%26aulast%3DProtassio%26aufirst%3DJ.%26aulast%3DRiff%26aufirst%3DT.%26aulast%3DTurner%26aufirst%3DH.%26aulast%3DJanus%26aufirst%3DC.%2BG.%26aulast%3DSankaranarayanan%26aufirst%3DS.%26aulast%3DPolson%26aufirst%3DC.%26aulast%3DMeredith%26aufirst%3DJ.%2BE.%26aulast%3DGray%26aufirst%3DG.%26aulast%3DHanna%26aufirst%3DA.%26aulast%3DOlson%26aufirst%3DR.%2BE.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DVite%26aufirst%3DG.%2BD.%26aulast%3DLee%26aufirst%3DF.%2BY.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26atitle%3DHyperdynamic%2520microtubules%252C%2520cognitive%2520deficits%252C%2520and%2520pathology%2520are%2520improved%2520in%2520tau%2520transgenic%2520mice%2520with%2520low%2520doses%2520of%2520the%2520microtubule-stabilizing%2520agent%2520BMS-241027%26jtitle%3DJ.%2520Neurosci.%26date%3D2012%26volume%3D32%26spage%3D7137%26epage%3D7145%26doi%3D10.1523%2FJNEUROSCI.0188-12.2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Herbst-Robinson, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">Inflammatory eicosanoids increase amyloid precursor protein expression via activation of multiple neuronal receptors</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">18286</span><span class="refDoi"> DOI: 10.1038/srep18286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1038%2Fsrep18286" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=18286&author=K.+J.+Herbst-Robinsonauthor=L.+Liuauthor=M.+Jamesauthor=Y.+Yaoauthor=S.+X.+Xieauthor=K.+R.+Brunden&title=Inflammatory+eicosanoids+increase+amyloid+precursor+protein+expression+via+activation+of+multiple+neuronal+receptors&doi=10.1038%2Fsrep18286"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fsrep18286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18286%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst-Robinson%26aufirst%3DK.%2BJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DInflammatory%2520eicosanoids%2520increase%2520amyloid%2520precursor%2520protein%2520expression%2520via%2520activation%2520of%2520multiple%2520neuronal%2520receptors%26jtitle%3DSci.%2520Rep.%26date%3D2016%26volume%3D5%26spage%3D18286%26doi%3D10.1038%2Fsrep18286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sidell, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crews, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Markesbery, W. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marnett, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. J.,  II</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span> </span><span class="NLM_article-title">Elevated CSF prostaglandin E2 levels in patients with probable AD</span> <span class="citation_source-journal">Neurology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">1495</span><span class="NLM_x">–</span> <span class="NLM_lpage">1498</span><span class="refDoi"> DOI: 10.1212/WNL.53.7.1495</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1212%2FWNL.53.7.1495" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=1999&pages=1495-1498&author=T.+J.+Montineauthor=K.+R.+Sidellauthor=B.+C.+Crewsauthor=W.+R.+Markesberyauthor=L.+J.+Marnettauthor=L.+J.+Robertsauthor=J.+D.+Morrow&title=Elevated+CSF+prostaglandin+E2+levels+in+patients+with+probable+AD&doi=10.1212%2FWNL.53.7.1495"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1212%2FWNL.53.7.1495&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.53.7.1495%26sid%3Dliteratum%253Aachs%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DSidell%26aufirst%3DK.%2BR.%26aulast%3DCrews%26aufirst%3DB.%2BC.%26aulast%3DMarkesbery%26aufirst%3DW.%2BR.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DRoberts%26aufirst%3DL.%2BJ.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26atitle%3DElevated%2520CSF%2520prostaglandin%2520E2%2520levels%2520in%2520patients%2520with%2520probable%2520AD%26jtitle%3DNeurology%26date%3D1999%26volume%3D53%26spage%3D1495%26epage%3D1498%26doi%3D10.1212%2FWNL.53.7.1495" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Manev, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dzitoyeva, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manev, R.</span><span> </span><span class="NLM_article-title">Cyclooxygenases and 5-lipoxygenase in Alzheimer’s disease</span> <span class="citation_source-journal">Prog. Neuro-Psychopharmacol. Biol. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">315</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span><span class="refDoi"> DOI: 10.1016/j.pnpbp.2010.07.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.pnpbp.2010.07.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=20691748" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjvVaqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2011&pages=315-319&author=H.+Manevauthor=H.+Chenauthor=S.+Dzitoyevaauthor=R.+Manev&title=Cyclooxygenases+and+5-lipoxygenase+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.pnpbp.2010.07.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease</span></div><div class="casAuthors">Manev, Hari; Chen, Hu; Dzitoyeva, Svetlana; Manev, Radmila</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neuro-Psychopharmacology & Biological Psychiatry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">315-319</span>CODEN:
                <span class="NLM_cas:coden">PNPPD7</span>;
        ISSN:<span class="NLM_cas:issn">0278-5846</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Typically, cyclooxygenases (COXs) and 5-lipoxygenase (5-LOX), enzymes that generate biol. active lipid mols. termed eicosanoids, are considered inflammatory.  Hence, their putative role in Alzheimer's disease (AD) has been explored in the framework of possible inflammatory mechanisms of AD pathobiol.  More recent data indicate that these enzymes and the biol. active lipid mols. they generate could influence the functioning of the central nervous system and the pathobiol. of neurodegenerative disorders such as AD via mechanisms different from classical inflammation.  These mechanisms include the cell-specific localization of COXs and 5-LOX in the brain, the type of lipid mols. generated by the activity of these enzymes, the type and the localization of receptors selective for a type of lipid mol., and the putative interactions of the COXs and 5-LOX pathways with intracellular components relevant for AD such as the gamma-secretase complex.  Considering the importance of these multiple and not necessarily inflammatory mechanisms may help us delineate the exact nature of the involvement of the brain COXs and 5-LOX in AD and would reinvigorate the search for novel targets for AD therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowCfvWyONgErVg90H21EOLACvtfcHk0lgcaf4iHtodSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjvVaqsro%253D&md5=31ec759a2b6b927d789d44bb4dd9ae93</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.pnpbp.2010.07.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pnpbp.2010.07.032%26sid%3Dliteratum%253Aachs%26aulast%3DManev%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DDzitoyeva%26aufirst%3DS.%26aulast%3DManev%26aufirst%3DR.%26atitle%3DCyclooxygenases%2520and%25205-lipoxygenase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DProg.%2520Neuro-Psychopharmacol.%2520Biol.%2520Psychiatry%26date%3D2011%26volume%3D35%26spage%3D315%26epage%3D319%26doi%3D10.1016%2Fj.pnpbp.2010.07.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kitamura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimohama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koike, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kakimura, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nomura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebicke-Haerter, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taniguchi, T.</span><span> </span><span class="NLM_article-title">Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer’s disease brains</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">254</span><span class="NLM_x">, </span> <span class="NLM_fpage">582</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1006/bbrc.1998.9981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1006%2Fbbrc.1998.9981" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=1999&pages=582-586&author=Y.+Kitamuraauthor=S.+Shimohamaauthor=H.+Koikeauthor=J.+Kakimuraauthor=Y.+Matsuokaauthor=Y.+Nomuraauthor=P.+J.+Gebicke-Haerterauthor=T.+Taniguchi&title=Increased+expression+of+cyclooxygenases+and+peroxisome+proliferator-activated+receptor-gamma+in+Alzheimer%E2%80%99s+disease+brains&doi=10.1006%2Fbbrc.1998.9981"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1006%2Fbbrc.1998.9981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fbbrc.1998.9981%26sid%3Dliteratum%253Aachs%26aulast%3DKitamura%26aufirst%3DY.%26aulast%3DShimohama%26aufirst%3DS.%26aulast%3DKoike%26aufirst%3DH.%26aulast%3DKakimura%26aufirst%3DJ.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DNomura%26aufirst%3DY.%26aulast%3DGebicke-Haerter%26aufirst%3DP.%2BJ.%26aulast%3DTaniguchi%26aufirst%3DT.%26atitle%3DIncreased%2520expression%2520of%2520cyclooxygenases%2520and%2520peroxisome%2520proliferator-activated%2520receptor-gamma%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1999%26volume%3D254%26spage%3D582%26epage%3D586%26doi%3D10.1006%2Fbbrc.1998.9981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Fujimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakisaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanizaki, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiyohara, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanba, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwaki, T.</span><span> </span><span class="NLM_article-title">Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer’s disease: the Hisayama Study</span> <span class="citation_source-journal">Dementia Geriatr. Cognit. Disord.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">423</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1159/000101957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1159%2F000101957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=17457030" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2sXmt1Sqsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2007&pages=423-431&author=K.+Fujimiauthor=K.+Nodaauthor=K.+Sasakiauthor=Y.+Wakisakaauthor=Y.+Tanizakiauthor=M.+Iidaauthor=Y.+Kiyoharaauthor=S.+Kanbaauthor=T.+Iwaki&title=Altered+expression+of+COX-2+in+subdivisions+of+the+hippocampus+during+aging+and+in+Alzheimer%E2%80%99s+disease%3A+the+Hisayama+Study&doi=10.1159%2F000101957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Altered expression of COX-2 in subdivisions of the hippocampus during aging and in Alzheimer's disease: the hisayama study</span></div><div class="casAuthors">Fujimi, Kouhei; Noda, Kazuhito; Sasaki, Kensuke; Wakisaka, Yoshinobu; Tanizaki, Yumihiro; Iida, Mitsuo; Kiyohara, Yutaka; Kanba, Shigenobu; Iwaki, Toru</div><div class="citationInfo"><span class="NLM_cas:title">Dementia and Geriatric Cognitive Disorders</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">423-431</span>CODEN:
                <span class="NLM_cas:coden">DGCDFX</span>;
        ISSN:<span class="NLM_cas:issn">1420-8008</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">It has been reported that nonsteroidal anti-inflammatory drugs may delay the onset of Alzheimer's disease (AD).  Since nonsteroidal anti-inflammatory drugs inhibit cyclooxygenase (COX), COX-2, an inducible form of COX, may be involved in the pathol. of AD in assocn. with the arachidonic acid cascade.  In addn., it has been suggested that alterations in the balance of polyunsatd. fatty acids are assocd. with brain dysfunctions such as neurodegenerative pathologies of the aging brain.  To explore COX-2 expression in the hippocampus, we analyzed 45 consecutive autopsy subjects without dementia and 25 AD patients derived from the town of Hisayama, Japan.  The neuronal expression of COX-2 in the CA3 subdivision of the hippocampus, subiculum, entorhinal cortex and transentorhinal cortex were consistently obsd. in both nondemented and AD brains, and COX-2 immunoreactivity correlated with age in nondemented brains.  In AD patients, neurons of CA1 exhibited increased COX-2 immunoreactivity which correlated with the severity of AD pathol.  This correlation was not apparent in nondemented subjects.  These results suggest that COX-2 expression may be differentially regulated among subdivisions of the hippocampus and that elevated COX-2 expression in the CA1 of AD brains may be assocd. with AD pathol. and thus cognitive dysfunction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfc15HXFpqybVg90H21EOLACvtfcHk0ljhBudPRqMybg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXmt1Sqsbg%253D&md5=991777f555947382c082f5cd225d021d</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1159%2F000101957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000101957%26sid%3Dliteratum%253Aachs%26aulast%3DFujimi%26aufirst%3DK.%26aulast%3DNoda%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DK.%26aulast%3DWakisaka%26aufirst%3DY.%26aulast%3DTanizaki%26aufirst%3DY.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DKiyohara%26aufirst%3DY.%26aulast%3DKanba%26aufirst%3DS.%26aulast%3DIwaki%26aufirst%3DT.%26atitle%3DAltered%2520expression%2520of%2520COX-2%2520in%2520subdivisions%2520of%2520the%2520hippocampus%2520during%2520aging%2520and%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520the%2520Hisayama%2520Study%26jtitle%3DDementia%2520Geriatr.%2520Cognit.%2520Disord.%26date%3D2007%26volume%3D23%26spage%3D423%26epage%3D431%26doi%3D10.1159%2F000101957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Zhen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yocum, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kapoor, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dobrowolski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narumiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dore, S.</span><span> </span><span class="NLM_article-title">PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer’s disease</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">2215</span><span class="NLM_x">–</span> <span class="NLM_lpage">2219</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2011.09.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neurobiolaging.2011.09.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22015313" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSgt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2012&pages=2215-2219&author=G.+Zhenauthor=Y.+T.+Kimauthor=R.+C.+Liauthor=J.+Yocumauthor=N.+Kapoorauthor=J.+Langerauthor=P.+Dobrowolskiauthor=T.+Maruyamaauthor=S.+Narumiyaauthor=S.+Dore&title=PGE2+EP1+receptor+exacerbated+neurotoxicity+in+a+mouse+model+of+cerebral+ischemia+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.neurobiolaging.2011.09.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease</span></div><div class="casAuthors">Zhen, Gehua; Kim, Yun Tai; Li, Rung-chi; Yocum, Jennifer; Kapoor, Nidhi; Langer, John; Dobrowolski, Peter; Maruyama, Takayuki; Narumiya, Shuh; Dore, Sylvain</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2215-2219</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Stroke and Alzheimer's disease (AD) are major age-related neurodegenerative diseases that may worsen the prognosis of each other.  Our study was designed to delineate the prostaglandin E2 EP1 receptor role in AD and in the setting of cerebral ischemia.  Genetic deletion of the prostaglandin EP1 receptor significantly attenuated the more severe neuronal damage (38.5 ± 10.6%) and memory loss induced by ischemic insult obsd. in AD transgenic mice (percentage of viable hippocampal CA1 neurons: 11.2 ± 2.9%) when compared with wild type mice (45.1 ± 9.1%).  In addn., we found that the amyloid plaques were reduced in EP1 deleted AD mice. β-amyloid-induced toxicity (18.0 ± 7.1%) and Ca2+ response (91.8 ± 12.9%) were also reduced in EP1-/- neurons compared with control neurons in in vitro.  Hence, EP1 might mediate most of the toxicity assocd. with cyclooxygenase-2 and contribute substantially to the cell death pathways in AD and stroke.  Exploring potential therapeutic agent targeting EP1 receptor could potentially benefit treatments for stroke and AD patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQHW6rIXIcUrVg90H21EOLACvtfcHk0ljAqybHBLc_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSgt7zF&md5=9fd9a156469fd8fdea9f043e0526eb81</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2011.09.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2011.09.017%26sid%3Dliteratum%253Aachs%26aulast%3DZhen%26aufirst%3DG.%26aulast%3DKim%26aufirst%3DY.%2BT.%26aulast%3DLi%26aufirst%3DR.%2BC.%26aulast%3DYocum%26aufirst%3DJ.%26aulast%3DKapoor%26aufirst%3DN.%26aulast%3DLanger%26aufirst%3DJ.%26aulast%3DDobrowolski%26aufirst%3DP.%26aulast%3DMaruyama%26aufirst%3DT.%26aulast%3DNarumiya%26aufirst%3DS.%26aulast%3DDore%26aufirst%3DS.%26atitle%3DPGE2%2520EP1%2520receptor%2520exacerbated%2520neurotoxicity%2520in%2520a%2520mouse%2520model%2520of%2520cerebral%2520ischemia%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2012%26volume%3D33%26spage%3D2215%26epage%3D2219%26doi%3D10.1016%2Fj.neurobiolaging.2011.09.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hand, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasson, K.</span><span> </span><span class="NLM_article-title">Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">10180</span><span class="NLM_x">–</span> <span class="NLM_lpage">10187</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.3591-05.2005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.3591-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=16267225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1Wqt77I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=10180-10187&author=X.+Liangauthor=Q.+Wangauthor=T.+Handauthor=L.+Wuauthor=R.+M.+Breyerauthor=T.+J.+Montineauthor=K.+Andreasson&title=Deletion+of+the+prostaglandin+E2+EP2+receptor+reduces+oxidative+damage+and+amyloid+burden+in+a+model+of+Alzheimer%E2%80%99s+disease&doi=10.1523%2FJNEUROSCI.3591-05.2005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease</span></div><div class="casAuthors">Liang, Xibin; Wang, Qian; Hand, Tracey; Wu, Liejun; Breyer, Richard M.; Montine, Thomas J.; Andreasson, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">44</span>),
    <span class="NLM_cas:pages">10180-10187</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Epidemiol. studies demonstrate that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) in normal aging populations reduces the risk of developing Alzheimer's disease (AD).  NSAIDs inhibit the enzymic activity of cyclooxygenase-1 (COX-1) and inducible COX-2, which catalyze the first committed step in the synthesis of prostaglandins.  These studies implicate COX-mediated inflammation as an early and potentially reversible preclin. event; however, the mechanism by which COX activity promotes development of AD has not been detd.  Recent studies implicate the prostaglandin E2 (PGE2) E prostanoid subtype 2 (EP2) receptor in the development of the innate immune response in brain.  Here, we report that deletion of the PGE2 EP2 receptor in the APPSwe-PS1ΔE9 model of familial AD results in marked redns. in lipid peroxidn. in aging mice.  This redn. in oxidative stress is assocd. with significant decreases in levels of amyloid-β (Aβ) 40 and 42 peptides and amyloid deposition.  Aged APPSwe-PS1ΔE9 mice lacking the EP2 receptor harbor lower levels of β C-terminal fragments, the product of β-site APP cleaving enzyme (BACE1) processing of amyloid precursor protein.  Increases in BACE1 processing have been demonstrated in models of aging and AD and after oxidative stress.  Our results indicate that PGE2 signaling via the EP2 receptor promotes age-dependent oxidative damage and increased Aβ peptide burden in this model of AD, possibly via effects on BACE1 activity.  Our findings identify EP2 receptor signaling as a novel proinflammatory and proamyloidogenic pathway in this model of AD, and suggest a rationale for development of therapeutics targeting the EP2 receptor in neuroinflammatory diseases such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvQcRSqBUHdrVg90H21EOLACvtfcHk0ljAqybHBLc_fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1Wqt77I&md5=fadd58f101e78d983b0be1832c5bbb10</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.3591-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.3591-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHand%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DBreyer%26aufirst%3DR.%2BM.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DAndreasson%26aufirst%3DK.%26atitle%3DDeletion%2520of%2520the%2520prostaglandin%2520E2%2520EP2%2520receptor%2520reduces%2520oxidative%2520damage%2520and%2520amyloid%2520burden%2520in%2520a%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26spage%3D10180%26epage%3D10187%26doi%3D10.1523%2FJNEUROSCI.3591-05.2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodling, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priyam, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loui, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breyer, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasson, K.</span><span> </span><span class="NLM_article-title">Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">788</span><span class="NLM_x">–</span> <span class="NLM_lpage">798</span><span class="refDoi"> DOI: 10.1002/ana.23677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fana.23677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22915243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnt1Sr" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=788-798&author=J.+Shiauthor=Q.+Wangauthor=J.+U.+Johanssonauthor=X.+Liangauthor=N.+S.+Woodlingauthor=P.+Priyamauthor=T.+M.+Louiauthor=M.+Merchantauthor=R.+M.+Breyerauthor=T.+J.+Montineauthor=K.+Andreasson&title=Inflammatory+prostaglandin+E2+signaling+in+a+mouse+model+of+Alzheimer+disease&doi=10.1002%2Fana.23677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammatory prostaglandin E2 signaling in a mouse model of Alzheimer disease</span></div><div class="casAuthors">Shi, Ju; Wang, Qian; Johansson, Jenny U.; Liang, Xibin; Woodling, Nathaniel S.; Priyam, Prachi; Loui, Taylor M.; Merchant, Milton; Breyer, Richard M.; Montine, Thomas J.; Andreasson, Katrin</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">788-798</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: : There is significant evidence for a central role of inflammation in the development of Alzheimer disease (AD).  Epidemiol. studies indicate that chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD in healthy aging populations.  As NSAIDs inhibit the enzymic activity of the inflammatory cyclooxygenases COX-1 and COX-2, these findings suggest that downstream prostaglandin signaling pathways function in the preclin. development of AD.  Here, we investigate the function of prostaglandin E2 (PGE2) signaling through its EP3 receptor in the neuroinflammatory response to Aβ peptide.  Methods: : The function of PGE2 signaling through its EP3 receptor was examd. in vivo in a model of subacute neuroinflammation induced by administration of Aβ42 peptides.  Our findings were then confirmed in young adult APPSwe-PS1ΔE9 transgenic mice.  Results: : Deletion of the PGE2 EP3 receptor in a model of Aβ42 peptide-induced neuroinflammation reduced proinflammatory gene expression, cytokine prodn., and oxidative stress.  In the APPSwe-PS1ΔE9 model of familial AD, deletion of the EP3 receptor blocked induction of proinflammatory gene and protein expression and lipid peroxidn.  In addn., levels of Aβ peptides were significantly decreased, as were β-secretase and β C-terminal fragment levels, suggesting that generation of Aβ peptides may be increased as a result of proinflammatory EP3 signaling.  Finally, deletion of EP3 receptor significantly reversed the decline in presynaptic proteins seen in APPSwe-PS1ΔE9 mice.  Interpretation: : Our findings identify the PGE2 EP3 receptor as a novel proinflammatory, proamyloidogenic, and synaptotoxic signaling pathway, and suggest a role for COX-PGE2-EP3 signaling in the development of AD.  ANN NEUROL 2012;72:788-798.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRmaJmkoToq7Vg90H21EOLACvtfcHk0ljRz6pvi5dqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnt1Sr&md5=a414b92089014b683619767d49a57831</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1002%2Fana.23677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.23677%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DJohansson%26aufirst%3DJ.%2BU.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DWoodling%26aufirst%3DN.%2BS.%26aulast%3DPriyam%26aufirst%3DP.%26aulast%3DLoui%26aufirst%3DT.%2BM.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DBreyer%26aufirst%3DR.%2BM.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DAndreasson%26aufirst%3DK.%26atitle%3DInflammatory%2520prostaglandin%2520E2%2520signaling%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2012%26volume%3D72%26spage%3D788%26epage%3D798%26doi%3D10.1002%2Fana.23677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Hoshino, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namba, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takehara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murao, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugimoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Narumiya, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mizushima, T.</span><span> </span><span class="NLM_article-title">Improvement of cognitive function in Alzheimer’s disease model mice by genetic and pharmacological inhibition of the EP(4) receptor</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">120</span><span class="NLM_x">, </span> <span class="NLM_fpage">795</span><span class="NLM_x">–</span> <span class="NLM_lpage">805</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2011.07567.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fj.1471-4159.2011.07567.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=22044482" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XksFCnt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=2012&pages=795-805&author=T.+Hoshinoauthor=T.+Nambaauthor=M.+Takeharaauthor=N.+Muraoauthor=T.+Matsushimaauthor=Y.+Sugimotoauthor=S.+Narumiyaauthor=T.+Suzukiauthor=T.+Mizushima&title=Improvement+of+cognitive+function+in+Alzheimer%E2%80%99s+disease+model+mice+by+genetic+and+pharmacological+inhibition+of+the+EP%284%29+receptor&doi=10.1111%2Fj.1471-4159.2011.07567.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of cognitive function in Alzheimer's disease model mice by genetic and pharmacological inhibition of the EP4 receptor</span></div><div class="casAuthors">Hoshino, Tatsuya; Namba, Takushi; Takehara, Masaya; Murao, Naoya; Matsushima, Takahide; Sugimoto, Yukihiko; Narumiya, Shuh; Suzuki, Toshiharu; Mizushima, Tohru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">5 & 6</span>),
    <span class="NLM_cas:pages">795-805</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Amyloid-β peptide (Aβ), which is generated by the β- and γ-secretase-mediated proteolysis of β-amyloid precursor protein (APP), plays an important role in the pathogenesis of Alzheimer's disease (AD).  We recently reported that prostaglandin E2 (PGE2) stimulates the prodn. of Aβ through both EP2 and EP4 receptors and that activation of the EP4 receptor stimulates Aβ prodn. through endocytosis and activation of γ-secretase.  We here found that transgenic mice expressing mutant APP (APP23) mice showed a greater or lesser apparent cognitive deficit when they were crossed with mice lacking EP2 or EP4 receptors, resp.  Mice lacking the EP4 receptor also displayed lower levels of Aβ plaque deposition and less neuronal and synaptic loss than control mice.  Oral administration of a specific EP4 receptor antagonist, AE3-208 to APP23 mice, improved their cognitive performance, as well as decreasing brain levels of Aβ and suppressing endocytosis and activation of γ-secretase.  Taken together, these results suggest that inhibition of the EP4 receptor improves the cognitive function of APP23 mice by suppressing Aβ prodn. and reducing neuronal and synaptic loss.  We therefore propose that EP4 receptor antagonists, such as AE3-208, could be therapeutically beneficial for the prevention and treatment of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6B8rTHzbvCLVg90H21EOLACvtfcHk0ljRz6pvi5dqpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksFCnt7g%253D&md5=973f037bca8e48ff2a4989f3bb15c543</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2011.07567.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2011.07567.x%26sid%3Dliteratum%253Aachs%26aulast%3DHoshino%26aufirst%3DT.%26aulast%3DNamba%26aufirst%3DT.%26aulast%3DTakehara%26aufirst%3DM.%26aulast%3DMurao%26aufirst%3DN.%26aulast%3DMatsushima%26aufirst%3DT.%26aulast%3DSugimoto%26aufirst%3DY.%26aulast%3DNarumiya%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DT.%26aulast%3DMizushima%26aufirst%3DT.%26atitle%3DImprovement%2520of%2520cognitive%2520function%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520model%2520mice%2520by%2520genetic%2520and%2520pharmacological%2520inhibition%2520of%2520the%2520EP%25284%2529%2520receptor%26jtitle%3DJ.%2520Neurochem.%26date%3D2012%26volume%3D120%26spage%3D795%26epage%3D805%26doi%3D10.1111%2Fj.1471-4159.2011.07567.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Woodling, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Priyam, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johansson, J. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zagol-Ikapitte, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutaud, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasson, K. I.</span><span> </span><span class="NLM_article-title">Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">5882</span><span class="NLM_x">–</span> <span class="NLM_lpage">5894</span><span class="refDoi"> DOI: 10.1523/JNEUROSCI.0410-14.2014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1523%2FJNEUROSCI.0410-14.2014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24760848" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OmtrrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=5882-5894&author=N.+S.+Woodlingauthor=Q.+Wangauthor=P.+G.+Priyamauthor=P.+Larkinauthor=J.+Shiauthor=J.+U.+Johanssonauthor=I.+Zagol-Ikapitteauthor=O.+Boutaudauthor=K.+I.+Andreasson&title=Suppression+of+Alzheimer-associated+inflammation+by+microglial+prostaglandin-E2+EP4+receptor+signaling&doi=10.1523%2FJNEUROSCI.0410-14.2014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling</span></div><div class="casAuthors">Woodling, Nathaniel S.; Wang, Qian; Priyam, Prachi G.; Larkin, Paul; Shi, Ju; Johansson, Jenny U.; Zagol-Ikapitte, Irene; Boutaud, Olivier; Andreasson, Katrin I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5882-5894, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">A persistent and nonresolving inflammatory response to accumulating Aβ peptide species is a cardinal feature in the development of Alzheimer's disease (AD).  In response to accumulating Aβ peptide species, microglia, the innate immune cells of the brain, generate a toxic inflammatory response that accelerates synaptic and neuronal injury.  Many proinflammatory signaling pathways are linked to progression of neurodegeneration.  However, endogenous anti-inflammatory pathways capable of suppressing Aβ-induced inflammation represent a relatively unexplored area.  Here we report that signaling through the prostaglandin-E2 (PGE2) EP4 receptor potently suppresses microglial inflammatory responses to Aβ42 peptides.  In cultured microglial cells, EP4 stimulation attenuated levels of Aβ42-induced inflammatory factors and potentiated phagocytosis of Aβ42.  Microarray anal. demonstrated that EP4 stimulation broadly opposed Aβ42-driven gene expression changes in microglia, with enrichment for targets of IRF1, IRF7, and NF-κB transcription factors.  In vivo, conditional deletion of microglial EP4 in APPSwe-PS1ΔE9 (APP-PS1) mice conversely increased inflammatory gene expression, oxidative protein modification, and Aβ deposition in brain at early stages of pathol., but not at later stages, suggesting an early anti-inflammatory function of microglial EP4 signaling in the APP-PS1 model.  Finally, EP4 receptor levels decreased significantly in human cortex with progression from normal to AD states, suggesting that early loss of this beneficial signaling system in preclin. AD development may contribute to subsequent progression of pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb5JcrDRCBeLVg90H21EOLACvtfcHk0lgxHYK7I5GoXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OmtrrL&md5=e00802138b2f71d01d0422b50beaa290</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0410-14.2014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0410-14.2014%26sid%3Dliteratum%253Aachs%26aulast%3DWoodling%26aufirst%3DN.%2BS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DPriyam%26aufirst%3DP.%2BG.%26aulast%3DLarkin%26aufirst%3DP.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DJohansson%26aufirst%3DJ.%2BU.%26aulast%3DZagol-Ikapitte%26aufirst%3DI.%26aulast%3DBoutaud%26aufirst%3DO.%26aulast%3DAndreasson%26aufirst%3DK.%2BI.%26atitle%3DSuppression%2520of%2520Alzheimer-associated%2520inflammation%2520by%2520microglial%2520prostaglandin-E2%2520EP4%2520receptor%2520signaling%26jtitle%3DJ.%2520Neurosci.%26date%3D2014%26volume%3D34%26spage%3D5882%26epage%3D5894%26doi%3D10.1523%2FJNEUROSCI.0410-14.2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Firuzi, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chinnici, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisniewski, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratico, D.</span><span> </span><span class="NLM_article-title">5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer’s disease</span> <span class="citation_source-journal">FASEB J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1169</span><span class="NLM_x">–</span> <span class="NLM_lpage">1178</span><span class="refDoi"> DOI: 10.1096/fj.07-9131.com</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1096%2Ffj.07-9131.com" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2007&pages=1169-1178&author=O.+Firuziauthor=J.+Zhuoauthor=C.+M.+Chinniciauthor=T.+Wisniewskiauthor=D.+Pratico&title=5-Lipoxygenase+gene+disruption+reduces+amyloid-beta+pathology+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1096%2Ffj.07-9131.com"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1096%2Ffj.07-9131.com&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1096%252Ffj.07-9131.com%26sid%3Dliteratum%253Aachs%26aulast%3DFiruzi%26aufirst%3DO.%26aulast%3DZhuo%26aufirst%3DJ.%26aulast%3DChinnici%26aufirst%3DC.%2BM.%26aulast%3DWisniewski%26aufirst%3DT.%26aulast%3DPratico%26aufirst%3DD.%26atitle%3D5-Lipoxygenase%2520gene%2520disruption%2520reduces%2520amyloid-beta%2520pathology%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DFASEB%2520J.%26date%3D2007%26volume%3D22%26spage%3D1169%26epage%3D1178%26doi%3D10.1096%2Ffj.07-9131.com" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Ikonomovic, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abrahamson, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uz, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manev, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dekosky, S. T.</span><span> </span><span class="NLM_article-title">Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer’s disease</span> <span class="citation_source-journal">J. Histochem. Cytochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">1065</span><span class="NLM_x">–</span> <span class="NLM_lpage">1073</span><span class="refDoi"> DOI: 10.1369/jhc.2008.951855</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1369%2Fjhc.2008.951855" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=18678882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVaitbzM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2008&pages=1065-1073&author=M.+D.+Ikonomovicauthor=E.+E.+Abrahamsonauthor=T.+Uzauthor=H.+Manevauthor=S.+T.+Dekosky&title=Increased+5-lipoxygenase+immunoreactivity+in+the+hippocampus+of+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1369%2Fjhc.2008.951855"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease</span></div><div class="casAuthors">Ikonomovic, Milos D.; Abrahamson, Eric E.; Uz, Tolga; Manev, Hari; DeKosky, Steven T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Histochemistry and Cytochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1065-1073</span>CODEN:
                <span class="NLM_cas:coden">JHCYAS</span>;
        ISSN:<span class="NLM_cas:issn">0022-1554</span>.
    
            (<span class="NLM_cas:orgname">Histochemical Society, Inc.</span>)
        </div><div class="casAbstract">The proinflammatory enzyme 5-lipoxygenase (5-LOX) is upregulated in Alzheimer's disease (AD), but its localization and assocn. with the hallmark lesions of the disease, β-amyloid (Aβ) plaques and neurofibrillary tangles (NFTs), is unknown.  This study examd. the distribution and cellular localization of 5-LOX in the medial temporal lobe from AD and control subjects.  The spatial relationship between 5-LOX immunoreactive structures and AD lesions was also examd.  We report that, in AD subjects, 5-LOX immunoreactivity is elevated relative to controls, and its localization is dependent on the antibody-targeted portion of the 5-LOX amino acid sequence.  Carboxy terminus-directed antibodies detected 5-LOX in glial cells and neurons, but less frequently in neurons with dystrophic (NFT) morphol.  In contrast, immunoreactivity obsd. using 5-LOX amino terminus-directed antibodies was virtually absent in neurons and abundant in NFTs, neuritic plaques, and glia.  Double-labeling studies showed a close assocn. of 5-LOX-immunoreactive processes and glial cells with Aβ immunoreactive plaques and vasculature and also detected 5-LOX in tau immunoreactive and amyloid contg. NFTs.  Different immunolabeling patterns with antibodies against carboxy vs amino terminus of 5-LOX may be caused by post-translational modifications of 5-LOX protein in Aβ plaques and NFTs.  The relationship between elevated intracellular 5-LOX and hallmark AD pathol. lesions provides further evidence that neuroinflammatory pathways contribute to the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp68zh8DbrN97Vg90H21EOLACvtfcHk0lgxHYK7I5GoXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVaitbzM&md5=0460938d96ba7bbd04ce02955fae4a8f</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1369%2Fjhc.2008.951855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1369%252Fjhc.2008.951855%26sid%3Dliteratum%253Aachs%26aulast%3DIkonomovic%26aufirst%3DM.%2BD.%26aulast%3DAbrahamson%26aufirst%3DE.%2BE.%26aulast%3DUz%26aufirst%3DT.%26aulast%3DManev%26aufirst%3DH.%26aulast%3DDekosky%26aufirst%3DS.%2BT.%26atitle%3DIncreased%25205-lipoxygenase%2520immunoreactivity%2520in%2520the%2520hippocampus%2520of%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Histochem.%2520Cytochem.%26date%3D2008%26volume%3D56%26spage%3D1065%26epage%3D1073%26doi%3D10.1369%2Fjhc.2008.951855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannopoulos, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceballos-Diaz, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golde, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratico, D.</span><span> </span><span class="NLM_article-title">5-Lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease</span> <span class="citation_source-journal">Ann. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">442</span><span class="NLM_x">–</span> <span class="NLM_lpage">454</span><span class="refDoi"> DOI: 10.1002/ana.23642</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fana.23642" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23034916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVentb7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=442-454&author=J.+Chuauthor=P.+F.+Giannopoulosauthor=C.+Ceballos-Diazauthor=T.+E.+Goldeauthor=D.+Pratico&title=5-Lipoxygenase+gene+transfer+worsens+memory%2C+amyloid%2C+and+tau+brain+pathologies+in+a+mouse+model+of+Alzheimer+disease&doi=10.1002%2Fana.23642"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">5-lipoxygenase gene transfer worsens memory, amyloid, and tau brain pathologies in a mouse model of Alzheimer disease</span></div><div class="casAuthors">Chu, Jin; Giannopoulos, Phillip F.; Ceballos-Diaz, Carolina; Golde, Todd E.; Pratico, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">442-454</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: : The 5-lipoxygenase (5LO) enzyme is upregulated in Alzheimer disease (AD), and its genetic absence reduces Aβ levels in APP mice.  However, its functional role in modulating tau neuropathol. remains to be elucidated.  Methods: To this end, we generated triple transgenic mice (3xTg-AD) overexpressing neuronal 5LO and investigated their phenotype.  Results: Compared with controls, 3xTg-AD mice overexpressing 5LO manifested an exacerbation of memory deficits, plaques, and tangle pathologies.  The elevation in Aβ was secondary to an upregulation of γ-secretase pathway, whereas tau hyperphosphorylation resulted from an activation of the Cdk5 kinase.  In vitro study confirmed the involvement of this kinase in the 5LO-dependent tau phosphorylation, which was independent of the effect on Aβ.  Interpretation: Our findings highlight the novel functional role that neuronal 5LO plays in exacerbating AD-related tau pathologies.  They provide crit. preclin. evidence to justify testing selective 5LO inhibitors for AD treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd-DgJyv0S3rVg90H21EOLACvtfcHk0lgZkP8fqQkY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVentb7E&md5=fbbacd2edec1dc2811efd16dd78a0236</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1002%2Fana.23642&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.23642%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DGiannopoulos%26aufirst%3DP.%2BF.%26aulast%3DCeballos-Diaz%26aufirst%3DC.%26aulast%3DGolde%26aufirst%3DT.%2BE.%26aulast%3DPratico%26aufirst%3DD.%26atitle%3D5-Lipoxygenase%2520gene%2520transfer%2520worsens%2520memory%252C%2520amyloid%252C%2520and%2520tau%2520brain%2520pathologies%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D2012%26volume%3D72%26spage%3D442%26epage%3D454%26doi%3D10.1002%2Fana.23642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Chu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pratico, D.</span><span> </span><span class="NLM_article-title">Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer’s disease transgenic mouse model involvement of gamma-secretase</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">178</span><span class="NLM_x">, </span> <span class="NLM_fpage">1762</span><span class="NLM_x">–</span> <span class="NLM_lpage">1769</span><span class="refDoi"> DOI: 10.1016/j.ajpath.2010.12.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.ajpath.2010.12.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=21435457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVKgu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=178&publication_year=2011&pages=1762-1769&author=J.+Chuauthor=D.+Pratico&title=Pharmacologic+blockade+of+5-lipoxygenase+improves+the+amyloidotic+phenotype+of+an+Alzheimer%E2%80%99s+disease+transgenic+mouse+model+involvement+of+gamma-secretase&doi=10.1016%2Fj.ajpath.2010.12.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic blockade of 5-lipoxygenase improves the amyloidotic phenotype of an Alzheimer's disease transgenic mouse model: Involvement of γ-Secretase</span></div><div class="casAuthors">Chu, Jin; Pratico, Domenico</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">178</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1762-1769</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The 5-lipoxygenase (5-LO) enzyme is widely distributed within the central nervous system.  Previous works showed that this protein is up-regulated in Alzheimer's disease (AD) and that its genetic absence results in a redn. of amyloid β (Aβ) levels in Tg2576 mice.  In the present study, we examd. the effect of 5-LO pharmacol. inhibition on the amyloidotic phenotype of these mice.  Aβ deposition in the brains of mice receiving zileuton, a selective and specific 5-LO inhibitor, was significantly reduced when compared with control Tg2576 mice receiving vehicle.  This redn. was assocd. with a similar decrease in brain Aβ peptides levels.  Zileuton treatment did not induce any change in the steady state levels of amyloid-β precursor protein (APP), BACE1 or ADAM10.  By contrast, it resulted in a significant redn. of presenilin 1 (PSEN1, alias PS1), nicastrin (NCSTN), presenilin enhancer 2 homolog (PSNEN, alias, Pen-2), and anterior pharynx defective 1 (APH-1), the four components of the γ-secretase complex-at the protein and message level.  Furthermore, in vitro studies confirmed that zileuton prevents Aβ formation by modulating γ-secretase complex levels without affecting Notch signaling.  These data establish a functional role for 5-LO in the pathogenesis of AD-like amyloidosis, whereby it modulates the γ-secretase pathway.  They suggest that pharmacol. inhibition of 5-LO could provide a novel therapeutic opportunity for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzjUbxjvX30rVg90H21EOLACvtfcHk0lgZkP8fqQkY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVKgu78%253D&md5=7c7ac68e942efc88b44c90994e1ee57d</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2010.12.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2010.12.032%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DPratico%26aufirst%3DD.%26atitle%3DPharmacologic%2520blockade%2520of%25205-lipoxygenase%2520improves%2520the%2520amyloidotic%2520phenotype%2520of%2520an%2520Alzheimer%25E2%2580%2599s%2520disease%2520transgenic%2520mouse%2520model%2520involvement%2520of%2520gamma-secretase%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2011%26volume%3D178%26spage%3D1762%26epage%3D1769%26doi%3D10.1016%2Fj.ajpath.2010.12.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Hawkes, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sampson, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaurin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carare, R. O.</span><span> </span><span class="NLM_article-title">MK886 reduces cerebral amyloid angiopathy severity in TgCRND8 mice</span> <span class="citation_source-journal">Neurodegener. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">23</span><span class="refDoi"> DOI: 10.1159/000351096</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1159%2F000351096" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24021653" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitVShsr3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=17-23&author=C.+A.+Hawkesauthor=J.+E.+Shawauthor=M.+Brownauthor=A.+P.+Sampsonauthor=J.+McLaurinauthor=R.+O.+Carare&title=MK886+reduces+cerebral+amyloid+angiopathy+severity+in+TgCRND8+mice&doi=10.1159%2F000351096"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">MK886 Reduces Cerebral Amyloid Angiopathy Severity in TgCRND8 Mice</span></div><div class="casAuthors">Hawkes, Cheryl A.; Shaw, James E.; Brown, Mary; Sampson, Anthony P.; McLaurin, JoAnne; Carare, Roxana O.</div><div class="citationInfo"><span class="NLM_cas:title">Neurodegenerative Diseases</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>CODEN:
                <span class="NLM_cas:coden">NDEIA6</span>;
        ISSN:<span class="NLM_cas:issn">1660-2854</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">Background: Deposition of amyloid-β (Aβ) in blood vessel walls as cerebral amyloid angiopathy (CAA) is obsd. in the majority of Alzheimer's disease (AD) brains.  Inhibition of the 5-lipoxygenase (5-LOX) pathway has recently been suggested to play a role in reducing parenchymal Aβ deposition.  However, products of the 5-LOX pathway also activate the peroxisome proliferator-activated receptor (PPAR) family, which promotes clearance of Aβ from the brain.  Methods: In the present study, we investigated the effect of MK886, a 5-LOX-activating protein (FLAP) inhibitor and PPARα antagonist, on CAA severity in TgCRND8 mice overexpressing the human Swedish and Indiana amyloid precursor protein mutations.  Results: We found that MK886 significantly reduced brain levels of nicastrin and PPARα, but did not affect levels of β-secretase, apolipoprotein E or low-d. lipoprotein receptor-related protein-1.  CAA severity and parenchymal plaque load was significantly decreased in both the cortex and hippocampus of mice treated with MK886 compared to control mice.  Conclusion: These data suggest that 5-LOX and FLAP inhibitors may be useful in the treatment of CAA and AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRE-PMQ_tPI7Vg90H21EOLACvtfcHk0lgZkP8fqQkY6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitVShsr3L&md5=9ceac602d6c3e5da3cdbd7ee5ef15b65</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1159%2F000351096&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000351096%26sid%3Dliteratum%253Aachs%26aulast%3DHawkes%26aufirst%3DC.%2BA.%26aulast%3DShaw%26aufirst%3DJ.%2BE.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DSampson%26aufirst%3DA.%2BP.%26aulast%3DMcLaurin%26aufirst%3DJ.%26aulast%3DCarare%26aufirst%3DR.%2BO.%26atitle%3DMK886%2520reduces%2520cerebral%2520amyloid%2520angiopathy%2520severity%2520in%2520TgCRND8%2520mice%26jtitle%3DNeurodegener.%2520Dis.%26date%3D2014%26volume%3D13%26spage%3D17%26epage%3D23%26doi%3D10.1159%2F000351096" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Tang, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, G. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, L. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ji, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F. Y.</span><span> </span><span class="NLM_article-title">Leukotriene D4 induces cognitive impairment through enhancement of CysLT(1) R-mediated amyloid-beta generation in mice</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">182</span><span class="NLM_x">–</span> <span class="NLM_lpage">192</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2012.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuropharm.2012.08.026" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=182-192&author=S.+S.+Tangauthor=X.+Y.+Wangauthor=H.+Hongauthor=Y.+Longauthor=Y.+Q.+Liauthor=G.+Q.+Xiangauthor=L.+Y.+Jiangauthor=H.+T.+Zhangauthor=L.+P.+Liuauthor=M.+X.+Miaoauthor=M.+Huauthor=T.+T.+Zhangauthor=W.+Huauthor=H.+Jiauthor=F.+Y.+Ye&title=Leukotriene+D4+induces+cognitive+impairment+through+enhancement+of+CysLT%281%29+R-mediated+amyloid-beta+generation+in+mice&doi=10.1016%2Fj.neuropharm.2012.08.026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2012.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2012.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DTang%26aufirst%3DS.%2BS.%26aulast%3DWang%26aufirst%3DX.%2BY.%26aulast%3DHong%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%2BQ.%26aulast%3DXiang%26aufirst%3DG.%2BQ.%26aulast%3DJiang%26aufirst%3DL.%2BY.%26aulast%3DZhang%26aufirst%3DH.%2BT.%26aulast%3DLiu%26aufirst%3DL.%2BP.%26aulast%3DMiao%26aufirst%3DM.%2BX.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DT.%2BT.%26aulast%3DHu%26aufirst%3DW.%26aulast%3DJi%26aufirst%3DH.%26aulast%3DYe%26aufirst%3DF.%2BY.%26atitle%3DLeukotriene%2520D4%2520induces%2520cognitive%2520impairment%2520through%2520enhancement%2520of%2520CysLT%25281%2529%2520R-mediated%2520amyloid-beta%2520generation%2520in%2520mice%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D65%26spage%3D182%26epage%3D192%26doi%3D10.1016%2Fj.neuropharm.2012.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span> </span><span class="NLM_article-title">Altered microtubule dynamics in neurodegenerative disease: therapeutic potential of microtubule-stabilizing drugs</span> <span class="citation_source-journal">Neurobiol. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">2016</span><span class="NLM_x">, </span> <span class="NLM_fpage">21</span><span class="refDoi"> DOI: 10.1016/j.nbd.2016.12.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.nbd.2016.12.021" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2016&publication_year=2017&pages=21&author=K.+R.+Brundenauthor=V.+M.+Leeauthor=A.+B.+Smithauthor=J.+Q.+Trojanowskiauthor=C.+Ballatore&title=Altered+microtubule+dynamics+in+neurodegenerative+disease%3A+therapeutic+potential+of+microtubule-stabilizing+drugs&doi=10.1016%2Fj.nbd.2016.12.021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2016.12.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2016.12.021%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DAltered%2520microtubule%2520dynamics%2520in%2520neurodegenerative%2520disease%253A%2520therapeutic%2520potential%2520of%2520microtubule-stabilizing%2520drugs%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2017%26volume%3D2016%26spage%3D21%26doi%3D10.1016%2Fj.nbd.2016.12.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Phillis, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horrocks, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farooqui, A. A.</span><span> </span><span class="NLM_article-title">Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders</span> <span class="citation_source-journal">Brain Res. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">243</span><span class="refDoi"> DOI: 10.1016/j.brainresrev.2006.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.brainresrev.2006.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=16647138" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFCit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2006&pages=201-243&author=J.+W.+Phillisauthor=L.+A.+Horrocksauthor=A.+A.+Farooqui&title=Cyclooxygenases%2C+lipoxygenases%2C+and+epoxygenases+in+CNS%3A+their+role+and+involvement+in+neurological+disorders&doi=10.1016%2Fj.brainresrev.2006.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders</span></div><div class="casAuthors">Phillis, John W.; Horrocks, Lloyd A.; Farooqui, Akhlaq A.</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research Reviews</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-243</span>CODEN:
                <span class="NLM_cas:coden">BRERD2</span>;
        ISSN:<span class="NLM_cas:issn">0165-0173</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Three enzyme systems, i.e., cyclooxygenases that generate prostaglandins, lipoxygenases that form hydroxy derivs. and leukotrienes, and epoxygenases that give rise to epoxyeicosatrienoic products, metabolize arachidonic acid after its release from neural membrane phospholipids by the action of phospholipase A2.  Lysophospholipids, the other products of phospholipase A2 reactions, are either reacylated or metabolized to platelet-activating factor.  Under normal conditions, these metabolites play important roles in synaptic function, cerebral blood flow regulation, apoptosis, angiogenesis, and gene expression.  Increased activities of cyclooxygenases, lipoxygenases, and epoxygenases under pathol. situations such as ischemia, epilepsy, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, and Creutzfeldt-Jakob disease produce neuroinflammation involving vasodilation and vasoconstriction, platelet aggregation, leukocyte chemotaxis and release of cytokines, and oxidative stress.  These are closely assocd. with the neural cell injury which occurs in these neurol. conditions.  The metabolic products of docosahexaenoic acid, through these enzymes, generate a new class of lipid mediators, namely docosatrienes and resolvins.  These metabolites antagonize the effect of metabolites derived from arachidonic acid.  Recent studies provide insight into how these arachidonic acid metabolites interact with each other and other bioactive mediators such as platelet-activating factor, endocannabinoids, and docosatrienes under normal and pathol. conditions.  A review of present knowledge of the functions of cyclooxygenases, lipoxygenases, and epoxygenases in brain and their assocn. with neurodegenerative diseases is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5_dHeDa_ayLVg90H21EOLACvtfcHk0ljTNnUfM2e5yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFCit7k%253D&md5=aeedeb2b8a4e576d770c4a24e350c7cd</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.brainresrev.2006.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainresrev.2006.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DPhillis%26aufirst%3DJ.%2BW.%26aulast%3DHorrocks%26aufirst%3DL.%2BA.%26aulast%3DFarooqui%26aufirst%3DA.%2BA.%26atitle%3DCyclooxygenases%252C%2520lipoxygenases%252C%2520and%2520epoxygenases%2520in%2520CNS%253A%2520their%2520role%2520and%2520involvement%2520in%2520neurological%2520disorders%26jtitle%3DBrain%2520Res.%2520Rev.%26date%3D2006%26volume%3D52%26spage%3D201%26epage%3D243%26doi%3D10.1016%2Fj.brainresrev.2006.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Kang, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hour, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liou, H. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, W. M.</span><span> </span><span class="NLM_article-title">Protection of dopaminergic neurons by 5-lipoxygenase inhibitor</span> <span class="citation_source-journal">Neuropharmacology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">380</span><span class="NLM_x">–</span> <span class="NLM_lpage">387</span><span class="refDoi"> DOI: 10.1016/j.neuropharm.2013.06.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuropharm.2013.06.014" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=380-387&author=K.+H.+Kangauthor=H.+H.+Liouauthor=M.+J.+Hourauthor=H.+C.+Liouauthor=W.+M.+Fu&title=Protection+of+dopaminergic+neurons+by+5-lipoxygenase+inhibitor&doi=10.1016%2Fj.neuropharm.2013.06.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2013.06.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2013.06.014%26sid%3Dliteratum%253Aachs%26aulast%3DKang%26aufirst%3DK.%2BH.%26aulast%3DLiou%26aufirst%3DH.%2BH.%26aulast%3DHour%26aufirst%3DM.%2BJ.%26aulast%3DLiou%26aufirst%3DH.%2BC.%26aulast%3DFu%26aufirst%3DW.%2BM.%26atitle%3DProtection%2520of%2520dopaminergic%2520neurons%2520by%25205-lipoxygenase%2520inhibitor%26jtitle%3DNeuropharmacology%26date%3D2013%26volume%3D73%26spage%3D380%26epage%3D387%26doi%3D10.1016%2Fj.neuropharm.2013.06.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Chou, V. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holman, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning-Bog, A. B.</span><span> </span><span class="NLM_article-title">Differential contribution of lipoxygenase isozymes to nigrostriatal vulnerability</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">228</span><span class="NLM_x">, </span> <span class="NLM_fpage">73</span><span class="NLM_x">–</span> <span class="NLM_lpage">82</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2012.10.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuroscience.2012.10.009" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=228&publication_year=2013&pages=73-82&author=V.+P.+Chouauthor=T.+R.+Holmanauthor=A.+B.+Manning-Bog&title=Differential+contribution+of+lipoxygenase+isozymes+to+nigrostriatal+vulnerability&doi=10.1016%2Fj.neuroscience.2012.10.009"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2012.10.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2012.10.009%26sid%3Dliteratum%253Aachs%26aulast%3DChou%26aufirst%3DV.%2BP.%26aulast%3DHolman%26aufirst%3DT.%2BR.%26aulast%3DManning-Bog%26aufirst%3DA.%2BB.%26atitle%3DDifferential%2520contribution%2520of%2520lipoxygenase%2520isozymes%2520to%2520nigrostriatal%2520vulnerability%26jtitle%3DNeuroscience%26date%3D2013%26volume%3D228%26spage%3D73%26epage%3D82%26doi%3D10.1016%2Fj.neuroscience.2012.10.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Thakur, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nehru, B.</span><span> </span><span class="NLM_article-title">Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson’s disease</span> <span class="citation_source-journal">Neuroscience</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">231</span><span class="NLM_x">, </span> <span class="NLM_fpage">420</span><span class="NLM_x">–</span> <span class="NLM_lpage">431</span><span class="refDoi"> DOI: 10.1016/j.neuroscience.2012.11.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neuroscience.2012.11.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=231&publication_year=2013&pages=420-431&author=P.+Thakurauthor=B.+Nehru&title=Anti-inflammatory+properties+rather+than+anti-oxidant+capability+is+the+major+mechanism+of+neuroprotection+by+sodium+salicylate+in+a+chronic+rotenone+model+of+Parkinson%E2%80%99s+disease&doi=10.1016%2Fj.neuroscience.2012.11.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.neuroscience.2012.11.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuroscience.2012.11.006%26sid%3Dliteratum%253Aachs%26aulast%3DThakur%26aufirst%3DP.%26aulast%3DNehru%26aufirst%3DB.%26atitle%3DAnti-inflammatory%2520properties%2520rather%2520than%2520anti-oxidant%2520capability%2520is%2520the%2520major%2520mechanism%2520of%2520neuroprotection%2520by%2520sodium%2520salicylate%2520in%2520a%2520chronic%2520rotenone%2520model%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DNeuroscience%26date%3D2013%26volume%3D231%26spage%3D420%26epage%3D431%26doi%3D10.1016%2Fj.neuroscience.2012.11.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Teismann, P.</span><span> </span><span class="NLM_article-title">COX-2 in the neurodegenerative process of Parkinson’s disease</span> <span class="citation_source-journal">Biofactors</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">395</span><span class="NLM_x">–</span> <span class="NLM_lpage">397</span><span class="refDoi"> DOI: 10.1002/biof.1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fbiof.1035" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2012&pages=395-397&author=P.+Teismann&title=COX-2+in+the+neurodegenerative+process+of+Parkinson%E2%80%99s+disease&doi=10.1002%2Fbiof.1035"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fbiof.1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbiof.1035%26sid%3Dliteratum%253Aachs%26aulast%3DTeismann%26aufirst%3DP.%26atitle%3DCOX-2%2520in%2520the%2520neurodegenerative%2520process%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DBiofactors%26date%3D2012%26volume%3D38%26spage%3D395%26epage%3D397%26doi%3D10.1002%2Fbiof.1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Yokota, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terada, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishizu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishihara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakashima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kugo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsuchiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayabara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murayama, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Checler, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuroda, S.</span><span> </span><span class="NLM_article-title">Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia</span> <span class="citation_source-journal">Acta Neuropathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">399</span><span class="NLM_x">–</span> <span class="NLM_lpage">405</span><span class="refDoi"> DOI: 10.1007/s00401-004-0826-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1007%2Fs00401-004-0826-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=14991384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtVWltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2004&pages=399-405&author=O.+Yokotaauthor=S.+Teradaauthor=H.+Ishizuauthor=T.+Ishiharaauthor=H.+Nakashimaauthor=A.+Kugoauthor=K.+Tsuchiyaauthor=K.+Ikedaauthor=T.+Hayabaraauthor=Y.+Saitoauthor=S.+Murayamaauthor=K.+Uedaauthor=F.+Checlerauthor=S.+Kuroda&title=Increased+expression+of+neuronal+cyclooxygenase-2+in+the+hippocampus+in+amyotrophic+lateral+sclerosis+both+with+and+without+dementia&doi=10.1007%2Fs00401-004-0826-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia</span></div><div class="casAuthors">Yokota, Osamu; Terada, Seishi; Ishizu, Hideki; Ishihara, Takeshi; Nakashima, Hanae; Kugo, Aki; Tsuchiya, Kuniaki; Ikeda, Kenji; Hayabara, Toshiyuki; Saito, Yuko; Murayama, Shigeo; Ueda, Kenji; Checler, Frederic; Kuroda, Shigetoshi</div><div class="citationInfo"><span class="NLM_cas:title">Acta Neuropathologica</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">399-405</span>CODEN:
                <span class="NLM_cas:coden">ANPTAL</span>;
        ISSN:<span class="NLM_cas:issn">0001-6322</span>.
    
            (<span class="NLM_cas:orgname">Springer-Verlag</span>)
        </div><div class="casAbstract">The pathophysiol. basis of cognitive dysfunction, including frontotemporal dementia (FTD), in patients with amyotrophic lateral sclerosis (ALS) and ALS with dementia (ALSD) remains unclear.  On the other hand, increased expression of cyclooxygenase-2 (COX-2) in the spinal cord is thought to play a pivotal role in motor neuron degeneration in ALS.  In this study, to assess the relationship between the neuronal COX-2 expression in the cerebrum, the formation of tau- and α-synuclein-neg. but ubiquitin-pos. neuronal inclusions (UPIs), and dementia in motor neuron disease (MND), we examd. neuronal COX-2 immunoreactivity in the frontal cortex and hippocampus of patients with non-demented ALS without UPIs (n=11), ALSD with UPIs (n=6), and normal controls (n=24) using a quant. immunohistochem. technique.  Neuronal COX-2 expression in all CA1-4 in the hippocampus was significantly up-regulated in the ALSD group, and, to lesser degree but significantly, in the ALS group.  Neuronal COX-2 expression in the frontal cortex was also significantly up-regulated in the ALSD group but not in the ALS group.  These findings suggest that (1) the frontal cortex and hippocampus of MND are involved in the same pathogenic process assocd. with COX-2 induction that has been obsd. in spinal anterior horn cells, (2) COX-2 induction in the cerebrum is a pathogenic process that can occur even in the absence of UPI formation in MND, and (3) COX-2 expression in the cerebrum may be assocd. with cognitive dysfunction in MND.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDF9FZbt1OtbVg90H21EOLACvtfcHk0lhjLANQUUiPrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtVWltL8%253D&md5=c2e9aad997b91f538151ec2e3238a3b7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1007%2Fs00401-004-0826-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00401-004-0826-2%26sid%3Dliteratum%253Aachs%26aulast%3DYokota%26aufirst%3DO.%26aulast%3DTerada%26aufirst%3DS.%26aulast%3DIshizu%26aufirst%3DH.%26aulast%3DIshihara%26aufirst%3DT.%26aulast%3DNakashima%26aufirst%3DH.%26aulast%3DKugo%26aufirst%3DA.%26aulast%3DTsuchiya%26aufirst%3DK.%26aulast%3DIkeda%26aufirst%3DK.%26aulast%3DHayabara%26aufirst%3DT.%26aulast%3DSaito%26aufirst%3DY.%26aulast%3DMurayama%26aufirst%3DS.%26aulast%3DUeda%26aufirst%3DK.%26aulast%3DChecler%26aufirst%3DF.%26aulast%3DKuroda%26aufirst%3DS.%26atitle%3DIncreased%2520expression%2520of%2520neuronal%2520cyclooxygenase-2%2520in%2520the%2520hippocampus%2520in%2520amyotrophic%2520lateral%2520sclerosis%2520both%2520with%2520and%2520without%2520dementia%26jtitle%3DActa%2520Neuropathol.%26date%3D2004%26volume%3D107%26spage%3D399%26epage%3D405%26doi%3D10.1007%2Fs00401-004-0826-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Kong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganea, D.</span><span> </span><span class="NLM_article-title">The natural dual cyclooxygenase and 5-lipoxygenase inhibitor flavocoxid is protective in EAE through effects on Th1/Th17 differentiation and macrophage/microglia activation</span> <span class="citation_source-journal">Brain, Behav., Immun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">71</span><span class="refDoi"> DOI: 10.1016/j.bbi.2015.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.bbi.2015.11.002" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2016&pages=59-71&author=W.+Kongauthor=K.+M.+Hooperauthor=D.+Ganea&title=The+natural+dual+cyclooxygenase+and+5-lipoxygenase+inhibitor+flavocoxid+is+protective+in+EAE+through+effects+on+Th1%2FTh17+differentiation+and+macrophage%2Fmicroglia+activation&doi=10.1016%2Fj.bbi.2015.11.002"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bbi.2015.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbi.2015.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DKong%26aufirst%3DW.%26aulast%3DHooper%26aufirst%3DK.%2BM.%26aulast%3DGanea%26aufirst%3DD.%26atitle%3DThe%2520natural%2520dual%2520cyclooxygenase%2520and%25205-lipoxygenase%2520inhibitor%2520flavocoxid%2520is%2520protective%2520in%2520EAE%2520through%2520effects%2520on%2520Th1%252FTh17%2520differentiation%2520and%2520macrophage%252Fmicroglia%2520activation%26jtitle%3DBrain%252C%2520Behav.%252C%2520Immun.%26date%3D2016%26volume%3D53%26spage%3D59%26epage%3D71%26doi%3D10.1016%2Fj.bbi.2015.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Morphy, R.; Rankovic, Z.; Abraham, D. J.</span><span> </span><span class="NLM_article-title">Medicinal chemistry approaches for multitarget drugs</span>. In  <span class="citation_source-book">Burger’s Medicinal Chemistry and Drug Discovery</span>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>,<span class="NLM_x"> </span><span class="NLM_year">2003</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">249</span><span class="NLM_x">–</span> <span class="NLM_lpage">274</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&pages=249-274&author=R.+Morphy&author=Z.+Rankovic&author=D.+J.+Abraham&title=Burger%E2%80%99s+Medicinal+Chemistry+and+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26atitle%3DMedicinal%2520chemistry%2520approaches%2520for%2520multitarget%2520drugs%26btitle%3DBurger%25E2%2580%2599s%2520Medicinal%2520Chemistry%2520and%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2003%26spage%3D249%26epage%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Smith, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koboldt, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muhammad, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zweifel, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talley, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Masferrer, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibert, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakson, P. C.</span><span> </span><span class="NLM_article-title">Pharmacological analysis of cyclooxygenase-1 in inflammation</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">13313</span><span class="NLM_x">–</span> <span class="NLM_lpage">13318</span><span class="refDoi"> DOI: 10.1073/pnas.95.22.13313</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1073%2Fpnas.95.22.13313" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=9789085" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADyaK1cXntFWrsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=13313-13318&author=C.+J.+Smithauthor=Y.+Zhangauthor=C.+M.+Koboldtauthor=J.+Muhammadauthor=B.+S.+Zweifelauthor=A.+Shafferauthor=J.+J.+Talleyauthor=J.+L.+Masferrerauthor=K.+Seibertauthor=P.+C.+Isakson&title=Pharmacological+analysis+of+cyclooxygenase-1+in+inflammation&doi=10.1073%2Fpnas.95.22.13313"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological analysis of cyclooxygenase-1 in inflammation</span></div><div class="casAuthors">Smith, Christopher J.; Zhang, Yan; Koboldt, Carol M.; Muhammad, Jerry; Zweifel, Ben S.; Shaffer, Alex; Talley, John J.; Masferrer, Jaime L.; Seibert, Karen; Isakson, Peter C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">13313-13318</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The enzymes cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) catalyze the conversion of arachidonic acid to prostaglandin (PG) H2, the precursor of PGs and thromboxane.  These lipid mediators play important roles in inflammation and pain and in normal physiol. functions.  While there are abundant data indicating that the inducible isoform, COX-2, is important in inflammation and pain, the constitutively expressed isoform, COX-1, has also been suggested to play a role in inflammatory processes.  To address the latter question pharmacol., we used a highly selective COX-1 inhibitor, SC-560 (COX-1 IC50 = 0.009 μM; COX-2 IC50 = 6.3 μM).  SC-560 inhibited COX-1-derived platelet thromboxane B2, gastric PGE2, and dermal PGE2 prodn., indicating that it was orally active, but did not inhibit COX-2-derived PGs in the lipopolysaccharide-induced rat air pouch.  Therapeutic or prophylactic administration of SC-560 in the rat carrageenan footpad model did not affect acute inflammation or hyperalgesia at doses that markedly inhibited in vivo COX-1 activity.  By contrast, celecoxib, a selective COX-2 inhibitor, was anti-inflammatory and analgesic in this model.  Paradoxically, both SC-560 and celecoxib reduced paw PGs to equiv. levels.  Increased levels of PGs were found in the cerebrospinal fluid after carrageenan injection and were markedly reduced by celecoxib, but were not affected by SC-560.  These results suggest that, in addn. to the role of peripherally produced PGs, there is a crit., centrally mediated neurol. component to inflammatory pain that is mediated at least in part by COX-2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo05VnKZU2CJrVg90H21EOLACvtfcHk0lhjLANQUUiPrg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXntFWrsLY%253D&md5=5b1af3003f9e099205bccf7e274401d9</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.22.13313&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.22.13313%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DKoboldt%26aufirst%3DC.%2BM.%26aulast%3DMuhammad%26aufirst%3DJ.%26aulast%3DZweifel%26aufirst%3DB.%2BS.%26aulast%3DShaffer%26aufirst%3DA.%26aulast%3DTalley%26aufirst%3DJ.%2BJ.%26aulast%3DMasferrer%26aufirst%3DJ.%2BL.%26aulast%3DSeibert%26aufirst%3DK.%26aulast%3DIsakson%26aufirst%3DP.%2BC.%26atitle%3DPharmacological%2520analysis%2520of%2520cyclooxygenase-1%2520in%2520inflammation%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D13313%26epage%3D13318%26doi%3D10.1073%2Fpnas.95.22.13313" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dannhardt, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, W.</span><span> </span><span class="NLM_article-title">6,7-Diaryldihydropyrrolizin-5-yl)acetic acids, a novel class of potent dual inhibitors of both cyclooxygenase and 5-lipoxygenase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1994</span><span class="NLM_x">, </span> <span class="NLM_volume">37</span><span class="NLM_x">, </span> <span class="NLM_fpage">1894</span><span class="NLM_x">–</span> <span class="NLM_lpage">1897</span><span class="refDoi"> DOI: 10.1021/jm00038a021</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00038a021" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1894-1897&author=S.+A.+Lauferauthor=J.+Augustinauthor=G.+Dannhardtauthor=W.+Kiefer&title=6%2C7-Diaryldihydropyrrolizin-5-yl%29acetic+acids%2C+a+novel+class+of+potent+dual+inhibitors+of+both+cyclooxygenase+and+5-lipoxygenase&doi=10.1021%2Fjm00038a021"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm00038a021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00038a021%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DAugustin%26aufirst%3DJ.%26aulast%3DDannhardt%26aufirst%3DG.%26aulast%3DKiefer%26aufirst%3DW.%26atitle%3D6%252C7-Diaryldihydropyrrolizin-5-yl%2529acetic%2520acids%252C%2520a%2520novel%2520class%2520of%2520potent%2520dual%2520inhibitors%2520of%2520both%2520cyclooxygenase%2520and%25205-lipoxygenase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1894%26epage%3D1897%26doi%3D10.1021%2Fjm00038a021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Lamberth, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumeunier, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trah, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendeborn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godwin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneiter, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corran, A.</span><span> </span><span class="NLM_article-title">Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 3: imidazoles</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.bmc.2012.10.052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23218777" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslyntbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=127-134&author=C.+Lamberthauthor=R.+Dumeunierauthor=S.+Trahauthor=S.+Wendebornauthor=J.+Godwinauthor=P.+Schneiterauthor=A.+Corran&title=Synthesis+and+fungicidal+activity+of+tubulin+polymerisation+promoters.+Part+3%3A+imidazoles&doi=10.1016%2Fj.bmc.2012.10.052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and fungicidal activity of tubulin polymerisation promoters. Part 3: Imidazoles</span></div><div class="casAuthors">Lamberth, Clemens; Dumeunier, Raphael; Trah, Stephan; Wendeborn, Sebastian; Godwin, Jeremy; Schneiter, Peter; Corran, Andy</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-134</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel class of exptl. fungicides has been discovered, which consists of special tetrasubstituted imidazoles.  They are highly active against important phytopathogens, such as Botrytis cinerea (gray mold), Uncinula necator (grape powdery mildew), Mycosphaerella graminicola (wheat leaf blotch) and Alternaria solani (potato and tomato early blight).  Their fungicidal efficacy is due to their ability to promote fungal tubulin polymn., which leads to a disruption of microtubule dynamics.  These imidazoles are five-membered ring analogs of similar substituted triazolopyrimidines and pyridazines with the same mode of action.  A concise four-step synthesis route, using Vilsmeier reagent, has been used to prep. them from com. available starting materials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojYoEF0X_pGLVg90H21EOLACvtfcHk0lgdFwYGEHkHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslyntbzK&md5=b945bfaff745f5d5c39187266889e8c8</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DLamberth%26aufirst%3DC.%26aulast%3DDumeunier%26aufirst%3DR.%26aulast%3DTrah%26aufirst%3DS.%26aulast%3DWendeborn%26aufirst%3DS.%26aulast%3DGodwin%26aufirst%3DJ.%26aulast%3DSchneiter%26aufirst%3DP.%26aulast%3DCorran%26aufirst%3DA.%26atitle%3DSynthesis%2520and%2520fungicidal%2520activity%2520of%2520tubulin%2520polymerisation%2520promoters.%2520Part%25203%253A%2520imidazoles%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D127%26epage%3D134%26doi%3D10.1016%2Fj.bmc.2012.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Van Leusen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wildeman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldenziel, O. H.</span><span> </span><span class="NLM_article-title">Chemistry of sulfonylmethyl isocyanides. 12. Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds. Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1977</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">1153</span><span class="NLM_x">–</span> <span class="NLM_lpage">1159</span><span class="refDoi"> DOI: 10.1021/jo00427a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00427a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADyaE2sXhvV2ku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1977&pages=1153-1159&author=A.+M.+Van+Leusenauthor=J.+Wildemanauthor=O.+H.+Oldenziel&title=Chemistry+of+sulfonylmethyl+isocyanides.+12.+Base-induced+cycloaddition+of+sulfonylmethyl+isocyanides+to+carbon%2Cnitrogen+double+bonds.+Synthesis+of+1%2C5-disubstituted+and+1%2C4%2C5-trisubstituted+imidazoles+from+aldimines+and+imidoyl+chlorides&doi=10.1021%2Fjo00427a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Chemistry of sulfonylmethyl isocyanides.  12.  Base-induced cycloaddition of sulfonylmethyl isocyanides to carbon,nitrogen double bonds.  Synthesis of 1,5-disubstituted and 1,4,5-trisubstituted imidazoles from aldimines and imidoyl chlorides</span></div><div class="casAuthors">Van Leusen, Albert M.; Wildeman, Jurjen; Oldenziel, Otto H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1153-9</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Base-induced cycloaddn. of tosylmethyl isocyanide (I) to aldimines R1CH:NR2 [R1 = Me, CMe3, CHMe2, C6H4R3-4 (R3 = H, Me, Cl, NO2); R2 = Me, Et, CHMe2, cyclohexyl, C6H4R4-4(R4 = H, Cl, NO2)] in protic medium occurs with concomitant elimination of p-toluenesulfinic acid to give the otherwise more difficultly accessible 1,5-disubstituted imidazoles II.  The influence of R1 and R2 on the formation of II was analyzed qual. α-Tosylbenzyl isocyanide and α-tosylethyl isocyanide, likewise, gave 1,4,5-trisubstituted imidazoles III (R1 = Me, Ph; R2 = Me, CMe3, Ph, C6H4NO2-4; R3 = Me, Ph (5 compds.).  The cycloaddn. of I to imidoyl chlorides was accompanied by loss of HCl, instead of 4-MeC6H4SO3H, and gave 1,4,5-trisubstituted imidazoles III (R1 = Ph, R2 = Ph, cyclohexyl, C6H4NO2-4, R1 = C6H4NO2-4, R2 = Ph, cyclohexyl, R3 = tosyl).  Under aprotic conditions trans-1,5-diaryl-4-tosyl-2-imidazolines IV (R1 = Ph, R2 = C6H4NO2-4, Ph; R1 = C6H4Me-4, R2 = Ph) were isolated and identified as the primary cycloadducts of I and aldimines, leading ultimately to the imidazoles II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrO_gFMQFymTLVg90H21EOLACvtfcHk0lgdFwYGEHkHgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXhvV2ku7s%253D&md5=429e9513419831f7e45baff226acf4ce</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjo00427a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00427a012%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BLeusen%26aufirst%3DA.%2BM.%26aulast%3DWildeman%26aufirst%3DJ.%26aulast%3DOldenziel%26aufirst%3DO.%2BH.%26atitle%3DChemistry%2520of%2520sulfonylmethyl%2520isocyanides.%252012.%2520Base-induced%2520cycloaddition%2520of%2520sulfonylmethyl%2520isocyanides%2520to%2520carbon%252Cnitrogen%2520double%2520bonds.%2520Synthesis%2520of%25201%252C5-disubstituted%2520and%25201%252C4%252C5-trisubstituted%2520imidazoles%2520from%2520aldimines%2520and%2520imidoyl%2520chlorides%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1977%26volume%3D42%26spage%3D1153%26epage%3D1159%26doi%3D10.1021%2Fjo00427a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Lou, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoye, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hyde, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span> </span><span class="NLM_article-title">Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer’s disease and related tauopathies</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6116</span><span class="NLM_x">–</span> <span class="NLM_lpage">6127</span><span class="refDoi"> DOI: 10.1021/jm5005623</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5005623" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtrnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6116-6127&author=K.+Louauthor=Y.+Yaoauthor=A.+T.+Hoyeauthor=M.+J.+Jamesauthor=A.+S.+Cornecauthor=E.+Hydeauthor=B.+Gayauthor=V.+M.+Leeauthor=J.+Q.+Trojanowskiauthor=A.+B.+Smithauthor=K.+R.+Brundenauthor=C.+Ballatore&title=Brain-penetrant%2C+orally+bioavailable+microtubule-stabilizing+small+molecules+are+potential+candidate+therapeutics+for+Alzheimer%E2%80%99s+disease+and+related+tauopathies&doi=10.1021%2Fjm5005623"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-Penetrant, Orally Bioavailable Microtubule-Stabilizing Small Molecules Are Potential Candidate Therapeutics for Alzheimer's Disease and Related Tauopathies</span></div><div class="casAuthors">Lou, Kevin; Yao, Yuemang; Hoye, Adam T.; James, Michael J.; Cornec, Anne-Sophie; Hyde, Edward; Gay, Bryant; Lee, Virginia M.-Y.; Trojanowski, John Q.; Smith, Amos B., III; Brunden, Kurt R.; Ballatore, Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6116-6127</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Microtubule (MT) stabilizing drugs hold promise as potential treatments for Alzheimer's disease (AD) and related tauopathies.  However, thus far epothilone D has been the only brain-penetrant MT-stabilizer to be evaluated in tau transgenic mice and in AD patients.  Furthermore, this natural product exhibits potential deficiencies as a drug candidate, including an i.v. route of administration and the inhibition of the P-glycoprotein (Pgp) transporter.  Thus, the identification of alternative CNS-active MT-stabilizing agents that lack these potential limitations is of interest.  Toward this objective, the authors have evaluated representative compds. from known classes of non-naturally occurring MT-stabilizing small mols.  This led to the identification of selected triazolopyrimidines and phenylpyrimidines that are orally bioavailable and brain-penetrant without disruption of Pgp function.  Pharmacodynamic studies confirmed that representative compds. from these series enhance MT-stabilization in the brains of wild-type mice.  Thus, these classes of MT-stabilizers hold promise for the development of orally active, CNS-directed MT-stabilizing therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYBaimrh_xYLVg90H21EOLACvtfcHk0ljbE-zUHsqhyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFWjtrnI&md5=17f0c92ee4515762f3f3b88fb37e38f2</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm5005623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5005623%26sid%3Dliteratum%253Aachs%26aulast%3DLou%26aufirst%3DK.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DHoye%26aufirst%3DA.%2BT.%26aulast%3DJames%26aufirst%3DM.%2BJ.%26aulast%3DCornec%26aufirst%3DA.%2BS.%26aulast%3DHyde%26aufirst%3DE.%26aulast%3DGay%26aufirst%3DB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DBrain-penetrant%252C%2520orally%2520bioavailable%2520microtubule-stabilizing%2520small%2520molecules%2520are%2520potential%2520candidate%2520therapeutics%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520tauopathies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6116%26epage%3D6127%26doi%3D10.1021%2Fjm5005623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Fukushima, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Furuta, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hidaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moriyama, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujiuchi, T.</span><span> </span><span class="NLM_article-title">Post-translational modifications of tubulin in the nervous system</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">109</span><span class="NLM_x">, </span> <span class="NLM_fpage">683</span><span class="NLM_x">–</span> <span class="NLM_lpage">693</span><span class="refDoi"> DOI: 10.1111/j.1471-4159.2009.06013.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fj.1471-4159.2009.06013.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=19250341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1MXlsFykt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2009&pages=683-693&author=N.+Fukushimaauthor=D.+Furutaauthor=Y.+Hidakaauthor=R.+Moriyamaauthor=T.+Tsujiuchi&title=Post-translational+modifications+of+tubulin+in+the+nervous+system&doi=10.1111%2Fj.1471-4159.2009.06013.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Post-translational modifications of tubulin in the nervous system</span></div><div class="casAuthors">Fukushima, Nobuyuki; Furuta, Daisuke; Hidaka, Yuji; Moriyama, Ryutaro; Tsujiuchi, Toshifumi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">683-693</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Many studies have shown that microtubules (MTs) interact with MT-assocd. proteins (MAPs) and motor proteins.  These interactions are essential for the formation and maintenance of the polarized morphol. of neurons and have been proposed to be regulated in part by highly diverse, unusual post-translational modifications (PTMs) of tubulin, including acetylation, tyrosination, detyrosination, Δ2 modification, polyglutamylation, polyglycylation, palmitoylation, and phosphorylation.  However, the precise mechanisms of PTM generation and the properties of modified MTs have been poorly understood until recently.  Recent PTM research has uncovered the enzymes mediating tubulin PTMs and provided new insights into the regulation of MT-based functions.  The identification of tubulin deacetylase and discovery of its specific inhibitors have paved the way to understand the roles of acetylated MTs in kinesin-mediated axonal transport and neurodegenerative diseases such as Huntington's disease.  Studies with tubulin tyrosine ligase (TTL)-null mice have shown that tyrosinated MTs are essential in normal brain development.  The discovery of TTL-like genes encoding polyglutamylase has led to the finding that polyglutamylated MTs which accumulate during brain development are involved in synapse vesicle transport or neurite outgrowth through interactions with motor proteins or MAPs, resp.  Here, the authors review current exciting topics that are expected to advance MT research in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqi_rjIFYcHo7Vg90H21EOLACvtfcHk0ljbE-zUHsqhyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXlsFykt70%253D&md5=4e6bf1ac11e7228edfb585f6ab0c0441</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2009.06013.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2009.06013.x%26sid%3Dliteratum%253Aachs%26aulast%3DFukushima%26aufirst%3DN.%26aulast%3DFuruta%26aufirst%3DD.%26aulast%3DHidaka%26aufirst%3DY.%26aulast%3DMoriyama%26aufirst%3DR.%26aulast%3DTsujiuchi%26aufirst%3DT.%26atitle%3DPost-translational%2520modifications%2520of%2520tubulin%2520in%2520the%2520nervous%2520system%26jtitle%3DJ.%2520Neurochem.%26date%3D2009%26volume%3D109%26spage%3D683%26epage%3D693%26doi%3D10.1111%2Fj.1471-4159.2009.06013.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kovalevich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornec, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crowe, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunden, K. R.</span><span> </span><span class="NLM_article-title">Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer’s disease and related tauopathies</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">357</span><span class="NLM_x">, </span> <span class="NLM_fpage">432</span><span class="NLM_x">–</span> <span class="NLM_lpage">450</span><span class="refDoi"> DOI: 10.1124/jpet.115.231175</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1124%2Fjpet.115.231175" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=26980057" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=357&publication_year=2016&pages=432-450&author=J.+Kovalevichauthor=A.+S.+Cornecauthor=Y.+Yaoauthor=M.+Jamesauthor=A.+Croweauthor=V.+M.+Leeauthor=J.+Q.+Trojanowskiauthor=A.+B.+Smithauthor=C.+Ballatoreauthor=K.+R.+Brunden&title=Characterization+of+brain-penetrant+pyrimidine-containing+molecules+with+differential+microtubule-stabilizing+activities+developed+as+potential+therapeutic+agents+for+Alzheimer%E2%80%99s+disease+and+related+tauopathies&doi=10.1124%2Fjpet.115.231175"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer's disease and related tauopathies</span></div><div class="casAuthors">Kovalevich, Jane; Cornec, Anne-Sophie; Yao, Yuemang; James, Michael; Crowe, Alexander; Lee, Virginia M.-Y.; Trojanowski, John Q.; Smith, Amos B., III; Ballatore, Carlo; Brunden, Kurt R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">357</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">432-450</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The microtubule (MT)-stabilizing protein tau disengages from MTs and forms intracellular inclusions known as neurofibrillary tangles in Alzheimer's disease and related tauopathies.  Reduced tau binding to MTs in tauopathies may contribute to neuronal dysfunction through decreased MT stabilization and disrupted axonal transport.  Thus, the introduction of brain-penetrant MT-stabilizing compds. might normalize MT dynamics and axonal deficits in these disorders.  We previously described a no. of phenylpyrimidines and triazolopyrimidines (TPDs) that induce tubulin post-translational modifications indicative of MT stabilization.  We now further characterize the biol. properties of these small mols., and our results reveal that these compds. can be divided into two general classes based on the cellular response they evoke.  One group composed of the phenylpyrimidines and several TPD examples showed a bell-shaped concn.-response effect on markers of MT stabilization in cellular assays.  Moreover, these compds. induced proteasome-dependent degrdn. of α- and β-tubulin and caused altered MT morphol. in both dividing cells and neuron cultures.  In contrast, a second group comprising a subset of TPD mols. (TPD+) increased markers of stable MTs in a concn.-dependent manner in dividing cells and in neurons without affecting total tubulin levels or disrupting MT architecture.  Moreover, an example TPD+ compd. was shown to increase MTs in a neuron culture model with induced tau hyperphosphorylation and assocd. MT deficits.  Several TPD+ compds. were shown to be both brain penetrant and orally bioavailable, and a TPD+ example increased MT stabilization in the mouse brain, making these compds. potential candidate therapeutics for neurodegenerative tauopathies such as Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCEADXoI6tlbVg90H21EOLACvtfcHk0ljbE-zUHsqhyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zK&md5=14cc76d21739ed6b63ba6f2754287b51</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.231175&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.231175%26sid%3Dliteratum%253Aachs%26aulast%3DKovalevich%26aufirst%3DJ.%26aulast%3DCornec%26aufirst%3DA.%2BS.%26aulast%3DYao%26aufirst%3DY.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DCrowe%26aufirst%3DA.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DBallatore%26aufirst%3DC.%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26atitle%3DCharacterization%2520of%2520brain-penetrant%2520pyrimidine-containing%2520molecules%2520with%2520differential%2520microtubule-stabilizing%2520activities%2520developed%2520as%2520potential%2520therapeutic%2520agents%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520and%2520related%2520tauopathies%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D357%26spage%3D432%26epage%3D450%26doi%3D10.1124%2Fjpet.115.231175" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Tries, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neupert, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2</span> <span class="citation_source-journal">Inflammation Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">135</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1007/PL00000285</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1007%2FPL00000285" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=12005204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD38XivFGqtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2002&pages=135-143&author=S.+Triesauthor=W.+Neupertauthor=S.+Laufer&title=The+mechanism+of+action+of+the+new+antiinflammatory+compound+ML3000%3A+inhibition+of+5-LOX+and+COX-1%2F2&doi=10.1007%2FPL00000285"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanism of action of the new anti-inflammatory compound ML3000: inhibition of 5-LOX and COX-1/2</span></div><div class="casAuthors">Tries, S.; Neupert, W.; Laufer, S.</div><div class="citationInfo"><span class="NLM_cas:title">Inflammation Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">135-143</span>CODEN:
                <span class="NLM_cas:coden">INREFB</span>;
        ISSN:<span class="NLM_cas:issn">1023-3830</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">This work examd. the effects of ML3000 and other nonsteroidal anti-inflammatory drugs (NSAIDs) (indomethacin, diclofenac) on the synthesis of 5-lipoxygenase (5-LOX) products (LTB4, LTC4) and cyclooxygenase (COX)-1 and -2 products (TXB2, PGE2) in vitro and ex vivo in order to further elucidate the mechanism of action of ML3000.  The effect of ML3000 on the shunt of arachidonic acid to the LOX pathway when COX is blocked was studied in a human whole-blood assay.  ML3000 (0.3, 1, 3, 10, 30 μg/mL) and indomethacin (0.3, 1, 3, 10, 30 μg/mL) concn.-dependently inhibited the synthesis of PGE2 (IC50 = 3.9 and 4.5 μM, resp.).  In contrast to ML3000, indomethacin increased LTC4 by ≤155.5% of control values.  5-LOX inhibition was further tested in a basophilic leukemia cell assay using RBL-1 cells.  ML3000 (1-10 μM) inhibited the synthesis of LTB4 in a concn.-related manner (IC50: 3.6 μM).  In carrageenan- induced rat paw edema, ML3000 and indomethacin completely blocked the formation of PGE2 in the inflamed tissue.  LTB4 prodn. in the inflamed paw was reduced to basal levels by ML3000, whereas LTB4 concns. remained markedly elevated after indomethacin.  5-LOX inhibition in the inflamed rat colon was investigated by measuring LTB4 synthesis.  MK-886 and ML3000 at 10 mg/kg orally reduced LTB4 prodn. as compared to that in controls.  LTB4 levels in the rat stomach were comparable to control values after oral administration of ML3000 (10, 30, 100 mg/kg), whereas oral treatment with indomethacin (0.3, 1, 3 mg/kg) or diclofenac (1, 3 mg/kg) increased LTB4.  These results provide further evidence, that ML3000 inhibits 5-LOX as well as COX-1 and COX-2 in vitro and in animal expts.  The favorable gastrointestinal tolerability of the compd. is believed to be linked to the mechanism of combined 5-LOX and COX-1/2 inhibition by ML3000.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2o9PX_wP1LrVg90H21EOLACvtfcHk0lg9xjFOd3jCiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XivFGqtLg%253D&md5=a015f1529175b3e3107bee0f103b6913</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1007%2FPL00000285&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FPL00000285%26sid%3Dliteratum%253Aachs%26aulast%3DTries%26aufirst%3DS.%26aulast%3DNeupert%26aufirst%3DW.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DThe%2520mechanism%2520of%2520action%2520of%2520the%2520new%2520antiinflammatory%2520compound%2520ML3000%253A%2520inhibition%2520of%25205-LOX%2520and%2520COX-1%252F2%26jtitle%3DInflammation%2520Res.%26date%3D2002%26volume%3D51%26spage%3D135%26epage%3D143%26doi%3D10.1007%2FPL00000285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Meirer, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinhilber, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proschak, E.</span><span> </span><span class="NLM_article-title">Inhibitors of the arachidonic acid cascade: interfering with multiple pathways</span> <span class="citation_source-journal">Basic Clin. Pharmacol. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">91</span><span class="refDoi"> DOI: 10.1111/bcpt.12134</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fbcpt.12134" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24015667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2014&pages=83-91&author=K.+Meirerauthor=D.+Steinhilberauthor=E.+Proschak&title=Inhibitors+of+the+arachidonic+acid+cascade%3A+interfering+with+multiple+pathways&doi=10.1111%2Fbcpt.12134"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the Arachidonic Acid Cascade: Interfering with Multiple Pathways</span></div><div class="casAuthors">Meirer, Karin; Steinhilber, Dieter; Proschak, Ewgenij</div><div class="citationInfo"><span class="NLM_cas:title">Basic & Clinical Pharmacology & Toxicology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-91</span>CODEN:
                <span class="NLM_cas:coden">BCPTBO</span>;
        ISSN:<span class="NLM_cas:issn">1742-7835</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  Modulators of the arachidonic acid cascade have been in the focus of research for treatments of inflammation and pain for several decades.  Targeting this complex pathway experiences a paradigm change towards the design and development of multi-target inhibitors, exhibiting improved efficacy and less undesired side effects.  This minireview summarizes recent developments in the field of designed multi-target ligands of the arachidonic acid cascade.  In addn. to the well-known dual inhibitors of 5-lipoxygenase and cyclooxygenase-2 such as licofelone, very recent developments are discussed.  Esp., multi-target inhibitors interfering with the cytochrome P 450 pathway via inhibition of sol. epoxide hydrolase seem to offer a novel opportunity for development of novel anti-inflammatory drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqxIto5Wb10iLVg90H21EOLACvtfcHk0lg9xjFOd3jCiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFGktL%252FF&md5=1b7c01f7e30d699dc57b25c215e4da9e</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fbcpt.12134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcpt.12134%26sid%3Dliteratum%253Aachs%26aulast%3DMeirer%26aufirst%3DK.%26aulast%3DSteinhilber%26aufirst%3DD.%26aulast%3DProschak%26aufirst%3DE.%26atitle%3DInhibitors%2520of%2520the%2520arachidonic%2520acid%2520cascade%253A%2520interfering%2520with%2520multiple%2520pathways%26jtitle%3DBasic%2520Clin.%2520Pharmacol.%2520Toxicol.%26date%3D2014%26volume%3D114%26spage%3D83%26epage%3D91%26doi%3D10.1111%2Fbcpt.12134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Gillard, J. W.; Morton, H. E.; Fortin, R.; Guindon, Y.</span><span> </span><span class="NLM_article-title">Preparation and formulation of 3-hetero-substituted-<i>N</i>-benzyl-indoles as inhibitors of leukotriene biosynthesis</span>. EP275667A1,<span class="NLM_x"> </span><span class="NLM_year">1988</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1988&author=J.+W.+Gillard&author=H.+E.+Morton&author=R.+Fortin&author=Y.+Guindon&title=Preparation+and+formulation+of+3-hetero-substituted-N-benzyl-indoles+as+inhibitors+of+leukotriene+biosynthesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGillard%26aufirst%3DJ.%2BW.%26atitle%3DPreparation%2520and%2520formulation%2520of%25203-hetero-substituted-N-benzyl-indoles%2520as%2520inhibitors%2520of%2520leukotriene%2520biosynthesis%26date%3D1988" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Schneider, L. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mangialasche, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andreasen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giacobini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mantua, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mecocci, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pani, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winblad, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kivipelto, M.</span><span> </span><span class="NLM_article-title">Clinical trials and late-stage drug development for Alzheimer’s disease: an appraisal from 1984 to 2014</span> <span class="citation_source-journal">J. Intern. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">275</span><span class="NLM_x">, </span> <span class="NLM_fpage">251</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span><span class="refDoi"> DOI: 10.1111/joim.12191</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fjoim.12191" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=24605808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BC2crhsFaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=275&publication_year=2014&pages=251-283&author=L.+S.+Schneiderauthor=F.+Mangialascheauthor=N.+Andreasenauthor=H.+Feldmanauthor=E.+Giacobiniauthor=R.+Jonesauthor=V.+Mantuaauthor=P.+Mecocciauthor=L.+Paniauthor=B.+Winbladauthor=M.+Kivipelto&title=Clinical+trials+and+late-stage+drug+development+for+Alzheimer%E2%80%99s+disease%3A+an+appraisal+from+1984+to+2014&doi=10.1111%2Fjoim.12191"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014</span></div><div class="casAuthors">Schneider L S; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M</div><div class="citationInfo"><span class="NLM_cas:title">Journal of internal medicine</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">275</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">251-83</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The modern era of drug development for Alzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research criteria for Alzheimer's disease.  Since then, despite the evaluation of numerous potential treatments in clinical trials, only four cholinesterase inhibitors and memantine have shown sufficient safety and efficacy to allow marketing approval at an international level.  Although this is probably because the other drugs tested were ineffective, inadequate clinical development methods have also been blamed for the failures.  Here, we review the development of treatments for Alzheimer's disease during the past 30 years, considering the drugs, potential targets, late-stage clinical trials, development methods, emerging use of biomarkers and evolution of regulatory considerations in order to summarize advances and anticipate future developments.  We have considered late-stage Alzheimer's disease drug development from 1984 to 2013, including individual clinical trials, systematic and qualitative reviews, meta-analyses, methods, commentaries, position papers and guidelines.  We then review the evolution of drugs in late clinical development, methods, biomarkers and regulatory issues.  Although a range of small molecules and biological products against many targets have been investigated in clinical trials, the predominant drug targets have been the cholinergic system and the amyloid cascade.  Trial methods have evolved incrementally: inclusion criteria have largely remained focused on mild-to-moderate Alzheimer's disease criteria, recently extending to early or prodromal Alzheimer disease or 'mild cognitive impairment due to Alzheimer's disease', for drugs considered to be disease modifying.  The duration of trials has remained at 6-12 months for drugs intended to improve symptoms; 18- to 24-month trials have been established for drugs expected to attenuate clinical course.  Cognitive performance, activities of daily living, global change and severity ratings have persisted as the primary clinically relevant outcomes.  Regulatory guidance and oversight have evolved to allow for enrichment of early-stage Alzheimer's disease trial samples using biomarkers and phase-specific outcomes.  In conclusion, validated drug targets for Alzheimer's disease remain to be developed.  Only drugs that affect an aspect of cholinergic function have shown consistent, but modest, clinical effects in late-phase trials.  There is opportunity for substantial improvements in drug discovery and clinical development methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSiLqeiU50WDCA3UY9EwTNrfW6udTcc2eay_3VxmsjAE7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2crhsFaqug%253D%253D&md5=7e34762560c7cb2ce25084827c348cdc</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1111%2Fjoim.12191&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjoim.12191%26sid%3Dliteratum%253Aachs%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DMangialasche%26aufirst%3DF.%26aulast%3DAndreasen%26aufirst%3DN.%26aulast%3DFeldman%26aufirst%3DH.%26aulast%3DGiacobini%26aufirst%3DE.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DMantua%26aufirst%3DV.%26aulast%3DMecocci%26aufirst%3DP.%26aulast%3DPani%26aufirst%3DL.%26aulast%3DWinblad%26aufirst%3DB.%26aulast%3DKivipelto%26aufirst%3DM.%26atitle%3DClinical%2520trials%2520and%2520late-stage%2520drug%2520development%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520appraisal%2520from%25201984%2520to%25202014%26jtitle%3DJ.%2520Intern.%2520Med.%26date%3D2014%26volume%3D275%26spage%3D251%26epage%3D283%26doi%3D10.1111%2Fjoim.12191" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Choi, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aid, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caracciolo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minami, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niikura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuoka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turner, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosetti, F.</span><span> </span><span class="NLM_article-title">Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">124</span><span class="NLM_x">, </span> <span class="NLM_fpage">59</span><span class="NLM_x">–</span> <span class="NLM_lpage">68</span><span class="refDoi"> DOI: 10.1111/jnc.12059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1111%2Fjnc.12059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=23083210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslyns7fI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=124&publication_year=2013&pages=59-68&author=S.+H.+Choiauthor=S.+Aidauthor=L.+Caraccioloauthor=S.+S.+Minamiauthor=T.+Niikuraauthor=Y.+Matsuokaauthor=R.+S.+Turnerauthor=M.+P.+Mattsonauthor=F.+Bosetti&title=Cyclooxygenase-1+inhibition+reduces+amyloid+pathology+and+improves+memory+deficits+in+a+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1111%2Fjnc.12059"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease</span></div><div class="casAuthors">Choi, Sang-Ho; Aid, Saba; Caracciolo, Luca; Sakura Minami, S.; Niikura, Takako; Matsuoka, Yasuji; Turner, R. Scott; Mattson, Mark P.; Bosetti, Francesca</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">124</span>
        (<span class="NLM_cas:issue">1&2</span>),
    <span class="NLM_cas:pages">59-68</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Several epidemiol. and preclin. studies suggest that non-steroidal anti-inflammatory drugs (NSAIDs), which inhibit cyclooxygenase (COX), reduce the risk of Alzheimer's disease (AD) and can lower β-amyloid (Aβ) prodn. and inhibit neuroinflammation.  However, follow-up clin. trials, mostly using selective cyclooxygenase (COX)-2 inhibitors, failed to show any beneficial effect in AD patients with mild to severe cognitive deficits.  Recent data indicated that COX-1, classically viewed as the homeostatic isoform, is localized in microglia and is actively involved in brain injury induced by pro-inflammatory stimuli including Aβ, lipopolysaccharide, and interleukins.  We hypothesized that neuroinflammation is crit. for disease progression and selective COX-1 inhibition, rather than COX-2 inhibition, can reduce neuroinflammation and AD pathol.  Here, we show that treatment of 20-mo-old triple transgenic AD (3 × Tg-AD) mice with the COX-1 selective inhibitor SC-560 improved spatial learning and memory, and reduced amyloid deposits and tau hyperphosphorylation.  SC-560 also reduced glial activation and brain expression of inflammatory markers in 3 × Tg-AD mice, and switched the activated microglia phenotype promoting their phagocytic ability.  The present findings are the first to demonstrate that selective COX-1 inhibition reduces neuroinflammation, neuropathol., and improves cognitive function in 3 × Tg-AD mice.  Thus, selective COX-1 inhibition should be further investigated as a potential therapeutic approach for AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-Fk5r6Fvr8bVg90H21EOLACvtfcHk0lhrIVN2wZ0JUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslyns7fI&md5=9fb95148a77a7b1787f4c56ef92f456f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1111%2Fjnc.12059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjnc.12059%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DS.%2BH.%26aulast%3DAid%26aufirst%3DS.%26aulast%3DCaracciolo%26aufirst%3DL.%26aulast%3DMinami%26aufirst%3DS.%2BS.%26aulast%3DNiikura%26aufirst%3DT.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DTurner%26aufirst%3DR.%2BS.%26aulast%3DMattson%26aufirst%3DM.%2BP.%26aulast%3DBosetti%26aufirst%3DF.%26atitle%3DCyclooxygenase-1%2520inhibition%2520reduces%2520amyloid%2520pathology%2520and%2520improves%2520memory%2520deficits%2520in%2520a%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurochem.%26date%3D2013%26volume%3D124%26spage%3D59%26epage%3D68%26doi%3D10.1111%2Fjnc.12059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">McGeer, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McGeer, E. G.</span><span> </span><span class="NLM_article-title">NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">639</span><span class="NLM_x">–</span> <span class="NLM_lpage">647</span><span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2006.03.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.neurobiolaging.2006.03.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=16697488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2sXislSrt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=639-647&author=P.+L.+McGeerauthor=E.+G.+McGeer&title=NSAIDs+and+Alzheimer+disease%3A+epidemiological%2C+animal+model+and+clinical+studies&doi=10.1016%2Fj.neurobiolaging.2006.03.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies</span></div><div class="casAuthors">McGeer, Patrick L.; McGeer, Edith G.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">639-647</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">This review reports correlations between four independent fields related to inflammation and Alzheimer disease: fundamental pathol., epidemiol., transgenic animal studies and clin. trials.  Activated microglia, along with a spectrum of inflammatory mediators, have been identified in assocn. with the lesions of Alzheimer disease (AD), suggesting that antiinflammatory agents such as NSAIDs should protect against the disease.  In multiple epidemiol. investigations testing this hypothesis, a significant risk redn., or a trend towards such a redn. has been obsd. in long term as opposed to short term users of traditional NSAIDs.  In studies where such NSAIDs have been administered to AD transgenic mice, a dose dependent redn. in pathol. was obsd.  The selective C0X-2 inhibitors were ineffective.  Results of clin. investigations have so far been disappointing but have nevertheless correlated with fundamental pathol. findings and with transgenic mouse results.  Four clin. trials using selective COX-2 inhibitors failed which is in keeping with the animal results and is consistent with pathol. findings demonstrating that COX-1 and not COX-2 is the appropriate target in activated human microglia.  A low dose trial of the traditional NSAID naproxen also failed, but pilot trials using therapeutically established doses of indomethacin and diclofenac/misoprostol showed promise.  Further clin. investigations with relatively high doses of traditional NSAIDs might be warranted, although significant side effects should be anticipated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr5CYtCv9mQ7Vg90H21EOLACvtfcHk0lhrIVN2wZ0JUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXislSrt74%253D&md5=b5b3f0052c0a0e8fdf1dea09f2541fa9</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2006.03.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2006.03.013%26sid%3Dliteratum%253Aachs%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DMcGeer%26aufirst%3DE.%2BG.%26atitle%3DNSAIDs%2520and%2520Alzheimer%2520disease%253A%2520epidemiological%252C%2520animal%2520model%2520and%2520clinical%2520studies%26jtitle%3DNeurobiol.%2520Aging%26date%3D2007%26volume%3D28%26spage%3D639%26epage%3D647%26doi%3D10.1016%2Fj.neurobiolaging.2006.03.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Yan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Babu-Khan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vassar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biere, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Citron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Landreth, G.</span><span> </span><span class="NLM_article-title">Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">7504</span><span class="NLM_x">–</span> <span class="NLM_lpage">7509</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=12930788" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvFaisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=7504-7509&author=Q.+Yanauthor=J.+Zhangauthor=H.+Liuauthor=S.+Babu-Khanauthor=R.+Vassarauthor=A.+L.+Biereauthor=M.+Citronauthor=G.+Landreth&title=Anti-inflammatory+drug+therapy+alters+beta-amyloid+processing+and+deposition+in+an+animal+model+of+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease</span></div><div class="casAuthors">Yan, Qiao; Zhang, Jianhua; Liu, Hantao; Babu-Khan, Safura; Vassar, Robert; Biere, Anja Leona; Citron, Martin; Landreth, Gary</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7504-7509</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is characterized by a microglial-mediated inflammatory response elicited by extensive amyloid deposition in the brain.  Nonsteroidal anti-inflammatory drug (NSAID) treatment reduces AD risk, slows disease progression, and reduces microglial activation; however, the basis of these effects is unknown.  We report that treatment of 11-mo-old Tg2576 mice overexpressing human amyloid precursor protein (APP) with the NSAID ibuprofen for 16 wk resulted in the dramatic and selective redn. of SDS-sol. β-amyloid (Aβ)42, whereas it had smaller effects on SDS-sol. Aβ40 levels.  Ibuprofen treatment resulted in 60% redn. of amyloid plaque load in the cortex of these animals.  In vitro studies using APP-expressing 293 cells showed that ibuprofen directly affected APP processing, specifically reducing the prodn. of Aβ42.  Ibuprofen treatment resulted in a significant redn. in microglial activation in the Tg2576 mice, as measured by CD45 and CD11b expression.  NSAIDs activate the nuclear hormone receptor peroxisome proliferator-activated receptor γ (PPARγ); however, a potent agonist of this receptor, pioglitazone, only modestly reduced SDS-sol.  Aβ levels and did not affect amyloid plaque burden or microglia activation, indicating that PPARγ activation is not involved in the Aβ lowering effect of NSAIDs.  These data show that chronic NSAID treatment can reduce brain Aβ levels, amyloid plaque burden, and microglial activation in an animal model of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4w_7ZE_lvKbVg90H21EOLACvtfcHk0lhrIVN2wZ0JUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvFaisLg%253D&md5=ae17d7abd50d1fd812e88dd86d62c29b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DBabu-Khan%26aufirst%3DS.%26aulast%3DVassar%26aufirst%3DR.%26aulast%3DBiere%26aufirst%3DA.%2BL.%26aulast%3DCitron%26aufirst%3DM.%26aulast%3DLandreth%26aufirst%3DG.%26atitle%3DAnti-inflammatory%2520drug%2520therapy%2520alters%2520beta-amyloid%2520processing%2520and%2520deposition%2520in%2520an%2520animal%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26spage%3D7504%26epage%3D7509" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Lim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teter, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubeda, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashe, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frautschy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, G. M.</span><span> </span><span class="NLM_article-title">Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5709</span><span class="NLM_x">–</span> <span class="NLM_lpage">5714</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10908610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2000&pages=5709-5714&author=G.+P.+Limauthor=F.+Yangauthor=T.+Chuauthor=P.+Chenauthor=W.+Beechauthor=B.+Teterauthor=T.+Tranauthor=O.+Ubedaauthor=K.+H.+Asheauthor=S.+A.+Frautschyauthor=G.+M.+Cole&title=Ibuprofen+suppresses+plaque+pathology+and+inflammation+in+a+mouse+model+for+Alzheimer%E2%80%99s+disease"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease</span></div><div class="casAuthors">Lim, G. P.; Yang, F.; Chu, T.; Chen, P.; Beech, W.; Teter, B.; Tran, T.; Ubeda, O.; Ashe, K. Hsiao; Frautschy, S. A.; Cole, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">5709-5714</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The brain in Alzheimer's disease (AD) shows a chronic inflammatory response characterized by activated glial cells and increased expression of cytokines and complement factors surrounding amyloid deposits.  Several epidemiol. studies have demonstrated a reduced risk for AD in patients using nonsteroidal anti-inflammatory drugs (NSAIDs), prompting further inquiries about how NSAIDs might influence the development of AD pathol. and inflammation in the CNS.  We tested the impact of chronic orally administered ibuprofen, the most commonly used NSAID, in a transgenic model of AD displaying widespread microglial activation, age-related amyloid deposits, and dystrophic neurites.  These mice were created by overexpressing a variant of the amyloid precursor protein found in familial AD.  Transgene-pos. (Tg+) and neg. (Tg-) mice began receiving chow contg. 375 ppm ibuprofen at 10 mo of age, when amyloid plaques first appear, and were fed continuously for 6 mo.  This treatment produced significant redns. in final interleukin-1β and glial fibrillary acidic protein levels, as well as a significant diminution in the ultimate no. and total area of β-amyloid deposits.  Redns. in amyloid deposition were supported by ELISA measurements showing significantly decreased SDS-insol. Aβ.  Ibuprofen also decreased the nos. of ubiquitin-labeled dystrophic neurites and the percentage area per plaque of antiphosphotyrosine-labeled microglia.  Thus, the anti-inflammatory drug ibuprofen, which has been assocd. with reduced AD risk in human epidemiol. studies, can significantly delay some forms of AD pathol., including amyloid deposition, when administered early in the disease course of a transgenic mouse model of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqu-NFgSW3HzrVg90H21EOLACvtfcHk0lickXweOjqW2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXlt1Gltbk%253D&md5=980c52238707aa8fba6cce1c1cdfc399</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DG.%2BP.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DBeech%26aufirst%3DW.%26aulast%3DTeter%26aufirst%3DB.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DUbeda%26aufirst%3DO.%26aulast%3DAshe%26aufirst%3DK.%2BH.%26aulast%3DFrautschy%26aufirst%3DS.%2BA.%26aulast%3DCole%26aufirst%3DG.%2BM.%26atitle%3DIbuprofen%2520suppresses%2520plaque%2520pathology%2520and%2520inflammation%2520in%2520a%2520mouse%2520model%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Neurosci.%26date%3D2000%26volume%3D20%26spage%3D5709%26epage%3D5714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Lim, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gahtan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubeda, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beech, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overmier, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hsiao-Ashec, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frautschy, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, G. M.</span><span> </span><span class="NLM_article-title">Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice</span> <span class="citation_source-journal">Neurobiol. Aging</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">983</span><span class="NLM_x">–</span> <span class="NLM_lpage">991</span><span class="refDoi"> DOI: 10.1016/S0197-4580(01)00299-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2FS0197-4580%2801%2900299-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=11755007" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFyksrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2001&pages=983-991&author=G.+P.+Limauthor=F.+Yangauthor=T.+Chuauthor=E.+Gahtanauthor=O.+Ubedaauthor=W.+Beechauthor=J.+B.+Overmierauthor=K.+Hsiao-Ashecauthor=S.+A.+Frautschyauthor=G.+M.+Cole&title=Ibuprofen+effects+on+Alzheimer+pathology+and+open+field+activity+in+APPsw+transgenic+mice&doi=10.1016%2FS0197-4580%2801%2900299-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice</span></div><div class="casAuthors">Lim, G. P.; Yang, F.; Chu, T.; Gahtan, E.; Ubeda, O.; Beech, W.; Overmier, J. B.; Hsiao-Ashec, K.; Frautschy, S. A.; Cole, G. M.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">983-991</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">We previously showed the non-steroidal anti-inflammatory drug (NSAID) ibuprofen suppresses inflammation and amyloid in the APPsw (Tg2576) Tg2576 transgenic mouse.  The mechanism for these effects and the impact on behavior are unknown.  We now show ibuprofen's effects were not mediated by alterations in amyloid precursor protein (APP) expression or oxidative damage (carbonyls).  Six months ibuprofen treatment in Tg+ females caused a decrease in open field behavior (p < 0.05), restoring values similar to Tg- mice.  Reduced caspase activation per plaque provided further evidence for a neuroprotective action of ibuprofen.  The impact of a shorter 3 mo duration ibuprofen trial, beginning at a later age (from 14 to 17 mo), was also investigated.  Repeated measures ANOVA of Aβ levels (sol. and insol.) demonstrated a significant ibuprofen treatment effect (p < 0.05).  Post-hoc anal. showed that ibuprofen-dependent redns. of both sol. Aβ and Aβ42 were most marked in entorhinal cortex (p < 0.05).  Although interleukin-1β and insol. Aβ were more effectively reduced with longer treatment, the magnitude of the effect on sol. Aβ was not dependent on treatment duration.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoApEz_j49VfrVg90H21EOLACvtfcHk0lickXweOjqW2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFyksrw%253D&md5=8070317c22b4881300673110619ce5e1</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2FS0197-4580%2801%2900299-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-4580%252801%252900299-8%26sid%3Dliteratum%253Aachs%26aulast%3DLim%26aufirst%3DG.%2BP.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DT.%26aulast%3DGahtan%26aufirst%3DE.%26aulast%3DUbeda%26aufirst%3DO.%26aulast%3DBeech%26aufirst%3DW.%26aulast%3DOvermier%26aufirst%3DJ.%2BB.%26aulast%3DHsiao-Ashec%26aufirst%3DK.%26aulast%3DFrautschy%26aufirst%3DS.%2BA.%26aulast%3DCole%26aufirst%3DG.%2BM.%26atitle%3DIbuprofen%2520effects%2520on%2520Alzheimer%2520pathology%2520and%2520open%2520field%2520activity%2520in%2520APPsw%2520transgenic%2520mice%26jtitle%3DNeurobiol.%2520Aging%26date%3D2001%26volume%3D22%26spage%3D983%26epage%3D991%26doi%3D10.1016%2FS0197-4580%2801%2900299-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Szekely, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorne, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zandi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ek, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messias, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, S. N.</span><span> </span><span class="NLM_article-title">Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer’s disease: a systematic review</span> <span class="citation_source-journal">Neuroepidemiology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">159</span><span class="NLM_x">–</span> <span class="NLM_lpage">169</span><span class="refDoi"> DOI: 10.1159/000078501</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1159%2F000078501" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2004&pages=159-169&author=C.+A.+Szekelyauthor=J.+E.+Thorneauthor=P.+P.+Zandiauthor=M.+Ekauthor=E.+Messiasauthor=J.+C.+Breitnerauthor=S.+N.+Goodman&title=Nonsteroidal+anti-inflammatory+drugs+for+the+prevention+of+Alzheimer%E2%80%99s+disease%3A+a+systematic+review&doi=10.1159%2F000078501"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1159%2F000078501&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078501%26sid%3Dliteratum%253Aachs%26aulast%3DSzekely%26aufirst%3DC.%2BA.%26aulast%3DThorne%26aufirst%3DJ.%2BE.%26aulast%3DZandi%26aufirst%3DP.%2BP.%26aulast%3DEk%26aufirst%3DM.%26aulast%3DMessias%26aufirst%3DE.%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DGoodman%26aufirst%3DS.%2BN.%26atitle%3DNonsteroidal%2520anti-inflammatory%2520drugs%2520for%2520the%2520prevention%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520a%2520systematic%2520review%26jtitle%3DNeuroepidemiology%26date%3D2004%26volume%3D23%26spage%3D159%26epage%3D169%26doi%3D10.1159%2F000078501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Martin, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekely, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piantadosi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craft, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullan, M.</span><span> </span><span class="NLM_article-title">Cognitive function over time in the Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib</span> <span class="citation_source-journal">Arch. Neurol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">896</span><span class="NLM_x">–</span> <span class="NLM_lpage">905</span><span class="refDoi"> DOI: 10.1001/archneur.2008.65.7.nct70006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1001%2Farchneur.2008.65.7.nct70006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=18474729" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BD1cvksFGntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2008&pages=896-905&author=B.+K.+Martinauthor=C.+Szekelyauthor=J.+Brandtauthor=S.+Piantadosiauthor=J.+C.+Breitnerauthor=S.+Craftauthor=D.+Evansauthor=R.+Greenauthor=M.+Mullan&title=Cognitive+function+over+time+in+the+Alzheimer%E2%80%99s+Disease+Anti-inflammatory+Prevention+Trial+%28ADAPT%29%3A+results+of+a+randomized%2C+controlled+trial+of+naproxen+and+celecoxib&doi=10.1001%2Farchneur.2008.65.7.nct70006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib</span></div><div class="casAuthors">Martin Barbara K; Szekely Christine; Brandt Jason; Piantadosi Steven; Breitner John C S; Craft Suzanne; Evans Denis; Green Robert; Mullan Michael</div><div class="citationInfo"><span class="NLM_cas:title">Archives of neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">896-905</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Observational studies have shown reduced risk of Alzheimer dementia in users of nonsteroidal anti-inflammatory drugs.  OBJECTIVE:  To evaluate the effects of naproxen sodium and celecoxib on cognitive function in older adults.  DESIGN:  Randomized, double-masked chemoprevention trial.  SETTING:  Six US memory clinics.  PARTICIPANTS:  Men and women aged 70 years and older with a family history of Alzheimer disease; 2117 of 2528 enrolled had follow-up cognitive assessment.  INTERVENTIONS:  Celecoxib (200 mg twice daily), naproxen sodium (220 mg twice daily), or placebo, randomly allocated in a ratio of 1:1:1.5, respectively.  MAIN OUTCOME MEASURES:  Seven tests of cognitive function and a global summary score measured annually.  RESULTS:  Longitudinal analyses showed lower global summary scores over time for naproxen compared with placebo (- 0.05 SDs; P = .02) and lower scores on the Modified Mini-Mental State Examination over time for both treatment groups compared with placebo (- 0.33 points for celecoxib [P = .04] and - 0.36 points for naproxen [P = .02]).  Restriction of analyses to measures collected from persons without dementia attenuated the treatment group differences.  Analyses limited to measures obtained while participants were being issued study drugs produced results similar to the intention-to-treat analyses.  CONCLUSIONS:  Use of naproxen or celecoxib did not improve cognitive function.  There was weak evidence for a detrimental effect of naproxen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT5MiMEA4EjlJ0d-O_J5C0AfW6udTcc2eb7z-8wjHvOorntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvksFGntg%253D%253D&md5=b1b9434737024bf183ab43d8a34afb31</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1001%2Farchneur.2008.65.7.nct70006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Farchneur.2008.65.7.nct70006%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DB.%2BK.%26aulast%3DSzekely%26aufirst%3DC.%26aulast%3DBrandt%26aufirst%3DJ.%26aulast%3DPiantadosi%26aufirst%3DS.%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DCraft%26aufirst%3DS.%26aulast%3DEvans%26aufirst%3DD.%26aulast%3DGreen%26aufirst%3DR.%26aulast%3DMullan%26aufirst%3DM.%26atitle%3DCognitive%2520function%2520over%2520time%2520in%2520the%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Anti-inflammatory%2520Prevention%2520Trial%2520%2528ADAPT%2529%253A%2520results%2520of%2520a%2520randomized%252C%2520controlled%2520trial%2520of%2520naproxen%2520and%2520celecoxib%26jtitle%3DArch.%2520Neurol.%26date%3D2008%26volume%3D65%26spage%3D896%26epage%3D905%26doi%3D10.1001%2Farchneur.2008.65.7.nct70006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montine, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinert, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyketsos, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashe, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Craft, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ismail, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, B. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mullan, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabbagh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tariot, P. N.</span><span> </span><span class="NLM_article-title">Extended results of the Alzheimer’s disease anti-inflammatory prevention trial</span> <span class="citation_source-journal">Alzheimer's Dementia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">402</span><span class="NLM_x">–</span> <span class="NLM_lpage">411</span><span class="refDoi"> DOI: 10.1016/j.jalz.2010.12.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.jalz.2010.12.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=21784351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BC3MjgslemtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=402-411&author=J.+C.+Breitnerauthor=L.+D.+Bakerauthor=T.+J.+Montineauthor=C.+L.+Meinertauthor=C.+G.+Lyketsosauthor=K.+H.+Asheauthor=J.+Brandtauthor=S.+Craftauthor=D.+E.+Evansauthor=R.+C.+Greenauthor=M.+S.+Ismailauthor=B.+K.+Martinauthor=M.+J.+Mullanauthor=M.+Sabbaghauthor=P.+N.+Tariot&title=Extended+results+of+the+Alzheimer%E2%80%99s+disease+anti-inflammatory+prevention+trial&doi=10.1016%2Fj.jalz.2010.12.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Extended results of the Alzheimer's disease anti-inflammatory prevention trial</span></div><div class="casAuthors">Breitner John C; Baker Laura D; Montine Thomas J; Meinert Curtis L; Lyketsos Constantine G; Ashe Karen H; Brandt Jason; Craft Suzanne; Evans Denis E; Green Robert C; Ismail M Saleem; Martin Barbara K; Mullan Michael J; Sabbagh Marwan; Tariot Pierre N</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia : the journal of the Alzheimer's Association</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">402-11</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Epidemiologic evidence suggests that nonsteroidal anti-inflammatory drugs (NSAIDs) delay onset of Alzheimer's dementia (AD), but randomized trials show no benefit from NSAIDs in patients with symptomatic AD.  The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) randomized 2,528 elderly persons to naproxen or celecoxib versus placebo for 2 years (standard deviation = 11 months) before treatments were terminated.  During the treatment interval, 32 cases of AD revealed increased rates in both NSAID-assigned groups.  METHODS:  We continued the double-masked ADAPT protocol for 2 additional years to investigate incidence of AD (primary outcome).  We then collected cerebrospinal fluid (CSF) from 117 volunteer participants to assess their ratio of CSF tau to Aβ(1-42.)  RESULTS:  Including 40 new events observed during follow-up of 2,071 randomized individuals (92% of participants at treatment cessation), there were 72 AD cases.  Overall, NSAID-related harm was no longer evident, but secondary analyses showed that increased risk remained notable in the first 2.5 years of observations, especially in 54 persons enrolled with cognitive impairment--no dementia (CIND).  These same analyses showed later reduction in AD incidence among asymptomatic enrollees who were given naproxen.  CSF biomarker assays suggested that the latter result reflected reduced Alzheimer-type neurodegeneration.  CONCLUSIONS:  These data suggest a revision of the original ADAPT hypothesis that NSAIDs reduce AD risk, as follows: NSAIDs have an adverse effect in later stages of AD pathogenesis, whereas asymptomatic individuals treated with conventional NSAIDs such as naproxen experience reduced AD incidence, but only after 2 to 3 years.  Thus, treatment effects differ at various stages of disease.  This hypothesis is consistent with data from both trials and epidemiological studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRp1vb8yEF2ZtenUz0lpNqnfW6udTcc2eZuomAHUq47Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjgslemtQ%253D%253D&md5=72baff395a1e0c2ead0e181d7d82a0f8</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.jalz.2010.12.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jalz.2010.12.014%26sid%3Dliteratum%253Aachs%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DBaker%26aufirst%3DL.%2BD.%26aulast%3DMontine%26aufirst%3DT.%2BJ.%26aulast%3DMeinert%26aufirst%3DC.%2BL.%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26aulast%3DAshe%26aufirst%3DK.%2BH.%26aulast%3DBrandt%26aufirst%3DJ.%26aulast%3DCraft%26aufirst%3DS.%26aulast%3DEvans%26aufirst%3DD.%2BE.%26aulast%3DGreen%26aufirst%3DR.%2BC.%26aulast%3DIsmail%26aufirst%3DM.%2BS.%26aulast%3DMartin%26aufirst%3DB.%2BK.%26aulast%3DMullan%26aufirst%3DM.%2BJ.%26aulast%3DSabbagh%26aufirst%3DM.%26aulast%3DTariot%26aufirst%3DP.%2BN.%26atitle%3DExtended%2520results%2520of%2520the%2520Alzheimer%25E2%2580%2599s%2520disease%2520anti-inflammatory%2520prevention%2520trial%26jtitle%3DAlzheimer%2527s%2520Dementia%26date%3D2011%26volume%3D7%26spage%3D402%26epage%3D411%26doi%3D10.1016%2Fj.jalz.2010.12.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Leoutsakos, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muthen, B. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Breitner, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lyketsos, C. G.</span><span> </span><span class="NLM_article-title">Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer’s Disease Anti-inflammatory Prevention Trial</span> <span class="citation_source-journal">Int. J. Geriatr. Psychiatry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">364</span><span class="NLM_x">–</span> <span class="NLM_lpage">374</span><span class="refDoi"> DOI: 10.1002/gps.2723</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1002%2Fgps.2723" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=21560159" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A280%3ADC%252BC38rmsFOiuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2012&pages=364-374&author=J.+M.+Leoutsakosauthor=B.+O.+Muthenauthor=J.+C.+Breitnerauthor=C.+G.+Lyketsos&title=Effects+of+non-steroidal+anti-inflammatory+drug+treatments+on+cognitive+decline+vary+by+phase+of+pre-clinical+Alzheimer+disease%3A+findings+from+the+randomized+controlled+Alzheimer%E2%80%99s+Disease+Anti-inflammatory+Prevention+Trial&doi=10.1002%2Fgps.2723"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial</span></div><div class="casAuthors">Leoutsakos Jeannie-Marie S; Muthen Bengt O; Breitner John C S; Lyketsos Constantine G</div><div class="citationInfo"><span class="NLM_cas:title">International journal of geriatric psychiatry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">364-74</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  We examined the effects of non-steroidal anti-inflammatory drugs on cognitive decline as a function of phase of pre-clinical Alzheimer disease.  METHODS:  Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre-clinical Alzheimer disease.  We fit growth mixture models of Modified Mini-Mental State (3MS) Examination trajectories with data from 2388 participants in the Alzheimer's Disease Anti-inflammatory Prevention Trial and included class-specific effects of naproxen and celecoxib.  RESULTS:  We identified three classes: "no decline", "slow decline", and "fast decline", and examined the effects of celecoxib and naproxen on linear slope and rate of change by class.  Inclusion of quadratic terms improved fit of the model (-2 log likelihood difference: 369.23; p < 0.001) but resulted in reversal of effects over time.  Over 4 years, participants in the slow-decline class on placebo typically lost 6.6 3MS points, whereas those on naproxen lost 3.1 points (p-value for difference: 0.19).  Participants in the fast-decline class on placebo typically lost 11.2 points, but those on celecoxib first declined and then gained points (p-value for difference from placebo: 0.04), whereas those on naproxen showed a typical decline of 24.9 points (p-value for difference from placebo: <0.0001).  CONCLUSIONS:  Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times.  Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners.  Celecoxib appeared to have similar effects at first but then attenuated change in fast decliners.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQnJ0tKP6v-QyMywPm6HgQfW6udTcc2eZuomAHUq47Zbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rmsFOiuw%253D%253D&md5=ba28ea938db996c5273eb44f64358537</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1002%2Fgps.2723&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.2723%26sid%3Dliteratum%253Aachs%26aulast%3DLeoutsakos%26aufirst%3DJ.%2BM.%26aulast%3DMuthen%26aufirst%3DB.%2BO.%26aulast%3DBreitner%26aufirst%3DJ.%2BC.%26aulast%3DLyketsos%26aufirst%3DC.%2BG.%26atitle%3DEffects%2520of%2520non-steroidal%2520anti-inflammatory%2520drug%2520treatments%2520on%2520cognitive%2520decline%2520vary%2520by%2520phase%2520of%2520pre-clinical%2520Alzheimer%2520disease%253A%2520findings%2520from%2520the%2520randomized%2520controlled%2520Alzheimer%25E2%2580%2599s%2520Disease%2520Anti-inflammatory%2520Prevention%2520Trial%26jtitle%3DInt.%2520J.%2520Geriatr.%2520Psychiatry%26date%3D2012%26volume%3D27%26spage%3D364%26epage%3D374%26doi%3D10.1002%2Fgps.2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Maxis, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delalandre, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martel-Pelletier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelletier, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duval, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lajeunesse, D.</span><span> </span><span class="NLM_article-title">The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein</span> <span class="citation_source-journal">Arthritis Res. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">R181</span><span class="refDoi"> DOI: 10.1186/ar2092</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1186%2Far2092" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2006&pages=R181&author=K.+Maxisauthor=A.+Delalandreauthor=J.+Martel-Pelletierauthor=J.+P.+Pelletierauthor=N.+Duvalauthor=D.+Lajeunesse&title=The+shunt+from+the+cyclooxygenase+to+lipoxygenase+pathway+in+human+osteoarthritic+subchondral+osteoblasts+is+linked+with+a+variable+expression+of+the+5-lipoxygenase-activating+protein&doi=10.1186%2Far2092"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1186%2Far2092&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Far2092%26sid%3Dliteratum%253Aachs%26aulast%3DMaxis%26aufirst%3DK.%26aulast%3DDelalandre%26aufirst%3DA.%26aulast%3DMartel-Pelletier%26aufirst%3DJ.%26aulast%3DPelletier%26aufirst%3DJ.%2BP.%26aulast%3DDuval%26aufirst%3DN.%26aulast%3DLajeunesse%26aufirst%3DD.%26atitle%3DThe%2520shunt%2520from%2520the%2520cyclooxygenase%2520to%2520lipoxygenase%2520pathway%2520in%2520human%2520osteoarthritic%2520subchondral%2520osteoblasts%2520is%2520linked%2520with%2520a%2520variable%2520expression%2520of%2520the%25205-lipoxygenase-activating%2520protein%26jtitle%3DArthritis%2520Res.%2520Ther.%26date%3D2006%26volume%3D8%26spage%3DR181%26doi%3D10.1186%2Far2092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Varghese, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockey, R. F.</span><span> </span><span class="NLM_article-title">Aspirin-exacerbated asthma</span> <span class="citation_source-journal">Allergy, Asthma, Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">75</span><span class="NLM_x">–</span> <span class="NLM_lpage">83</span><span class="refDoi"> DOI: 10.1186/1710-1492-4-2-75</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1186%2F1710-1492-4-2-75" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=20525128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVaisb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=75-83&author=M.+Vargheseauthor=R.+F.+Lockey&title=Aspirin-exacerbated+asthma&doi=10.1186%2F1710-1492-4-2-75"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Aspirin-exacerbated asthma</span></div><div class="casAuthors">Varghese, Mathew; Lockey, Richard F.</div><div class="citationInfo"><span class="NLM_cas:title">Allergy, Asthma, and Clinical Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">75-83</span>CODEN:
                <span class="NLM_cas:coden">AACIB3</span>;
        ISSN:<span class="NLM_cas:issn">1710-1484</span>.
    
            (<span class="NLM_cas:orgname">BC Decker Inc.</span>)
        </div><div class="casAbstract">This review focuses on aspirin-exacerbated asthma (AEA).  The review includes historical perspective of aspirin, prevalence, pathogenesis, clin. features and treatment of AEA.  The pathogenesis of AEA involves the cyclooxygenase and lipooxygenase pathway.  Aspirin affects both of these pathways by inhibiting the enzyme cycooxygenase-1 (COX-1).  Inhibition of COX-1 leads to a decrease in prostaglandin E2 (PGE2).  The decrease in PGE2 results in an increase in cysteinyl leukotrienes by the lipooxygenase pathway involving the enzyme 5-lipooxygenase (5-LO).  Leukotriene C4 (LTC4) synthase is the enzyme responsible for the prodn. of leukotriene C4, the chief cysteinyl leukotriene responsible for AEA.  There have been familial occurrences of AEA.  An allele of the LTC4 synthase gene in AEA is known as allele C.  Allele C has a higher frequency in AEA.  Clin. presentation includes a history of asthma after ingestion of aspirin, nasal congestion, watery rhinorrhea and nasal polyposis.  Treatment includes leukotriene receptor antagonists, leukotriene inhibitors, aspirin desensitization and surgery.  AEA is the most well-defined phenotype of asthma.  Although AEA affects adults and children with physician-diagnosed asthma, in some cases there is no history of asthma and AEA often goes unrecognized and underdiagnosed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLd2EYSDJtr7Vg90H21EOLACvtfcHk0liFAAEWAEktJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVaisb8%253D&md5=c0a02be15197a112112b1fd3dfa0e0bc</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1186%2F1710-1492-4-2-75&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1710-1492-4-2-75%26sid%3Dliteratum%253Aachs%26aulast%3DVarghese%26aufirst%3DM.%26aulast%3DLockey%26aufirst%3DR.%2BF.%26atitle%3DAspirin-exacerbated%2520asthma%26jtitle%3DAllergy%252C%2520Asthma%252C%2520Clin.%2520Immunol.%26date%3D2008%26volume%3D4%26spage%3D75%26epage%3D83%26doi%3D10.1186%2F1710-1492-4-2-75" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Duffield-Lillico, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boyle, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butala, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subbaramaiah, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newman, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrow, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milne, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dannenberg, A. J.</span><span> </span><span class="NLM_article-title">Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway</span> <span class="citation_source-journal">Cancer Prev. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">322</span><span class="NLM_x">–</span> <span class="NLM_lpage">329</span><span class="refDoi"> DOI: 10.1158/1940-6207.CAPR-09-0005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1158%2F1940-6207.CAPR-09-0005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=19336727" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC3cXptFKgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=322-329&author=A.+J.+Duffield-Lillicoauthor=J.+O.+Boyleauthor=X.+K.+Zhouauthor=A.+Ghoshauthor=G.+S.+Butalaauthor=K.+Subbaramaiahauthor=R.+A.+Newmanauthor=J.+D.+Morrowauthor=G.+L.+Milneauthor=A.+J.+Dannenberg&title=Levels+of+prostaglandin+E+metabolite+and+leukotriene+E%284%29+are+increased+in+the+urine+of+smokers%3A+evidence+that+celecoxib+shunts+arachidonic+acid+into+the+5-lipoxygenase+pathway&doi=10.1158%2F1940-6207.CAPR-09-0005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway</span></div><div class="casAuthors">Duffield-Lillico, Anna J.; Boyle, Jay O.; Zhou, Xi Kathy; Ghosh, Aradhana; Butala, Geera S.; Subbaramaiah, Kotha; Newman, Robert A.; Morrow, Jason D.; Milne, Ginger L.; Dannenberg, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Prevention Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">322-329</span>CODEN:
                <span class="NLM_cas:coden">CPRACC</span>;
        ISSN:<span class="NLM_cas:issn">1940-6207</span>.
    
            (<span class="NLM_cas:orgname">American Association of Cancer Research</span>)
        </div><div class="casAbstract">Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO) play a role in inflammation and carcinogenesis.  Biomarkers that reflect tobacco smoke-induced tissue injury are needed.  In this study, levels of urinary prostaglandin E metabolite (PGE-M) and leukotriene E4 (LTE4), biomarkers of the COX and 5-LO pathways, were compared in never smokers, former smokers, and current smokers.  The effects of celecoxib, a selective COX-2 inhibitor, on levels of PGE-M and LTE4 were detd.  Baseline levels of PGE-M and LTE4 were pos. assocd. with smoking status; levels of PGE-M and LTE4 were higher in current vs. never smokers.  Treatment with 200 mg celecoxib twice daily for 6 ± 1 days led to a redn. in urinary PGE-M levels in all groups but exhibited the greatest effect among subjects with high baseline PGE-M levels.  Thus, high baseline PGE-M levels in smokers reflected increased COX-2 activity.  In individuals with high baseline PGE-M levels, treatment with celecoxib led to a significant increase in levels of urinary LTE4, an effect that was not found in individuals with low baseline PGE-M levels.  In conclusion, increased levels of urinary PGE-M and LTE4 were found in human smokers, a result that may reflect subclin. lung inflammation.  In individuals with high baseline levels of PGE-M (elevated COX-2 activity), celecoxib administration shunted arachidonic acid into the proinflammatory 5-LO pathway.  Because 5-LO activity and LTE4 have been suggested to play a role in cardiovascular disease, these results may help to explain the link between use of COX-2 inhibitors and cardiovascular complications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQXJp1FZG--LVg90H21EOLACvtfcHk0liFAAEWAEktJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXptFKgu74%253D&md5=245a39372c092dba4b0417ed19018105</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F1940-6207.CAPR-09-0005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1940-6207.CAPR-09-0005%26sid%3Dliteratum%253Aachs%26aulast%3DDuffield-Lillico%26aufirst%3DA.%2BJ.%26aulast%3DBoyle%26aufirst%3DJ.%2BO.%26aulast%3DZhou%26aufirst%3DX.%2BK.%26aulast%3DGhosh%26aufirst%3DA.%26aulast%3DButala%26aufirst%3DG.%2BS.%26aulast%3DSubbaramaiah%26aufirst%3DK.%26aulast%3DNewman%26aufirst%3DR.%2BA.%26aulast%3DMorrow%26aufirst%3DJ.%2BD.%26aulast%3DMilne%26aufirst%3DG.%2BL.%26aulast%3DDannenberg%26aufirst%3DA.%2BJ.%26atitle%3DLevels%2520of%2520prostaglandin%2520E%2520metabolite%2520and%2520leukotriene%2520E%25284%2529%2520are%2520increased%2520in%2520the%2520urine%2520of%2520smokers%253A%2520evidence%2520that%2520celecoxib%2520shunts%2520arachidonic%2520acid%2520into%2520the%25205-lipoxygenase%2520pathway%26jtitle%3DCancer%2520Prev.%2520Res.%26date%3D2009%26volume%3D2%26spage%3D322%26epage%3D329%26doi%3D10.1158%2F1940-6207.CAPR-09-0005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Perry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sperling, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berry, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dilts, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanna, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salloway, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bountra, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krams, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potkin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribkoff, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Temple, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carrillo, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephenson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snyder, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKew, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fields, F. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bain, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bens, C.</span><span> </span><span class="NLM_article-title">Building a roadmap for developing combination therapies for Alzheimer’s disease</span> <span class="citation_source-journal">Expert Rev. Neurother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">333</span><span class="refDoi"> DOI: 10.1586/14737175.2015.996551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1586%2F14737175.2015.996551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=25708309" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjt1ansrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2015&pages=327-333&author=D.+Perryauthor=R.+Sperlingauthor=R.+Katzauthor=D.+Berryauthor=D.+Diltsauthor=D.+Hannaauthor=S.+Sallowayauthor=J.+Q.+Trojanowskiauthor=C.+Bountraauthor=M.+Kramsauthor=J.+Luthmanauthor=S.+Potkinauthor=V.+Gribkoffauthor=R.+Templeauthor=Y.+Wangauthor=M.+C.+Carrilloauthor=D.+Stephensonauthor=H.+Snyderauthor=E.+Liuauthor=T.+Wareauthor=J.+McKewauthor=F.+O.+Fieldsauthor=L.+J.+Bainauthor=C.+Bens&title=Building+a+roadmap+for+developing+combination+therapies+for+Alzheimer%E2%80%99s+disease&doi=10.1586%2F14737175.2015.996551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Building a roadmap for developing combination therapies for Alzheimer's disease</span></div><div class="casAuthors">Perry, Daniel; Sperling, Reisa; Katz, Russell; Berry, Donald; Dilts, David; Hanna, Debra; Salloway, Stephen; Trojanowski, John Q.; Bountra, Chas; Krams, Michael; Luthman, Johan; Potkin, Steven; Gribkoff, Val; Temple, Robert; Wang, Yaning; Carrillo, Maria C.; Stephenson, Diane; Snyder, Heather; Liu, Enchi; Ware, Tony; McKew, John; Fields, F. Owen; Bain, Lisa J.; Bens, Cynthia</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">327-333</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Combination therapy has proven to be an effective strategy for treating many of the world's most intractable diseases.  A growing no. of investigators in academia, industry, regulatory agencies, foundations and advocacy organizations are interested in pursuing a combination approach to treating Alzheimer's disease.  A meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition, the Crit. Path Institute and the Alzheimer's Assocn. addressed challenges in designing clin. trials to test multiple treatments in combination and outlined a roadmap for making such trials a reality.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqreFl8-aV74LVg90H21EOLACvtfcHk0liFAAEWAEktJg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjt1ansrs%253D&md5=7791d6ba7ee40aed546917a4d3e853a1</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1586%2F14737175.2015.996551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1586%252F14737175.2015.996551%26sid%3Dliteratum%253Aachs%26aulast%3DPerry%26aufirst%3DD.%26aulast%3DSperling%26aufirst%3DR.%26aulast%3DKatz%26aufirst%3DR.%26aulast%3DBerry%26aufirst%3DD.%26aulast%3DDilts%26aufirst%3DD.%26aulast%3DHanna%26aufirst%3DD.%26aulast%3DSalloway%26aufirst%3DS.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DBountra%26aufirst%3DC.%26aulast%3DKrams%26aufirst%3DM.%26aulast%3DLuthman%26aufirst%3DJ.%26aulast%3DPotkin%26aufirst%3DS.%26aulast%3DGribkoff%26aufirst%3DV.%26aulast%3DTemple%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCarrillo%26aufirst%3DM.%2BC.%26aulast%3DStephenson%26aufirst%3DD.%26aulast%3DSnyder%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DE.%26aulast%3DWare%26aufirst%3DT.%26aulast%3DMcKew%26aufirst%3DJ.%26aulast%3DFields%26aufirst%3DF.%2BO.%26aulast%3DBain%26aufirst%3DL.%2BJ.%26aulast%3DBens%26aufirst%3DC.%26atitle%3DBuilding%2520a%2520roadmap%2520for%2520developing%2520combination%2520therapies%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2015%26volume%3D15%26spage%3D327%26epage%3D333%26doi%3D10.1586%2F14737175.2015.996551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Mariano, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralinaghi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Catto, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartmann, R. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engel, M.</span><span> </span><span class="NLM_article-title">First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer’s disease</span> <span class="citation_source-journal">ACS Chem. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">1198</span><span class="NLM_x">–</span> <span class="NLM_lpage">202</span><span class="refDoi"> DOI: 10.1021/cn5001815</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cn5001815" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=1198-202&author=M.+Marianoauthor=C.+Schmittauthor=P.+Miralinaghiauthor=M.+Cattoauthor=R.+W.+Hartmannauthor=A.+Carottiauthor=M.+Engel&title=First+selective+dual+inhibitors+of+tau+phosphorylation+and+Beta-amyloid+aggregation%2C+two+major+pathogenic+mechanisms+in+Alzheimer%E2%80%99s+disease&doi=10.1021%2Fcn5001815"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">First Selective Dual Inhibitors of Tau Phosphorylation and Beta-Amyloid Aggregation, Two Major Pathogenic Mechanisms in Alzheimer's Disease</span></div><div class="casAuthors">Mariano, Marica; Schmitt, Christian; Miralinaghi, Parisa; Catto, Marco; Hartmann, Rolf W.; Carotti, Angelo; Engel, Matthias</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1198-1202</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In Alzheimer's disease (AD), multiple factors account for the accumulation of neurocellular changes, which may begin several years before symptoms appear.  The most important pathogenic brain changes that are contributing to the development of AD are the formation of the cytotoxic β-amyloid aggregates and of the neurofibrillary tangles, which originate from amyloid-β peptides and hyperphosphorylated tau protein, resp.  New therapeutic agents that target both major pathogenic mechanisms may be particularly efficient.  In this study, the authors introduce bis(hydroxyphenyl)-substituted thiophenes I [R1 = 3-Me, 3-MeO, 3-Me-4-MeO, 3-Et-4-MeO; R2 = 3-MeO, 4-MeO, 3-Me-4-MeO, 3-Et-4-MeO] as a novel class of selective, dual inhibitors of the tau kinase Dyrk1A and of the amyloid-β aggregation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNgPu3VSQ64rVg90H21EOLACvtfcHk0liGN_hF4HVxTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsFyrsL3K&md5=31754e003032609beeb9568418bc30d7</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1021%2Fcn5001815&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcn5001815%26sid%3Dliteratum%253Aachs%26aulast%3DMariano%26aufirst%3DM.%26aulast%3DSchmitt%26aufirst%3DC.%26aulast%3DMiralinaghi%26aufirst%3DP.%26aulast%3DCatto%26aufirst%3DM.%26aulast%3DHartmann%26aufirst%3DR.%2BW.%26aulast%3DCarotti%26aufirst%3DA.%26aulast%3DEngel%26aufirst%3DM.%26atitle%3DFirst%2520selective%2520dual%2520inhibitors%2520of%2520tau%2520phosphorylation%2520and%2520Beta-amyloid%2520aggregation%252C%2520two%2520major%2520pathogenic%2520mechanisms%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2014%26volume%3D5%26spage%3D1198%26epage%3D202%26doi%3D10.1021%2Fcn5001815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Zhang, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ayral-Kaloustian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Afragola, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hernandez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lucas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbons, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beyer, C.</span><span> </span><span class="NLM_article-title">Synthesis and SAR of [1,2,4]triazolo[1,5-a]pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1021/jm060717i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060717i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhtleiu7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=319-327&author=N.+Zhangauthor=S.+Ayral-Kaloustianauthor=T.+Nguyenauthor=J.+Afragolaauthor=R.+Hernandezauthor=J.+Lucasauthor=J.+Gibbonsauthor=C.+Beyer&title=Synthesis+and+SAR+of+%5B1%2C2%2C4%5Dtriazolo%5B1%2C5-a%5Dpyrimidines%2C+a+class+of+anticancer+agents+with+a+unique+mechanism+of+tubulin+inhibition&doi=10.1021%2Fjm060717i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and SAR of [1,2,4]Triazolo[1,5-a]pyrimidines, a Class of Anticancer Agents with a Unique Mechanism of Tubulin Inhibition</span></div><div class="casAuthors">Zhang, Nan; Ayral-Kaloustian, Semiramis; Nguyen, Thai; Afragola, Jay; Hernandez, Richard; Lucas, Judy; Gibbons, James; Beyer, Carl</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">319-327</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of [1,2,4]triazolo[1,5-a]pyrimidines I [R1 = Cl, Br; R2, R3 = H, Me; R4 = H, F, Me2N(CH2)3S, HO(CH2)4O, Me2N(CH2)3NH, etc.; R5 = H, F, Me2N(CH2)3O; R6 = H, F] was synthesized via arom. nucleophilic substitution reactions using alcs., thiols or amines as nucleophiles, and the structure-activity relationship of the products as anticancer agents was evaluated.  (1S)-2,2,2-Trifluoro-1-methylethylamino group or an achiral 2,2,2-trifluoroethylamino group is required at the 5-position to achieve high potency.  On the Ph ring, both fluoro atoms, at the positions ortho to the triazolopyrimidine core, are needed for optimal activity.  At the position para to the triazolopyrimidine core, on the Ph ring, the best activity is achieved with an oxygen linkage followed by a three-methylene unit, and an alkylamino or a hydroxy group.  The mechanism of action for this series of triazolopyrimidines was shown to be unique in that they promoted tubulin polymn. in vitro, but did not bind competitively with paclitaxel.  Instead, these compds. inhibit the binding of vincas to tubulin.  Selected compds. were studied further, and it was shown that these compds. were able to overcome resistance attributed to several multidrug resistance transporter proteins.  Lead compds. were shown to inhibit tumor growth in several nude mouse xenograft models, with high potency and efficacy, when dosed either orally or i.v.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomL5qunsB_7bVg90H21EOLACvtfcHk0liGN_hF4HVxTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhtleiu7fN&md5=769f225dbaa90b634cd86ff5f0c9504d</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1021%2Fjm060717i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060717i%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DN.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DT.%26aulast%3DAfragola%26aufirst%3DJ.%26aulast%3DHernandez%26aufirst%3DR.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DGibbons%26aufirst%3DJ.%26aulast%3DBeyer%26aufirst%3DC.%26atitle%3DSynthesis%2520and%2520SAR%2520of%2520%255B1%252C2%252C4%255Dtriazolo%255B1%252C5-a%255Dpyrimidines%252C%2520a%2520class%2520of%2520anticancer%2520agents%2520with%2520a%2520unique%2520mechanism%2520of%2520tubulin%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D319%26epage%3D327%26doi%3D10.1021%2Fjm060717i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Brunden, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, A. B.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballatore, C.</span><span> </span><span class="NLM_article-title">Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5040</span><span class="NLM_x">–</span> <span class="NLM_lpage">5049</span><span class="refDoi"> DOI: 10.1016/j.bmc.2013.12.046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1016%2Fj.bmc.2013.12.046" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5040-5049&author=K.+R.+Brundenauthor=J.+Q.+Trojanowskiauthor=A.+B.+Smithauthor=V.+M.+Leeauthor=C.+Ballatore&title=Microtubule-stabilizing+agents+as+potential+therapeutics+for+neurodegenerative+disease&doi=10.1016%2Fj.bmc.2013.12.046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.12.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.12.046%26sid%3Dliteratum%253Aachs%26aulast%3DBrunden%26aufirst%3DK.%2BR.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26aulast%3DSmith%26aufirst%3DA.%2BB.%26aulast%3DLee%26aufirst%3DV.%2BM.%26aulast%3DBallatore%26aufirst%3DC.%26atitle%3DMicrotubule-stabilizing%2520agents%2520as%2520potential%2520therapeutics%2520for%2520neurodegenerative%2520disease%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5040%26epage%3D5049%26doi%3D10.1016%2Fj.bmc.2013.12.046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Zhang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiti, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shively, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakhani, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald-Jones, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruce, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, E. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joyce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toleikis, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, V. M. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trojanowski, J. Q.</span><span> </span><span class="NLM_article-title">Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">231</span><span class="refDoi"> DOI: 10.1073/pnas.0406361102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=10.1073%2Fpnas.0406361102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=15615853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtlemtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=227-231&author=B.+Zhangauthor=A.+Maitiauthor=S.+Shivelyauthor=F.+Lakhaniauthor=G.+McDonald-Jonesauthor=J.+Bruceauthor=E.+B.+Leeauthor=S.+X.+Xieauthor=S.+Joyceauthor=C.+Liauthor=P.+M.+Toleikisauthor=V.+M.+Y.+Leeauthor=J.+Q.+Trojanowski&title=Microtubule-binding+drugs+offset+tau+sequestration+by+stabilizing+microtubules+and+reversing+fast+axonal+transport+deficits+in+a+tauopathy+model&doi=10.1073%2Fpnas.0406361102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model</span></div><div class="casAuthors">Zhang, Bin; Maiti, Arpita; Shively, Sharon; Lakhani, Fara; McDonald-Jones, Gaye; Bruce, Jennifer; Lee, Edward B.; Xie, Sharon X.; Joyce, Sonali; Li, Chi; Toleikis, Philip M.; Lee, Virginia M.-Y.; Trojanowski, John Q.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">227-231</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">We tested the hypothesis that microtubule (MT)-binding drugs could be therapeutically beneficial in tauopathies by functionally substituting for the MT-binding protein tau, which is sequestered into inclusions of human tauopathies and transgenic mouse models thereof.  Transgenic mice were treated for 12 wk with weekly i.p. injections of 10 or 25 mg/m2 paclitaxel (Paxceed).  Both doses restored fast axonal transport in spinal axons, wherein MT nos. and stable (detyrosinated) tubulins were increased, compared with sham treatment, and only Paxceed ameliorated motor impairments in tau transgenic mice.  Thus, MT-stabilizing drugs could have therapeutic potential for treating neurodegenerative tauopathies by offsetting losses of tau function that result from the sequestration of this MT-stabilizing protein into filamentous inclusions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0Xfh_fgcZrLVg90H21EOLACvtfcHk0lhGJ_YwXSaq3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtlemtA%253D%253D&md5=bf2746acbdcf115ac7fc9042232c9c36</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0406361102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0406361102%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DMaiti%26aufirst%3DA.%26aulast%3DShively%26aufirst%3DS.%26aulast%3DLakhani%26aufirst%3DF.%26aulast%3DMcDonald-Jones%26aufirst%3DG.%26aulast%3DBruce%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DE.%2BB.%26aulast%3DXie%26aufirst%3DS.%2BX.%26aulast%3DJoyce%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DToleikis%26aufirst%3DP.%2BM.%26aulast%3DLee%26aufirst%3DV.%2BM.%2BY.%26aulast%3DTrojanowski%26aufirst%3DJ.%2BQ.%26atitle%3DMicrotubule-binding%2520drugs%2520offset%2520tau%2520sequestration%2520by%2520stabilizing%2520microtubules%2520and%2520reversing%2520fast%2520axonal%2520transport%2520deficits%2520in%2520a%2520tauopathy%2520model%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2005%26volume%3D102%26spage%3D227%26epage%3D231%26doi%3D10.1073%2Fpnas.0406361102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i125"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00475">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_50080"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00475">10.1021/acs.jmedchem.7b00475</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">NMR spectra of test compounds; X-ray crystal structures of compound <b>98</b> (CCDC 1529316); details for the docking studies; analysis of <a class="ref internalNav" href="#tbl2">Table 2</a> compounds for their ability to reduce multiple COX and 5-LOX products (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES string structures along the full data set in tabular form (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_001.pdf">jm7b00475_si_001.pdf (3.12 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00475/suppl_file/jm7b00475_si_002.csv">jm7b00475_si_002.csv (5.92 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00475&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-12%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00475%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00475" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679948c22c8c21d6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
